{"celestra_export":3,"exported_at":"2026-10-01T11:41:09.942574+00:00","run":{"id":"run_2058f031b9db","reference":"RUN-B09E17F3","name":"test project","config":{"therapy_area":"Oncology","drug_brand":"","population":"All","indication":"Acute Lymphoblastic Leukemia","indication_key":"ALL","geography":"United States","objective":"Build Claims Line of Therapy","target_population":"All patients","additional_context":"","mode":"full","selected_agent":null,"research_cutoff":"2026-09-22"},"status":"awaiting_review","agents":{"A":{"bucket":"A","key":"clinical-landscape-agent","name":"Clinical Landscape Agent","tagline":"Disease context, patient journey, clinical events","icon":"leaf","stages":["stage_1"],"depends_on":[],"status":"complete","wave":1,"progress":1.0,"message":"5/5 questions answered from 10 sources","questions_total":5,"questions_answered":5,"evidence_count":63,"sources_used":["nci","orphanet","seer","who_gho","ashpublications","europepmc","pubmed","cdc_icd10","who","open_web"],"started_at":"2026-09-22T11:08:02.008190Z","finished_at":"2026-09-22T11:19:00.520419Z","error":""},"C":{"bucket":"C","key":"treatment-evidence-agent","name":"Treatment Evidence Agent","tagline":"Therapies, treatment settings, regulatory evidence","icon":"pill","stages":["stage_2"],"depends_on":[],"status":"complete","wave":1,"progress":1.0,"message":"9/10 questions answered from 10 sources","questions_total":10,"questions_answered":9,"evidence_count":117,"sources_used":["dailymed","esmo","nci","openfda_drugsfda","openfda_label","asco","ashpublications","clinicaltrials","fda","open_web"],"started_at":"2026-09-22T11:08:02.302359Z","finished_at":"2026-09-22T11:59:47.428594Z","error":""},"B":{"bucket":"B","key":"diagnostic-footprint-agent","name":"Diagnostic Footprint Agent","tagline":"Claims signals, diagnosis & procedure codes","icon":"microscope","stages":["stage_3"],"depends_on":["A"],"status":"queued","wave":2,"progress":0.0,"message":"","questions_total":0,"questions_answered":0,"evidence_count":0,"sources_used":[],"started_at":null,"finished_at":null,"error":""},"D":{"bucket":"D","key":"treatment-logic-agent","name":"Treatment Logic Agent","tagline":"Treatment patterns, episode logic, LOT rules","icon":"flow","stages":["stage_4"],"depends_on":["C"],"status":"queued","wave":2,"progress":0.0,"message":"","questions_total":0,"questions_answered":0,"evidence_count":0,"sources_used":[],"started_at":null,"finished_at":null,"error":""},"E":{"bucket":"E","key":"patient-journey-agent","name":"Patient Journey Agent","tagline":"Discontinuation, monitoring, response and outcomes","icon":"route","stages":["stage_5"],"depends_on":["B","C","D"],"status":"queued","wave":3,"progress":0.0,"message":"","questions_total":0,"questions_answered":0,"evidence_count":0,"sources_used":[],"started_at":null,"finished_at":null,"error":""},"F":{"bucket":"F","key":"information-synthesis-agent","name":"Information Synthesis Agent","tagline":"Cross-agent analysis, key insights and gaps","icon":"sparkle","stages":["stage_6"],"depends_on":["A","B","C","D","E"],"status":"queued","wave":4,"progress":0.0,"message":"","questions_total":0,"questions_answered":0,"evidence_count":0,"sources_used":[],"started_at":null,"finished_at":null,"error":""}},"created_at":"2026-09-22T11:08:01.907301Z","started_at":"2026-09-22T11:08:01.981289Z","finished_at":null,"error":"","approved_at":null,"context":{"web_search_notice":"Firecrawl credits are exhausted (402). Web search is off for the rest of this session; questions the registry sources cannot answer stay unanswered. Top up the account and restart to re-enable it.","test_names":["flow cytometry","ECOG performance status","measurable residual disease","minimal residual disease","BCR::ABL1"],"drugs":["6-mercaptopurine","amphotericin B","imatinib"],"subtypes":["Acute lymphoblastic leukemia","Acute lymphocytic leukemia","B-acute lymphoblastic leukemia","B-cell acute lymphoblastic leukemia","T-cell acute lymphoblastic leukemia","Ph-positive ALL","relapsed/refractory acute lymphoblastic leukemia"],"biomarkers":["CD19","CD22","CD79a","CD10"],"regimens":["remission induction therapy","multiagent induction regimens","allogeneic bone marrow transplant","conventional ALL chemotherapy","maintenance therapy","frontline management"],"application_numbers":["ANDA218554","ANDA208857","NDA021588","NDA021986","ANDA217217","ANDA079179","NDA203469","NDA021877"],"set_ids":["03ad6056-0e71-4e7c-842a-a5f87649bdcd","0a273a2d-a1ff-412a-925e-696648730dae","02b04c6f-4ea5-4fcb-bf6d-2631d5ab31e4","0291eca5-7a1d-4a79-30be-252224d96509","0c3a355b-d4cf-42a0-9560-3798e1a2ee36"],"phase_cards_done":["discovery"]},"review_after_wave":1,"resume_from_wave":2,"reviewed_at":null,"rules_status":"not_started","rules_started_at":null,"rules_finished_at":null,"rules_approved_at":null,"rules_error":"","rules_message":"","business_questions":[],"kbq_submitted_at":null},"questions":[{"id":"q_6f442701d567","run_id":"run_2058f031b9db","stage":"stage_1","bucket":"A","text":"In United States patients with acute lymphoblastic leukemia through 2026, what are the standard disease definitions, lineage classifications, and typical natural history patterns relevant to claims-based line-of-therapy cohort construction?","seed_text":"What is the disease definition and natural history of acute lymphoblastic leukemia?","aspects":["WHO/ICC disease classification","B-cell vs T-cell lineage","disease presentation patterns","relapse and progression course","pediatric vs adult disease patterns"],"aspects_from_model":true,"status":"sufficient","coverage_score":0.687,"refinement_rounds":2,"used_web_fallback":true,"sources_attempted":["cdc_wonder","nci","orphanet","seer","who_gho","ashpublications","europepmc","pubmed","cdc_icd10","who","open_web"],"sources_answered":["nci","orphanet","seer","who_gho","ashpublications","europepmc","pubmed","cdc_icd10","who","open_web"],"unmet_reason":"","answer_text":"The supplied documents define acute lymphoblastic leukemia (ALL) as \"A group of rare Non-Hodgkin lymphoma characterized by malignant proliferation of lymphoid cells blocked at an early stage of differentiation\" and note synonymous terminology including \"ALL, Acute lymphoblastic leukemia/lymphoma, Acute lymphocytic leukemia, Precursor lymphoid neoplasm.\" The documents do not provide WHO or ICC disease classification schemas, and they do not explicitly define B-cell versus T-cell lineage classifications. Clinical presentation and natural history information relevant to cohort construction includes that patients \"may present with symptoms, frequently including lymphadenopathy, hepatosplenomegaly, bone pain, fever and signs of hemorrhage or they may remain asymptomatic,\" and that disease can involve marrow, blood, and extranodal tissues because \"the abnormal cells can infiltrate any organ or tissue.\" The documents also describe relapse patterns and age-related treatment differences: adult ALL induction regimens achieve \"complete response rates that range from 60% to 90%\" but \"Responses were short lived, with most of these patients experiencing disease relapse,\" while adolescents and young adults are described as \"a unique population\" in whom \"Treatment regimens can vary significantly depending on whether they receive care in a pediatric or in an adult setting\" and who have \"distinctive care needs, social risk factors, and disease behavior compared with other age groups.\" The supplied document addresses lineage classifications and some relapse/natural history patterns for acute lymphoblastic leukemia (ALL), particularly in adolescents and young adults (AYAs) with relapsed/refractory disease. It specifically distinguishes “B-cell acute lymphoblastic leukemia (B-ALL)” and “T-cell ALL,” and describes relapsed/refractory ALL as involving “greater treatment resistance” and “higher rates of toxicity.” The document also references relapse states including “CNS relapse” and patients who “achieve a second (or greater) remission (CR2).” However, the document does not provide WHO/ICC disease definitions, comprehensive disease presentation patterns, or detailed pediatric-versus-adult epidemiology and natural history needed for claims-based line-of-therapy cohort construction. The supplied document identifies acute lymphocytic leukemia (ALL) epidemiology and age-related disease patterns in the United States through 2026, but it does not provide WHO/ICC disease definitions, lineage classifications such as B-cell versus T-cell ALL, or detailed relapse/progression natural history relevant to claims-based line-of-therapy construction. The document states that \"Acute lymphocytic leukemia is most common in children, adolescents, and young adults, or those 15 to 39 years of age\" and that \"Acute lymphocytic leukemia is most frequently diagnosed among people aged <20,\" which supports pediatric and young adult predominance. It also reports U.S. burden estimates including \"Estimated New Cases in 2026: 6,250\" and \"Estimated Deaths in 2026: 1,600.\" The supplied document only addresses a limited aspect of pediatric acute lymphoblastic leukemia management and does not provide WHO/ICC disease definitions, lineage classifications, relapse patterns, progression course, or pediatric-versus-adult epidemiology relevant to claims-based line-of-therapy cohort construction. The document states that \"Pediatric maintenance therapy for acute lymphoblastic leukemia requires prolonged daily administration of 6-mercaptopurine (6-MP), a drug characterized by a narrow therapeutic index and substantial interindividual variability.\" It also describes that this therapy involves \"prolonged daily administration\" during pediatric maintenance treatment.","answer_status":"partial","answer_citations":["Orphanet","National Cancer Institute","American Society of Hematology","National Cancer Institute, Surveillance, Epidemiology, and End Results Program","AAPS PharmSciTech"],"web_sites":[{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12712861/","title":"Adult Acute Lymphoblastic Leukemia: 2025 Update on Diagnosis ... - PMC","site":"pmc.ncbi.nlm.nih.gov","scraped":true,"used":false},{"url":"https://emedicine.medscape.com/article/207631-overview","title":"Acute Lymphoblastic Leukemia (ALL) - Medscape Reference","site":"emedicine.medscape.com","scraped":true,"used":true},{"url":"https://www.youtube.com/watch?v=kEJ382ZJM8o","title":"Acute Lymphoblastic Leukemia (ALL) Treatment - YouTube","site":"youtube.com","scraped":true,"used":true}],"reviewer_sections":[],"reviewer_sections_dropped":[]},{"id":"q_0207dfec5c74","run_id":"run_2058f031b9db","stage":"stage_1","bucket":"A","text":"In the United States through 2026, what are the incidence, prevalence, survival, and mortality estimates for acute lymphoblastic leukemia overall and by age group and major subtype including B-ALL, T-ALL, and Philadelphia chromosome-positive ALL?","seed_text":"What is the incidence, prevalence, survival and mortality of ALL in the United States, stratified by age group and subtype (B-ALL, T-ALL, Ph-positive)?","aspects":["incidence rates","prevalence estimates","overall and subtype survival","mortality rates","age-stratified epidemiology","subtype distribution"],"aspects_from_model":true,"status":"sufficient","coverage_score":0.764,"refinement_rounds":2,"used_web_fallback":true,"sources_attempted":["cdc_wonder","nci","orphanet","seer","who_gho","ashpublications","europepmc","pubmed","cdc_icd10","who","open_web"],"sources_answered":["nci","orphanet","seer","who_gho","ashpublications","europepmc","pubmed","cdc_icd10","who"],"unmet_reason":"","answer_text":"The supplied documents provide limited U.S. epidemiology and survival information for acute lymphoblastic leukemia (ALL), primarily for pediatric ALL incidence and adult leukemia survival trends, but they do not provide comprehensive U.S. estimates through 2026, prevalence estimates, mortality rates, or subtype-specific epidemiology for B-ALL, T-ALL, and Philadelphia chromosome-positive ALL. One CDC report states that “Acute lymphoblastic leukemia (ALL) is the most prevalent cancer among children and adolescents in the United States” and reported that “Overall incidence of pediatric ALL during 2001–2014 was 34.0 cases per 1 million persons and among all racial/ethnic groups was highest among Hispanics (42.9 per 1 million).” The same report noted that “Both overall and among Hispanics, pediatric ALL incidence increased during 2001–2008 and remained stable during 2008–2014.” A separate population-based survival study stated that “The lifetime risk of developing leukemia in the United States is 1.5%” and that “Five-year net survival was estimated using data for 370,994 patients from 43 registries in 37 states and in 6 metropolitan areas, covering approximately 81% of the adult (15–99 years) US population,” but the excerpt provided does not include ALL-specific survival values. In the United States, SEER reports that “The rate of new cases of acute lymphocytic leukemia was 1.9 per 100,000 men and women per year” and “The death rate was 0.4 per 100,000 men and women per year,” with “Estimated New Cases in 2026: 6,250” and “Estimated Deaths in 2026: 1,600.” SEER also states that “In 2023, there were an estimated 126,118 people living with acute lymphocytic leukemia in the United States” and that “5-YearRelative Survival: 73.2% (2016–2022).” Age-related epidemiology is described as follows: “Acute lymphocytic leukemia is most common in children, adolescents, and young adults, or those 15 to 39 years of age,” “Acute lymphocytic leukemia is most frequently diagnosed among people aged <20,” and Orphanet reports that “The peak incidence occurs between 2 and 5 years of age.” The supplied documents do not provide U.S. incidence, prevalence, survival, mortality, or subtype distribution estimates specifically for B-ALL, T-ALL, or Philadelphia chromosome-positive ALL. The supplied document provides childhood lymphoid leukaemia 5-year net survival estimates for multiple countries in 2021, but it does not provide United States-specific incidence, prevalence, mortality, subtype distribution, or subtype-specific epidemiology for acute lymphoblastic leukemia (ALL), including B-ALL, T-ALL, or Philadelphia chromosome-positive ALL. The document reports that childhood cancer survival for lymphoid leukaemia reached high levels in several countries, including “GBR 2021 AGEGROUP_YEARSLESS20 = 92.5 [90.2-94.3]”, “DEU 2021 AGEGROUP_YEARSLESS20 = 90.6 [87.1-93.2]”, and “DNK 2021 AGEGROUP_YEARSLESS20 = 92.2 [88.3-94.8]”. No data through 2026 for the United States are included. The supplied document does not provide numerical estimates for incidence, prevalence, survival, or mortality of acute lymphoblastic leukemia (ALL) in the United States through 2026, nor does it provide subtype-specific epidemiology for B-ALL, T-ALL, or Philadelphia chromosome-positive ALL. The document does identify adolescents and young adults (AYAs) as a distinct population with differing disease behavior and treatment settings, and it references major ALL subtypes including B-cell and T-cell ALL. It also states that pediatric-inspired frontline regimens are recommended for AYAs with B-ALL or T-ALL.","answer_status":"partial","answer_citations":["CDC / NCHS","National Cancer Institute, Surveillance, Epidemiology, and End Results Program","Orphanet","World Health Organization","American Society of Hematology"],"web_sites":[{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12712861/","title":"Adult Acute Lymphoblastic Leukemia: 2025 Update on Diagnosis ... - PMC","site":"pmc.ncbi.nlm.nih.gov","scraped":true,"used":false},{"url":"https://www.shebaonline.org/kn-base/acute-lymphoblastic-leukemia-survival-rate/","title":"Acute Lymphoblastic Leukemia Survival Rate by Age & Type","site":"shebaonline.org","scraped":true,"used":false},{"url":"https://emedicine.medscape.com/article/207631-overview","title":"Acute Lymphoblastic Leukemia (ALL) - Medscape Reference","site":"emedicine.medscape.com","scraped":true,"used":false}],"reviewer_sections":[],"reviewer_sections_dropped":[]},{"id":"q_f38fdd338919","run_id":"run_2058f031b9db","stage":"stage_1","bucket":"A","text":"In United States patients with acute lymphoblastic leukemia through 2026, which immunophenotypic, cytogenetic, and molecular subtypes are clinically important for diagnosis, prognosis, and treatment cohort definition in claims-based analyses?","seed_text":"What are the clinically important immunophenotypic and molecular subtypes of ALL?","aspects":["immunophenotypic subtypes","cytogenetic abnormalities","molecular alterations","Philadelphia chromosome status","prognostic subtype groups","targetable biomarkers"],"aspects_from_model":true,"status":"sufficient","coverage_score":0.654,"refinement_rounds":2,"used_web_fallback":true,"sources_attempted":["cdc_wonder","nci","orphanet","seer","who_gho","ashpublications","europepmc","pubmed","cdc_icd10","who","open_web"],"sources_answered":["nci","orphanet","seer","who_gho","ashpublications","europepmc","pubmed","cdc_icd10","who","open_web"],"unmet_reason":"","answer_text":"The supplied documents identify acute lymphoblastic leukemia (ALL) broadly as “a group of rare Non-Hodgkin lymphoma characterized by malignant proliferation of lymphoid cells blocked at an early stage of differentiation,” but they do not provide a comprehensive listing of immunophenotypic, cytogenetic, molecular, Philadelphia chromosome, prognostic, or biomarker-defined ALL subtypes for claims-based cohort definition. The relapsed/refractory ASH guideline specifically references “ALL subsets (T-cell ALL)” and discusses “immunotherapy” and “targeted therapies,” while the frontline guideline states that “higher-risk subsets” and “targeted agents” are clinically relevant in management decisions. No explicit cytogenetic abnormalities, molecular alterations, Philadelphia chromosome-positive/negative categories, or named targetable biomarkers are enumerated in the provided documents. The supplied document identifies Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph-positive ALL) as a clinically important molecular/cytogenetic subtype in adult ALL treatment. It states that “inclusion of imatinib into a relatively standard chemotherapy regimen for newly diagnosed adult patients with Ph-positive ALL may provide a significant survival advantage,” and that “Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.” The document also notes prognostic implications for this subtype, stating that “remissions are generally short with conventional ALL chemotherapy clinical trials.” The document does not provide additional immunophenotypic subtypes, broader cytogenetic or molecular alteration categories, prognostic subtype groups, or other targetable biomarkers. The supplied document identifies clinically relevant immunophenotypic subtypes of acute lymphoblastic leukemia (ALL), specifically B-cell ALL and T-cell ALL, and describes marker-defined lineage assignment by flow cytometry. B-ALL was characterized by expression of \"pan B-cell markers (CD19,CD22 and cytoplasmic CD79a)\" with many cases expressing CD10, while T-ALL was characterized by \"cytoplasmic CD3 and CD5.\" The document also notes aberrant myeloid marker expression in some B-ALL cases and describes immunophenotyping as important for \"diagnosis, accurate classification, subtyping and treatment programs.\" However, the document does not provide a comprehensive description of clinically important cytogenetic abnormalities, molecular alterations, Philadelphia chromosome status, prognostic subtype groups, or targetable biomarkers for U.S. ALL patients through 2026. The documents identify clinically important immunophenotypic ALL subtypes including B-cell and T-cell categories. One source states that the WHO system recognizes “Precursor B cell ALL,” “Precursor T cell ALL,” and “Mature B cell ALL (Burkitt type ALL),” while another notes that “the only subtype recognized by the World Health Organization’s International Consensus Classification is early T-cell precursor ALL.” The materials also identify Philadelphia chromosome-related disease biology, including “Philadelphia chromosome-like ALL (Ph-like ALL)” as “a precursor B-cell ALL that results in a change of the chromosomes on the leukemia cells.” Cytogenetic and molecular characterization is described broadly through “genomic subtypes,” “whole transcriptome, exome, or genome sequencing,” “immunophenotyping and cytogenetic testing,” and “specific genomic alterations,” but the supplied documents do not provide a complete enumeration of clinically important cytogenetic abnormalities, molecular alterations, prognostic subtype groups, or targetable biomarkers through 2026.","answer_status":"partial","answer_citations":["Orphanet","American Society of Hematology","National Cancer Institute","WHO","Open web"],"web_sites":[{"url":"https://www.nature.com/articles/s41375-025-02599-2","title":"T-cell acute lymphoblastic leukaemia: subtype prevalence, clinical ...","site":"nature.com","scraped":true,"used":false},{"url":"https://www.kucancercenter.org/news-room/blog/2020/10/what-you-should-know-acute-lymphoblastic-leukemia","title":"What You Should Know About Acute Lymphoblastic Leukemia ‌","site":"kucancercenter.org","scraped":true,"used":true},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10646822/","title":"International Consensus Classification of Acute Lymphoblastic Leukemia ...","site":"pmc.ncbi.nlm.nih.gov","scraped":true,"used":false}],"reviewer_sections":[],"reviewer_sections_dropped":[]},{"id":"q_0b2efc095c4f","run_id":"run_2058f031b9db","stage":"stage_1","bucket":"A","text":"In United States clinical practice through 2026, what diagnostic criteria and confirmatory workup are used to establish acute lymphoblastic leukemia diagnosis and subtype classification for treatment initiation and claims cohort identification?","seed_text":"How is ALL diagnosed and what confirmatory workup is required?","aspects":["bone marrow evaluation","flow cytometry","cytogenetic testing","molecular diagnostics","imaging and CNS assessment","laboratory workup"],"aspects_from_model":true,"status":"sufficient","coverage_score":0.794,"refinement_rounds":2,"used_web_fallback":true,"sources_attempted":["cdc_wonder","nci","orphanet","seer","who_gho","ashpublications","europepmc","pubmed","cdc_icd10","who","open_web"],"sources_answered":["nci","orphanet","seer","who_gho","ashpublications","europepmc","pubmed","cdc_icd10","who","open_web"],"unmet_reason":"","answer_text":"The supplied document identifies acute lymphoblastic leukemia (ALL) as \"a group of rare Non-Hodgkin lymphoma characterized by malignant proliferation of lymphoid cells blocked at an early stage of differentiation\" and states that it \"primarily affects the bone marrow and peripheral blood.\" It also notes that \"the abnormal cells can infiltrate any organ or tissue\" and describes common presenting features including \"lymphadenopathy, hepatosplenomegaly, bone pain, fever and signs of hemorrhage.\" However, the documents do not provide diagnostic criteria or confirmatory workup details such as bone marrow evaluation methods, flow cytometry, cytogenetic testing, molecular diagnostics, imaging/CNS assessment, or laboratory testing used for subtype classification, treatment initiation, or claims cohort identification. The supplied document is a frontline management guideline for adolescents and young adults with acute lymphoblastic leukemia and does not describe detailed diagnostic criteria or confirmatory diagnostic workup for establishing ALL diagnosis or subtype classification. The document identifies disease categories relevant to treatment initiation, including “B-cell or T-cell acute lymphoblastic leukemia (B-ALL/T-ALL) or T-cell acute lymphoblastic lymphoma (T-LBL/LLy),” and discusses frontline therapy recommendations and therapeutic drug monitoring for asparaginase management. The document does not provide specific recommendations or criteria regarding bone marrow evaluation, flow cytometry, cytogenetic testing, molecular diagnostics, imaging, CNS assessment, or laboratory diagnostic workup. The supplied document concerns management recommendations for relapsed/refractory acute lymphoblastic leukemia (ALL) in adolescents and young adults and does not describe the diagnostic criteria or confirmatory workup used to establish ALL diagnosis and subtype classification. The document references disease subsets and central nervous system (CNS)-directed therapy but does not provide details on bone marrow evaluation, flow cytometry, cytogenetic testing, molecular diagnostics, imaging/CNS assessment methods, or laboratory workup for treatment initiation or claims cohort identification. The supplied document discusses remission induction therapy for adult acute lymphoblastic leukemia (ALL) and mentions treatment considerations for newly diagnosed and Philadelphia chromosome–positive ALL, but it does not describe the diagnostic criteria or confirmatory diagnostic workup used to establish ALL diagnosis or subtype classification. The document does not provide information on bone marrow evaluation, flow cytometry, cytogenetic testing, molecular diagnostics, imaging or CNS assessment, or laboratory workup for treatment initiation or claims cohort identification. The supplied documents indicate that NCCN Guidelines through 2026 address acute lymphoblastic leukemia (ALL) diagnosis and classification with emphasis on subtype classification using immunophenotype and cytogenetic/molecular markers, as well as risk assessment and treatment strategies. However, the documents provided do not contain the detailed diagnostic criteria or confirmatory workup elements requested, such as specific bone marrow evaluation parameters, flow cytometry panels, cytogenetic assays, molecular diagnostics, CNS/imaging assessment, or laboratory workup protocols for treatment initiation or claims cohort identification.","answer_status":"partial","answer_citations":["Orphanet","American Society of Hematology","National Cancer Institute","Open web"],"web_sites":[{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1489.","title":"Acute Lymphoblastic Leukemia - Guidelines Detail - nccn.org","site":"nccn.org","scraped":true,"used":true},{"url":"https://www.nccn.org/patients/guidelines/content/PDF/all-patient.pdf","title":"NCCN Guidelines for Patients: Acute Lymphoblastic Leukemia","site":"nccn.org","scraped":true,"used":false},{"url":"https://jnccn.org/view/journals/jnccn/22/8/article-p563.xml","title":"Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice ...","site":"jnccn.org","scraped":true,"used":true}],"reviewer_sections":[],"reviewer_sections_dropped":[]},{"id":"q_9df80b42710c","run_id":"run_2058f031b9db","stage":"stage_1","bucket":"A","text":"In United States patients with newly diagnosed acute lymphoblastic leukemia through 2026, how is risk stratification performed at diagnosis and which demographic and clinical characteristics define treatment eligibility and cohort segmentation for claims-based line-of-therapy analyses?","seed_text":"How is ALL risk-stratified at diagnosis, and which patient characteristics drive cohort segmentation and treatment eligibility (age, comorbidity, performance status, organ function)?","aspects":["risk stratification systems","age-based eligibility","performance status","comorbidity burden","organ function criteria","minimal residual disease status"],"aspects_from_model":true,"status":"sufficient","coverage_score":0.621,"refinement_rounds":2,"used_web_fallback":true,"sources_attempted":["cdc_wonder","nci","orphanet","seer","who_gho","ashpublications","europepmc","pubmed","open_web"],"sources_answered":["nci","orphanet","seer","who_gho","ashpublications","europepmc","pubmed","open_web"],"unmet_reason":"","answer_text":"The supplied document discusses treatment approaches for newly diagnosed adult acute lymphoblastic leukemia (ALL), including distinctions for Philadelphia chromosome (Ph)-positive disease, but it does not describe formal risk stratification systems, claims-based cohort segmentation methods, age-based eligibility thresholds, performance status criteria, comorbidity burden measures, organ function criteria, or minimal residual disease (MRD) status definitions. The document states that “Most current induction regimens for patients with adult ALL include combination chemotherapy with prednisone, vincristine, and an anthracycline” and that “Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.” It also notes that “If a suitable donor is available, allogeneic bone marrow transplant should be considered because remissions are generally short with conventional ALL chemotherapy clinical trials.” The supplied documents describe adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) as a distinct population and note that frontline treatment decisions differ between pediatric and adult treatment settings. They also state that allogeneic hematopoietic stem cell transplantation in first remission “may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy,” implying some form of risk stratification and response assessment. However, the documents do not specify the diagnostic risk stratification systems, claims-based cohort segmentation methods, age cutoffs for treatment eligibility, performance status criteria, comorbidity burden measures, organ function requirements, or minimal residual disease (MRD) definitions used in United States patients through 2026. The supplied documents indicate that NCCN guidelines for acute lymphoblastic leukemia (ALL) through 2026 emphasize “classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers” and “risk assessment and stratification for risk-adapted therapy.” The documents also specify that treatment strategies are differentiated for “Philadelphia chromosome (Ph)-positive and Ph ...” disease categories. However, the provided materials do not describe the detailed risk stratification systems, age-based eligibility thresholds, performance status criteria, comorbidity burden measures, organ function requirements, minimal residual disease criteria, or the demographic and clinical cohort segmentation variables used in claims-based line-of-therapy analyses.","answer_status":"partial","answer_citations":["National Cancer Institute","American Society of Hematology","Orphanet","Open web"],"web_sites":[{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1489.","title":"Acute Lymphoblastic Leukemia - Guidelines Detail - nccn.org","site":"nccn.org","scraped":true,"used":true},{"url":"https://www.sciencedirect.com/science/article/pii/S1532046419302540","title":"Temporal phenotyping by mining healthcare data to derive lines of ...","site":"sciencedirect.com","scraped":true,"used":true},{"url":"https://jnccn.org/view/journals/jnccn/22/8/article-p563.xml","title":"Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice ...","site":"jnccn.org","scraped":true,"used":true}],"reviewer_sections":[],"reviewer_sections_dropped":[]},{"id":"q_bf36e105dc68","run_id":"run_2058f031b9db","stage":"stage_2","bucket":"C","text":"As of 2026-09-22 in the United States, what first-line treatment regimens are recommended by major clinical guidelines for acute lymphoblastic leukemia across induction, consolidation, maintenance, and MRD-positive settings, stratified by guideline preference category and relevant disease subtype or patient segment for all patients?","seed_text":"What are the current guideline-recommended first-line regimens for ALL, by treatment setting (induction, consolidation, maintenance, MRD-positive) and guideline preference category (e.g., NCCN Preferred / Other Recommended / Useful in Certain Circumstances)?","aspects":["guideline bodies","guideline versions","first-line regimens","treatment settings","preference categories","risk or biomarker stratification"],"aspects_from_model":true,"status":"sufficient","coverage_score":0.801,"refinement_rounds":2,"used_web_fallback":true,"sources_attempted":["dailymed","esmo","nci","openfda_drugsfda","openfda_label","asco","ashpublications","clinicaltrials","fda","open_web"],"sources_answered":["dailymed","esmo","nci","openfda_drugsfda","openfda_label","asco","ashpublications","clinicaltrials","fda","open_web"],"unmet_reason":"","answer_text":"The supplied documents do not provide a comprehensive list of United States first-line treatment regimens for acute lymphoblastic leukemia across induction, consolidation, maintenance, and MRD-positive settings stratified by guideline preference categories. The documents do identify some guideline or cooperative-group treatment approaches and disease subsets. An ASCO Educational Book review states that “Contemporary COG HR ALL treatment regimens were developed from the BFM-76 regimen, with subsequent changes that led to development and refinement of a so-called augmented BFM (ABFM) regimen used today,” and notes that “introduction of the tyrosine kinase inhibitor imatinib has led to dramatic outcome improvements for children and adolescents with Philadelphia chromosome–positive ALL.” A pediatric maintenance-focused recommendation document from the French Society for Childhood and Adolescent Cancer and Leukemia states that “Maintenance therapy is the last phase of treatment for acute lymphoblastic leukemia in children and adolescents” and that it “is an essential phase of treatment that reduces the risk of relapse.” An ASH 2026 guideline document addresses relapsed/refractory AYA ALL rather than first-line disease, reporting that “Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction.” The supplied documents identify two major guideline bodies relevant to frontline acute lymphoblastic leukemia (ALL) management in the United States as of 2025–2026: the NCCN and the American Society of Hematology (ASH). The NCCN Pediatric ALL Version 2.2025 guideline states that it addresses “risk assessment and stratification of risk-adapted therapy” and includes “treatment strategies for BCR::ABL1 (Philadelphia chromosome [Ph])-negative and BCR::ABL1-positive B-cell lineage, T-cell lineage, and infant ALL,” but the supplied text does not provide specific first-line induction, consolidation, maintenance, or MRD-positive regimens, nor preference categories. The ASH 2026 AYA ALL guideline states that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols,” that “Allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy,” and that “The use of targeted agents in frontline therapy is increasingly supported,” but the supplied excerpts do not enumerate regimen names, treatment phases, MRD-directed regimens, or formal preference categories. The supplied documents do not provide a comprehensive list of U.S. major clinical guideline recommendations, versions, preference categories, or complete first-line regimens across induction, consolidation, maintenance, and MRD-positive settings for acute lymphoblastic leukemia. The documents only describe selected induction-treatment concepts and asparaginase-related recommendations for specific populations. For adult ALL induction, the NCI PDQ document states that \"Most current induction regimens for patients with adult ALL include combination chemotherapy with prednisone, vincristine, and an anthracycline,\" and that some regimens \"also add other drugs, such as asparaginase or cyclophosphamide.\" For Ph-positive ALL, the same document states that \"Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL.\" Separate consensus-panel documents for adolescent and young adult patients state that \"Asparaginase is an integral component of therapy for pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma\" and describe use of \"pediatric/pediatric-inspired regimens incorporating asparaginase for treating adolescent and young adult (AYA) and adult populations.\" The supplied documents do not provide a complete accounting of U.S. first-line treatment regimens for acute lymphoblastic leukemia across induction, consolidation, maintenance, and MRD-positive settings by guideline preference category. The documents only identify limited guideline-related statements. One document states that \"guidelines from the National Comprehensive Cancer Network now recommend consideration of pediatric inspired treatment\" for adolescent and young adult patients with ALL. Another document describes the \"American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults,\" which \"cover[] remission reinduction and consolidation\" and include recommendations such as \"the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction.\" The documents do not provide the requested full stratification by induction, consolidation, maintenance, MRD-positive settings, preference categories, or comprehensive disease subtype segmentation for all patients. The supplied documents do not provide a comprehensive set of major U.S. clinical guideline recommendations for first-line acute lymphoblastic leukemia treatment across induction, consolidation, maintenance, and MRD-positive settings stratified by guideline preference categories. One FDA document describes a regimen used with ponatinib for newly diagnosed Philadelphia chromosome-positive ALL in adults: “Chemotherapy consisted of 3 cycles of induction with vincristine and dexamethasone, 6 cycles of consolidation alternating between methotrexate and cytarabine, and 11 cycles of maintenance with vincristine and prednisone.” The pediatric evidence-based review documents state that “allogeneic SCT may be considered for hypodiploid ALL and persistent minimal residual disease [corrected] (MRD) positivity in ALL in CR1 or greater,” and also note that “preliminary tyrosine kinase inhibitor (TKI) data demonstrate that early outcomes are comparable for allogeneic SCT and chemotherapy + imatinib” for children with Ph+ ALL in CR1. The supplied documents identify NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia and pediatric acute lymphoblastic leukemia, including risk-stratified and frontline management concepts, but they do not provide the specific first-line treatment regimens, induction/consolidation/maintenance protocols, MRD-positive regimens, or preference categories requested. The adult ALL NCCN guideline documents state that they provide \"risk-stratified treatment approaches based on the Philadelphia chromosome status and age (adults vs. adolescents/young adults), assessment of minimal residual disease,\" while the pediatric guideline states that it \"focuses on the frontline and relapsed/refractory management of pediatric ALL.\" The pediatric guideline also identifies high-risk groups including \"T-ALL\" and \"infant ALL.\" No guideline version dated 2026-09-22, no regimen names, and no recommendation categories are present in the supplied text. The supplied documents identify NCCN Clinical Practice Guidelines as major U.S. clinical guidelines for acute lymphoblastic leukemia (ALL), including adult ALL Version 2.2024 and Pediatric ALL Version 2.2025. The documents state that these guidelines cover “risk assessment and stratification for risk-adapted therapy” and “treatment strategies” for multiple disease subtypes and patient groups, including “Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients” and pediatric “BCR::ABL1-positive B-cell lineage, T-cell lineage, and infant ALL.” However, the documents provided do not include the actual first-line treatment regimens, induction/consolidation/maintenance recommendations, MRD-positive recommendations, or preference categories requested in the question. The supplied documents identify the National Comprehensive Cancer Network (NCCN) pediatric and adult acute lymphoblastic leukemia (ALL) guidelines and state that they provide treatment recommendations for frontline and relapsed/refractory management, but they do not provide the specific first-line treatment regimens across induction, consolidation, maintenance, or MRD-positive settings requested in the question. The documents also do not provide guideline preference categories, detailed subtype-specific regimen recommendations, or risk/biomarker-stratified first-line regimen tables. One document specifies \"Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology,\" while another specifies \"NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017.\" The supplied documents identify guideline bodies and some treatment-structure and stratification concepts for acute lymphoblastic leukemia (ALL), but they do not provide a complete list of first-line treatment regimens across induction, consolidation, maintenance, and MRD-positive settings stratified by guideline preference category. The Medscape summary updated March 17, 2026 states that ALL therapy includes “an induction phase with a goal of achieving complete remission (CR)” followed by “a consolidation phase to maintain CR,” and that follow-up is “with maintenance therapy or allogeneic hematopoietic stem cell transplantation (HSCT).” It also states that treatment decisions may be influenced by “Philadelphia chromosome (Ph)(BCR::ABL1) status,” “Presence of CD20-positive disease,” “Cell origin (B-cell vs T-cell),” and “Minimal residual disease (MRD) status.” The ASH document identifies itself as the “American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults,” but the supplied text does not include the specific frontline regimens, recommendation strengths, or preference categories requested.","answer_status":"partial","answer_citations":["American Society of Clinical Oncology Educational Book","Bulletin du cancer","Blood advances","Journal of the National Comprehensive Cancer Network : JNCCN","National Cancer Institute","American journal of hematology","Journal of Clinical Oncology","American Society of Hematology","FDA","Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation","Open web"],"web_sites":[{"url":"https://emedicine.medscape.com/article/2004705-overview","title":"Acute Lymphoblastic Leukemia (ALL) Treatment Protocols","site":"emedicine.medscape.com","scraped":true,"used":true},{"url":"https://ashpublications.org/bloodadvances/article/10/13/4671/566561/American-Society-of-Hematology-2026-guidelines-for","title":"American Society of Hematology 2026 guidelines for frontline ...","site":"ashpublications.org","scraped":true,"used":false},{"url":"https://www.cancer.org/cancer/types/acute-lymphocytic-leukemia/treating/typical-treatment.html","title":"Typical Treatment of Acute Lymphocytic Leukemia (ALL)","site":"cancer.org","scraped":true,"used":false}],"reviewer_sections":[],"reviewer_sections_dropped":[]},{"id":"q_a687f9ed49c6","run_id":"run_2058f031b9db","stage":"stage_2","bucket":"C","text":"As of 2026-09-22 in the United States, what regimens are recommended by major clinical guidelines for relapsed, refractory, and later-line acute lymphoblastic leukemia, organized by treatment setting, line of therapy, and guideline preference category for all patients?","seed_text":"What are the guideline-recommended regimens for later-line, relapsed, or refractory ALL, by treatment setting and guideline preference category?","aspects":["relapsed or refractory settings","later-line regimens","line of therapy","guideline preference categories","disease subtype stratification","cellular and transplant therapies"],"aspects_from_model":true,"status":"sufficient","coverage_score":0.725,"refinement_rounds":2,"used_web_fallback":true,"sources_attempted":["dailymed","esmo","nci","openfda_drugsfda","openfda_label","asco","ashpublications","clinicaltrials","open_web"],"sources_answered":["dailymed","esmo","nci","openfda_drugsfda","openfda_label","asco","ashpublications","clinicaltrials","open_web"],"unmet_reason":"","answer_text":"The supplied documents discuss recommendations for relapsed/refractory acute lymphoblastic leukemia (ALL), including immunotherapy, targeted therapy, transplantation, and CNS-directed therapy, but they do not provide a complete regimen-by-regimen listing organized by treatment setting, line of therapy, and guideline preference category for all patients in the United States as of 2026-09-22. The ASH 2026 guideline for adolescents and young adults (AYAs) states that recommendations \"focused on the following treatment modalities: immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy\" and that \"Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction.\" The NCCN Guidelines Insights document states that recommendations for relapsed/refractory ALL include \"more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation,\" but the provided text does not enumerate specific preferred regimens, later-line sequences, or preference categories. The supplied documents do not provide a complete listing of U.S. guideline-recommended regimens for relapsed, refractory, and later-line acute lymphoblastic leukemia organized by treatment setting, line of therapy, and guideline preference category. The NCCN documents only state that the guidelines include “treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients,” but the excerpts provided specifically note that the selection “focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence.” The ASH 2026 guideline document specifically addresses “management of relapsed/refractory ALL in adolescents and young adults” and states that “Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction,” while also addressing “T-cell ALL,” “CNS relapse,” and “the role of consolidation with allogeneic transplant.” The documents do not provide the full regimen tables, later-line sequencing, or NCCN preference categories requested. The supplied documents do not provide major clinical guideline recommendations organized by treatment setting, line of therapy, preference category, disease subtype, or transplant/cellular therapy pathways for relapsed, refractory, and later-line acute lymphoblastic leukemia in the United States as of 2026-09-22. The documents only identify selected therapies and populations in relapsed/refractory ALL, including clofarabine for pediatric patients after at least two prior regimens and references to studies involving blinatumomab and inotuzumab ozogamicin in relapsed/refractory adult ALL. One document states that clofarabine \"is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.\" Another document references \"adult patients with relapsed or refractory acute lymphoblastic leukemia receiving zero or one prior salvage therapy,\" and another references \"Relapsed/Refractory Philadelphia Chromosome–Negative B-Cell Acute Lymphoblastic Leukemia.\" The supplied documents do not provide major United States clinical guideline recommendations, preference categories, or organized line-of-therapy tables for relapsed, refractory, or later-line acute lymphoblastic leukemia as of 2026-09-22. The documents do describe investigational and salvage approaches in relapsed/refractory ALL settings, including venetoclax-based regimens in relapsed/refractory T-ALL/LBL, CD7 CAR-T therapy in relapsed/refractory T-ALL/LBL, and comparisons between CAR-T therapy and allogeneic HSCT in relapsed/refractory B-ALL. Reported treatment approaches include “Ven monotherapy,” “Ven + hypomethylating agent,” “Ven + chemotherapy,” “Ven + nelarabine,” “Ven + targeted agent,” and “Ven + navitoclax” for heavily pre-treated relapsed/refractory T-ALL/LBL patients, while cellular and transplant therapies discussed include “autologous CD7 CAR T-cell therapy,” “stem cell transplantation (SCT),” “Allogenic Hematopoietic Stem Cell Transplantation (HSCT),” and “CAR-T Cell Therapy.” The supplied document discusses relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) in children, adolescents, and young adults in the context of CAR-T-cell therapy and bridging therapy, but it does not provide a comprehensive list of United States major clinical guideline regimens by treatment setting, line of therapy, or preference category. It states that \"there is currently no available guidelines\" for the bridging period before CAR-T-cell reinfusion and describes an effort to \"define recommendations of treatment in each situation of relapsed or refractory B-ALL, Ph+/ABL-like B-ALL and in case of CNS disease or non-CNS extra medullary disease, precising the specific place of immunotherapy.\" The document also identifies CAR-T cells as a major therapeutic modality in relapsed/refractory B-ALL and references disease subtype stratification including \"Ph+/ABL-like B-ALL\" and CNS versus non-CNS extramedullary disease. The supplied documents identify that NCCN guidelines for acute lymphoblastic leukemia (ALL) include recommendations for “risk-stratified treatment approaches based on the Philadelphia chromosome status and age (adults vs. adolescents/young adults),” and that pediatric NCCN guidelines address “frontline and relapsed/refractory management of pediatric ALL,” including “hematopoietic stem cell transplantation.” However, the documents provided do not list specific relapsed, refractory, or later-line regimens, do not provide line-of-therapy tables, do not identify guideline preference categories, and do not specify cellular therapy regimens or transplant sequencing recommendations. One document also identifies the topic of “Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults: Progress and Challenges,” but provides no regimen-level recommendations in the supplied text. The supplied document does not provide major clinical guideline recommendations for relapsed, refractory, or later-line acute lymphoblastic leukemia (ALL), including treatment setting, line of therapy, guideline preference categories, disease subtype stratification, or cellular therapies. It does contain limited statements relevant to transplantation and Philadelphia chromosome (Ph)-positive ALL in the context of remission duration and treatment considerations. Specifically, the document states that “Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials” and that “If a suitable donor is available, allogeneic bone marrow transplant should be considered because remissions are generally short with conventional ALL chemotherapy clinical trials.” The supplied documents do not contain major clinical guideline recommendations, preference categories, treatment-setting organization, transplant guidance, or cellular therapy recommendations for relapsed, refractory, or later-line acute lymphoblastic leukemia. The documents only provide FDA labeling indications for specific agents in relapsed or refractory ALL/T-ALL settings after at least two prior regimens. Nelarabine is indicated for \"T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL)\" in patients \"whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.\" Clofarabine is indicated for \"pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.\" The supplied documents identify that NCCN Clinical Practice Guidelines for acute lymphoblastic leukemia (ALL) include recommendations on “risk-stratified treatment approaches based on the Philadelphia chromosome status and age (adults vs. adolescents/young adults)” and that pediatric ALL guidelines address “treatment strategies for BCR::ABL1 (Philadelphia chromosome [Ph])-negative and BCR::ABL1-positive B-cell lineage, T-cell lineage, and infant ALL.” The documents also state that the pediatric guidelines focus on “the diagnosis of and management of pediatric T-ALL.” However, the supplied excerpts do not provide the requested relapsed/refractory or later-line regimens, line-of-therapy recommendations, preference categories, cellular therapies, or transplant recommendations. The supplied documents identify that NCCN maintains \"NCCN Guidelines Version 3.2026 - Acute Lymphoblastic Leukemia\" and \"NCCN Guidelines with Evidence Blocks Version 2.2026,\" but they do not provide the actual recommended regimens, treatment settings, lines of therapy, preference categories, subtype stratification, or cellular/transplant therapy recommendations requested. One supplementary document mentions blinatumomab in \"chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients,\" but no organized guideline recommendations for relapsed, refractory, or later-line ALL are included in the provided text.","answer_status":"partial","answer_citations":["American Society of Hematology","Journal of the National Comprehensive Cancer Network : JNCCN","Blood advances","Dr.Reddy's Laboratories Inc","Journal of Clinical Oncology","JCO Precision Oncology","Bulletin du cancer","JCO Oncology Practice","National Cancer Institute","Alembic Pharmaceuticals Limited","Amneal Pharmaceuticals LLC","US Food and Drug Administration","Open web"],"web_sites":[{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1489.","title":"Acute Lymphoblastic Leukemia - Guidelines Detail - nccn.org","site":"nccn.org","scraped":true,"used":true},{"url":"https://www.annalsofoncology.org/article/S0923-7534%2823%2904009-7/fulltext","title":"ESMO Clinical Practice Guideline interim update on the use of targeted ...","site":"annalsofoncology.org","scraped":true,"used":false},{"url":"https://www.nccn.org/patients/guidelines/content/PDF/all-patient.pdf","title":"NCCN Guidelines for Patients: Acute Lymphoblastic Leukemia","site":"nccn.org","scraped":true,"used":false}],"reviewer_sections":[],"reviewer_sections_dropped":[]},{"id":"q_2bee5da1afa0","run_id":"run_2058f031b9db","stage":"stage_2","bucket":"C","text":"As of 2026-09-22 in the United States, which drugs, biologics, and cellular therapies have FDA or other official regulatory approval for acute lymphoblastic leukemia, including labeled indication, approved treatment line, biomarker restriction, approval date, and coding identifiers for all patients?","seed_text":"Which therapies are FDA-approved (or otherwise officially approved) for ALL, with label indication, approved line, biomarker restriction, and approval date?","aspects":["approved products","label indications","approved treatment lines","biomarker restrictions","approval dates","billing or product codes"],"aspects_from_model":true,"status":"sufficient","coverage_score":0.531,"refinement_rounds":1,"used_web_fallback":false,"sources_attempted":["dailymed","esmo","nci","openfda_drugsfda","openfda_label","asco","ashpublications","clinicaltrials"],"sources_answered":["dailymed","esmo","nci","openfda_drugsfda","openfda_label","asco","ashpublications","clinicaltrials"],"unmet_reason":"","answer_text":"The supplied documents identify three FDA-approved drug products for acute lymphoblastic leukemia (ALL): clofarabine, imatinib mesylate, and dasatinib. Clofarabine injection is indicated for “pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens,” with “Initial U.S. Approval: 2004.” Imatinib mesylate is indicated for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)” and for “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy,” with “Initial U.S. Approval: 2001.” Dasatinib tablets are indicated for “Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy” in adults and for “pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy,” with “Initial U.S. Approval: 2006.” The documents provide biomarker restrictions through the requirement for “Philadelphia chromosome-positive (Ph+)” disease where applicable, but they do not provide billing codes, HCPCS codes, NDC-based coding summaries, biologics approvals, or cellular therapy approvals for ALL. The supplied documents identify several FDA-approved therapies for acute lymphoblastic leukemia (ALL) in the United States, but they do not provide comprehensive coverage of all approved drugs, biologics, cellular therapies, or billing/product coding identifiers. SPRYCEL (dasatinib) is indicated for “adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy,” establishing a biomarker restriction of Ph+ status and a relapsed/refractory treatment setting; the label also states “Initial U.S. Approval: 2006.” Imatinib mesylate is indicated for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)” and for “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy,” again restricting use to Ph+ ALL. ARRANON (nelarabine) appears in the FDA Drugs@FDA record with “ORIG 1 AP 2005-10-28,” but the provided text does not include the ALL indication, treatment line, biomarker restriction, or coding identifiers. The supplied documents identify FDA-approved treatments for acute lymphoblastic leukemia including nelarabine and clofarabine, but they do not provide a complete list of all approved drugs, biologics, or cellular therapies in the United States as of 2026-09-22, and they do not provide billing or product coding identifiers. Nelarabine injection received \"Initial U.S. Approval: 2005\" and is indicated for \"T-cell acute lymphoblastic leukemia (T-ALL)\" in \"adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens,\" establishing a relapsed/refractory setting after at least two prior regimens and a biomarker/disease restriction to T-cell ALL. Clofarabine injection received \"Initial U.S. Approval: 2004\" and is indicated for \"pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens,\" defining a pediatric relapsed/refractory treatment line after at least two prior regimens without an additional biomarker restriction stated in the supplied text. The supplied document discusses hematopoietic stem cell transplantation recommendations in pediatric acute lymphoblastic leukemia (ALL), including certain disease settings and biomarkers such as Philadelphia chromosome positive (Ph+) ALL, but it does not provide FDA or other regulatory approvals, approval dates, labeled indications, treatment lines in regulatory labeling, or billing/product coding identifiers for drugs, biologics, or cellular therapies in the United States. The document states that “Allogeneic SCT is recommended for children who: are in second complete remission (CR2) after experiencing an early marrow relapse for precursor-B ALL; experienced primary induction failure, but subsequently achieved a CR1; have T-lineage ALL in CR2; or have ALL in third or greater remission.” It also notes that “the 2005 pediatric ALL evidence-based review (EBR) recommended allogeneic SCT for children with Philadelphia chromosome positive (Ph+) ALL in CR1,” and references “chemotherapy + imatinib,” but no regulatory approval details are given. The supplied documents do not provide a comprehensive list of FDA- or regulator-approved drugs, biologics, or cellular therapies for acute lymphoblastic leukemia, nor do they provide approval dates or billing/product coding identifiers. The documents do identify certain therapies discussed in guideline contexts for relapsed/refractory ALL, including “tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation” and recommendations involving “blinatumomab and/or inotuzumab over chemotherapy for reinduction.” The ASH guideline document specifically addresses adolescents and young adults with relapsed/refractory ALL and states that recommendations focused on “immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy.” No document supplies labeled FDA indications, treatment lines, biomarker restrictions, approval dates, HCPCS/J-codes, NDCs, or other coding identifiers for all approved ALL products. The supplied documents do not provide a complete list of FDA- or regulator-approved drugs, biologics, or cellular therapies for acute lymphoblastic leukemia in the United States, nor do they provide approval dates or billing/product coding identifiers. The documents mention several therapies in the context of ALL management and future or investigational use. One guideline states: “Patients with refractory/relapsed disease have a poor prognosis which highlights the importance of acquiring in the future new therapies such as: blinatumumab, inotuzumab, and CAR-T cells.” Another document describes CAR-T therapy as investigational and notes that “CAR-T therapy may be offered to people when their cancer comes back.” The documents also mention a biomarker-restricted subgroup: “For patients with Philadelphia chromosome positive (Phi+) ALL, post-transplantation tyrosine kinase inhibitors as a systematic maintenance strategy is recommended.” The supplied documents discuss treatment approaches and guideline recommendations for acute lymphoblastic leukemia (ALL), including T-cell ALL and adolescent/young adult ALL, but they do not provide a list of FDA-approved drugs, biologics, or cellular therapies, approval dates, labeled indications, treatment lines, biomarker restrictions, or billing/product coding identifiers. The documents state that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols” and that “The use of targeted agents in frontline therapy is increasingly supported, although further research is needed to optimize this strategy.” They also describe asparaginase as “an integral component of therapy for pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma.” No document supplies the requested regulatory approval tables or coding data. The supplied documents identify two FDA-labeled drugs for acute lymphoblastic leukemia (ALL): mercaptopurine and methotrexate. Mercaptopurine is labeled for “the treatment of patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen,” with no explicit biomarker restriction for indication, although TPMT and NUDT15 testing and dose modifications are discussed for toxicity management. Methotrexate Injection is labeled for “the treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy regimen.” The documents also include an FDA Drugs@FDA entry for ICLUSIG (ponatinib), but the supplied text does not state an ALL indication, treatment line, biomarker restriction, or approval details specific to ALL. The documents do not provide billing codes, HCPCS/J-codes, NDCs, or other coding identifiers for ALL products. The supplied documents identify FDA-approved tyrosine kinase inhibitor products for Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), specifically imatinib mesylate/Gleevec and Sprycel. Imatinib mesylate is indicated for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)” and for “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.” The biomarker restriction stated is “Philadelphia chromosome positive (Ph+ ALL).” The documents also provide FDA approval history for Gleevec and Sprycel, including “ORIG 1 AP 2003-04-18” for Gleevec and “ORIG 1 AP 2006-06-28” for Sprycel, but they do not provide ALL-specific approval dates, labeled ALL treatment lines for Sprycel, or any billing/product coding identifiers such as HCPCS or J-codes. The supplied documents identify methotrexate and doxorubicin as FDA-labeled products for acute lymphoblastic leukemia (ALL). Methotrexate tablets are indicated for the “treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen,” which specifies a maintenance treatment setting and includes both adult and pediatric patients without a biomarker restriction. Doxorubicin hydrochloride injection is indicated “for the treatment of acute lymphoblastic leukemia,” and the labeling also provides dosing for “Metastatic Disease, Leukemia, or Lymphoma,” including single-agent and combination therapy dosing, but no biomarker restriction is stated. The documents do not provide approval dates, HCPCS/CPT/NDC billing or product codes, or a complete list of all FDA-approved drugs, biologics, or cellular therapies for ALL in the United States. The supplied documents discuss clinical practice guidelines and diagnostic/cytogenetic stratification for acute lymphoblastic leukemia (ALL), including pediatric, adult, Philadelphia chromosome (Ph)-positive and Ph-negative disease, but they do not provide a list of FDA-approved drugs, biologics, or cellular therapies, nor approval dates, labeled indications, treatment lines, biomarker restrictions tied to approvals, or billing/product coding identifiers. The NCCN guideline documents state that they focus on “treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL” and “management of ALL, with a focus on the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers.” The cytogenetics document notes that “Ph-like ALL ... can benefit from targeted therapy,” but does not identify approved products or regulatory details. The supplied documents identify methotrexate products as FDA-labeled therapies for acute lymphoblastic leukemia (ALL) in the United States. Methotrexate Injection is indicated for “treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy regimen,” while methotrexate tablets are indicated for “treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.” The documents do not provide approval dates, biomarker restrictions, cellular therapies, biologics, or billing/product coding identifiers, and they do not comprehensively list all FDA-approved ALL therapies as of 2026-09-22. The supplied documents identify doxorubicin products as approved/indicated for acute lymphoblastic leukemia in the United States. One label states: “Doxorubicin is indicated for the treatment of acute lymphoblastic leukemia,” and another states that “DOXOrubicin HCl Injection, USP and DOXOrubicin HCl for Injection, USP have been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia.” The documents do not provide FDA approval dates, biomarker restrictions, treatment-line limitations, or billing/product coding identifiers for acute lymphoblastic leukemia, nor do they identify other approved ALL drugs, biologics, or cellular therapies. The documents discuss several therapies used or under development for acute lymphoblastic leukemia (ALL), including imatinib for newly diagnosed Philadelphia chromosome–positive ALL, blinatumomab and inotuzumab in relapsed/refractory ALL, and CAR-T cells being tested in ALL. However, the documents do not provide comprehensive FDA or other official regulatory approval information, approved labeling language, approval dates, treatment-line specifications, billing/product codes, or complete biomarker restrictions. The only explicit biomarker-linked treatment statement is for “Ph-positive ALL” or “Philadelphia chromosome positive (Phi+) ALL” in relation to imatinib and tyrosine kinase inhibitors. One document describes a clinical trial regimen for “adult patients with Ph Negative ALL,” but it is explicitly a study and not an approval document. Another document lists FDA Drugs@FDA product information for methotrexate formulations, including NDA and submission dates, but it does not state an ALL indication, treatment line, biomarker restriction, approval for ALL, or billing/product coding identifiers.","answer_status":"partial","answer_citations":["Dr.Reddy's Laboratories Inc","Apotex Corp","BluePoint Laboratories","US Food and Drug Administration","SANDOZ","Alembic Pharmaceuticals Limited","Amneal Pharmaceuticals LLC","Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation","Journal of the National Comprehensive Cancer Network : JNCCN","American Society of Hematology","Bulletin du cancer","National Cancer Institute (NCI)","Journal of Clinical Oncology","Hikma Pharmaceuticals USA Inc.","Hospira, Inc.","NOVARTIS","BRISTOL MYERS SQUIBB","Sun Pharmaceutical Industries, Inc.","Bryant Ranch Prepack","Pfizer Laboratories Div Pfizer Inc","Current research in translational medicine","Alembic Pharmaceuticals Inc.","Aurobindo Pharma Limited","National Cancer Institute","American Society of Clinical Oncology Educational Book","Memorial Sloan Kettering Cancer Center","HOSPIRA"],"web_sites":[],"reviewer_sections":[],"reviewer_sections_dropped":[]},{"id":"q_bf22d864f4bc","run_id":"run_2058f031b9db","stage":"stage_2","bucket":"C","text":"As of 2026-09-22 in the United States, how do guideline-recommended treatment pathways for acute lymphoblastic leukemia differ by Philadelphia chromosome status, molecular biomarkers, MRD status, and other risk segments, and at which clinical timepoints is biomarker testing recommended or expected for treatment selection in all patients?","seed_text":"How does ALL treatment differ between Ph-positive and Ph-negative disease and by other biomarker or risk segments, and at what point in the journey is biomarker testing expected (at diagnosis vs. at progression)?","aspects":["Philadelphia chromosome status","molecular biomarkers","MRD status","risk stratification","testing timepoints","treatment pathway differences"],"aspects_from_model":true,"status":"sufficient","coverage_score":0.796,"refinement_rounds":2,"used_web_fallback":true,"sources_attempted":["dailymed","esmo","nci","openfda_drugsfda","openfda_label","asco","ashpublications","clinicaltrials","open_web"],"sources_answered":["dailymed","esmo","nci","openfda_drugsfda","openfda_label","asco","ashpublications","clinicaltrials","open_web"],"unmet_reason":"","answer_text":"The documents distinguish treatment pathways primarily by Philadelphia chromosome/BCR-ABL status, MRD status, and selected biomarkers such as CD20 positivity and BCR-ABL-like phenotype. For Ph-positive ALL, the NCI PDQ states that \"inclusion of imatinib into a relatively standard chemotherapy regimen for newly diagnosed adult patients with Ph-positive ALL may provide a significant survival advantage\" and that \"Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials,\" with consideration of \"allogeneic bone marrow transplant\" because remissions are short with conventional chemotherapy. For BCR-ABL-negative B-lineage ALL, the trial document evaluates adding blinatumomab to chemotherapy specifically in patients who are \"minimal residual disease (MRD) negative after induction and intensification chemotherapy,\" while also comparing outcomes in patients who are MRD positive and later convert to MRD negative after blinatumomab. Biomarker-directed elements in the protocol include evaluation of \"BCR/ABL1-like B-lineage ALL\" and optional rituximab use for \"CD20 positive patients.\" The documents indicate biomarker or disease-status assessment at diagnosis and after induction/intensification chemotherapy, including \"multiparameter flow cytometric (MFC) assessment of residual blasts\" for MRD-based treatment selection, but they do not provide comprehensive U.S. guideline-recommended pathways across all ALL risk groups or all expected testing timepoints. The supplied ASH 2026 guidelines describe that frontline and relapsed/refractory ALL treatment pathways differ for certain higher-risk subsets and disease subsets, but they do not provide a complete biomarker-based treatment algorithm by Philadelphia chromosome status, molecular biomarkers, MRD status, or testing timepoints. For frontline AYA ALL, the guidelines state that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols,” and that “Allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy.” They also state that “The use of targeted agents in frontline therapy is increasingly supported.” For relapsed/refractory AYA ALL, the guidelines report that recommendations “focused on the following treatment modalities: immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy,” including “the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction,” and they additionally mention “ALL subsets (T-cell ALL), CNS relapse, and the role of consolidation with allogeneic transplant.” The documents do not specify Philadelphia chromosome-directed pathways, MRD-directed treatment changes, required biomarker panels, or when biomarker testing is recommended or expected for all patients. The supplied documents indicate that acute lymphoblastic leukemia treatment and outcomes may differ by Philadelphia chromosome status, including references to “Philadelphia chromosome-associated acute lymphoblastic leukemia (Ph+ ALL)” and to “Clinical outcome of adult acute lymphoblastic leukemia based on Philadelphia chromosome status and socioeconomic status.” One document also references “BCR-ABL mutation status” in “imatinib-resistant patients,” implying molecular biomarker considerations in Ph+ ALL. However, the documents do not provide guideline-recommended treatment pathways, MRD-based stratification, testing timepoints, or detailed risk-segment recommendations. The supplied documents identify that NCCN maintains U.S. Acute Lymphoblastic Leukemia guidelines and biomarker-testing resources through “NCCN Guidelines Version 3.2026 - Acute Lymphoblastic Leukemia” and the “NCCN Biomarkers Compendium®,” but they do not provide the actual treatment pathways, biomarker-specific recommendations, MRD-directed algorithms, Philadelphia chromosome–specific regimens, risk stratification categories, or testing timepoints requested in the question. The documents do state that the NCCN Biomarkers Compendium includes tests used for “Diagnosis,” “Monitoring,” “Prediction,” and “Prognostication,” and that these tests are “recommended within the NCCN Guidelines.” No detailed ALL treatment algorithms or biomarker-triggered treatment selection rules are included in the supplied text.","answer_status":"partial","answer_citations":["National Cancer Institute","National Cancer Institute (NCI)","American Society of Hematology","Blood advances","Journal of Clinical Oncology","Open web"],"web_sites":[{"url":"https://www.nccn.org/compendia-templates/compendia/biomarkers-compendium","title":"Biomarkers Compendium - NCCN","site":"nccn.org","scraped":true,"used":true},{"url":"https://www.asco.org/guidelines","title":"Guidelines - ASCO","site":"asco.org","scraped":true,"used":false},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1489.","title":"Acute Lymphoblastic Leukemia - Guidelines Detail - nccn.org","site":"nccn.org","scraped":true,"used":true}],"reviewer_sections":[],"reviewer_sections_dropped":[]},{"id":"q_7ca3756217b1","run_id":"run_2058f031b9db","stage":"stage_2","bucket":"C","text":"In the United States through 2026-09-22, what recent FDA approvals and label expansions have occurred for acute lymphoblastic leukemia therapies, including the affected products, indications, biomarker requirements, and effective dates for all patients?","seed_text":"What recent FDA approvals or label expansions have occurred in ALL?","aspects":["new approvals","label expansions","effective dates","indication changes","biomarker requirements"],"aspects_from_model":true,"status":"sufficient","coverage_score":0.485,"refinement_rounds":2,"used_web_fallback":true,"sources_attempted":["dailymed","esmo","nci","openfda_drugsfda","openfda_label","asco","ashpublications","clinicaltrials","open_web"],"sources_answered":["dailymed","esmo","nci","openfda_drugsfda","openfda_label","asco","ashpublications","clinicaltrials","open_web"],"unmet_reason":"","answer_text":"The supplied documents identify FDA-related submissions and current labeled acute lymphoblastic leukemia (ALL) indications for GLEEVEC and dasatinib, but they do not comprehensively describe all recent FDA approvals or label expansions for ALL therapies through 2026-09-22. For GLEEVEC, the Drugs@FDA record lists multiple approved supplements, including \"SUPPL 63 AP 2024-03-01 Manufacturing (CMC) N/A\" and earlier efficacy and labeling approvals, but the document does not state the ALL indication changes associated with those actions. For dasatinib, the labeling states that it is indicated for \"Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy\" in adults and for \"pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy,\" establishing a biomarker requirement of \"Philadelphia chromosome-positive (Ph+).\" The dasatinib label also states \"Initial U.S. Approval: 2006,\" but no recent FDA effective dates or expansion approval dates are provided in the supplied text. The supplied FDA Drugs@FDA records show recent supplemental FDA actions for several acute lymphoblastic leukemia therapies, but they do not provide the underlying indication text, label-expansion details, biomarker requirements, or patient populations. For SPRYCEL (dasatinib), the record includes recent actions such as “SUPPL 28 AP 2024-07-31 Labeling STANDARD” and earlier efficacy supplements including “SUPPL 21 AP 2018-12-21 Efficacy PRIORITY.” For ARRANON (nelarabine), the record includes “SUPPL 14 AP 2025-03-11 Labeling STANDARD” and “SUPPL 10 AP 2019-07-31 Efficacy STANDARD.” For ICLUSIG (ponatinib), the record includes “SUPPL 38 AP 2025-10-10 Efficacy STANDARD” and “SUPPL 34 AP 2020-12-18 Efficacy PRIORITY.” The documents do not state the specific ALL indications, label-expansion wording, biomarker requirements, or effective-date language for patients. The supplied document identifies FDA-labeled acute lymphoblastic leukemia (ALL) indications for imatinib mesylate, but it does not describe any recent FDA approvals or label expansions through 2026-09-22. The label states that imatinib mesylate is indicated for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)” and for “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.” The biomarker requirement specified for these ALL indications is “Philadelphia chromosome positive (Ph+).” The only approval timing provided is “Initial U.S. Approval: 2001,” and no effective dates for newer approvals or label expansions are included in the supplied material. On March 19, 2024, the FDA granted accelerated approval to ponatinib (Iclusig) with chemotherapy for “adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).” The biomarker/eligibility requirement specified in the indication was Philadelphia chromosome-positive disease. In June 2024, the FDA expanded approval of Blincyto (blinatumomab) to include “adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase, regardless of measurable residual disease (MRD) status.” The expanded Blincyto indication therefore changed eligibility to include patients regardless of MRD status, while retaining biomarker requirements of CD19-positive and Philadelphia chromosome-negative disease.","answer_status":"partial","answer_citations":["NOVARTIS","BluePoint Laboratories","BRISTOL MYERS SQUIBB","SANDOZ","TAKEDA PHARMS USA","Apotex Corp","Open web"],"web_sites":[{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-ponatinib-chemotherapy-newly-diagnosed-philadelphia-chromosome","title":"FDA grants accelerated approval to ponatinib with chemotherapy for ...","site":"fda.gov","scraped":true,"used":true},{"url":"https://news.cancerconnect.com/fda-expands-blincyto-approval-in-frontline-b-cell-precursor-acute-lymphoblastic-leukemia/","title":"FDA Expands Blincyto Approval in Frontline B-Cell Precursor Acute ...","site":"news.cancerconnect.com","scraped":true,"used":true}],"reviewer_sections":[],"reviewer_sections_dropped":[]},{"id":"q_b5cd05555f81","run_id":"run_2058f031b9db","stage":"stage_2","bucket":"C","text":"In the United States through 2026-09-22, which acute lymphoblastic leukemia therapy approvals or indications have been withdrawn, restricted, or otherwise modified by regulators, including accelerated-approval changes and the associated effective dates for all patients?","seed_text":"Which approvals or indications in ALL have been withdrawn or restricted (e.g., accelerated-approval withdrawals), and on what dates?","aspects":["withdrawn indications","restricted approvals","accelerated-approval changes","effective dates","affected therapies"],"aspects_from_model":true,"status":"sufficient","coverage_score":0.749,"refinement_rounds":2,"used_web_fallback":true,"sources_attempted":["dailymed","esmo","nci","openfda_drugsfda","openfda_label","asco","ashpublications","clinicaltrials","open_web"],"sources_answered":["dailymed","esmo","nci","openfda_drugsfda","openfda_label","asco","ashpublications","clinicaltrials","open_web"],"unmet_reason":"","answer_text":"The supplied documents do not identify any acute lymphoblastic leukemia therapy approvals or indications that were withdrawn, restricted, or otherwise modified by regulators, and they do not provide effective dates for such actions. The only relevant regulatory qualification in the documents is for clofarabine injection, where the indication states that it is \"based upon response rate\" and that there are \"no trials verifying an improvement in disease-related symptoms or increased survival.\" The ICLUSIG record lists multiple FDA supplement actions and dates, including efficacy and labeling supplements, but does not describe any withdrawn or restricted ALL indications. The supplied documents do not identify any acute lymphoblastic leukemia (ALL) therapy approvals or indications in the United States that were withdrawn, restricted, or modified through 2026-09-22. The documents discuss oncology accelerated approvals and withdrawals generally, including examples in lung, breast, and bladder cancers, but they do not name any ALL therapies, indications, or effective dates relevant to ALL patients. The provided documents do not identify any withdrawn acute lymphoblastic leukemia (ALL) indications in the United States through 2026-09-22. They do identify regulatory modifications affecting ALL therapies: on March 19, 2024, the FDA granted “accelerated approval” to ponatinib (Iclusig) with chemotherapy for “adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).” The documents also show regulatory changes for TECARTUS (brexucabtagene autoleucel), including a “REMS Major Modification Approval Letter” dated June 12, 2024, and a “REMS Elimination Approval Letter” dated June 26, 2025, for a product indicated for “Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).”","answer_status":"partial","answer_citations":["US Food and Drug Administration","TAKEDA PHARMS USA","Journal of Clinical Oncology","Open web"],"web_sites":[{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-ponatinib-chemotherapy-newly-diagnosed-philadelphia-chromosome","title":"FDA grants accelerated approval to ponatinib with chemotherapy for ...","site":"fda.gov","scraped":true,"used":true},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-cancer-accelerated-approvals","title":"Withdrawn | Cancer Accelerated Approvals | FDA","site":"fda.gov","scraped":true,"used":false},{"url":"https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/tecartus","title":"TECARTUS | FDA","site":"fda.gov","scraped":true,"used":true}],"reviewer_sections":[],"reviewer_sections_dropped":[]},{"id":"q_7e8639e73505","run_id":"run_2058f031b9db","stage":"stage_2","bucket":"C","text":"As of 2026-09-22 in the United States, which drugs, biologics, and cellular therapies are used off-label or supported by compendia for acute lymphoblastic leukemia by line of therapy, including supporting compendia status and relevant coding identifiers for all patients?","seed_text":"Which products are used off-label or are compendia-supported for ALL, by line of therapy, and what codes represent each?","aspects":["off-label therapies","compendia-supported uses","line of therapy","coding identifiers","therapy classes"],"aspects_from_model":true,"status":"sufficient","coverage_score":0.711,"refinement_rounds":1,"used_web_fallback":false,"sources_attempted":["dailymed","esmo","nci","openfda_drugsfda","openfda_label","asco","ashpublications","clinicaltrials"],"sources_answered":["dailymed","esmo","nci","openfda_drugsfda","openfda_label","asco","ashpublications","clinicaltrials"],"unmet_reason":"","answer_text":"The supplied documents identify FDA-labeled therapies for acute lymphoblastic leukemia (ALL) and relapsed/refractory T-cell ALL, including therapy class and prior-line context, but they do not provide off-label uses, compendia-supported uses, compendia status, or coding identifiers. Clofarabine is described as “a nucleoside metabolic inhibitor indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens,” establishing a relapsed/refractory setting after at least two prior lines. Nelarabine is described as “a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens,” also specifying treatment after at least two prior regimens. Methotrexate is identified as “a folate analog metabolic inhibitor” indicated for “treatment of adult and pediatric patients with acute lymphoblastic leukemia as part of a combination chemotherapy regimen” and for “prophylaxis and treatment of adult and pediatric patients with meningeal leukemia,” but no line-of-therapy, off-label, compendia, biologic, cellular therapy, or coding information is supplied. The supplied documents identify several therapies used in acute lymphoblastic leukemia (ALL), including immunotherapy, targeted therapies, CAR-T cellular therapy, and methotrexate, but they do not provide compendia status details, coding identifiers, or a comprehensive off-label-use listing by line of therapy. For relapsed/refractory ALL in adolescents and young adults, the ASH 2026 guideline states that recommendations for remission reinduction and consolidation “focused on the following treatment modalities: immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy,” and that “Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction.” CD19 CAR therapy is described as an emerging cellular immunotherapy for B-cell ALL with “remarkable clinical outcomes in adults and children with ALL,” and methotrexate is FDA-indicated for “treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.” The documents do not provide HCPCS, CPT, ICD-10, NDC, or other coding identifiers, and they do not explicitly identify any therapy as off-label or compendia-supported. The documents identify FDA-labeled therapies and guideline-supported modalities for acute lymphoblastic leukemia (ALL), but they do not provide compendia status details, coding identifiers, or a comprehensive list of off-label therapies. Methotrexate is described as a “folate analog metabolic inhibitor” indicated for “adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy regimen,” and mercaptopurine is described as a “nucleoside metabolic inhibitor” indicated for “patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.” The ASH 2026 relapsed/refractory ALL guideline addresses later-line therapy concepts in adolescents and young adults, stating that recommendations “focused on the following treatment modalities: immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy,” and that “Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction.” The supplied documents do not provide billing or coding identifiers, explicit compendia classifications, or explicit statements that these uses are off-label. The documents describe several therapies and therapy classes used in acute lymphoblastic leukemia (ALL), including first-line chemotherapy, hematopoietic stem-cell transplantation, targeted therapy, CAR-T cellular therapies, and lymphodepletion regimens, but they do not provide compendia support status, coding identifiers, or a comprehensive off-label use listing. For first-line therapy, one source states that \"Modern first-line therapy consists of standard- and high-dose chemotherapy (increasingly inspired to pediatric principles), hematopoietic stem-cell transplantation, and new targeted therapy.\" For relapsed or refractory B-cell ALL, investigational CAR-T approaches described include TSLPR-CART and commercial tisagenlecleucel CAR T-cell therapy, with one study requiring disease that \"is relapsed or refractory after initial systemic therapy and at least one salvage treatment.\" The supplied documents do not identify NCCN or other compendia recommendations, HCPCS/CPT/ICD coding identifiers, or a complete by-line-of-therapy catalog of off-label therapies for all ALL patients in the United States as of 2026-09-22. The documents discuss asparaginase-containing pediatric-inspired regimens and targeted agents for acute lymphoblastic leukemia (ALL), particularly in adolescents and young adults (AYA), but they do not provide a comprehensive list of off-label therapies, compendia-supported uses, coding identifiers, or detailed line-of-therapy classifications. The available text states that \"Asparaginase is an integral component of therapy for pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma\" and that \"trials of pediatric/pediatric-inspired regimens incorporating asparaginase\" have been extended to \"adolescent and young adult (AYA) and adult populations.\" The ASH 2026 guideline document further states that \"Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols\" and that \"The use of targeted agents in frontline therapy is increasingly supported.\" No compendia status labels, HCPCS/CPT/NDC/ICD coding identifiers, or explicit off-label regulatory determinations are provided in the supplied documents. The documents identify some therapies used for acute lymphoblastic leukemia (ALL), including doxorubicin, pediatric-inspired regimens containing asparaginase, targeted agents, and allogeneic hematopoietic stem cell transplantation. Doxorubicin is FDA-indicated for ALL and is described for use in “Metastatic Disease, Leukemia, or Lymphoma,” but no line-of-therapy designation is provided. ASH guidelines describe “frontline therapy” in adolescents and young adults using “Pediatric-inspired regimens containing asparaginase” and note that “The use of targeted agents in frontline therapy is increasingly supported,” while “Allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy.” The documents do not provide compendia-supported off-label use determinations, coding identifiers, HCPCS/NDC/CPT identifiers, or a complete line-of-therapy mapping for all drugs, biologics, and cellular therapies in ALL. The documents identify dasatinib (SPRYCEL), a kinase inhibitor, as an FDA-labeled therapy for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) \"with resistance or intolerance to prior therapy,\" which corresponds to a later-line setting after prior treatment. The label also provides a disease-specific dosage for \"Ph+ ALL\" of \"140 mg administered orally once daily.\" The NCI PDQ document describes induction regimens for adult ALL using combination chemotherapy including \"prednisone, vincristine, and an anthracycline,\" with some regimens adding \"asparaginase or cyclophosphamide,\" and states that \"Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.\" The supplied documents do not provide compendia status classifications, billing or coding identifiers, cellular therapy coding, or a comprehensive list of off-label therapies across all lines of therapy for ALL. The supplied documents identify some therapies and therapy classes being studied or discussed for acute lymphoblastic leukemia (ALL), but they do not provide a comprehensive United States 2026 list of off-label therapies, compendia-supported uses, line-of-therapy recommendations, or coding identifiers. One clinical trial document describes the addition of venetoclax and blinatumomab to chemotherapy for infants with newly diagnosed ALL, stating that “Venetoclax is in a class of medications called B-cell lymphoma-2 (Bcl-2) inhibitors” and “Blinatumomab is a monoclonal antibody.” Another guideline document states that “the rapid development of immunotherapy has improved the efficacy of adult ALL, and commercial antibodies and CAR-T cell products have been available in China.” The documents do not provide compendia status, NCCN support categories, HCPCS/CPT/NDC/J-codes, or explicit off-label line-of-therapy mappings for all patients in the United States. The documents describe investigational and relapsed/refractory acute lymphoblastic leukemia therapies, including small-molecule combinations and cellular therapies, but they do not provide comprehensive United States off-label or compendia-supported use listings, coding identifiers, or formal line-of-therapy compendia status as of 2026-09-22. One study evaluates the drug combination of calaspargase pegol-mknl, decitabine, and venetoclax in pediatric, adolescent, and young adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma. Another study evaluates a CD19-directed CAR T-cell therapy (AUTO1/obe-cel) in pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia. The supplied documents do not include HCPCS, CPT, ICD-10, NDC, or other coding identifiers, and they do not state NCCN Compendia or other compendia support categories. The supplied documents identify several therapies used or studied in acute lymphoblastic leukemia (ALL), including tyrosine kinase inhibitors, monoclonal antibodies, and cellular therapies, but they do not provide compendia status details, coding identifiers, or a comprehensive off-label listing by line of therapy. For relapsed/refractory ALL and minimal residual disease settings, the documents describe blinatumomab, inotuzumab ozogamicin, rituximab, and autologous chimeric antigen receptor (CAR) cells. For newly diagnosed Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-like) B-ALL, a clinical trial document describes use of blinatumomab with dasatinib or imatinib plus chemotherapy. The documents also identify ponatinib (ICLUSIG) as an FDA-approved product, but they do not specify ALL line-of-therapy use, compendia support, or billing/coding identifiers. The supplied documents describe investigational and treatment regimens for acute lymphoblastic leukemia (ALL), including therapies used in newly diagnosed and high-risk or relapsed settings, but they do not provide compendia-supported indications, off-label status determinations, or coding identifiers. Document 0 describes selected use of blinatumomab and cellular therapies in pediatric and young adult patients with high-risk ALL in remission states including CR1, CR2, and CR3 or subsequent relapse settings in the context of haploidentical hematopoietic cell transplantation. Document 1 describes a “pediatric-inspired” chemotherapy regimen for adults aged 18-60 with newly diagnosed Philadelphia chromosome-negative ALL and lists the chemotherapy agents used. No document provides United States compendia status, HCPCS/CPT/NDC coding identifiers, or explicit regulatory off-label classifications. The supplied documents identify that the NCCN Clinical Practice Guidelines for Pediatric Acute Lymphoblastic Leukemia address treatment strategies for multiple ALL subtypes and include recommendations for “frontline and relapsed/refractory management,” but they do not enumerate specific off-label drugs, biologics, cellular therapies, compendia-supported indications, line-of-therapy mappings, or coding identifiers. The documents state that the guidelines include “guidance on supportive care, hematopoietic stem cell transplantation, and pharmacogenomics” and cover “treatment strategies for BCR::ABL1 (Philadelphia chromosome [Ph])-negative and BCR::ABL1-positive B-cell lineage, T-cell lineage, and infant ALL.” No HCPCS, CPT, ICD-10, NDC, or other coding identifiers are provided in the supplied text. The supplied documents identify doxorubicin hydrochloride as a drug used in acute lymphoblastic leukemia, but they do not provide the requested comprehensive list of off-label therapies, biologics, cellular therapies, compendia-supported uses, lines of therapy, or coding identifiers for acute lymphoblastic leukemia in the United States as of 2026-09-22. One FDA labeling document states that \"DOXOrubicin HCl Injection, USP and DOXOrubicin HCl for Injection, USP have been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia.\" The documents discussing oncology drug compendia and off-label coverage do not provide specific acute lymphoblastic leukemia therapies, compendia status categories, or line-of-therapy details. The supplied documents identify clofarabine as a nucleoside metabolic inhibitor used in acute lymphoblastic leukemia (ALL) for pediatric patients with relapsed or refractory disease after at least two prior regimens, which corresponds to a later-line therapy setting. The documents state: \"Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.\" The documents do not provide information on off-label ALL therapies, compendia-supported uses, compendia status, cellular therapies, biologics beyond clofarabine, therapy coding identifiers, or line-of-therapy categorizations for all patients in the United States as of 2026-09-22. The supplied documents identify FDA-labeled therapies for acute lymphoblastic leukemia (ALL), but they do not provide compendia-supported off-label uses, line-of-therapy categorizations beyond resistance/intolerance language, coding identifiers, or cellular therapies. Doxorubicin is described as \"indicated for the treatment of acute lymphoblastic leukemia\" and is an \"anthracycline topoisomerase inhibitor.\" Dasatinib is described as a \"kinase inhibitor\" indicated for \"adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy\" and for \"pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.\" The supplied documents do not provide a comprehensive list of off-label therapies, compendia-supported uses, lines of therapy, coding identifiers, or therapy classes for acute lymphoblastic leukemia in the United States as of 2026-09-22. The documents do mention immunotherapy approaches including monoclonal antibodies, CAR-T cell products, and blinatumomab in adult or newly diagnosed B-lineage acute lymphoblastic leukemia. One clinical trial document specifically evaluates “combination chemotherapy with blinatumomab” in “newly diagnosed BCR-ABL-negative B lineage acute lymphoblastic leukemia,” which corresponds to a frontline/newly diagnosed treatment setting. The supplied documents identify that NCCN Guidelines for acute lymphoblastic leukemia (ALL) include \"treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients\" and that pediatric guidelines include \"treatment strategies for BCR::ABL1 (Philadelphia chromosome [Ph])-negative and BCR::ABL1-positive B-cell lineage, T-cell lineage, and infant ALL.\" However, the documents do not provide specific off-label drugs, biologics, cellular therapies, compendia-supported uses, line-of-therapy details, or coding identifiers for ALL therapies in the United States as of 2026-09-22.","answer_status":"partial","answer_citations":["Dr.Reddy's Laboratories Inc","Alembic Pharmaceuticals Limited","Hospira, Inc.","American Society of Clinical Oncology Educational Book","American Society of Hematology","Alembic Pharmaceuticals Inc.","Blood advances","Hikma Pharmaceuticals USA Inc.","Journal of Clinical Oncology","National Cancer Institute (NCI)","Memorial Sloan Kettering Cancer Center","American journal of hematology","US Food and Drug Administration","NOVARTIS","National Cancer Institute","Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","M.D. Anderson Cancer Center","Autolus Limited","TAKEDA PHARMS USA","St. Jude Children's Research Hospital","Journal of the National Comprehensive Cancer Network : JNCCN","Journal of Oncology Practice","Amneal Pharmaceuticals LLC","Pfizer Laboratories Div Pfizer Inc","BluePoint Laboratories","Default Digital Object Group"],"web_sites":[],"reviewer_sections":[],"reviewer_sections_dropped":[]},{"id":"q_fd97687cf608","run_id":"run_2058f031b9db","stage":"stage_2","bucket":"C","text":"In the United States through 2026-09-22, how have major clinical guideline recommendations for acute lymphoblastic leukemia changed over time, including version dates, recommendation changes, and affected treatment settings or patient subgroups for all patients?","seed_text":"How have guideline recommendations for ALL changed over the study period, and on what dates?","aspects":["guideline versions","change dates","recommendation updates","affected regimens","treatment settings","patient subgroups"],"aspects_from_model":true,"status":"sufficient","coverage_score":0.748,"refinement_rounds":2,"used_web_fallback":true,"sources_attempted":["dailymed","esmo","nci","openfda_drugsfda","openfda_label","asco","ashpublications","clinicaltrials","open_web"],"sources_answered":["dailymed","esmo","nci","openfda_drugsfda","openfda_label","asco","ashpublications","clinicaltrials"],"unmet_reason":"","answer_text":"The supplied document describes contemporary remission induction approaches for adult acute lymphoblastic leukemia (ALL), including that \"Most current induction regimens for patients with adult ALL include combination chemotherapy with prednisone, vincristine, and an anthracycline\" and that some regimens \"also add other drugs, such as asparaginase or cyclophosphamide.\" It also notes a treatment change within a CALGB study involving the \"omission of L-asparaginase\" midway through the study. For newly diagnosed adult patients with Philadelphia chromosome (Ph)-positive ALL, the document states that \"inclusion of imatinib into a relatively standard chemotherapy regimen... may provide a significant survival advantage\" and that \"Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.\" The document further states that \"If a suitable donor is available, allogeneic bone marrow transplant should be considered because remissions are generally short with conventional ALL chemotherapy clinical trials\" and that \"the use of myeloid growth factors during remission-induction therapy appears to decrease the time to hematopoietic reconstitution.\" The documents do not provide guideline version histories, dates of recommendation changes, or a chronological evolution of U.S. clinical guidelines through 2026-09-22. The supplied documents describe new 2026 American Society of Hematology (ASH) guidelines for adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL), including frontline and relapsed/refractory settings, but they do not provide a longitudinal history of guideline changes over time or prior version dates. For frontline management, the 2026 ASH guideline states that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols,” and that “Allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy.” For relapsed/refractory disease, the 2026 ASH guideline reports that recommendations “focused on the following treatment modalities: immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy,” and that “Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction.” The affected settings and patient subgroups described are AYAs with frontline ALL and AYAs with relapsed/refractory ALL, including “ALL subsets (T-cell ALL), CNS relapse, and the role of consolidation with allogeneic transplant.”","answer_status":"partial","answer_citations":["National Cancer Institute","American Society of Hematology","Blood advances"],"web_sites":[],"reviewer_sections":[],"reviewer_sections_dropped":[]},{"id":"q_1a2fac4b0d38","run_id":"run_2058f031b9db","stage":"stage_2","bucket":"C","text":"In the United States through 2026-09-22, what published benchmarks are available for time on treatment, time to next treatment, progression-free survival, and related outcomes in acute lymphoblastic leukemia by line of therapy and key regimen for all patients?","seed_text":"What are the published benchmarks for time on treatment, time to next treatment, and PFS (progression-free survival) in ALL by line and key regimen?","aspects":["time on treatment","time to next treatment","progression-free survival","line of therapy","key regimens","data sources"],"aspects_from_model":true,"status":"sufficient","coverage_score":0.946,"refinement_rounds":2,"used_web_fallback":true,"sources_attempted":["dailymed","esmo","nci","openfda_drugsfda","openfda_label","asco","ashpublications","clinicaltrials","open_web"],"sources_answered":["dailymed","esmo","nci","openfda_drugsfda","openfda_label","asco","ashpublications","clinicaltrials","open_web"],"unmet_reason":"","answer_text":"The supplied documents contain limited published benchmark information for outcomes in acute lymphoblastic leukemia (ALL), mostly related to remission duration, relapse-free survival objectives, and treatment context rather than comprehensive benchmarks for time on treatment (TOT), time to next treatment (TTNT), or progression-free survival (PFS) by line of therapy and regimen. For newly diagnosed adult ALL induction therapy, the NCI PDQ states that \"Current multiagent induction regimens result in complete response rates that range from 60% to 90%\" and reports that in Ph-positive ALL treated with imatinib-containing therapy, \"most of these patients experiencing disease relapse at a median of 58 days after the start of therapy\" and \"The responses again were short, with a median duration of 2.2 months.\" A ClinicalTrials.gov phase III study in newly diagnosed BCR-ABL-negative B-lineage ALL lists overall survival (OS) and relapse-free survival (RFS) as primary and secondary objectives for blinatumomab plus chemotherapy versus chemotherapy alone, but does not provide benchmark results. The ASH 2026 guideline document discusses relapsed/refractory ALL in adolescents and young adults and focuses on treatment recommendations such as \"the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction,\" but does not provide numeric TOT, TTNT, or PFS benchmarks. The supplied document is an ASH guideline for relapsed/refractory acute lymphoblastic leukemia (ALL) in adolescents and young adults and discusses treatment recommendations by regimen and disease setting, but it does not provide published benchmarks for time on treatment, time to next treatment, progression-free survival, or related outcomes by line of therapy. The document identifies treatment modalities and regimens including “blinatumomab,” “inotuzumab,” “CAR T-cell therapy,” and “chemotherapy” in relapsed/refractory B-ALL and references remission status such as “second (or greater) remission (CR2).” The document is a guideline evidence review source rather than an outcomes benchmark dataset. The provided document discusses frontline management recommendations for acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs), including regimen selection and supportive care considerations, but it does not provide published benchmarks for time on treatment, time to next treatment, progression-free survival, or related outcomes by line of therapy and regimen. The document does identify frontline therapy approaches and key regimens, particularly pediatric-inspired asparaginase-containing regimens versus adult-inspired protocols. No quantitative benchmark data sources for treatment duration or survival endpoints are reported in the supplied material. The supplied documents do not provide published benchmarks for “time on treatment,” “time to next treatment,” or “progression-free survival” in acute lymphoblastic leukemia stratified by line of therapy and key regimen. The documents instead discuss overall treatment duration and frontline regimen recommendations. One review states that “Contemporary ALL therapy usually consists of cycles of multiagent chemotherapy administered over 2 to 3 years” and that “ALL therapy typically begins with 5 to 9 months of more-intensive chemotherapy followed by a prolonged low-intensity maintenance phase.” The ASH 2026 guideline document provides frontline treatment recommendations for adolescents and young adults, including that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols,” but it does not report benchmark outcomes such as progression-free survival, time on treatment, or time to next treatment by line of therapy.","answer_status":"partial","answer_citations":["National Cancer Institute","National Cancer Institute (NCI)","American Society of Hematology","Blood advances","Open web"],"web_sites":[{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7820874/","title":"Optimizing therapy in the modern age: differences in length of ...","site":"pmc.ncbi.nlm.nih.gov","scraped":true,"used":true},{"url":"https://ashpublications.org/bloodadvances/article/10/13/4671/566561/American-Society-of-Hematology-2026-guidelines-for","title":"American Society of Hematology 2026 guidelines for frontline management ...","site":"ashpublications.org","scraped":true,"used":false}],"reviewer_sections":[],"reviewer_sections_dropped":[]},{"id":"q_e71eae3bd237","run_id":"run_2058f031b9db","stage":"stage_2","bucket":"C","text":"In the United States through 2026-09-22, what proportion of acute lymphoblastic leukemia patients progress from first-line to subsequent lines of therapy, and what clinical or treatment-related factors are associated with attrition between lines for all patients?","seed_text":"What proportion of ALL patients advance from 1L to 2L, 3L, and beyond, and what drives attrition between lines?","aspects":["line advancement rates","attrition between lines","clinical drivers","treatment-related drivers","line of therapy transitions","real-world benchmarks"],"aspects_from_model":true,"status":"unanswered","coverage_score":0.0,"refinement_rounds":0,"used_web_fallback":false,"sources_attempted":[],"sources_answered":[],"unmet_reason":"no usable evidence after 1 retrieval round(s); abandoned after 480s; sources did not respond","answer_text":"","answer_status":"not_found","answer_citations":[],"web_sites":[],"reviewer_sections":[],"reviewer_sections_dropped":[]}],"evidence":[{"id":"ev_c9706e9f4f7c","question_id":"q_6f442701d567","source_id":"orphanet","source_name":"Orphanet / Orphadata","organization":"Orphanet","tier":1,"url":"https://www.orpha.net/en/disease/detail/513","title":"Orphanet Acute lymphoblastic leukemia (ORPHA:513)","published":"","quote":"Definition: A group of rare Non-Hodgkin lymphoma characterized by malignant proliferation of lymphoid cells blocked at an early stage of differentiation.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.99,"identifiers":{"orphacode":"513","icd10":"C91.0","mesh":"D054198","umls":"C1961102"},"retrieved_at":"2026-09-22T11:09:58.165266Z"},{"id":"ev_ca4a962dac12","question_id":"q_6f442701d567","source_id":"nci","source_name":"National Cancer Institute (NCI) PDQ","organization":"National Cancer Institute","tier":1,"url":"https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq","title":"PDQ: Remission induction therapy","published":"","quote":"Responses were short lived, with most of these patients experiencing disease relapse at a median of 58 days after the start of therapy.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.95,"identifiers":{"pdq_summary":"adult-all-treatment-pdq","section":"Remission induction therapy"},"retrieved_at":"2026-09-22T11:09:58.165399Z"},{"id":"ev_f7fb02fda72b","question_id":"q_6f442701d567","source_id":"seer","source_name":"NCI SEER","organization":"National Cancer Institute, Surveillance, Epidemiology, and End Results Program","tier":1,"url":"https://seer.cancer.gov/statfacts/html/alyl.html","title":"Acute Lymphocytic Leukemia — Cancer Stat Facts","published":"","quote":"Acute lymphocytic leukemia is most frequently diagnosed among people aged <20.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.94,"identifiers":{"slug":"alyl"},"retrieved_at":"2026-09-22T11:10:31.873849Z"},{"id":"ev_4ad9686adf8f","question_id":"q_6f442701d567","source_id":"orphanet","source_name":"Orphanet / Orphadata","organization":"Orphanet","tier":1,"url":"https://www.orpha.net/en/disease/detail/513","title":"Orphanet Acute lymphoblastic leukemia (ORPHA:513)","published":"","quote":"Patients may present with symptoms, frequently including lymphadenopathy, hepatosplenomegaly, bone pain, fever and signs of hemorrhage or they may remain asymptomatic.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.94,"identifiers":{"orphacode":"513","icd10":"C91.0","mesh":"D054198","umls":"C1961102"},"retrieved_at":"2026-09-22T11:09:58.165319Z"},{"id":"ev_66731dfaf256","question_id":"q_6f442701d567","source_id":"seer","source_name":"NCI SEER","organization":"National Cancer Institute, Surveillance, Epidemiology, and End Results Program","tier":1,"url":"https://seer.cancer.gov/statfacts/html/alyl.html","title":"Acute Lymphocytic Leukemia — Cancer Stat Facts","published":"","quote":"Acute lymphocytic leukemia is most common in children, adolescents, and young adults, or those 15 to 39 years of age.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.93,"identifiers":{"slug":"alyl"},"retrieved_at":"2026-09-22T11:10:31.873767Z"},{"id":"ev_f627156d82c2","question_id":"q_6f442701d567","source_id":"orphanet","source_name":"Orphanet / Orphadata","organization":"Orphanet","tier":1,"url":"https://www.orpha.net/en/disease/detail/513","title":"Orphanet Acute lymphoblastic leukemia (ORPHA:513)","published":"","quote":"Although it primarily affects the bone marrow and peripheral blood, the abnormal cells can infiltrate any organ or tissue.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.9,"identifiers":{"orphacode":"513","icd10":"C91.0","mesh":"D054198","umls":"C1961102"},"retrieved_at":"2026-09-22T11:09:58.165343Z"},{"id":"ev_018c0d99b1c3","question_id":"q_6f442701d567","source_id":"nci","source_name":"National Cancer Institute (NCI) PDQ","organization":"National Cancer Institute","tier":1,"url":"https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq","title":"PDQ: Remission induction therapy","published":"","quote":"If a suitable donor is available, allogeneic bone marrow transplant should be considered because remissions are generally short with conventional ALL chemotherapy clinical trials.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.84,"identifiers":{"pdq_summary":"adult-all-treatment-pdq","section":"Remission induction therapy"},"retrieved_at":"2026-09-22T11:09:58.165425Z"},{"id":"ev_dfedeb04e1d0","question_id":"q_6f442701d567","source_id":"nci","source_name":"National Cancer Institute (NCI) PDQ","organization":"National Cancer Institute","tier":1,"url":"https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq","title":"PDQ: Remission induction therapy","published":"","quote":"Current multiagent induction regimens result in complete response rates that range from 60% to 90%.[ 1 , 4 , 5 , 11 , 12 ]","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.82,"identifiers":{"pdq_summary":"adult-all-treatment-pdq","section":"Remission induction therapy"},"retrieved_at":"2026-09-22T11:09:58.165374Z"},{"id":"ev_d657beab5bba","question_id":"q_6f442701d567","source_id":"pubmed","source_name":"PubMed","organization":"AAPS PharmSciTech","tier":2,"url":"https://pubmed.ncbi.nlm.nih.gov/42768180/","title":"Beyond Immediate Release: FDM-Printed Pediatric 6-Mercaptopurine Chewable Tablets with Spontaneous In Situ Nanostructure Formation.","published":"2026 Sep 21","quote":"Pediatric maintenance therapy for acute lymphoblastic leukemia requires prolonged daily administration of 6-mercaptopurine (6-MP), a drug characterized by a narrow therapeutic index and substantial interindividual variability, creating a need for flexible and patient-friendly dosage forms.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.98,"identifiers":{"pmid":"42768180","doi":"10.1208/s12249-026-03556-7"},"retrieved_at":"2026-09-22T11:10:18.538094Z"},{"id":"ev_9e42f72ef49a","question_id":"q_6f442701d567","source_id":"ashpublications","source_name":"ASH / Blood (American Society of Hematology)","organization":"American Society of Hematology","tier":2,"url":"https://pubmed.ncbi.nlm.nih.gov/41670624/","title":"American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults.","published":"2026-07-01","quote":"Background Adolescents and young adults (AYAs) with relapsed/refractory acute lymphoblastic leukemia (ALL) face unique challenges as they experience greater treatment resistance, higher rates of toxicity, and present at a specific life stage with distinct priorities.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.94,"identifiers":{"pmid":"41670624","pmcid":"PMC13366310","doi":"10.1182/bloodadvances.2021006479","epmc_id":"41670624","source":"MED"},"retrieved_at":"2026-09-22T11:10:05.952939Z"},{"id":"ev_2e69084f0f32","question_id":"q_6f442701d567","source_id":"ashpublications","source_name":"ASH / Blood (American Society of Hematology)","organization":"American Society of Hematology","tier":2,"url":"https://pubmed.ncbi.nlm.nih.gov/41670627/","title":"American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults.","published":"2026-07-01","quote":"Treatment regimens can vary significantly depending on whether they receive care in a pediatric or in an adult setting.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.92,"identifiers":{"pmid":"41670627","pmcid":"PMC13366240","doi":"10.1182/bloodadvances.2021006469","epmc_id":"41670627","source":"MED"},"retrieved_at":"2026-09-22T11:09:58.165471Z"},{"id":"ev_939986aec67f","question_id":"q_6f442701d567","source_id":"pubmed","source_name":"PubMed","organization":"Drug design, development and therapy","tier":2,"url":"https://pubmed.ncbi.nlm.nih.gov/42769089/","title":"Amphotericin B Colloidal Dispersion Is Effective and Safe for the Treatment of Invasive Aspergillosis in Chinese Patients with Hematologic Disease: A Multicenter, Prospective, Observational, Real-World Study.","published":"2026","quote":"Furthermore, exploratory subgroup analysis revealed higher response rates in patients with possible IA, Eastern Cooperative Oncology Group performance status score (ECOG) score of 0-2, baseline body temperature below 38°C, and acute lymphoblastic leukemia.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.1,"identifiers":{"pmid":"42769089","pmcid":"pmc-id: PMC13590257;","doi":"10.2147/DDDT.S613724"},"retrieved_at":"2026-09-22T11:10:57.182139Z"},{"id":"ev_a08dd3413d0e","question_id":"q_6f442701d567","source_id":"open_web","source_name":"Open Web (Supplementary)","organization":"Open web","tier":3,"url":"https://emedicine.medscape.com/article/207631-overview","title":"Acute Lymphoblastic Leukemia (ALL) - Medscape Reference","published":"","quote":"Acute Lymphoblastic Leukemia (ALL) Updated: Mar 19, 2026 - Author: Karen Seiter, MD; Chief Editor: Emmanuel C Besa, MD more...","context":"","origin":"open_web","tag":"GENERAL KNOWLEDGE","relevance":0.2,"identifiers":{},"retrieved_at":"2026-09-22T11:11:11.187584Z"},{"id":"ev_546f67a67fc0","question_id":"q_6f442701d567","source_id":"open_web","source_name":"Open Web (Supplementary)","organization":"Open web","tier":3,"url":"https://www.youtube.com/watch?v=kEJ382ZJM8o","title":"Acute Lymphoblastic Leukemia (ALL) Treatment - YouTube","published":"","quote":"The server cannot process the request because it is malformed.","context":"","origin":"open_web","tag":"GENERAL KNOWLEDGE","relevance":0.0,"identifiers":{},"retrieved_at":"2026-09-22T11:11:11.187782Z"},{"id":"ev_d6702a8c8417","question_id":"q_bf36e105dc68","source_id":"fda","source_name":"FDA","organization":"FDA","tier":1,"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-ponatinib-chemotherapy-newly-diagnosed-philadelphia-chromosome","title":"FDA grants accelerated approval to ponatinib with chemotherapy for ...","published":"","quote":"Chemotherapy consisted of 3 cycles of induction with vincristine and dexamethasone, 6 cycles of consolidation alternating between methotrexate and cytarabine, and 11 cycles of maintenance with vincristine and prednisone.","context":"","origin":"targeted_search","tag":"VERIFIED","relevance":0.99,"identifiers":{"domain":"fda.gov","search_backend":"duckduckgo"},"retrieved_at":"2026-09-22T11:12:05.742360Z"},{"id":"ev_49c6e81c290d","question_id":"q_bf36e105dc68","source_id":"esmo","source_name":"ESMO","organization":"Journal of the National Comprehensive Cancer Network : JNCCN","tier":1,"url":"https://pubmed.ncbi.nlm.nih.gov/39413812/","title":"Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.","published":"2024-10-01","quote":"The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia (ALL) provide recommendations for management of ALL, with a focus on the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk assessment and stratification for risk-adapted therapy; treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients; and supportive care considerations.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.98,"identifiers":{"pmid":"39413812","doi":"10.6004/jnccn.2024.0051","epmc_id":"39413812","source":"MED"},"retrieved_at":"2026-09-22T11:09:07.870882Z"},{"id":"ev_d31182c7cd43","question_id":"q_bf36e105dc68","source_id":"nci","source_name":"National Cancer Institute (NCI) PDQ","organization":"National Cancer Institute","tier":1,"url":"https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq","title":"PDQ: Remission induction therapy","published":"","quote":"Most current induction regimens for patients with adult ALL include combination chemotherapy with prednisone, vincristine, and an anthracycline.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.98,"identifiers":{"pdq_summary":"adult-all-treatment-pdq","section":"Remission induction therapy"},"retrieved_at":"2026-09-22T11:09:39.201772Z"},{"id":"ev_913f6ac14044","question_id":"q_bf36e105dc68","source_id":"fda","source_name":"FDA","organization":"FDA","tier":1,"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-ponatinib-chemotherapy-newly-diagnosed-philadelphia-chromosome","title":"FDA grants accelerated approval to ponatinib with chemotherapy for ...","published":"","quote":"On March 19, 2024, the Food and Drug Administration granted accelerated approval to ponatinib (Iclusig, Takeda Pharmaceuticals U.S.A., Inc.) with chemotherapy for adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).","context":"","origin":"targeted_search","tag":"VERIFIED","relevance":0.98,"identifiers":{"domain":"fda.gov","search_backend":"duckduckgo"},"retrieved_at":"2026-09-22T11:12:05.742302Z"},{"id":"ev_2ef71da17f30","question_id":"q_bf36e105dc68","source_id":"esmo","source_name":"ESMO","organization":"Journal of the National Comprehensive Cancer Network : JNCCN","tier":1,"url":"https://pubmed.ncbi.nlm.nih.gov/39938467/","title":"Pediatric Acute Lymphoblastic Leukemia, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.","published":"2025-02-01","quote":"The NCCN Guidelines for pediatric ALL focus on risk assessment and stratification of risk-adapted therapy; treatment strategies for BCR::ABL1 (Philadelphia chromosome [Ph])-negative and BCR::ABL1-positive B-cell lineage, T-cell lineage, and infant ALL; and supportive care considerations.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.98,"identifiers":{"pmid":"39938467","doi":"10.6004/jnccn.2025.0006","epmc_id":"39938467","source":"MED"},"retrieved_at":"2026-09-22T11:09:07.871202Z"},{"id":"ev_1153f96a4bd5","question_id":"q_bf36e105dc68","source_id":"nci","source_name":"National Cancer Institute (NCI) PDQ","organization":"National Cancer Institute","tier":1,"url":"https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq","title":"PDQ: Remission induction therapy","published":"","quote":"Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.96,"identifiers":{"pdq_summary":"adult-all-treatment-pdq","section":"Remission induction therapy"},"retrieved_at":"2026-09-22T11:09:39.201853Z"},{"id":"ev_2c9248174500","question_id":"q_bf36e105dc68","source_id":"ashpublications","source_name":"ASH / Blood (American Society of Hematology)","organization":"Journal of the National Comprehensive Cancer Network : JNCCN","tier":2,"url":"https://pubmed.ncbi.nlm.nih.gov/31910389/","title":"Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.","published":"2020-01-01","quote":"Title: Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.96,"identifiers":{"pmid":"31910389","doi":"10.6004/jnccn.2020.0001","epmc_id":"31910389","source":"MED"},"retrieved_at":"2026-09-22T11:09:30.331202Z"},{"id":"ev_b80c7d1d38ae","question_id":"q_bf36e105dc68","source_id":"asco","source_name":"ASCO","organization":"Journal of Clinical Oncology","tier":2,"url":"https://doi.org/10.1200/jco.2018.36.30_suppl.50","title":"Implementation of a multifaceted program to improve uptake of guideline recommendations for adolescent and young adults (AYAs) with acute lymphoblastic leukemia (ALL).","published":"2018-10-20","quote":"There is compelling evidence demonstrating a survival benefit for AYAs treated with pediatric regimens vs adult regimens, and guidelines from the National Comprehensive Cancer Network now recommend consideration of pediatric inspired treatment.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.95,"identifiers":{"doi":"10.1200/jco.2018.36.30_suppl.50"},"retrieved_at":"2026-09-22T11:09:58.443925Z"},{"id":"ev_0243c39a7be7","question_id":"q_bf36e105dc68","source_id":"ashpublications","source_name":"ASH / Blood (American Society of Hematology)","organization":"American Society of Hematology","tier":2,"url":"https://pubmed.ncbi.nlm.nih.gov/41670624/","title":"American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults.","published":"2026-07-01","quote":"Conclusions Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.95,"identifiers":{"pmid":"41670624","pmcid":"PMC13366310","doi":"10.1182/bloodadvances.2021006479","epmc_id":"41670624","source":"MED"},"retrieved_at":"2026-09-22T11:09:58.444059Z"},{"id":"ev_b4843d9ecda3","question_id":"q_bf36e105dc68","source_id":"asco","source_name":"ASCO","organization":"American Society of Clinical Oncology Educational Book","tier":2,"url":"https://doi.org/10.14694/edbook_am.2012.32.180","title":"Development and Refinement of Augmented Treatment Regimens for Pediatric High-Risk Acute Lymphoblastic Leukemia","published":"2012-06","quote":"Contemporary COG HR ALL treatment regimens were developed from the BFM-76 regimen, with subsequent changes that led to development and refinement of a so-called augmented BFM (ABFM) regimen used today.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.89,"identifiers":{"doi":"10.14694/edbook_am.2012.32.180"},"retrieved_at":"2026-09-22T11:09:51.568940Z"},{"id":"ev_1e61c95d0f76","question_id":"q_bf36e105dc68","source_id":"clinicaltrials","source_name":"ClinicalTrials.gov","organization":"National Cancer Institute (NCI)","tier":2,"url":"https://clinicaltrials.gov/study/NCT02003222","title":"Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia","published":"2014-05-19","quote":"CONSOLIDATION THERAPY: Beginning after the second cycle of blinatumomab (patients randomized to the blinatumomab group) or after intensification therapy (patients not randomized to blinatumomab), patients receive cytarabine IV over 30 minutes or SC on days 1-5, etoposide IV over 1 hour on days 1-5, methotrexate IT on day 1, and pegaspargase IM or IV on day 5, and CD20 positive patients may optionally receive rituximab IV on day 5.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.741,"identifiers":{"nct":"NCT02003222","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING"},"retrieved_at":"2026-09-22T11:11:22.474319Z"},{"id":"ev_04afdf650765","question_id":"q_bf36e105dc68","source_id":"clinicaltrials","source_name":"ClinicalTrials.gov","organization":"National Cancer Institute (NCI)","tier":2,"url":"https://clinicaltrials.gov/study/NCT02003222","title":"Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia","published":"2014-05-19","quote":"MAINTENANCE THERAPY: Within 6 weeks after beginning last cycle of consolidation therapy, patients receive mercaptopurine PO daily, methotrexate PO or IV over 2 hours once weekly for 2.5 years, vincristine sulfate IV on day 1 every 3 months, prednisone PO on days 1-5 every 3 months, and methotrexate IT on day 1 every 3 months.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.741,"identifiers":{"nct":"NCT02003222","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING"},"retrieved_at":"2026-09-22T11:11:22.474377Z"},{"id":"ev_c3c0e67a1c26","question_id":"q_bf36e105dc68","source_id":"open_web","source_name":"Open Web (Supplementary)","organization":"Open web","tier":3,"url":"https://emedicine.medscape.com/article/2004705-overview","title":"Acute Lymphoblastic Leukemia (ALL) Treatment Protocols","published":"","quote":"Treatment generally consists of a pretreatment phase (typically using corticosteroids), followed by an induction phase with a goal of achieving complete remission (CR) while maintaining quality of life, followed by a consolidation phase to maintain CR.","context":"","origin":"open_web","tag":"GENERAL KNOWLEDGE","relevance":0.98,"identifiers":{},"retrieved_at":"2026-09-22T11:12:18.806374Z"},{"id":"ev_3362d9309218","question_id":"q_bf36e105dc68","source_id":"open_web","source_name":"Open Web (Supplementary)","organization":"Open web","tier":3,"url":"https://emedicine.medscape.com/article/2004705-overview","title":"Acute Lymphoblastic Leukemia (ALL) Treatment Protocols","published":"","quote":"Follow-up is either with maintenance therapy or allogeneic hematopoietic stem cell transplantation (HSCT).","context":"","origin":"open_web","tag":"GENERAL KNOWLEDGE","relevance":0.93,"identifiers":{},"retrieved_at":"2026-09-22T11:12:18.806501Z"},{"id":"ev_4163242615d7","question_id":"q_0207dfec5c74","source_id":"cdc_icd10","source_name":"CDC / NCHS","organization":"CDC / NCHS","tier":1,"url":"https://www.cdc.gov/mmwr/volumes/66/wr/mm6636a3.htm","title":"Rates and Trends of Pediatric Acute Lymphoblastic Leukemia - CDC","published":"","quote":"Overall incidence of pediatric ALL during 2001–2014 was 34.0 cases per 1 million persons and among all racial/ethnic groups was highest among Hispanics (42.9 per 1 million).","context":"","origin":"targeted_search","tag":"VERIFIED","relevance":1.0,"identifiers":{"domain":"cdc.gov","search_backend":"firecrawl"},"retrieved_at":"2026-09-22T11:12:21.121663Z"},{"id":"ev_5996ab18e475","question_id":"q_0207dfec5c74","source_id":"seer","source_name":"NCI SEER","organization":"National Cancer Institute, Surveillance, Epidemiology, and End Results Program","tier":1,"url":"https://seer.cancer.gov/statfacts/html/alyl.html","title":"Acute Lymphocytic Leukemia — Cancer Stat Facts","published":"","quote":"The rate of new cases of acute lymphocytic leukemia was 1.9 per 100,000 men and women per year.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.99,"identifiers":{"slug":"alyl"},"retrieved_at":"2026-09-22T11:11:28.351413Z"},{"id":"ev_868dbce5142e","question_id":"q_0207dfec5c74","source_id":"seer","source_name":"NCI SEER","organization":"National Cancer Institute, Surveillance, Epidemiology, and End Results Program","tier":1,"url":"https://seer.cancer.gov/statfacts/html/alyl.html","title":"Acute Lymphocytic Leukemia — Cancer Stat Facts","published":"","quote":"The death rate was 0.4 per 100,000 men and women per year.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.99,"identifiers":{"slug":"alyl"},"retrieved_at":"2026-09-22T11:11:28.351464Z"},{"id":"ev_ae2e51c35a5b","question_id":"q_0207dfec5c74","source_id":"seer","source_name":"NCI SEER","organization":"National Cancer Institute, Surveillance, Epidemiology, and End Results Program","tier":1,"url":"https://seer.cancer.gov/statfacts/html/alyl.html","title":"Acute Lymphocytic Leukemia — Cancer Stat Facts","published":"","quote":"In 2023, there were an estimated 126,118 people living with acute lymphocytic leukemia in the United States.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.98,"identifiers":{"slug":"alyl"},"retrieved_at":"2026-09-22T11:11:28.351497Z"},{"id":"ev_338001d3311a","question_id":"q_0207dfec5c74","source_id":"cdc_icd10","source_name":"CDC / NCHS","organization":"CDC / NCHS","tier":1,"url":"https://www.cdc.gov/mmwr/volumes/66/wr/mm6636a3.htm","title":"Rates and Trends of Pediatric Acute Lymphoblastic Leukemia - CDC","published":"","quote":"Both overall and among Hispanics, pediatric ALL incidence increased during 2001–2008 and remained stable during 2008–2014.","context":"","origin":"targeted_search","tag":"VERIFIED","relevance":0.95,"identifiers":{"domain":"cdc.gov","search_backend":"firecrawl"},"retrieved_at":"2026-09-22T11:12:21.121720Z"},{"id":"ev_258f61e5a57f","question_id":"q_0207dfec5c74","source_id":"who_gho","source_name":"WHO Global Health Observatory","organization":"World Health Organization","tier":1,"url":"https://ghoapi.azureedge.net/api/CANCERSURVIVAL_CHILDREN_LEUKAEMIA","title":"WHO GHO CANCERSURVIVAL_CHILDREN_LEUKAEMIA: Childhood cancer survival for lymphoid leukaemia, age-standardized 5-year net survival (%)","published":"2021","quote":"Observations: TUR 2021 AGEGROUP_YEARSLESS20 = 80.7 [75.2-85.3] | IND 2021 AGEGROUP_YEARSLESS20 = 60.5 [44.6-74.1] | SOM 2021 AGEGROUP_YEARSLESS20 = 18.8 [8.5-37.8] | ROU 2021 AGEGROUP_YEARSLESS20 = 74.1 [60.0-83.5] | NER 2021 AGEGROUP_YEARSLESS20 = 25.0 [12.5-44.2] | SLV 2021 AGEGROUP_YEARSLESS20 = 69.7 [54.0-81.0] | PRK 2021 AGEGROUP_YEARSLESS20 = 52.1 [34.1-68.4] | DEU 2021 AGEGROUP_YEARSLESS20 = 90.6 [87.1-93.2] | GBR 2021 AGEGROUP_YEARSLESS20 = 92.5 [90.2-94.3] | ARM 2021 AGEGROUP_YEARSLESS20 = 74.7 [59.9-84.4] | SWZ 2021 AGEGROUP_YEARSLESS20 = 24.8 [11.7-45.7] | SEAR 2021 AGEGROUP_YEARSLESS20 = 57.8 [46.0-67.7] | TON 2021 AGEGROUP_YEARSLESS20 = 35.1 [17.7-59.0] | DNK 2021 AGEGROUP_YEARSLESS20 = 92.2 [88.3-94.8] | ZMB 2021 AGEGROUP_YEARSLESS20 = 43.6 [26.3-61.3] | ESP 2021 AGEGROUP_YEARSLESS20 = 88.6 [83.2-92.1] | AZE 2021 AGEGROUP_YEARSLESS20 = 66.5 [49.6-79.0] | TTO 2021 AGEGROUP_YEARSLESS20 = 76.0 [60.0-85.5] | CHL 2021 AGEGROUP_YEARSLESS20 = 75.6 [66.4-82.9] | NAM 2021 AGEGROUP_YEARSLESS20 = 55.0 [36.5-70.3] | GTM 2021 AGEGROUP_YEARSLESS20 = 59.3 [42.2-73.4] | MUS 2021 AGEGROUP_YEARSLESS20 = 74.6 [59.3-83.7] | LTU 2021 AGEGROUP_YEARSLESS20 = 83.9 [76.0-89.6] | MLT 2021 AGEGROUP_YEARSLESS20 = 89.8 [82.2-94.2] | ITA 2021 AGEGROUP_YEARSLESS20 = 87.8 [84.1-90.8]","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.89,"identifiers":{"indicator_code":"CANCERSURVIVAL_CHILDREN_LEUKAEMIA"},"retrieved_at":"2026-09-22T11:11:44.996402Z"},{"id":"ev_30c09fef4cb4","question_id":"q_0207dfec5c74","source_id":"orphanet","source_name":"Orphanet / Orphadata","organization":"Orphanet","tier":1,"url":"https://www.orpha.net/en/disease/detail/513","title":"Orphanet Acute lymphoblastic leukemia (ORPHA:513)","published":"","quote":"The peak incidence occurs between 2 and 5 years of age.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.88,"identifiers":{"orphacode":"513","icd10":"C91.0","mesh":"D054198","umls":"C1961102"},"retrieved_at":"2026-09-22T11:11:28.351551Z"},{"id":"ev_a90de929ee38","question_id":"q_0207dfec5c74","source_id":"cdc_icd10","source_name":"CDC / NCHS","organization":"CDC / NCHS","tier":1,"url":"https://www.cdc.gov/mmwr/volumes/66/wr/mm6636a3.htm","title":"Rates and Trends of Pediatric Acute Lymphoblastic Leukemia - CDC","published":"","quote":"Acute lymphoblastic leukemia (ALL) is the most prevalent cancer among children and adolescents in the United States, representing 20% of all cancers diagnosed in persons aged 3,000 new cases each year ( _1_).","context":"","origin":"targeted_search","tag":"VERIFIED","relevance":0.8,"identifiers":{"domain":"cdc.gov","search_backend":"firecrawl"},"retrieved_at":"2026-09-22T11:12:21.121593Z"},{"id":"ev_5b596a37cfa7","question_id":"q_0207dfec5c74","source_id":"orphanet","source_name":"Orphanet / Orphadata","organization":"Orphanet","tier":1,"url":"https://www.orpha.net/en/disease/detail/513","title":"Orphanet Acute lymphoblastic leukemia (ORPHA:513)","published":"","quote":"It accounts for 75% of all cases of childhood leukemia cases.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.67,"identifiers":{"orphacode":"513","icd10":"C91.0","mesh":"D054198","umls":"C1961102"},"retrieved_at":"2026-09-22T11:11:28.351530Z"},{"id":"ev_7d73ce6f2a4e","question_id":"q_0207dfec5c74","source_id":"ashpublications","source_name":"ASH / Blood (American Society of Hematology)","organization":"American Society of Hematology","tier":2,"url":"https://pubmed.ncbi.nlm.nih.gov/41670627/","title":"American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults.","published":"2026-07-01","quote":"Background Adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) represent a unique population.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.92,"identifiers":{"pmid":"41670627","pmcid":"PMC13366240","doi":"10.1182/bloodadvances.2021006469","epmc_id":"41670627","source":"MED"},"retrieved_at":"2026-09-22T11:12:00.255808Z"},{"id":"ev_689eb350b7f2","question_id":"q_0207dfec5c74","source_id":"ashpublications","source_name":"ASH / Blood (American Society of Hematology)","organization":"American Society of Hematology","tier":2,"url":"https://pubmed.ncbi.nlm.nih.gov/41670627/","title":"American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults.","published":"2026-07-01","quote":"They also have distinctive care needs, social risk factors, and disease behavior compared with other age groups.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.75,"identifiers":{"pmid":"41670627","pmcid":"PMC13366240","doi":"10.1182/bloodadvances.2021006469","epmc_id":"41670627","source":"MED"},"retrieved_at":"2026-09-22T11:12:00.255893Z"},{"id":"ev_4c55ced0ef82","question_id":"q_0207dfec5c74","source_id":"ashpublications","source_name":"ASH / Blood (American Society of Hematology)","organization":"American Society of Hematology","tier":2,"url":"https://pubmed.ncbi.nlm.nih.gov/41670627/","title":"American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults.","published":"2026-07-01","quote":"Treatment regimens can vary significantly depending on whether they receive care in a pediatric or in an adult setting.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.72,"identifiers":{"pmid":"41670627","pmcid":"PMC13366240","doi":"10.1182/bloodadvances.2021006469","epmc_id":"41670627","source":"MED"},"retrieved_at":"2026-09-22T11:12:00.255863Z"},{"id":"ev_514eaf63445a","question_id":"q_f38fdd338919","source_id":"nci","source_name":"National Cancer Institute (NCI) PDQ","organization":"National Cancer Institute","tier":1,"url":"https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq","title":"PDQ: Remission induction therapy","published":"","quote":"However, the results suggested that inclusion of imatinib into a relatively standard chemotherapy regimen for newly diagnosed adult patients with Ph-positive ALL may provide a significant survival advantage.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.99,"identifiers":{"pdq_summary":"adult-all-treatment-pdq","section":"Remission induction therapy"},"retrieved_at":"2026-09-22T11:13:08.412531Z"},{"id":"ev_fca4129b43c4","question_id":"q_f38fdd338919","source_id":"who","source_name":"WHO","organization":"WHO","tier":1,"url":"https://applications.emro.who.int/imemrf/J_Royal_Med_Serv/J_Royal_Med_Serv_2015_22_3_53_58.pdf","title":"PDF Immunophenotypic Profile of Acute Leukemia Cases Using Multicolor Flow ...","published":"","quote":"All cases of B-acute lymphoblastic leukemia showed expression of pan B-cell markers (CD19,CD22 and cytoplasmic CD79a) and 117 (90%) of cases expressed CD10.","context":"","origin":"targeted_search","tag":"VERIFIED","relevance":0.99,"identifiers":{"domain":"applications.emro.who.int","search_backend":"duckduckgo"},"retrieved_at":"2026-09-22T11:13:42.655672Z"},{"id":"ev_26e9b9e77c4f","question_id":"q_f38fdd338919","source_id":"who","source_name":"WHO","organization":"WHO","tier":1,"url":"https://applications.emro.who.int/imemrf/J_Royal_Med_Serv/J_Royal_Med_Serv_2015_22_3_53_58.pdf","title":"PDF Immunophenotypic Profile of Acute Leukemia Cases Using Multicolor Flow ...","published":"","quote":"Of the acute lymphoblastic leukemia cases, 130 cases (79.3%) were B-cell type and 34 cases (20.7%) were T-cell type.","context":"","origin":"targeted_search","tag":"VERIFIED","relevance":0.98,"identifiers":{"domain":"applications.emro.who.int","search_backend":"duckduckgo"},"retrieved_at":"2026-09-22T11:13:42.655581Z"},{"id":"ev_a732c8f47456","question_id":"q_f38fdd338919","source_id":"nci","source_name":"National Cancer Institute (NCI) PDQ","organization":"National Cancer Institute","tier":1,"url":"https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq","title":"PDQ: Remission induction therapy","published":"","quote":"Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.97,"identifiers":{"pdq_summary":"adult-all-treatment-pdq","section":"Remission induction therapy"},"retrieved_at":"2026-09-22T11:13:08.412582Z"},{"id":"ev_3f9d438a3c1c","question_id":"q_f38fdd338919","source_id":"who","source_name":"WHO","organization":"WHO","tier":1,"url":"https://applications.emro.who.int/imemrf/J_Royal_Med_Serv/J_Royal_Med_Serv_2015_22_3_53_58.pdf","title":"PDF Immunophenotypic Profile of Acute Leukemia Cases Using Multicolor Flow ...","published":"","quote":"Cytoplasmic CD3 and CD5 were the most sensitive markers for diagnosis of T-acute lymphoblastic leukemia.","context":"","origin":"targeted_search","tag":"VERIFIED","relevance":0.97,"identifiers":{"domain":"applications.emro.who.int","search_backend":"duckduckgo"},"retrieved_at":"2026-09-22T11:13:42.655702Z"},{"id":"ev_7e9a669b0be5","question_id":"q_f38fdd338919","source_id":"orphanet","source_name":"Orphanet / Orphadata","organization":"Orphanet","tier":1,"url":"https://www.orpha.net/en/disease/detail/513","title":"Orphanet Acute lymphoblastic leukemia (ORPHA:513)","published":"","quote":"A group of rare Non-Hodgkin lymphoma characterized by malignant proliferation of lymphoid cells blocked at an early stage of differentiation.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.74,"identifiers":{"orphacode":"513","icd10":"C91.0","mesh":"D054198","umls":"C1961102"},"retrieved_at":"2026-09-22T11:12:52.316186Z"},{"id":"ev_c854ac12b4f3","question_id":"q_f38fdd338919","source_id":"nci","source_name":"National Cancer Institute (NCI) PDQ","organization":"National Cancer Institute","tier":1,"url":"https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq","title":"PDQ: Remission induction therapy","published":"","quote":"If a suitable donor is available, allogeneic bone marrow transplant should be considered because remissions are generally short with conventional ALL chemotherapy clinical trials.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.7,"identifiers":{"pdq_summary":"adult-all-treatment-pdq","section":"Remission induction therapy"},"retrieved_at":"2026-09-22T11:13:08.412616Z"},{"id":"ev_3c3b04664610","question_id":"q_f38fdd338919","source_id":"ashpublications","source_name":"ASH / Blood (American Society of Hematology)","organization":"American Society of Hematology","tier":2,"url":"https://pubmed.ncbi.nlm.nih.gov/41670624/","title":"American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults.","published":"2026-07-01","quote":"Additional management of ALL subsets (T-cell ALL), CNS relapse, and the role of consolidation with allogeneic transplant are addressed.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.95,"identifiers":{"pmid":"41670624","pmcid":"PMC13366310","doi":"10.1182/bloodadvances.2021006479","epmc_id":"41670624","source":"MED"},"retrieved_at":"2026-09-22T11:12:52.316397Z"},{"id":"ev_4fe6496bdc42","question_id":"q_f38fdd338919","source_id":"ashpublications","source_name":"ASH / Blood (American Society of Hematology)","organization":"American Society of Hematology","tier":2,"url":"https://pubmed.ncbi.nlm.nih.gov/41670627/","title":"American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults.","published":"2026-07-01","quote":"The use of targeted agents in frontline therapy is increasingly supported, although further research is needed to optimize this strategy.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.85,"identifiers":{"pmid":"41670627","pmcid":"PMC13366240","doi":"10.1182/bloodadvances.2021006469","epmc_id":"41670627","source":"MED"},"retrieved_at":"2026-09-22T11:12:52.316318Z"},{"id":"ev_f4062db24c05","question_id":"q_f38fdd338919","source_id":"ashpublications","source_name":"ASH / Blood (American Society of Hematology)","organization":"American Society of Hematology","tier":2,"url":"https://pubmed.ncbi.nlm.nih.gov/41670624/","title":"American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults.","published":"2026-07-01","quote":"They focused on the following treatment modalities: immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.83,"identifiers":{"pmid":"41670624","pmcid":"PMC13366310","doi":"10.1182/bloodadvances.2021006479","epmc_id":"41670624","source":"MED"},"retrieved_at":"2026-09-22T11:12:52.316347Z"},{"id":"ev_2a6244027a00","question_id":"q_f38fdd338919","source_id":"pubmed","source_name":"PubMed","organization":"AAPS PharmSciTech","tier":2,"url":"https://pubmed.ncbi.nlm.nih.gov/42768180/","title":"Beyond Immediate Release: FDM-Printed Pediatric 6-Mercaptopurine Chewable Tablets with Spontaneous In Situ Nanostructure Formation.","published":"2026 Sep 21","quote":"Pediatric maintenance therapy for acute lymphoblastic leukemia requires prolonged daily administration of 6-mercaptopurine (6-MP), a drug characterized by a narrow therapeutic index and substantial interindividual variability, creating a need for flexible and patient-friendly dosage forms.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.1,"identifiers":{"pmid":"42768180","doi":"10.1208/s12249-026-03556-7"},"retrieved_at":"2026-09-22T11:13:20.333864Z"},{"id":"ev_1dd338e2d267","question_id":"q_f38fdd338919","source_id":"pubmed","source_name":"PubMed","organization":"AAPS PharmSciTech","tier":2,"url":"https://pubmed.ncbi.nlm.nih.gov/42768180/","title":"Beyond Immediate Release: FDM-Printed Pediatric 6-Mercaptopurine Chewable Tablets with Spontaneous In Situ Nanostructure Formation.","published":"2026 Sep 21","quote":"This study aimed to develop pediatric chewable tablets 6-MP using hot-melt extrusion and fused deposition modeling (FDM) 3D printing.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.05,"identifiers":{"pmid":"42768180","doi":"10.1208/s12249-026-03556-7"},"retrieved_at":"2026-09-22T11:13:20.333929Z"},{"id":"ev_c46ce82dab79","question_id":"q_f38fdd338919","source_id":"open_web","source_name":"Open Web (Supplementary)","organization":"Open web","tier":3,"url":"https://www.kucancercenter.org/news-room/blog/2020/10/what-you-should-know-acute-lymphoblastic-leukemia","title":"What You Should Know About Acute Lymphoblastic Leukemia ‌","published":"","quote":"There are 3 subtypes: 1. Precursor B cell ALL: Most common type in adults 2. Precursor T cell ALL: More likely to affect young adults and men 3. Mature B cell ALL (Burkitt type ALL): Identified by specific genetic changes","context":"","origin":"open_web","tag":"GENERAL KNOWLEDGE","relevance":0.99,"identifiers":{},"retrieved_at":"2026-09-22T11:13:56.925630Z"},{"id":"ev_1b40ba955be5","question_id":"q_f38fdd338919","source_id":"open_web","source_name":"Open Web (Supplementary)","organization":"Open web","tier":3,"url":"https://www.kucancercenter.org/news-room/blog/2020/10/what-you-should-know-acute-lymphoblastic-leukemia","title":"What You Should Know About Acute Lymphoblastic Leukemia ‌","published":"","quote":"Philadelphia chromosome-like ALL (Ph-like ALL) is a precursor B-cell ALL that results in a change of the chromosomes on the leukemia cells.","context":"","origin":"open_web","tag":"GENERAL KNOWLEDGE","relevance":0.98,"identifiers":{},"retrieved_at":"2026-09-22T11:13:56.925732Z"},{"id":"ev_fe52db01cd48","question_id":"q_0b2efc095c4f","source_id":"orphanet","source_name":"Orphanet / Orphadata","organization":"Orphanet","tier":1,"url":"https://www.orpha.net/en/disease/detail/513","title":"Orphanet Acute lymphoblastic leukemia (ORPHA:513)","published":"","quote":"A group of rare Non-Hodgkin lymphoma characterized by malignant proliferation of lymphoid cells blocked at an early stage of differentiation.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.92,"identifiers":{"orphacode":"513","icd10":"C91.0","mesh":"D054198","umls":"C1961102"},"retrieved_at":"2026-09-22T11:14:08.382646Z"},{"id":"ev_8339986034b7","question_id":"q_0b2efc095c4f","source_id":"orphanet","source_name":"Orphanet / Orphadata","organization":"Orphanet","tier":1,"url":"https://www.orpha.net/en/disease/detail/513","title":"Orphanet Acute lymphoblastic leukemia (ORPHA:513)","published":"","quote":"Although it primarily affects the bone marrow and peripheral blood, the abnormal cells can infiltrate any organ or tissue.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.84,"identifiers":{"orphacode":"513","icd10":"C91.0","mesh":"D054198","umls":"C1961102"},"retrieved_at":"2026-09-22T11:14:08.382735Z"},{"id":"ev_175ccc0c54c4","question_id":"q_0b2efc095c4f","source_id":"orphanet","source_name":"Orphanet / Orphadata","organization":"Orphanet","tier":1,"url":"https://www.orpha.net/en/disease/detail/513","title":"Orphanet Acute lymphoblastic leukemia (ORPHA:513)","published":"","quote":"Patients may present with symptoms, frequently including lymphadenopathy, hepatosplenomegaly, bone pain, fever and signs of hemorrhage or they may remain asymptomatic.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.71,"identifiers":{"orphacode":"513","icd10":"C91.0","mesh":"D054198","umls":"C1961102"},"retrieved_at":"2026-09-22T11:14:08.382703Z"},{"id":"ev_74a8e7cba6cf","question_id":"q_0b2efc095c4f","source_id":"nci","source_name":"National Cancer Institute (NCI) PDQ","organization":"National Cancer Institute","tier":1,"url":"https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq","title":"PDQ: Remission induction therapy","published":"","quote":"However, the results suggested that inclusion of imatinib into a relatively standard chemotherapy regimen for newly diagnosed adult patients with Ph-positive ALL may provide a significant survival advantage.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.46,"identifiers":{"pdq_summary":"adult-all-treatment-pdq","section":"Remission induction therapy"},"retrieved_at":"2026-09-22T11:15:24.200129Z"},{"id":"ev_686c318142e4","question_id":"q_0b2efc095c4f","source_id":"nci","source_name":"National Cancer Institute (NCI) PDQ","organization":"National Cancer Institute","tier":1,"url":"https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq","title":"PDQ: Remission induction therapy","published":"","quote":"Most current induction regimens for patients with adult ALL include combination chemotherapy with prednisone, vincristine, and an anthracycline.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.42,"identifiers":{"pdq_summary":"adult-all-treatment-pdq","section":"Remission induction therapy"},"retrieved_at":"2026-09-22T11:15:24.200067Z"},{"id":"ev_73f85a9b1648","question_id":"q_0b2efc095c4f","source_id":"nci","source_name":"National Cancer Institute (NCI) PDQ","organization":"National Cancer Institute","tier":1,"url":"https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq","title":"PDQ: Remission induction therapy","published":"","quote":"Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.37,"identifiers":{"pdq_summary":"adult-all-treatment-pdq","section":"Remission induction therapy"},"retrieved_at":"2026-09-22T11:15:24.200161Z"},{"id":"ev_d0cbf82b6047","question_id":"q_0b2efc095c4f","source_id":"ashpublications","source_name":"ASH / Blood (American Society of Hematology)","organization":"American Society of Hematology","tier":2,"url":"https://pubmed.ncbi.nlm.nih.gov/41670627/","title":"American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults.","published":"2026-07-01","quote":"For adolescents and young adults (AYAs) with B-cell or T-cell acute lymphoblastic leukemia (B-ALL/T-ALL) or T-cell acute lymphoblastic lymphoma (T-LBL/LLy) receiving frontline therapy, the American Society of Hematology (ASH) guideline panel recommends pediatric-inspired (asparaginase-containing) regimens (strong recommendation based on moderate certainty in the evidence of effects ⨁⨁⨁◯).","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.89,"identifiers":{"pmid":"41670627","pmcid":"PMC13366240","doi":"10.1182/bloodadvances.2021006469","epmc_id":"41670627","source":"MED"},"retrieved_at":"2026-09-22T11:14:25.266904Z"},{"id":"ev_77090229ca10","question_id":"q_0b2efc095c4f","source_id":"ashpublications","source_name":"ASH / Blood (American Society of Hematology)","organization":"American Society of Hematology","tier":2,"url":"https://pubmed.ncbi.nlm.nih.gov/41670627/","title":"American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults.","published":"2026-07-01","quote":"These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about the frontline management of ALL in AYAs.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.83,"identifiers":{"pmid":"41670627","pmcid":"PMC13366240","doi":"10.1182/bloodadvances.2021006469","epmc_id":"41670627","source":"MED"},"retrieved_at":"2026-09-22T11:14:25.266988Z"},{"id":"ev_912a955c92f0","question_id":"q_0b2efc095c4f","source_id":"ashpublications","source_name":"ASH / Blood (American Society of Hematology)","organization":"American Society of Hematology","tier":2,"url":"https://pubmed.ncbi.nlm.nih.gov/41670624/","title":"American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults.","published":"2026-07-01","quote":"They focused on the following treatment modalities: immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.73,"identifiers":{"pmid":"41670624","pmcid":"PMC13366310","doi":"10.1182/bloodadvances.2021006479","epmc_id":"41670624","source":"MED"},"retrieved_at":"2026-09-22T11:14:39.438892Z"},{"id":"ev_ab066abf322c","question_id":"q_0b2efc095c4f","source_id":"open_web","source_name":"Open Web (Supplementary)","organization":"Open web","tier":5,"url":"https://jnccn.org/view/journals/jnccn/22/8/article-p563.xml","title":"Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice ...","published":"","quote":"The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia (ALL) provide recommendations for management of ALL, with a focus on the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk assessment and stratification for risk-adapted therapy; treatment strategies ...","context":"","origin":"open_web","tag":"GENERAL KNOWLEDGE","relevance":0.98,"identifiers":{"domain":"jnccn.org","search_backend":"azure_web_search"},"retrieved_at":"2026-09-22T11:16:16.968172Z"},{"id":"ev_c355e539ab79","question_id":"q_0b2efc095c4f","source_id":"open_web","source_name":"Open Web (Supplementary)","organization":"Open web","tier":5,"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1489.","title":"Acute Lymphoblastic Leukemia - Guidelines Detail - nccn.org","published":"","quote":"Acute Lymphoblastic Leukemia Guidelines NCCN Guidelines Version 3.2026 - Acute Lymphoblastic Leukemia Guidelines Navigator","context":"","origin":"open_web","tag":"GENERAL KNOWLEDGE","relevance":0.76,"identifiers":{"domain":"nccn.org","search_backend":"azure_web_search"},"retrieved_at":"2026-09-22T11:16:16.968108Z"},{"id":"ev_518d2567f527","question_id":"q_a687f9ed49c6","source_id":"esmo","source_name":"ESMO","organization":"Journal of the National Comprehensive Cancer Network : JNCCN","tier":1,"url":"https://pubmed.ncbi.nlm.nih.gov/39413812/","title":"Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.","published":"2024-10-01","quote":"This selection from the NCCN Guidelines for ALL focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.99,"identifiers":{"pmid":"39413812","doi":"10.6004/jnccn.2024.0051","epmc_id":"39413812","source":"MED"},"retrieved_at":"2026-09-22T11:13:07.945306Z"},{"id":"ev_3177e0973b83","question_id":"q_a687f9ed49c6","source_id":"openfda_label","source_name":"FDA Drug Labeling (openFDA)","organization":"Alembic Pharmaceuticals Limited","tier":1,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03ad6056-0e71-4e7c-842a-a5f87649bdcd","title":"NELARABINE (NELARABINE)","published":"2024-08-07","quote":"Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.99,"identifiers":{"set_id":"03ad6056-0e71-4e7c-842a-a5f87649bdcd","spl_id":"482d7978-12a5-467a-b10e-1789df5dd0f8","application_number":"ANDA218554","rxcui":"603566","unii":"60158CV180","spl_version":"2"},"retrieved_at":"2026-09-22T11:14:51.070201Z"},{"id":"ev_2ff754c9884d","question_id":"q_a687f9ed49c6","source_id":"esmo","source_name":"ESMO","organization":"Bulletin du cancer","tier":1,"url":"https://pubmed.ncbi.nlm.nih.gov/40975678/","title":"[Choice of bridging therapy prior to reinjection of autologous CAR-T cells in patients aged 0-25 years treated for B-ALL (SFGM-TC)].","published":"2025-09-19","quote":"Consequently, there is currently no available guidelines.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.99,"identifiers":{"pmid":"40975678","doi":"10.1016/j.bulcan.2025.07.016","epmc_id":"40975678","source":"MED"},"retrieved_at":"2026-09-22T11:13:58.354225Z"},{"id":"ev_1f18856240c5","question_id":"q_a687f9ed49c6","source_id":"openfda_label","source_name":"FDA Drug Labeling (openFDA)","organization":"Amneal Pharmaceuticals LLC","tier":1,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a273a2d-a1ff-412a-925e-696648730dae","title":"Clofarabine (CLOFARABINE)","published":"2022-08-23","quote":"Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.99,"identifiers":{"set_id":"0a273a2d-a1ff-412a-925e-696648730dae","spl_id":"9371cb36-5f01-4afa-bbd4-6886ae0fc277","application_number":"ANDA208857","rxcui":"486419","unii":"762RDY0Y2H","spl_version":"5"},"retrieved_at":"2026-09-22T11:14:51.070384Z"},{"id":"ev_cd0d12f0029b","question_id":"q_a687f9ed49c6","source_id":"esmo","source_name":"ESMO","organization":"Blood advances","tier":1,"url":"https://pubmed.ncbi.nlm.nih.gov/41670624/","title":"American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults.","published":"2026-07-01","quote":"Conclusions Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.97,"identifiers":{"pmid":"41670624","pmcid":"PMC13366310","doi":"10.1182/bloodadvances.2021006479","epmc_id":"41670624","source":"MED"},"retrieved_at":"2026-09-22T11:13:07.945408Z"},{"id":"ev_0efaaf99b916","question_id":"q_a687f9ed49c6","source_id":"nci","source_name":"National Cancer Institute (NCI) PDQ","organization":"National Cancer Institute","tier":1,"url":"https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq","title":"PDQ: Remission induction therapy","published":"","quote":"If a suitable donor is available, allogeneic bone marrow transplant should be considered because remissions are generally short with conventional ALL chemotherapy clinical trials.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.95,"identifiers":{"pdq_summary":"adult-all-treatment-pdq","section":"Remission induction therapy"},"retrieved_at":"2026-09-22T11:15:52.303478Z"},{"id":"ev_8e12075ab437","question_id":"q_a687f9ed49c6","source_id":"nci","source_name":"National Cancer Institute (NCI) PDQ","organization":"National Cancer Institute","tier":1,"url":"https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq","title":"PDQ: Remission induction therapy","published":"","quote":"Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.92,"identifiers":{"pdq_summary":"adult-all-treatment-pdq","section":"Remission induction therapy"},"retrieved_at":"2026-09-22T11:15:52.303380Z"},{"id":"ev_f7fabb14591a","question_id":"q_a687f9ed49c6","source_id":"asco","source_name":"ASCO","organization":"Journal of Clinical Oncology","tier":2,"url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e18528","title":"Response to venetoclax-containing regimens in patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL).","published":"2026-06-01","quote":"Ven monotherapy 2 (10.5%) Ven + hypomethylating agent 7 (36.9%) Ven + chemotherapy 3 (15.8%) Ven + nelarabine 2 (10.5%) Ven + targeted agent 2 (10.5%) Ven + navitoclax 3 (15.8%)","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.99,"identifiers":{"doi":"10.1200/jco.2026.44.16_suppl.e18528"},"retrieved_at":"2026-09-22T11:15:08.177015Z"},{"id":"ev_1f4c71a7e815","question_id":"q_a687f9ed49c6","source_id":"asco","source_name":"ASCO","organization":"Journal of Clinical Oncology","tier":2,"url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e18528","title":"Response to venetoclax-containing regimens in patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL).","published":"2026-06-01","quote":"The pts were heavily pre-treated prior to ven-based therapy for R/R disease, with 68% receiving ≥ 3 lines of therapy and 42% previously receiving an allogeneic hematopoietic stem cell transplant (allo-HCT).","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.96,"identifiers":{"doi":"10.1200/jco.2026.44.16_suppl.e18528"},"retrieved_at":"2026-09-22T11:15:08.176929Z"},{"id":"ev_54e1fcbbe2be","question_id":"q_a687f9ed49c6","source_id":"ashpublications","source_name":"ASH / Blood (American Society of Hematology)","organization":"Journal of the National Comprehensive Cancer Network : JNCCN","tier":2,"url":"https://pubmed.ncbi.nlm.nih.gov/22773801/","title":"Acute lymphoblastic leukemia.","published":"2012-07-01","quote":"These NCCN Guidelines provide recommendations on the diagnostic evaluation and workup for ALL, risk assessment, risk-stratified treatment approaches based on the Philadelphia chromosome status and age (adults vs. adolescents/young adults), assessment of minimal residual disease, and supportive care considerations.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.95,"identifiers":{"pmid":"22773801","doi":"10.6004/jnccn.2012.0089","epmc_id":"22773801","source":"MED"},"retrieved_at":"2026-09-22T11:13:30.532173Z"},{"id":"ev_ad6c4f26f9b0","question_id":"q_a687f9ed49c6","source_id":"ashpublications","source_name":"ASH / Blood (American Society of Hematology)","organization":"American Society of Hematology","tier":2,"url":"https://pubmed.ncbi.nlm.nih.gov/41670624/","title":"American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults.","published":"2026-07-01","quote":"Results The panel agreed on 8 recommendations and 1 research-only recommendation, covering remission reinduction and consolidation.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.91,"identifiers":{"pmid":"41670624","pmcid":"PMC13366310","doi":"10.1182/bloodadvances.2021006479","epmc_id":"41670624","source":"MED"},"retrieved_at":"2026-09-22T11:13:16.790203Z"},{"id":"ev_9252fe2e2a48","question_id":"q_a687f9ed49c6","source_id":"clinicaltrials","source_name":"ClinicalTrials.gov","organization":"M.D. Anderson Cancer Center","tier":2,"url":"https://clinicaltrials.gov/study/NCT06561074","title":"A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)","published":"2025-09-25","quote":"Inclusion Criteria: 1. Pediatric, adolescent, or young adult patients who have relapse or refractory T-cell lymphoblastic leukemia (T-ALL) or T-Cell lymphoblastic lymphoma (T-LLy) according to 2017 WHO classification and NCCN v1 2021.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.44,"identifiers":{"nct":"NCT06561074","phase":"PHASE2","status":"RECRUITING"},"retrieved_at":"2026-09-22T11:15:11.967667Z"},{"id":"ev_cb511a6e4a1b","question_id":"q_a687f9ed49c6","source_id":"open_web","source_name":"Open Web (Supplementary)","organization":"Open web","tier":5,"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1489.","title":"Acute Lymphoblastic Leukemia - Guidelines Detail - nccn.org","published":"","quote":"Acute Lymphoblastic Leukemia Guidelines NCCN Guidelines Version 3.2026 - Acute Lymphoblastic Leukemia Guidelines Navigator NCCN Guidelines Navigator™ Version 3.2026 NEW! - Interactive Digital Guideline Tool","context":"","origin":"open_web","tag":"GENERAL KNOWLEDGE","relevance":0.96,"identifiers":{"domain":"nccn.org","search_backend":"azure_web_search"},"retrieved_at":"2026-09-22T11:16:45.480357Z"},{"id":"ev_0fbbff4885d1","question_id":"q_a687f9ed49c6","source_id":"open_web","source_name":"Open Web (Supplementary)","organization":"Open web","tier":5,"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1489.","title":"Acute Lymphoblastic Leukemia - Guidelines Detail - nccn.org","published":"","quote":"Evidence Blocks NCCN Guidelines with Evidence Blocks Version 2.2026","context":"","origin":"open_web","tag":"GENERAL KNOWLEDGE","relevance":0.83,"identifiers":{"domain":"nccn.org","search_backend":"azure_web_search"},"retrieved_at":"2026-09-22T11:16:45.480518Z"},{"id":"ev_8da63899d25d","question_id":"q_9df80b42710c","source_id":"nci","source_name":"National Cancer Institute (NCI) PDQ","organization":"National Cancer Institute","tier":1,"url":"https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq","title":"PDQ: Remission induction therapy","published":"","quote":"Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.95,"identifiers":{"pdq_summary":"adult-all-treatment-pdq","section":"Remission induction therapy"},"retrieved_at":"2026-09-22T11:16:48.467802Z"},{"id":"ev_11c33702e27d","question_id":"q_9df80b42710c","source_id":"nci","source_name":"National Cancer Institute (NCI) PDQ","organization":"National Cancer Institute","tier":1,"url":"https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq","title":"PDQ: Remission induction therapy","published":"","quote":"Most current induction regimens for patients with adult ALL include combination chemotherapy with prednisone, vincristine, and an anthracycline.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.9,"identifiers":{"pdq_summary":"adult-all-treatment-pdq","section":"Remission induction therapy"},"retrieved_at":"2026-09-22T11:16:48.467745Z"},{"id":"ev_fce1f259bb63","question_id":"q_9df80b42710c","source_id":"nci","source_name":"National Cancer Institute (NCI) PDQ","organization":"National Cancer Institute","tier":1,"url":"https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq","title":"PDQ: Remission induction therapy","published":"","quote":"If a suitable donor is available, allogeneic bone marrow transplant should be considered because remissions are generally short with conventional ALL chemotherapy clinical trials.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.77,"identifiers":{"pdq_summary":"adult-all-treatment-pdq","section":"Remission induction therapy"},"retrieved_at":"2026-09-22T11:16:48.467839Z"},{"id":"ev_d3a229ba9b2b","question_id":"q_9df80b42710c","source_id":"orphanet","source_name":"Orphanet / Orphadata","organization":"Orphanet","tier":1,"url":"https://www.orpha.net/en/disease/detail/513","title":"Orphanet Acute lymphoblastic leukemia (ORPHA:513)","published":"","quote":"The peak incidence occurs between 2 and 5 years of age.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.34,"identifiers":{"orphacode":"513","icd10":"C91.0","mesh":"D054198","umls":"C1961102"},"retrieved_at":"2026-09-22T11:16:33.493366Z"},{"id":"ev_c59595ca2fc8","question_id":"q_9df80b42710c","source_id":"ashpublications","source_name":"ASH / Blood (American Society of Hematology)","organization":"American Society of Hematology","tier":2,"url":"https://pubmed.ncbi.nlm.nih.gov/41670627/","title":"American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults.","published":"2026-07-01","quote":"Allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.96,"identifiers":{"pmid":"41670627","pmcid":"PMC13366240","doi":"10.1182/bloodadvances.2021006469","epmc_id":"41670627","source":"MED"},"retrieved_at":"2026-09-22T11:16:33.492807Z"},{"id":"ev_49a4959cee37","question_id":"q_9df80b42710c","source_id":"ashpublications","source_name":"ASH / Blood (American Society of Hematology)","organization":"American Society of Hematology","tier":2,"url":"https://pubmed.ncbi.nlm.nih.gov/41670627/","title":"American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults.","published":"2026-07-01","quote":"Background Adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) represent a unique population.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.9,"identifiers":{"pmid":"41670627","pmcid":"PMC13366240","doi":"10.1182/bloodadvances.2021006469","epmc_id":"41670627","source":"MED"},"retrieved_at":"2026-09-22T11:16:33.492619Z"},{"id":"ev_367e1dd3c40f","question_id":"q_9df80b42710c","source_id":"ashpublications","source_name":"ASH / Blood (American Society of Hematology)","organization":"American Society of Hematology","tier":2,"url":"https://pubmed.ncbi.nlm.nih.gov/41670627/","title":"American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults.","published":"2026-07-01","quote":"Treatment regimens can vary significantly depending on whether they receive care in a pediatric or in an adult setting.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.83,"identifiers":{"pmid":"41670627","pmcid":"PMC13366240","doi":"10.1182/bloodadvances.2021006469","epmc_id":"41670627","source":"MED"},"retrieved_at":"2026-09-22T11:16:33.492758Z"},{"id":"ev_65d7b862056c","question_id":"q_9df80b42710c","source_id":"pubmed","source_name":"PubMed","organization":"AAPS PharmSciTech","tier":2,"url":"https://pubmed.ncbi.nlm.nih.gov/42768180/","title":"Beyond Immediate Release: FDM-Printed Pediatric 6-Mercaptopurine Chewable Tablets with Spontaneous In Situ Nanostructure Formation.","published":"2026 Sep 21","quote":"Pediatric maintenance therapy for acute lymphoblastic leukemia requires prolonged daily administration of 6-mercaptopurine (6-MP), a drug characterized by a narrow therapeutic index and substantial interindividual variability, creating a need for flexible and patient-friendly dosage forms.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.06,"identifiers":{"pmid":"42768180","doi":"10.1208/s12249-026-03556-7"},"retrieved_at":"2026-09-22T11:17:01.345989Z"},{"id":"ev_93081b84add9","question_id":"q_9df80b42710c","source_id":"pubmed","source_name":"PubMed","organization":"AAPS PharmSciTech","tier":2,"url":"https://pubmed.ncbi.nlm.nih.gov/42768180/","title":"Beyond Immediate Release: FDM-Printed Pediatric 6-Mercaptopurine Chewable Tablets with Spontaneous In Situ Nanostructure Formation.","published":"2026 Sep 21","quote":"This study aimed to develop pediatric chewable tablets 6-MP using hot-melt extrusion and fused deposition modeling (FDM) 3D printing.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.03,"identifiers":{"pmid":"42768180","doi":"10.1208/s12249-026-03556-7"},"retrieved_at":"2026-09-22T11:17:01.346036Z"},{"id":"ev_44470bb29387","question_id":"q_9df80b42710c","source_id":"open_web","source_name":"Open Web (Supplementary)","organization":"Open web","tier":5,"url":"https://jnccn.org/view/journals/jnccn/22/8/article-p563.xml","title":"Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice ...","published":"","quote":"The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia (ALL) provide recommendations for management of ALL, with a focus on the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk assessment and stratification for risk-adapted therapy; treatment strategies for Philadelphia chromosome (Ph)-positive and Ph ...","context":"","origin":"open_web","tag":"GENERAL KNOWLEDGE","relevance":0.99,"identifiers":{"domain":"jnccn.org","search_backend":"azure_web_search"},"retrieved_at":"2026-09-22T11:17:43.706782Z"},{"id":"ev_2b8431ac1378","question_id":"q_9df80b42710c","source_id":"open_web","source_name":"Open Web (Supplementary)","organization":"Open web","tier":5,"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1489.","title":"Acute Lymphoblastic Leukemia - Guidelines Detail - nccn.org","published":"","quote":"Acute Lymphoblastic Leukemia Guidelines NCCN Guidelines Version 3.2026 - Acute Lymphoblastic Leukemia Guidelines Navigator NCCN Guidelines Navigator™ Version 3.2026 NEW! - Interactive Digital Guideline Tool","context":"","origin":"open_web","tag":"GENERAL KNOWLEDGE","relevance":0.54,"identifiers":{"domain":"nccn.org","search_backend":"azure_web_search"},"retrieved_at":"2026-09-22T11:17:43.706855Z"},{"id":"ev_4f41b06fbab3","question_id":"q_9df80b42710c","source_id":"open_web","source_name":"Open Web (Supplementary)","organization":"Open web","tier":5,"url":"https://www.sciencedirect.com/science/article/pii/S1532046419302540","title":"Temporal phenotyping by mining healthcare data to derive lines of ...","published":"","quote":"Our approach to identify temporal patient phenotypes can increase the quality and utility of analyses conducted using claims datasets, with the potential for application to multiple oncology disease areas across diverse healthcare data sources.","context":"","origin":"open_web","tag":"GENERAL KNOWLEDGE","relevance":0.35,"identifiers":{"domain":"sciencedirect.com","search_backend":"azure_web_search"},"retrieved_at":"2026-09-22T11:17:43.706901Z"},{"id":"ev_0efeb2d33090","question_id":"q_2bee5da1afa0","source_id":"openfda_label","source_name":"FDA Drug Labeling (openFDA)","organization":"Alembic Pharmaceuticals Limited","tier":1,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03ad6056-0e71-4e7c-842a-a5f87649bdcd","title":"NELARABINE (NELARABINE)","published":"2024-08-07","quote":"Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.99,"identifiers":{"set_id":"03ad6056-0e71-4e7c-842a-a5f87649bdcd","spl_id":"482d7978-12a5-467a-b10e-1789df5dd0f8","application_number":"ANDA218554","rxcui":"603566","unii":"60158CV180","spl_version":"2"},"retrieved_at":"2026-09-22T11:17:45.067189Z"},{"id":"ev_23da31bd88f0","question_id":"q_2bee5da1afa0","source_id":"openfda_label","source_name":"FDA Drug Labeling (openFDA)","organization":"Amneal Pharmaceuticals LLC","tier":1,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a273a2d-a1ff-412a-925e-696648730dae","title":"Clofarabine (CLOFARABINE)","published":"2022-08-23","quote":"Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.99,"identifiers":{"set_id":"0a273a2d-a1ff-412a-925e-696648730dae","spl_id":"9371cb36-5f01-4afa-bbd4-6886ae0fc277","application_number":"ANDA208857","rxcui":"486419","unii":"762RDY0Y2H","spl_version":"5"},"retrieved_at":"2026-09-22T11:17:45.067281Z"},{"id":"ev_fefba3481bed","question_id":"q_2bee5da1afa0","source_id":"nci","source_name":"National Cancer Institute (NCI) PDQ","organization":"National Cancer Institute","tier":1,"url":"https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq","title":"PDQ: Remission induction therapy","published":"","quote":"However, the results suggested that inclusion of imatinib into a relatively standard chemotherapy regimen for newly diagnosed adult patients with Ph-positive ALL may provide a significant survival advantage.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.96,"identifiers":{"pdq_summary":"adult-all-treatment-pdq","section":"Remission induction therapy"},"retrieved_at":"2026-09-22T11:19:57.722258Z"},{"id":"ev_deff95ec2cfd","question_id":"q_2bee5da1afa0","source_id":"esmo","source_name":"ESMO","organization":"Bulletin du cancer","tier":1,"url":"https://pubmed.ncbi.nlm.nih.gov/35562231/","title":"[Acute lymphoblastic leukemia in developing countries: Management from the transplant indication (allo/auto) until post-transplant follow-up. Guidelines from the SFGM-TC].","published":"2022-05-11","quote":"Patients with refractory/relapsed disease have a poor prognosis which highlights the importance of acquiring in the future new therapies such as: blinatumumab, inotuzumab, and CAR-T cells.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.95,"identifiers":{"pmid":"35562231","doi":"10.1016/j.bulcan.2022.02.011","epmc_id":"35562231","source":"MED"},"retrieved_at":"2026-09-22T11:19:57.722405Z"},{"id":"ev_ec973034d54a","question_id":"q_2bee5da1afa0","source_id":"esmo","source_name":"ESMO","organization":"Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation","tier":1,"url":"https://pubmed.ncbi.nlm.nih.gov/22209888/","title":"Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review.","published":"2011-12-29","quote":"Allogeneic SCT is recommended for children who: are in second complete remission (CR2) after experiencing an early marrow relapse for precursor-B ALL; experienced primary induction failure, but subsequently achieved a CR1; have T-lineage ALL in CR2; or have ALL in third or greater remission.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.95,"identifiers":{"pmid":"22209888","doi":"10.1016/j.bbmt.2011.12.585","epmc_id":"22209888","source":"MED"},"retrieved_at":"2026-09-22T11:21:10.617725Z"},{"id":"ev_c3dd8f795d7b","question_id":"q_2bee5da1afa0","source_id":"nci","source_name":"National Cancer Institute (NCI) PDQ","organization":"National Cancer Institute","tier":1,"url":"https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq","title":"PDQ: Remission induction therapy","published":"","quote":"Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.93,"identifiers":{"pdq_summary":"adult-all-treatment-pdq","section":"Remission induction therapy"},"retrieved_at":"2026-09-22T11:19:57.722329Z"},{"id":"ev_6ca5bc1954c3","question_id":"q_2bee5da1afa0","source_id":"openfda_drugsfda","source_name":"FDA Drugs@FDA (openFDA)","organization":"NOVARTIS","tier":1,"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021588","title":"Drugs@FDA NDA021588: GLEEVEC","published":"2026-07-13","quote":"Submissions: SUPPL 10 AP 2006-05-31 Labeling STANDARD | SUPPL 49 AP 2017-04-24 Labeling STANDARD | SUPPL 63 AP 2024-03-01 Manufacturing (CMC) N/A | SUPPL 47 AP 2016-09-27 Labeling STANDARD | SUPPL 39 AP 2013-10-30 Labeling STANDARD | SUPPL 53 AP 2018-08-21 Labeling STANDARD | SUPPL 45 AP 2016-08-25 Efficacy STANDARD | ORIG 1 AP 2003-04-18 Type 3 - New Dosage Form PRIORITY","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.8,"identifiers":{"application_number":"NDA021588","sponsor":"NOVARTIS"},"retrieved_at":"2026-09-22T11:18:37.623127Z"},{"id":"ev_93b30cbe8295","question_id":"q_2bee5da1afa0","source_id":"openfda_drugsfda","source_name":"FDA Drugs@FDA (openFDA)","organization":"BRISTOL MYERS SQUIBB","tier":1,"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021986","title":"Drugs@FDA NDA021986: SPRYCEL","published":"2024-07-31","quote":"Submissions: SUPPL 28 AP 2024-07-31 Labeling STANDARD | SUPPL 18 AP 2016-09-27 Labeling STANDARD | SUPPL 9 AP 2011-10-07 Labeling UNKNOWN | SUPPL 16 AP 2015-08-12 Efficacy STANDARD | SUPPL 7 AP 2010-10-28 Efficacy STANDARD | SUPPL 14 AP 2014-04-10 Labeling STANDARD | SUPPL 5 AP 2010-07-28 Labeling STANDARD | SUPPL 20 AP 2017-11-09 Efficacy PRIORITY | SUPPL 3 AP 2008-05-30 Manufacturing (CMC) N/A | SUPPL 1 AP 2007-11-08 Efficacy PRIORITY | SUPPL 10 AP 2011-10-07 Labeling UNKNOWN | SUPPL 27 AP 2023-02-08 Labeling STANDARD | SUPPL 19 AP 2017-08-10 Labeling STANDARD | SUPPL 25 AP 2021-06-29 Labeling STANDARD | SUPPL 17 AP 2015-08-12 Labeling STANDARD | SUPPL 8 AP 2010-10-28 Efficacy PRIORITY | SUPPL 23 AP 2018-11-15 Labeling STANDARD | ORIG 1 AP 2006-06-28 Type 1 - New Molecular Entity PRIORITY","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.76,"identifiers":{"application_number":"NDA021986","sponsor":"BRISTOL MYERS SQUIBB"},"retrieved_at":"2026-09-22T11:18:37.623242Z"},{"id":"ev_6737f3e1b95a","question_id":"q_2bee5da1afa0","source_id":"clinicaltrials","source_name":"ClinicalTrials.gov","organization":"Memorial Sloan Kettering Cancer Center","tier":2,"url":"https://clinicaltrials.gov/study/NCT01920737","title":"A Novel \"Pediatric-Inspired\" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia","published":"2013-08-07","quote":"In this study we want to see whether this combination of chemotherapy drugs will be safe and effective in treating adult patients with Ph Negative ALL.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.98,"identifiers":{"nct":"NCT01920737","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING"},"retrieved_at":"2026-09-22T11:20:51.719040Z"},{"id":"ev_9a1472ce6a59","question_id":"q_2bee5da1afa0","source_id":"asco","source_name":"ASCO","organization":"American Society of Clinical Oncology Educational Book","tier":2,"url":"https://doi.org/10.14694/edbook_am.2013.33.294","title":"Monoclonal Antibody-Based Therapies in the Treatment of Acute Lymphoblastic Leukemia","published":"2013-05","quote":"These include inotuzumab ozogamicin, an anti-CD22 antibody linked to calicheamicin that has produced significant single-agent responses in relapsed and refractory ALL.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.95,"identifiers":{"doi":"10.14694/edbook_am.2013.33.294"},"retrieved_at":"2026-09-22T11:19:57.724793Z"},{"id":"ev_cf6ec1622ef0","question_id":"q_2bee5da1afa0","source_id":"ashpublications","source_name":"ASH / Blood (American Society of Hematology)","organization":"American Society of Hematology","tier":2,"url":"https://pubmed.ncbi.nlm.nih.gov/41670627/","title":"American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults.","published":"2026-07-01","quote":"Conclusions Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols, requiring significant supportive care and close follow-up.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.93,"identifiers":{"pmid":"41670627","pmcid":"PMC13366240","doi":"10.1182/bloodadvances.2021006469","epmc_id":"41670627","source":"MED"},"retrieved_at":"2026-09-22T11:20:20.754020Z"},{"id":"ev_400b61e0ce87","question_id":"q_2bee5da1afa0","source_id":"clinicaltrials","source_name":"ClinicalTrials.gov","organization":"Memorial Sloan Kettering Cancer Center","tier":2,"url":"https://clinicaltrials.gov/study/NCT01920737","title":"A Novel \"Pediatric-Inspired\" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia","published":"2013-08-07","quote":"The purpose of the study is to find out whether the combination of chemotherapy drugs that are routinely used in children with ALL, will be safe and effective in treating adult patients with ALL.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.93,"identifiers":{"nct":"NCT01920737","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING"},"retrieved_at":"2026-09-22T11:20:51.719168Z"},{"id":"ev_5850d777aa9a","question_id":"q_2bee5da1afa0","source_id":"ashpublications","source_name":"ASH / Blood (American Society of Hematology)","organization":"American Society of Hematology","tier":2,"url":"https://pubmed.ncbi.nlm.nih.gov/41670624/","title":"American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults.","published":"2026-07-01","quote":"Conclusions Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.92,"identifiers":{"pmid":"41670624","pmcid":"PMC13366310","doi":"10.1182/bloodadvances.2021006479","epmc_id":"41670624","source":"MED"},"retrieved_at":"2026-09-22T11:20:38.423719Z"},{"id":"ev_74834422de95","question_id":"q_2bee5da1afa0","source_id":"asco","source_name":"ASCO","organization":"American Society of Clinical Oncology Educational Book","tier":2,"url":"https://doi.org/10.14694/edbook_am.2013.33.294","title":"Monoclonal Antibody-Based Therapies in the Treatment of Acute Lymphoblastic Leukemia","published":"2013-05","quote":"Blinatumomab is a novel bispecific T-cell engaging antibody that combines single chain antibodies to CD19 and CD3 and brings a T cell in close proximity to a leukemic lymphoblast with resulting redirected lysis.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.9,"identifiers":{"doi":"10.14694/edbook_am.2013.33.294"},"retrieved_at":"2026-09-22T11:19:57.725424Z"},{"id":"ev_02ebd2416f56","question_id":"q_bf22d864f4bc","source_id":"nci","source_name":"National Cancer Institute (NCI) PDQ","organization":"National Cancer Institute","tier":1,"url":"https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq","title":"PDQ: Remission induction therapy","published":"","quote":"However, the results suggested that inclusion of imatinib into a relatively standard chemotherapy regimen for newly diagnosed adult patients with Ph-positive ALL may provide a significant survival advantage.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.99,"identifiers":{"pdq_summary":"adult-all-treatment-pdq","section":"Remission induction therapy"},"retrieved_at":"2026-09-22T11:21:44.379590Z"},{"id":"ev_d407566fa413","question_id":"q_bf22d864f4bc","source_id":"nci","source_name":"National Cancer Institute (NCI) PDQ","organization":"National Cancer Institute","tier":1,"url":"https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq","title":"PDQ: Remission induction therapy","published":"","quote":"Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.99,"identifiers":{"pdq_summary":"adult-all-treatment-pdq","section":"Remission induction therapy"},"retrieved_at":"2026-09-22T11:21:44.379652Z"},{"id":"ev_9182343de04d","question_id":"q_bf22d864f4bc","source_id":"esmo","source_name":"ESMO","organization":"Blood advances","tier":1,"url":"https://pubmed.ncbi.nlm.nih.gov/41670624/","title":"American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults.","published":"2026-07-01","quote":"Additional management of ALL subsets (T-cell ALL), CNS relapse, and the role of consolidation with allogeneic transplant are addressed.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.89,"identifiers":{"pmid":"41670624","pmcid":"PMC13366310","doi":"10.1182/bloodadvances.2021006479","epmc_id":"41670624","source":"MED"},"retrieved_at":"2026-09-22T11:21:33.910107Z"},{"id":"ev_bc278a23e777","question_id":"q_bf22d864f4bc","source_id":"nci","source_name":"National Cancer Institute (NCI) PDQ","organization":"National Cancer Institute","tier":1,"url":"https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq","title":"PDQ: Remission induction therapy","published":"","quote":"If a suitable donor is available, allogeneic bone marrow transplant should be considered because remissions are generally short with conventional ALL chemotherapy clinical trials.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.86,"identifiers":{"pdq_summary":"adult-all-treatment-pdq","section":"Remission induction therapy"},"retrieved_at":"2026-09-22T11:21:44.379692Z"},{"id":"ev_c5bca0d585a6","question_id":"q_bf22d864f4bc","source_id":"esmo","source_name":"ESMO","organization":"Bulletin du cancer","tier":1,"url":"https://pubmed.ncbi.nlm.nih.gov/42749602/","title":"[Management of venous thromboembolism in children with acute lymphoblastic leukemia: Recommendations from the harmonization workshops of the Leukemia Committee of the French Society for Childhood Cancer (SFCE)].","published":"2026-09-16","quote":"The recommendations issued by the SFCE harmonization workshop aim to standardize the management of venous thromboembolism (VTE) in children treated for acute lymphoblastic leukemia (ALL).","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.12,"identifiers":{"pmid":"42749602","doi":"10.1016/j.bulcan.2026.06.004","epmc_id":"42749602","source":"MED"},"retrieved_at":"2026-09-22T11:22:33.835429Z"},{"id":"ev_7787a43e64f8","question_id":"q_bf22d864f4bc","source_id":"esmo","source_name":"ESMO","organization":"Bulletin du cancer","tier":1,"url":"https://pubmed.ncbi.nlm.nih.gov/42749602/","title":"[Management of venous thromboembolism in children with acute lymphoblastic leukemia: Recommendations from the harmonization workshops of the Leukemia Committee of the French Society for Childhood Cancer (SFCE)].","published":"2026-09-16","quote":"However, it may be considered during the induction phase in high-risk subgroups (T-cell ALL, adolescents older than 10years, overweight patients), particularly when multiple risk factors are present.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.09,"identifiers":{"pmid":"42749602","doi":"10.1016/j.bulcan.2026.06.004","epmc_id":"42749602","source":"MED"},"retrieved_at":"2026-09-22T11:22:33.837637Z"},{"id":"ev_5bbae4108cd9","question_id":"q_bf22d864f4bc","source_id":"clinicaltrials","source_name":"ClinicalTrials.gov","organization":"National Cancer Institute (NCI)","tier":2,"url":"https://clinicaltrials.gov/study/NCT02003222","title":"Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia","published":"2014-05-19","quote":"To compare the overall survival (OS) of blinatumomab in conjunction with chemotherapy to chemotherapy alone in patients with BCR-ABL-negative B cell precursor acute lymphoblastic leukemia (ALL) who are minimal residual disease (MRD) negative after induction and intensification chemotherapy, based on multiparameter flow cytometric (MFC) assessment of residual blasts.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":1.0,"identifiers":{"nct":"NCT02003222","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING"},"retrieved_at":"2026-09-22T11:21:44.379796Z"},{"id":"ev_4531684dd1a7","question_id":"q_bf22d864f4bc","source_id":"ashpublications","source_name":"ASH / Blood (American Society of Hematology)","organization":"American Society of Hematology","tier":2,"url":"https://pubmed.ncbi.nlm.nih.gov/41670627/","title":"American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults.","published":"2026-07-01","quote":"Allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.97,"identifiers":{"pmid":"41670627","pmcid":"PMC13366240","doi":"10.1182/bloodadvances.2021006469","epmc_id":"41670627","source":"MED"},"retrieved_at":"2026-09-22T11:21:33.909926Z"},{"id":"ev_85b69c7d95f1","question_id":"q_bf22d864f4bc","source_id":"asco","source_name":"ASCO","organization":"Journal of Clinical Oncology","tier":2,"url":"https://doi.org/10.1200/jco.2005.23.16_suppl.6521","title":"Correlation of clinical response to BMS-354825 with BCR-ABL mutation status in imatinib-resistant patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-associated acute lymphoblastic leukemia (Ph+ ALL)","published":"2005-06","quote":"Correlation of clinical response to BMS-354825 with BCR-ABL mutation status in imatinib-resistant patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-associated acute lymphoblastic leukemia (Ph+ ALL).","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.97,"identifiers":{"doi":"10.1200/jco.2005.23.16_suppl.6521"},"retrieved_at":"2026-09-22T11:22:22.098538Z"},{"id":"ev_1f184e56211f","question_id":"q_bf22d864f4bc","source_id":"clinicaltrials","source_name":"ClinicalTrials.gov","organization":"National Cancer Institute (NCI)","tier":2,"url":"https://clinicaltrials.gov/study/NCT02003222","title":"Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia","published":"2014-05-19","quote":"This randomized phase III trial studies combination chemotherapy with blinatumomab to see how well it works compared to induction chemotherapy alone in treating patients with newly diagnosed breakpoint cluster region (BCR)-c-abl oncogene 1, non-receptor tyrosine kinase (ABL)-negative B lineage acute lymphoblastic leukemia.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.96,"identifiers":{"nct":"NCT02003222","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING"},"retrieved_at":"2026-09-22T11:21:44.379745Z"},{"id":"ev_1f156e37d788","question_id":"q_bf22d864f4bc","source_id":"ashpublications","source_name":"ASH / Blood (American Society of Hematology)","organization":"American Society of Hematology","tier":2,"url":"https://pubmed.ncbi.nlm.nih.gov/41670627/","title":"American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults.","published":"2026-07-01","quote":"Conclusions Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols, requiring significant supportive care and close follow-up.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.95,"identifiers":{"pmid":"41670627","pmcid":"PMC13366240","doi":"10.1182/bloodadvances.2021006469","epmc_id":"41670627","source":"MED"},"retrieved_at":"2026-09-22T11:21:33.909719Z"},{"id":"ev_fda538891bc6","question_id":"q_bf22d864f4bc","source_id":"asco","source_name":"ASCO","organization":"Journal of Clinical Oncology","tier":2,"url":"https://doi.org/10.1200/jco.2015.33.15_suppl.7083","title":"Clinical outcome of adult acute lymphoblastic leukemia based on Philadelphia chromosome status and socioeconomic status.","published":"2015-05-20","quote":"Clinical outcome of adult acute lymphoblastic leukemia based on Philadelphia chromosome status and socioeconomic status..","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.88,"identifiers":{"doi":"10.1200/jco.2015.33.15_suppl.7083"},"retrieved_at":"2026-09-22T11:22:22.098604Z"},{"id":"ev_92acc73fe391","question_id":"q_bf22d864f4bc","source_id":"open_web","source_name":"Open Web (Supplementary)","organization":"Open web","tier":5,"url":"https://www.nccn.org/compendia-templates/compendia/biomarkers-compendium","title":"Biomarkers Compendium - NCCN","published":"","quote":"The goal of the NCCN Biomarkers Compendium ® is to provide essential details for those tests which have been approved by NCCN Guideline Panels and are recommended within the NCCN Guidelines .","context":"","origin":"open_web","tag":"GENERAL KNOWLEDGE","relevance":0.95,"identifiers":{"domain":"nccn.org","search_backend":"azure_web_search"},"retrieved_at":"2026-09-22T11:23:31.985414Z"},{"id":"ev_7f44713567b2","question_id":"q_bf22d864f4bc","source_id":"open_web","source_name":"Open Web (Supplementary)","organization":"Open web","tier":5,"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1489.","title":"Acute Lymphoblastic Leukemia - Guidelines Detail - nccn.org","published":"","quote":"Acute Lymphoblastic Leukemia Guidelines NCCN Guidelines Version 3.2026 - Acute Lymphoblastic Leukemia Guidelines Navigator NCCN Guidelines Navigator™ Version 3.2026 NEW! - Interactive Digital Guideline Tool","context":"","origin":"open_web","tag":"GENERAL KNOWLEDGE","relevance":0.93,"identifiers":{"domain":"nccn.org","search_backend":"azure_web_search"},"retrieved_at":"2026-09-22T11:23:31.984655Z"},{"id":"ev_a6db9cc6bed1","question_id":"q_7ca3756217b1","source_id":"openfda_label","source_name":"FDA Drug Labeling (openFDA)","organization":"BluePoint Laboratories","tier":1,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02b04c6f-4ea5-4fcb-bf6d-2631d5ab31e4","title":"Dasatinib (DASATINIB)","published":"2026-03-05","quote":"Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.99,"identifiers":{"set_id":"02b04c6f-4ea5-4fcb-bf6d-2631d5ab31e4","spl_id":"4c4a021d-a810-26d0-e063-6294a90abd2d","application_number":"ANDA217217","rxcui":"643105","unii":"RBZ1571X5H","spl_version":"2"},"retrieved_at":"2026-09-22T11:24:34.999180Z"},{"id":"ev_5ea773907865","question_id":"q_7ca3756217b1","source_id":"openfda_label","source_name":"FDA Drug Labeling (openFDA)","organization":"Apotex Corp","tier":1,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0291eca5-7a1d-4a79-30be-252224d96509","title":"Imatinib Mesylate (IMATINIB MESYLATE)","published":"2026-09-08","quote":"• Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) ( 1.3 ) • Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy ( 1.4 )","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.99,"identifiers":{"set_id":"0291eca5-7a1d-4a79-30be-252224d96509","spl_id":"7560461e-a5f5-b4c8-c4c6-3145a0e98fda","application_number":"ANDA079179","rxcui":"403878","unii":"8A1O1M485B","spl_version":"21"},"retrieved_at":"2026-09-22T11:25:14.381167Z"},{"id":"ev_fe787f4f9539","question_id":"q_7ca3756217b1","source_id":"openfda_label","source_name":"FDA Drug Labeling (openFDA)","organization":"BluePoint Laboratories","tier":1,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02b04c6f-4ea5-4fcb-bf6d-2631d5ab31e4","title":"Dasatinib (DASATINIB)","published":"2026-03-05","quote":"pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.97,"identifiers":{"set_id":"02b04c6f-4ea5-4fcb-bf6d-2631d5ab31e4","spl_id":"4c4a021d-a810-26d0-e063-6294a90abd2d","application_number":"ANDA217217","rxcui":"643105","unii":"RBZ1571X5H","spl_version":"2"},"retrieved_at":"2026-09-22T11:24:34.999212Z"},{"id":"ev_b5172d83504a","question_id":"q_7ca3756217b1","source_id":"openfda_drugsfda","source_name":"FDA Drugs@FDA (openFDA)","organization":"TAKEDA PHARMS USA","tier":1,"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203469","title":"Drugs@FDA NDA203469: ICLUSIG","published":"2025-10-10","quote":"SUPPL 38 AP 2025-10-10 Efficacy STANDARD | SUPPL 9 AP 2014-07-24 Labeling STANDARD | SUPPL 28 AP 2017-12-20 Labeling STANDARD | SUPPL 34 AP 2020-12-18 Efficacy PRIORITY","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.92,"identifiers":{"application_number":"NDA203469","sponsor":"TAKEDA PHARMS USA"},"retrieved_at":"2026-09-22T11:24:25.909243Z"},{"id":"ev_63cb61d6aaae","question_id":"q_7ca3756217b1","source_id":"openfda_drugsfda","source_name":"FDA Drugs@FDA (openFDA)","organization":"BRISTOL MYERS SQUIBB","tier":1,"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021986","title":"Drugs@FDA NDA021986: SPRYCEL","published":"2024-07-31","quote":"Submissions: SUPPL 28 AP 2024-07-31 Labeling STANDARD | SUPPL 18 AP 2016-09-27 Labeling STANDARD | SUPPL 9 AP 2011-10-07 Labeling UNKNOWN | SUPPL 16 AP 2015-08-12 Efficacy STANDARD | SUPPL 7 AP 2010-10-28 Efficacy STANDARD | SUPPL 14 AP 2014-04-10 Labeling STANDARD | SUPPL 5 AP 2010-07-28 Labeling STANDARD | SUPPL 20 AP 2017-11-09 Efficacy PRIORITY","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.9,"identifiers":{"application_number":"NDA021986","sponsor":"BRISTOL MYERS SQUIBB"},"retrieved_at":"2026-09-22T11:24:25.908881Z"},{"id":"ev_c324073e53df","question_id":"q_7ca3756217b1","source_id":"openfda_drugsfda","source_name":"FDA Drugs@FDA (openFDA)","organization":"SANDOZ","tier":1,"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021877","title":"Drugs@FDA NDA021877: ARRANON","published":"2025-03-11","quote":"Submissions: SUPPL 5 AP 2012-02-06 Labeling STANDARD | SUPPL 1 AP 2009-12-15 Labeling STANDARD | SUPPL 8 AP 2018-07-03 Labeling STANDARD | SUPPL 6 AP 2015-06-04 Manufacturing (CMC) PRIORITY | SUPPL 14 AP 2025-03-11 Labeling STANDARD","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.89,"identifiers":{"application_number":"NDA021877","sponsor":"SANDOZ"},"retrieved_at":"2026-09-22T11:24:25.909127Z"},{"id":"ev_556436b02457","question_id":"q_7ca3756217b1","source_id":"esmo","source_name":"ESMO","organization":"Journal of the National Comprehensive Cancer Network : JNCCN","tier":1,"url":"https://pubmed.ncbi.nlm.nih.gov/39413812/","title":"Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.","published":"2024-10-01","quote":"The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia (ALL) provide recommendations for management of ALL, with a focus on the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk assessment and stratification for risk-adapted therapy; treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients; and supportive care considerations.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.22,"identifiers":{"pmid":"39413812","doi":"10.6004/jnccn.2024.0051","epmc_id":"39413812","source":"MED"},"retrieved_at":"2026-09-22T11:26:12.261922Z"},{"id":"ev_c620fdd21783","question_id":"q_7ca3756217b1","source_id":"esmo","source_name":"ESMO","organization":"Journal of the National Comprehensive Cancer Network : JNCCN","tier":1,"url":"https://pubmed.ncbi.nlm.nih.gov/39413812/","title":"Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.","published":"2024-10-01","quote":"This selection from the NCCN Guidelines for ALL focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.12,"identifiers":{"pmid":"39413812","doi":"10.6004/jnccn.2024.0051","epmc_id":"39413812","source":"MED"},"retrieved_at":"2026-09-22T11:26:12.262001Z"},{"id":"ev_6592850d6958","question_id":"q_7ca3756217b1","source_id":"open_web","source_name":"Open Web (Supplementary)","organization":"Open web","tier":5,"url":"https://news.cancerconnect.com/fda-expands-blincyto-approval-in-frontline-b-cell-precursor-acute-lymphoblastic-leukemia/","title":"FDA Expands Blincyto Approval in Frontline B-Cell Precursor Acute ...","published":"","quote":"In June, 2024, the U.S. Food and Drug Administration (FDA) has expanded approval of Blincyto (blinatumomab) in to include the treatment of adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase, regardless of measurable residual disease (MRD) status.","context":"","origin":"open_web","tag":"GENERAL KNOWLEDGE","relevance":1.0,"identifiers":{"domain":"news.cancerconnect.com","search_backend":"azure_web_search"},"retrieved_at":"2026-09-22T11:26:45.149002Z"},{"id":"ev_2970a59c13db","question_id":"q_7ca3756217b1","source_id":"open_web","source_name":"Open Web (Supplementary)","organization":"Open web","tier":5,"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-ponatinib-chemotherapy-newly-diagnosed-philadelphia-chromosome","title":"FDA grants accelerated approval to ponatinib with chemotherapy for ...","published":"","quote":"On March 19, 2024, the Food and Drug Administration granted accelerated approval to ponatinib (Iclusig, Takeda Pharmaceuticals U.S.A., Inc.) with chemotherapy for adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).","context":"","origin":"open_web","tag":"GENERAL KNOWLEDGE","relevance":0.99,"identifiers":{"domain":"fda.gov","search_backend":"azure_web_search"},"retrieved_at":"2026-09-22T11:26:45.148915Z"},{"id":"ev_0c2a3ecb9148","question_id":"q_7ca3756217b1","source_id":"open_web","source_name":"Open Web (Supplementary)","organization":"Open web","tier":5,"url":"https://news.cancerconnect.com/fda-expands-blincyto-approval-in-frontline-b-cell-precursor-acute-lymphoblastic-leukemia/","title":"FDA Expands Blincyto Approval in Frontline B-Cell Precursor Acute ...","published":"","quote":"Blincyto now approved for CD19-positive PH(-) B-cell precursor ALL regardless of MRD status or age based on superior overall survival versus chemotherapy alone","context":"","origin":"open_web","tag":"GENERAL KNOWLEDGE","relevance":0.89,"identifiers":{"domain":"news.cancerconnect.com","search_backend":"azure_web_search"},"retrieved_at":"2026-09-22T11:26:45.149047Z"},{"id":"ev_b7d392b7cec0","question_id":"q_b5cd05555f81","source_id":"openfda_label","source_name":"FDA Drug Labeling (openFDA)","organization":"US Food and Drug Administration","tier":1,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0c3a355b-d4cf-42a0-9560-3798e1a2ee36","title":"SPL label 0c3a355b","published":"2021-12-07","quote":"This indication is based upon response rate.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.93,"identifiers":{"set_id":"0c3a355b-d4cf-42a0-9560-3798e1a2ee36","spl_id":"e9dd24fb-6aee-461e-87b3-2822d817523f","spl_version":"7"},"retrieved_at":"2026-09-22T11:27:53.840711Z"},{"id":"ev_d514be8bfecf","question_id":"q_b5cd05555f81","source_id":"openfda_label","source_name":"FDA Drug Labeling (openFDA)","organization":"US Food and Drug Administration","tier":1,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0c3a355b-d4cf-42a0-9560-3798e1a2ee36","title":"SPL label 0c3a355b","published":"2021-12-07","quote":"There are no trials verifying an improvement in disease-related symptoms or increased survival with clofarabine injection.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.88,"identifiers":{"set_id":"0c3a355b-d4cf-42a0-9560-3798e1a2ee36","spl_id":"e9dd24fb-6aee-461e-87b3-2822d817523f","spl_version":"7"},"retrieved_at":"2026-09-22T11:27:53.840766Z"},{"id":"ev_c92815eda10c","question_id":"q_b5cd05555f81","source_id":"openfda_drugsfda","source_name":"FDA Drugs@FDA (openFDA)","organization":"TAKEDA PHARMS USA","tier":1,"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203469","title":"Drugs@FDA NDA203469: ICLUSIG","published":"2025-10-10","quote":"Submissions: SUPPL 27 AP 2017-12-20 Labeling STANDARD | SUPPL 19 AP 2015-12-01 Manufacturing (CMC) PRIORITY | SUPPL 33 AP 2020-07-10 Labeling STANDARD | SUPPL 6 AP 2014-03-27 Manufacturing (CMC) PRIORITY | SUPPL 17 AP 2015-04-23 Manufacturing (CMC) PRIORITY | SUPPL 31 AP 2020-01-10 Labeling STANDARD | SUPPL 4 AP 2014-01-30 Manufacturing (CMC) PRIORITY | SUPPL 23 AP 2016-08-31 Labeling STANDARD | SUPPL 15 AP 2015-05-20 Manufacturing (CMC) PRIORITY | SUPPL 2 AP 2013-06-25 Manufacturing (CMC) PRIORITY | SUPPL 21 AP 2016-06-02 Efficacy STANDARD | SUPPL 13 AP 2015-01-20 Manufacturing (CMC) PRIORITY | SUPPL 11 AP 2014-08-15 Manufacturing (CMC) PRIORITY | SUPPL 38 AP 2025-10-10 Efficacy STANDARD | SUPPL 9 AP 2014-07-24 Labeling STANDARD | SUPPL 28 AP 2017-12-20 Labeling STANDARD | SUPPL 34 AP 2020-12-18 Efficacy PRIORITY | SUPPL 7 AP 2013-12-20 Labeling | SUPPL 18 AP 2015-08-24 Manufacturing (CMC) PRIORITY | SUPPL 32 AP 2020-06-17 Labeling STANDARD","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.61,"identifiers":{"application_number":"NDA203469","sponsor":"TAKEDA PHARMS USA"},"retrieved_at":"2026-09-22T11:27:53.840864Z"},{"id":"ev_1846adef13fd","question_id":"q_b5cd05555f81","source_id":"esmo","source_name":"ESMO","organization":"Journal of the National Comprehensive Cancer Network : JNCCN","tier":1,"url":"https://pubmed.ncbi.nlm.nih.gov/39413812/","title":"Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.","published":"2024-10-01","quote":"The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia (ALL) provide recommendations for management of ALL, with a focus on the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk assessment and stratification for risk-adapted therapy; treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients; and supportive care considerations.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.61,"identifiers":{"pmid":"39413812","doi":"10.6004/jnccn.2024.0051","epmc_id":"39413812","source":"MED"},"retrieved_at":"2026-09-22T11:29:07.502280Z"},{"id":"ev_df7e8b4455c2","question_id":"q_b5cd05555f81","source_id":"esmo","source_name":"ESMO","organization":"Journal of the National Comprehensive Cancer Network : JNCCN","tier":1,"url":"https://pubmed.ncbi.nlm.nih.gov/39413812/","title":"Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.","published":"2024-10-01","quote":"This selection from the NCCN Guidelines for ALL focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.54,"identifiers":{"pmid":"39413812","doi":"10.6004/jnccn.2024.0051","epmc_id":"39413812","source":"MED"},"retrieved_at":"2026-09-22T11:29:07.502386Z"},{"id":"ev_8ed3c32d2fb3","question_id":"q_b5cd05555f81","source_id":"openfda_drugsfda","source_name":"FDA Drugs@FDA (openFDA)","organization":"SANDOZ","tier":1,"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021877","title":"Drugs@FDA NDA021877: ARRANON","published":"2025-03-11","quote":"Submissions: SUPPL 5 AP 2012-02-06 Labeling STANDARD | SUPPL 1 AP 2009-12-15 Labeling STANDARD | SUPPL 8 AP 2018-07-03 Labeling STANDARD | SUPPL 6 AP 2015-06-04 Manufacturing (CMC) PRIORITY | SUPPL 14 AP 2025-03-11 Labeling STANDARD | SUPPL 2 AP 2009-12-15 Labeling STANDARD | SUPPL 12 AP 2019-08-02 Manufacturing (CMC) STANDARD | SUPPL 10 AP 2019-07-31 Efficacy STANDARD | SUPPL 9 AP 2018-11-29 Labeling STANDARD | ORIG 1 AP 2005-10-28 Type 1 - New Molecular Entity PRIORITY Products: ARRANON INJECTABLE INTRAVENOUS strength 250MG/50ML (5MG/ML) marketing status Prescription Application: NDA021877 sponsored by SANDOZ","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.31,"identifiers":{"application_number":"NDA021877","sponsor":"SANDOZ"},"retrieved_at":"2026-09-22T11:28:30.196092Z"},{"id":"ev_3020062e8499","question_id":"q_b5cd05555f81","source_id":"asco","source_name":"ASCO","organization":"Journal of Clinical Oncology","tier":2,"url":"https://doi.org/10.1200/jco.2025.43.16_suppl.e13573","title":"Real-world use of accelerated approval oncology drugs subsequently withdrawn in the United States.","published":"2025-06","quote":"Included AA drugs were mobocertinib (NSCLC), sacituzumab govitecan (bladder cancer), atezolizumab (breast cancer), nivolumab (SCLC), and pembrolizumab (SCLC).","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.89,"identifiers":{"doi":"10.1200/jco.2025.43.16_suppl.e13573"},"retrieved_at":"2026-09-22T11:27:37.448869Z"},{"id":"ev_4c56f3992709","question_id":"q_b5cd05555f81","source_id":"asco","source_name":"ASCO","organization":"Journal of Clinical Oncology","tier":2,"url":"https://doi.org/10.1200/jco.2025.43.16_suppl.e13573","title":"Real-world use of accelerated approval oncology drugs subsequently withdrawn in the United States.","published":"2025-06","quote":"From 1995–2024, 107 oncology indications demonstrated verified clinical benefit; 31 were withdrawn and 66 have ongoing trials.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.77,"identifiers":{"doi":"10.1200/jco.2025.43.16_suppl.e13573"},"retrieved_at":"2026-09-22T11:27:37.448750Z"},{"id":"ev_0b22c0ee4bb9","question_id":"q_b5cd05555f81","source_id":"asco","source_name":"ASCO","organization":"Journal of Clinical Oncology","tier":2,"url":"https://doi.org/10.1200/jco.2025.43.16_suppl.e13573","title":"Real-world use of accelerated approval oncology drugs subsequently withdrawn in the United States.","published":"2025-06","quote":"Conclusions: Findings indicate mixed real-world uptake of AA therapies and no consistent differences in patient characteristics.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.51,"identifiers":{"doi":"10.1200/jco.2025.43.16_suppl.e13573"},"retrieved_at":"2026-09-22T11:27:37.448920Z"},{"id":"ev_1148904526a3","question_id":"q_b5cd05555f81","source_id":"open_web","source_name":"Open Web (Supplementary)","organization":"Open web","tier":5,"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-ponatinib-chemotherapy-newly-diagnosed-philadelphia-chromosome","title":"FDA grants accelerated approval to ponatinib with chemotherapy for ...","published":"","quote":"On March 19, 2024, the Food and Drug Administration granted accelerated approval to ponatinib (Iclusig, Takeda Pharmaceuticals U.S.A., Inc.) with chemotherapy for adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).","context":"","origin":"open_web","tag":"GENERAL KNOWLEDGE","relevance":0.99,"identifiers":{"domain":"fda.gov","search_backend":"azure_web_search"},"retrieved_at":"2026-09-22T11:29:44.369482Z"},{"id":"ev_65037a0ca4f4","question_id":"q_b5cd05555f81","source_id":"open_web","source_name":"Open Web (Supplementary)","organization":"Open web","tier":5,"url":"https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/tecartus","title":"TECARTUS | FDA","published":"","quote":"Indication TECARTUS is indicated for the treatment of: Adult patients with relapsed or refractory mantle cell lymphoma (MCL). Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).","context":"","origin":"open_web","tag":"GENERAL KNOWLEDGE","relevance":0.94,"identifiers":{"domain":"fda.gov","search_backend":"azure_web_search"},"retrieved_at":"2026-09-22T11:29:44.369588Z"},{"id":"ev_706564f3720a","question_id":"q_b5cd05555f81","source_id":"open_web","source_name":"Open Web (Supplementary)","organization":"Open web","tier":5,"url":"https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/tecartus","title":"TECARTUS | FDA","published":"","quote":"June 26, 2025 REMS Elimination Approval Letter – TECARTUS","context":"","origin":"open_web","tag":"GENERAL KNOWLEDGE","relevance":0.89,"identifiers":{"domain":"fda.gov","search_backend":"azure_web_search"},"retrieved_at":"2026-09-22T11:29:44.369644Z"},{"id":"ev_ea0ed12f8542","question_id":"q_7e8639e73505","source_id":"openfda_label","source_name":"FDA Drug Labeling (openFDA)","organization":"Amneal Pharmaceuticals LLC","tier":1,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a273a2d-a1ff-412a-925e-696648730dae","title":"Clofarabine (CLOFARABINE)","published":"2022-08-23","quote":"Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.99,"identifiers":{"set_id":"0a273a2d-a1ff-412a-925e-696648730dae","spl_id":"9371cb36-5f01-4afa-bbd4-6886ae0fc277","application_number":"ANDA208857","rxcui":"486419","unii":"762RDY0Y2H","spl_version":"5"},"retrieved_at":"2026-09-22T11:30:56.635952Z"},{"id":"ev_6145072e79ae","question_id":"q_7e8639e73505","source_id":"openfda_label","source_name":"FDA Drug Labeling (openFDA)","organization":"Alembic Pharmaceuticals Limited","tier":1,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03ad6056-0e71-4e7c-842a-a5f87649bdcd","title":"NELARABINE (NELARABINE)","published":"2024-08-07","quote":"Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.99,"identifiers":{"set_id":"03ad6056-0e71-4e7c-842a-a5f87649bdcd","spl_id":"482d7978-12a5-467a-b10e-1789df5dd0f8","application_number":"ANDA218554","rxcui":"603566","unii":"60158CV180","spl_version":"2"},"retrieved_at":"2026-09-22T11:31:06.226343Z"},{"id":"ev_2de3a2b8b37d","question_id":"q_7e8639e73505","source_id":"esmo","source_name":"ESMO","organization":"Journal of the National Comprehensive Cancer Network : JNCCN","tier":1,"url":"https://pubmed.ncbi.nlm.nih.gov/31910389/","title":"Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.","published":"2020-01-01","quote":"This portion of the NCCN Guidelines focuses on the frontline and relapsed/refractory management of pediatric ALL.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.97,"identifiers":{"pmid":"31910389","doi":"10.6004/jnccn.2020.0001","epmc_id":"31910389","source":"MED"},"retrieved_at":"2026-09-22T11:30:44.490946Z"},{"id":"ev_f1faee6d75b3","question_id":"q_7e8639e73505","source_id":"esmo","source_name":"ESMO","organization":"American journal of hematology","tier":1,"url":"https://pubmed.ncbi.nlm.nih.gov/41074700/","title":"Optimizing Asparaginase Treatment for Adolescent and Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations.","published":"2025-10-11","quote":"Asparaginase is an integral component of therapy for pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.97,"identifiers":{"pmid":"41074700","pmcid":"PMC12669943","doi":"10.1002/ajh.70103","epmc_id":"41074700","source":"MED"},"retrieved_at":"2026-09-22T11:33:56.410231Z"},{"id":"ev_516351eb23f5","question_id":"q_7e8639e73505","source_id":"nci","source_name":"National Cancer Institute (NCI) PDQ","organization":"National Cancer Institute","tier":1,"url":"https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq","title":"PDQ: Remission induction therapy","published":"","quote":"Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.92,"identifiers":{"pdq_summary":"adult-all-treatment-pdq","section":"Remission induction therapy"},"retrieved_at":"2026-09-22T11:33:22.332385Z"},{"id":"ev_71987d46f280","question_id":"q_7e8639e73505","source_id":"nci","source_name":"National Cancer Institute (NCI) PDQ","organization":"National Cancer Institute","tier":1,"url":"https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq","title":"PDQ: Remission induction therapy","published":"","quote":"Most current induction regimens for patients with adult ALL include combination chemotherapy with prednisone, vincristine, and an anthracycline.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.86,"identifiers":{"pdq_summary":"adult-all-treatment-pdq","section":"Remission induction therapy"},"retrieved_at":"2026-09-22T11:33:22.332329Z"},{"id":"ev_d1408c361bbe","question_id":"q_7e8639e73505","source_id":"openfda_drugsfda","source_name":"FDA Drugs@FDA (openFDA)","organization":"TAKEDA PHARMS USA","tier":1,"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203469","title":"Drugs@FDA NDA203469: ICLUSIG","published":"2025-10-10","quote":"Products: ICLUSIG TABLET ORAL strength EQ 10MG BASE marketing status Prescription | ICLUSIG TABLET ORAL strength EQ 45MG BASE marketing status Prescription | ICLUSIG TABLET ORAL strength EQ 30MG BASE marketing status Prescription | ICLUSIG TABLET ORAL strength EQ 15MG BASE marketing status Prescription","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.59,"identifiers":{"application_number":"NDA203469","sponsor":"TAKEDA PHARMS USA"},"retrieved_at":"2026-09-22T11:33:32.589859Z"},{"id":"ev_6a2fc993513b","question_id":"q_7e8639e73505","source_id":"openfda_drugsfda","source_name":"FDA Drugs@FDA (openFDA)","organization":"NOVARTIS","tier":1,"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021588","title":"Drugs@FDA NDA021588: GLEEVEC","published":"2026-07-13","quote":"Products: GLEEVEC TABLET ORAL strength EQ 100MG BASE marketing status Prescription | GLEEVEC TABLET ORAL strength EQ 400MG BASE marketing status Prescription","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.34,"identifiers":{"application_number":"NDA021588","sponsor":"NOVARTIS"},"retrieved_at":"2026-09-22T11:32:12.037835Z"},{"id":"ev_6c988844eb71","question_id":"q_7e8639e73505","source_id":"ashpublications","source_name":"ASH / Blood (American Society of Hematology)","organization":"American Society of Hematology","tier":2,"url":"https://pubmed.ncbi.nlm.nih.gov/41670627/","title":"American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults.","published":"2026-07-01","quote":"Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols, requiring significant supportive care and close follow-up.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.99,"identifiers":{"pmid":"41670627","pmcid":"PMC13366240","doi":"10.1182/bloodadvances.2021006469","epmc_id":"41670627","source":"MED"},"retrieved_at":"2026-09-22T11:33:56.410461Z"},{"id":"ev_9dff9e1b8b01","question_id":"q_7e8639e73505","source_id":"clinicaltrials","source_name":"ClinicalTrials.gov","organization":"M.D. Anderson Cancer Center","tier":2,"url":"https://clinicaltrials.gov/study/NCT06561074","title":"A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)","published":"2025-09-25","quote":"To learn if giving the study drugs calaspargase pegol-mknl and decitabine in combination with venetoclax can help to control relapsed/refractory T-ALL and T-LLy.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.99,"identifiers":{"nct":"NCT06561074","phase":"PHASE2","status":"RECRUITING"},"retrieved_at":"2026-09-22T11:34:05.204481Z"},{"id":"ev_342f90e51548","question_id":"q_7e8639e73505","source_id":"clinicaltrials","source_name":"ClinicalTrials.gov","organization":"Autolus Limited","tier":2,"url":"https://clinicaltrials.gov/study/NCT06173518","title":"A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)","published":"2023-11-16","quote":"This is a Phase 1b/2 study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 in pediatric patients with relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B ALL) and r/r B cell Non-Hodgkin lymphoma (B NHL).","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.98,"identifiers":{"nct":"NCT06173518","phase":"PHASE1","status":"RECRUITING"},"retrieved_at":"2026-09-22T11:34:05.204614Z"},{"id":"ev_951871bbb7ce","question_id":"q_7e8639e73505","source_id":"asco","source_name":"ASCO","organization":"American Society of Clinical Oncology Educational Book","tier":2,"url":"https://doi.org/10.14694/edbook_am.2013.33.294","title":"Monoclonal Antibody-Based Therapies in the Treatment of Acute Lymphoblastic Leukemia","published":"2013-05","quote":"These include inotuzumab ozogamicin, an anti-CD22 antibody linked to calicheamicin that has produced significant single-agent responses in relapsed and refractory ALL.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.96,"identifiers":{"doi":"10.14694/edbook_am.2013.33.294"},"retrieved_at":"2026-09-22T11:33:32.589921Z"},{"id":"ev_72885d7b6299","question_id":"q_7e8639e73505","source_id":"asco","source_name":"ASCO","organization":"Journal of Clinical Oncology","tier":2,"url":"https://doi.org/10.1200/jco.2010.30.1382","title":"Modern Therapy of Acute Lymphoblastic Leukemia","published":"2011-02-10","quote":"Modern first-line therapy consists of standard- and high-dose chemotherapy (increasingly inspired to pediatric principles), hematopoietic stem-cell transplantation, and new targeted therapy, all integrated with the analysis of prognostic factors and the study of subclinical residual disease for key therapeutic decisions.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.95,"identifiers":{"doi":"10.1200/jco.2010.30.1382"},"retrieved_at":"2026-09-22T11:34:14.247918Z"},{"id":"ev_d6b3daf47ce5","question_id":"q_7e8639e73505","source_id":"ashpublications","source_name":"ASH / Blood (American Society of Hematology)","organization":"American Society of Hematology","tier":2,"url":"https://pubmed.ncbi.nlm.nih.gov/41670624/","title":"American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults.","published":"2026-07-01","quote":"They focused on the following treatment modalities: immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.94,"identifiers":{"pmid":"41670624","pmcid":"PMC13366310","doi":"10.1182/bloodadvances.2021006479","epmc_id":"41670624","source":"MED"},"retrieved_at":"2026-09-22T11:31:32.382825Z"},{"id":"ev_9fbedc6025ea","question_id":"q_fd97687cf608","source_id":"nci","source_name":"National Cancer Institute (NCI) PDQ","organization":"National Cancer Institute","tier":1,"url":"https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq","title":"PDQ: Remission induction therapy","published":"","quote":"Most current induction regimens for patients with adult ALL include combination chemotherapy with prednisone, vincristine, and an anthracycline.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.99,"identifiers":{"pdq_summary":"adult-all-treatment-pdq","section":"Remission induction therapy"},"retrieved_at":"2026-09-22T11:34:59.492902Z"},{"id":"ev_76163c9f247f","question_id":"q_fd97687cf608","source_id":"esmo","source_name":"ESMO","organization":"Blood advances","tier":1,"url":"https://pubmed.ncbi.nlm.nih.gov/41670624/","title":"American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults.","published":"2026-07-01","quote":"Additional management of ALL subsets (T-cell ALL), CNS relapse, and the role of consolidation with allogeneic transplant are addressed.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.95,"identifiers":{"pmid":"41670624","pmcid":"PMC13366310","doi":"10.1182/bloodadvances.2021006479","epmc_id":"41670624","source":"MED"},"retrieved_at":"2026-09-22T11:34:41.751415Z"},{"id":"ev_1bf20950643c","question_id":"q_fd97687cf608","source_id":"nci","source_name":"National Cancer Institute (NCI) PDQ","organization":"National Cancer Institute","tier":1,"url":"https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq","title":"PDQ: Remission induction therapy","published":"","quote":"Some regimens, including those used in a Cancer and Leukemia Group B (CALGB) study (CLB-8811), also add other drugs, such as asparaginase or cyclophosphamide.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.93,"identifiers":{"pdq_summary":"adult-all-treatment-pdq","section":"Remission induction therapy"},"retrieved_at":"2026-09-22T11:34:59.492990Z"},{"id":"ev_f27500842f2c","question_id":"q_fd97687cf608","source_id":"nci","source_name":"National Cancer Institute (NCI) PDQ","organization":"National Cancer Institute","tier":1,"url":"https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq","title":"PDQ: Remission induction therapy","published":"","quote":"The drawbacks of this nonrandomized study were the small sample size (94 total patients) and the change in the treatment regimen (omission of L-asparaginase) midway through the study.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.83,"identifiers":{"pdq_summary":"adult-all-treatment-pdq","section":"Remission induction therapy"},"retrieved_at":"2026-09-22T11:34:59.493031Z"},{"id":"ev_0fae3159251d","question_id":"q_fd97687cf608","source_id":"ashpublications","source_name":"ASH / Blood (American Society of Hematology)","organization":"American Society of Hematology","tier":2,"url":"https://pubmed.ncbi.nlm.nih.gov/41670627/","title":"American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults.","published":"2026-07-01","quote":"Conclusions Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols, requiring significant supportive care and close follow-up.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.99,"identifiers":{"pmid":"41670627","pmcid":"PMC13366240","doi":"10.1182/bloodadvances.2021006469","epmc_id":"41670627","source":"MED"},"retrieved_at":"2026-09-22T11:34:41.751143Z"},{"id":"ev_b0f7342e7e44","question_id":"q_fd97687cf608","source_id":"ashpublications","source_name":"ASH / Blood (American Society of Hematology)","organization":"American Society of Hematology","tier":2,"url":"https://pubmed.ncbi.nlm.nih.gov/41670624/","title":"American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults.","published":"2026-07-01","quote":"Conclusions Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.99,"identifiers":{"pmid":"41670624","pmcid":"PMC13366310","doi":"10.1182/bloodadvances.2021006479","epmc_id":"41670624","source":"MED"},"retrieved_at":"2026-09-22T11:34:41.751383Z"},{"id":"ev_784b1c070de9","question_id":"q_fd97687cf608","source_id":"ashpublications","source_name":"ASH / Blood (American Society of Hematology)","organization":"American Society of Hematology","tier":2,"url":"https://pubmed.ncbi.nlm.nih.gov/41670627/","title":"American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults.","published":"2026-07-01","quote":"Allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.98,"identifiers":{"pmid":"41670627","pmcid":"PMC13366240","doi":"10.1182/bloodadvances.2021006469","epmc_id":"41670627","source":"MED"},"retrieved_at":"2026-09-22T11:34:41.751247Z"},{"id":"ev_29faee036ecb","question_id":"q_fd97687cf608","source_id":"clinicaltrials","source_name":"ClinicalTrials.gov","organization":"National Cancer Institute (NCI)","tier":2,"url":"https://clinicaltrials.gov/study/NCT02003222","title":"Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia","published":"2014-05-19","quote":"PRIMARY OBJECTIVE: I. To compare the overall survival (OS) of blinatumomab in conjunction with chemotherapy to chemotherapy alone in patients with BCR-ABL-negative B cell precursor acute lymphoblastic leukemia (ALL) who are minimal residual disease (MRD) negative after induction and intensification chemotherapy, based on multiparameter flow cytometric (MFC) assessment of residual blasts.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.18,"identifiers":{"nct":"NCT02003222","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING"},"retrieved_at":"2026-09-22T11:35:12.863204Z"},{"id":"ev_2af9506a4cbf","question_id":"q_fd97687cf608","source_id":"clinicaltrials","source_name":"ClinicalTrials.gov","organization":"National Cancer Institute (NCI)","tier":2,"url":"https://clinicaltrials.gov/study/NCT02003222","title":"Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia","published":"2014-05-19","quote":"This randomized phase III trial studies combination chemotherapy with blinatumomab to see how well it works compared to induction chemotherapy alone in treating patients with newly diagnosed breakpoint cluster region (BCR)-c-abl oncogene 1, non-receptor tyrosine kinase (ABL)-negative B lineage acute lymphoblastic leukemia.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.16,"identifiers":{"nct":"NCT02003222","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING"},"retrieved_at":"2026-09-22T11:35:12.863099Z"},{"id":"ev_6bc1dcf4a899","question_id":"q_fd97687cf608","source_id":"clinicaltrials","source_name":"ClinicalTrials.gov","organization":"National Cancer Institute (NCI)","tier":2,"url":"https://clinicaltrials.gov/study/NCT02003222","title":"Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia","published":"2014-05-19","quote":"It is not yet known whether combination chemotherapy is more effective with or without blinatumomab in treating newly diagnosed acute lymphoblastic leukemia.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.11,"identifiers":{"nct":"NCT02003222","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING"},"retrieved_at":"2026-09-22T11:35:12.863156Z"},{"id":"ev_a52e9eb48e4e","question_id":"q_1a2fac4b0d38","source_id":"nci","source_name":"National Cancer Institute (NCI) PDQ","organization":"National Cancer Institute","tier":1,"url":"https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq","title":"PDQ: Remission induction therapy","published":"","quote":"Responses were short lived, with most of these patients experiencing disease relapse at a median of 58 days after the start of therapy.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.96,"identifiers":{"pdq_summary":"adult-all-treatment-pdq","section":"Remission induction therapy"},"retrieved_at":"2026-09-22T11:37:42.055944Z"},{"id":"ev_83fb787fde0e","question_id":"q_1a2fac4b0d38","source_id":"esmo","source_name":"ESMO","organization":"Blood advances","tier":1,"url":"https://pubmed.ncbi.nlm.nih.gov/41670624/","title":"American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults.","published":"2026-07-01","quote":"For adolescents and young adults (AYAs) with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), the American Society of Hematology (ASH) guideline panel recommends the use of blinatumomab over chemotherapy (strong recommendation based on low certainty in the evidence of effects ⨁⨁◯◯).","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.89,"identifiers":{"pmid":"41670624","pmcid":"PMC13366310","doi":"10.1182/bloodadvances.2021006479","epmc_id":"41670624","source":"MED"},"retrieved_at":"2026-09-22T11:37:49.386535Z"},{"id":"ev_71c9ad8ae308","question_id":"q_1a2fac4b0d38","source_id":"nci","source_name":"National Cancer Institute (NCI) PDQ","organization":"National Cancer Institute","tier":1,"url":"https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq","title":"PDQ: Remission induction therapy","published":"","quote":"Current multiagent induction regimens result in complete response rates that range from 60% to 90%.[ 1 , 4 , 5 , 11 , 12 ]","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.87,"identifiers":{"pdq_summary":"adult-all-treatment-pdq","section":"Remission induction therapy"},"retrieved_at":"2026-09-22T11:37:42.055853Z"},{"id":"ev_a692331b8f0c","question_id":"q_1a2fac4b0d38","source_id":"esmo","source_name":"ESMO","organization":"Blood advances","tier":1,"url":"https://pubmed.ncbi.nlm.nih.gov/41670624/","title":"American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults.","published":"2026-07-01","quote":"These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support clinicians, patients, and other health care professionals in their decisions about management of AYAs with relapsed/refractory ALL.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.84,"identifiers":{"pmid":"41670624","pmcid":"PMC13366310","doi":"10.1182/bloodadvances.2021006479","epmc_id":"41670624","source":"MED"},"retrieved_at":"2026-09-22T11:37:49.386393Z"},{"id":"ev_99f68b1f1fcc","question_id":"q_1a2fac4b0d38","source_id":"nci","source_name":"National Cancer Institute (NCI) PDQ","organization":"National Cancer Institute","tier":1,"url":"https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq","title":"PDQ: Remission induction therapy","published":"","quote":"However, the results suggested that inclusion of imatinib into a relatively standard chemotherapy regimen for newly diagnosed adult patients with Ph-positive ALL may provide a significant survival advantage.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.79,"identifiers":{"pdq_summary":"adult-all-treatment-pdq","section":"Remission induction therapy"},"retrieved_at":"2026-09-22T11:37:42.055915Z"},{"id":"ev_180c5c21ede1","question_id":"q_1a2fac4b0d38","source_id":"esmo","source_name":"ESMO","organization":"Blood advances","tier":1,"url":"https://pubmed.ncbi.nlm.nih.gov/41670624/","title":"American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults.","published":"2026-07-01","quote":"They focused on the following treatment modalities: immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)–directed therapy.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.72,"identifiers":{"pmid":"41670624","pmcid":"PMC13366310","doi":"10.1182/bloodadvances.2021006479","epmc_id":"41670624","source":"MED"},"retrieved_at":"2026-09-22T11:37:49.386475Z"},{"id":"ev_fbe4c741d329","question_id":"q_1a2fac4b0d38","source_id":"asco","source_name":"ASCO","organization":"Journal of Clinical Oncology","tier":2,"url":"https://doi.org/10.1200/jco.2020.38.15_suppl.e19135","title":"Performance of time to discontinuation and time to next treatment as proxy measures of progression-free survival, overall and by treatment group.","published":"2020-05-20","quote":"This report cites findings from the metastatic breast cancer (mBC) setting.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.98,"identifiers":{"doi":"10.1200/jco.2020.38.15_suppl.e19135"},"retrieved_at":"2026-09-22T11:38:04.346428Z"},{"id":"ev_f9db53789436","question_id":"q_1a2fac4b0d38","source_id":"asco","source_name":"ASCO","organization":"Journal of Clinical Oncology","tier":2,"url":"https://doi.org/10.1200/jco.2020.38.15_suppl.e19135","title":"Performance of time to discontinuation and time to next treatment as proxy measures of progression-free survival, overall and by treatment group.","published":"2020-05-20","quote":"Methods: Previously curated EMR data were collected from Concerto’s Definitive Oncology Dataset for adult, female, hormone receptor-positive/human epidermal growth factor receptor-negative mBC patients diagnosed 2008 or later who received at least one line of systemic therapy.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.96,"identifiers":{"doi":"10.1200/jco.2020.38.15_suppl.e19135"},"retrieved_at":"2026-09-22T11:38:04.346533Z"},{"id":"ev_66e4f3d80648","question_id":"q_1a2fac4b0d38","source_id":"ashpublications","source_name":"ASH / Blood (American Society of Hematology)","organization":"American Society of Hematology","tier":2,"url":"https://pubmed.ncbi.nlm.nih.gov/41670627/","title":"American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults.","published":"2026-07-01","quote":"Conclusions Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols, requiring significant supportive care and close follow-up.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.93,"identifiers":{"pmid":"41670627","pmcid":"PMC13366240","doi":"10.1182/bloodadvances.2021006469","epmc_id":"41670627","source":"MED"},"retrieved_at":"2026-09-22T11:38:23.750450Z"},{"id":"ev_0536c7d5f381","question_id":"q_1a2fac4b0d38","source_id":"ashpublications","source_name":"ASH / Blood (American Society of Hematology)","organization":"American Society of Hematology","tier":2,"url":"https://pubmed.ncbi.nlm.nih.gov/41670627/","title":"American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults.","published":"2026-07-01","quote":"Recommendation 1 For adolescents and young adults (AYAs) with B-cell or T-cell acute lymphoblastic leukemia (B-ALL/T-ALL) or T-cell acute lymphoblastic lymphoma (T-LBL/LLy) receiving frontline therapy, the American Society of Hematology (ASH) guideline panel recommends pediatric-inspired (asparaginase-containing) regimens (strong recommendation based on moderate certainty in the evidence of effects ⨁⨁⨁◯).","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.91,"identifiers":{"pmid":"41670627","pmcid":"PMC13366240","doi":"10.1182/bloodadvances.2021006469","epmc_id":"41670627","source":"MED"},"retrieved_at":"2026-09-22T11:38:23.750606Z"},{"id":"ev_a2bd9afb5a1b","question_id":"q_1a2fac4b0d38","source_id":"clinicaltrials","source_name":"ClinicalTrials.gov","organization":"National Cancer Institute (NCI)","tier":2,"url":"https://clinicaltrials.gov/study/NCT02003222","title":"Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia","published":"2014-05-19","quote":"SECONDARY OBJECTIVES: I. To compare the relapse-free survival (RFS) of blinatumomab in conjunction with chemotherapy to chemotherapy alone in MRD negative patients after induction and intensification chemotherapy.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.9,"identifiers":{"nct":"NCT02003222","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING"},"retrieved_at":"2026-09-22T11:37:42.056025Z"},{"id":"ev_1703fdf5e463","question_id":"q_1a2fac4b0d38","source_id":"clinicaltrials","source_name":"ClinicalTrials.gov","organization":"National Cancer Institute (NCI)","tier":2,"url":"https://clinicaltrials.gov/study/NCT02003222","title":"Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia","published":"2014-05-19","quote":"PRIMARY OBJECTIVE: I. To compare the overall survival (OS) of blinatumomab in conjunction with chemotherapy to chemotherapy alone in patients with BCR-ABL-negative B cell precursor acute lymphoblastic leukemia (ALL) who are minimal residual disease (MRD) negative after induction and intensification chemotherapy, based on multiparameter flow cytometric (MFC) assessment of residual blasts.","context":"","origin":"approved_api","tag":"VERIFIED","relevance":0.78,"identifiers":{"nct":"NCT02003222","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING"},"retrieved_at":"2026-09-22T11:37:42.055998Z"},{"id":"ev_e68c3a57a70a","question_id":"q_1a2fac4b0d38","source_id":"open_web","source_name":"Open Web (Supplementary)","organization":"Open web","tier":5,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7820874/","title":"Optimizing therapy in the modern age: differences in length of ...","published":"","quote":"Contemporary ALL therapy usually consists of cycles of multiagent chemotherapy administered over 2 to 3 years that includes central nervous system (CNS) prophylaxis, primarily consisting of CNS-penetrating systemic agents and intrathecal therapy.","context":"","origin":"open_web","tag":"GENERAL KNOWLEDGE","relevance":0.96,"identifiers":{"domain":"pmc.ncbi.nlm.nih.gov","search_backend":"azure_web_search"},"retrieved_at":"2026-09-22T11:39:18.042516Z"},{"id":"ev_391bd052fba3","question_id":"q_1a2fac4b0d38","source_id":"open_web","source_name":"Open Web (Supplementary)","organization":"Open web","tier":5,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7820874/","title":"Optimizing therapy in the modern age: differences in length of ...","published":"","quote":"ALL therapy typically begins with 5 to 9 months of more-intensive chemotherapy followed by a prolonged low-intensity maintenance phase.","context":"","origin":"open_web","tag":"GENERAL KNOWLEDGE","relevance":0.96,"identifiers":{"domain":"pmc.ncbi.nlm.nih.gov","search_backend":"azure_web_search"},"retrieved_at":"2026-09-22T11:39:18.042593Z"}],"answers":[{"id":"ans_10f514b58bc3","run_id":"run_2058f031b9db","question_id":"q_6f442701d567","stage":"stage_1","status":"partial","text":"The supplied documents define acute lymphoblastic leukemia (ALL) as \"A group of rare Non-Hodgkin lymphoma characterized by malignant proliferation of lymphoid cells blocked at an early stage of differentiation\" and note synonymous terminology including \"ALL, Acute lymphoblastic leukemia/lymphoma, Acute lymphocytic leukemia, Precursor lymphoid neoplasm.\" The documents do not provide WHO or ICC disease classification schemas, and they do not explicitly define B-cell versus T-cell lineage classifications. Clinical presentation and natural history information relevant to cohort construction includes that patients \"may present with symptoms, frequently including lymphadenopathy, hepatosplenomegaly, bone pain, fever and signs of hemorrhage or they may remain asymptomatic,\" and that disease can involve marrow, blood, and extranodal tissues because \"the abnormal cells can infiltrate any organ or tissue.\" The documents also describe relapse patterns and age-related treatment differences: adult ALL induction regimens achieve \"complete response rates that range from 60% to 90%\" but \"Responses were short lived, with most of these patients experiencing disease relapse,\" while adolescents and young adults are described as \"a unique population\" in whom \"Treatment regimens can vary significantly depending on whether they receive care in a pediatric or in an adult setting\" and who have \"distinctive care needs, social risk factors, and disease behavior compared with other age groups.\"","aspects_covered":["General ALL disease definition and terminology","Clinical presentation patterns","Relapse/progression course in adult ALL","Pediatric versus adult/AYA disease and treatment patterns"],"evidence_ids":["ev_c9706e9f4f7c","ev_4ad9686adf8f","ev_f627156d82c2","ev_dfedeb04e1d0","ev_ca4a962dac12","ev_018c0d99b1c3","ev_529464b6e0eb","ev_2e69084f0f32","ev_04f49978385b"],"source_ids":["orphanet","nci","ashpublications"],"citations":["Orphanet","National Cancer Institute","American Society of Hematology"],"origin":"approved_api","batch_index":0,"round_index":0,"created_at":"2026-09-22T11:09:58.165626Z"},{"id":"ans_5079c042d518","run_id":"run_2058f031b9db","question_id":"q_6f442701d567","stage":"stage_1","status":"partial","text":"The supplied document addresses lineage classifications and some relapse/natural history patterns for acute lymphoblastic leukemia (ALL), particularly in adolescents and young adults (AYAs) with relapsed/refractory disease. It specifically distinguishes “B-cell acute lymphoblastic leukemia (B-ALL)” and “T-cell ALL,” and describes relapsed/refractory ALL as involving “greater treatment resistance” and “higher rates of toxicity.” The document also references relapse states including “CNS relapse” and patients who “achieve a second (or greater) remission (CR2).” However, the document does not provide WHO/ICC disease definitions, comprehensive disease presentation patterns, or detailed pediatric-versus-adult epidemiology and natural history needed for claims-based line-of-therapy cohort construction.","aspects_covered":["B-cell vs T-cell lineage","Relapsed/refractory disease course","CNS relapse","Second or greater remission (CR2) concepts","AYA disease patterns"],"evidence_ids":["ev_9e42f72ef49a","ev_073e844d7c36","ev_98c0ac51f5ab"],"source_ids":["ashpublications"],"citations":["American Society of Hematology"],"origin":"approved_api","batch_index":1,"round_index":0,"created_at":"2026-09-22T11:10:05.953341Z"},{"id":"ans_5278227b245c","run_id":"run_2058f031b9db","question_id":"q_6f442701d567","stage":"stage_1","status":"partial","text":"The supplied document only addresses a limited aspect of pediatric acute lymphoblastic leukemia management and does not provide WHO/ICC disease definitions, lineage classifications, relapse patterns, progression course, or pediatric-versus-adult epidemiology relevant to claims-based line-of-therapy cohort construction. The document states that \"Pediatric maintenance therapy for acute lymphoblastic leukemia requires prolonged daily administration of 6-mercaptopurine (6-MP), a drug characterized by a narrow therapeutic index and substantial interindividual variability.\" It also describes that this therapy involves \"prolonged daily administration\" during pediatric maintenance treatment.","aspects_covered":["Pediatric acute lymphoblastic leukemia maintenance therapy","Use of prolonged daily 6-mercaptopurine administration in pediatric ALL"],"evidence_ids":["ev_d657beab5bba","ev_02aa543089c9"],"source_ids":["pubmed"],"citations":["AAPS PharmSciTech"],"origin":"approved_api","batch_index":0,"round_index":1,"created_at":"2026-09-22T11:10:18.538230Z"},{"id":"ans_cc9fa32bf2f3","run_id":"run_2058f031b9db","question_id":"q_6f442701d567","stage":"stage_1","status":"partial","text":"The supplied document identifies acute lymphocytic leukemia (ALL) epidemiology and age-related disease patterns in the United States through 2026, but it does not provide WHO/ICC disease definitions, lineage classifications such as B-cell versus T-cell ALL, or detailed relapse/progression natural history relevant to claims-based line-of-therapy construction. The document states that \"Acute lymphocytic leukemia is most common in children, adolescents, and young adults, or those 15 to 39 years of age\" and that \"Acute lymphocytic leukemia is most frequently diagnosed among people aged <20,\" which supports pediatric and young adult predominance. It also reports U.S. burden estimates including \"Estimated New Cases in 2026: 6,250\" and \"Estimated Deaths in 2026: 1,600.\"","aspects_covered":["U.S. epidemiology through 2026","Pediatric and young adult disease patterns","Incidence and mortality estimates"],"evidence_ids":["ev_66731dfaf256","ev_f7fb02fda72b","ev_5088a05b2bee"],"source_ids":["seer"],"citations":["National Cancer Institute, Surveillance, Epidemiology, and End Results Program"],"origin":"approved_api","batch_index":0,"round_index":2,"created_at":"2026-09-22T11:10:31.875248Z"},{"id":"ans_e3b373e0274e","run_id":"run_2058f031b9db","question_id":"q_bf36e105dc68","stage":"stage_2","status":"partial","text":"The supplied documents identify NCCN Clinical Practice Guidelines as major U.S. clinical guidelines for acute lymphoblastic leukemia (ALL), including adult ALL Version 2.2024 and Pediatric ALL Version 2.2025. The documents state that these guidelines cover “risk assessment and stratification for risk-adapted therapy” and “treatment strategies” for multiple disease subtypes and patient groups, including “Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients” and pediatric “BCR::ABL1-positive B-cell lineage, T-cell lineage, and infant ALL.” However, the documents provided do not include the actual first-line treatment regimens, induction/consolidation/maintenance recommendations, MRD-positive recommendations, or preference categories requested in the question.","aspects_covered":["Guideline bodies","Guideline versions","Disease subtype stratification","Patient segment stratification"],"evidence_ids":["ev_49c6e81c290d","ev_95147d6f5520","ev_7ebf3fdcef49","ev_ac2da8722cbb","ev_2ef71da17f30","ev_b3fce2fde4e9"],"source_ids":["esmo"],"citations":["Journal of the National Comprehensive Cancer Network : JNCCN"],"origin":"approved_api","batch_index":0,"round_index":0,"created_at":"2026-09-22T11:09:07.871998Z"},{"id":"ans_5696a7b29620","run_id":"run_2058f031b9db","question_id":"q_bf36e105dc68","stage":"stage_2","status":"partial","text":"The supplied documents identify two major guideline bodies relevant to frontline acute lymphoblastic leukemia (ALL) management in the United States as of 2025–2026: the NCCN and the American Society of Hematology (ASH). The NCCN Pediatric ALL Version 2.2025 guideline states that it addresses “risk assessment and stratification of risk-adapted therapy” and includes “treatment strategies for BCR::ABL1 (Philadelphia chromosome [Ph])-negative and BCR::ABL1-positive B-cell lineage, T-cell lineage, and infant ALL,” but the supplied text does not provide specific first-line induction, consolidation, maintenance, or MRD-positive regimens, nor preference categories. The ASH 2026 AYA ALL guideline states that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols,” that “Allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy,” and that “The use of targeted agents in frontline therapy is increasingly supported,” but the supplied excerpts do not enumerate regimen names, treatment phases, MRD-directed regimens, or formal preference categories.","aspects_covered":["Guideline bodies","Guideline versions","Disease subtype stratification","AYA patient segment","General frontline treatment approach","Higher-risk or suboptimal response considerations"],"evidence_ids":["ev_239c686a3b18","ev_0e6e77f6742c","ev_35905d560476","ev_9a9fe7136332","ev_5ed30fb70547"],"source_ids":["ashpublications","esmo"],"citations":["Journal of the National Comprehensive Cancer Network : JNCCN","Blood advances"],"origin":"approved_api","batch_index":1,"round_index":0,"created_at":"2026-09-22T11:09:16.326213Z"},{"id":"ans_4b0dfe4973d0","run_id":"run_2058f031b9db","question_id":"q_bf36e105dc68","stage":"stage_2","status":"partial","text":"The supplied documents identify NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia and pediatric acute lymphoblastic leukemia, including risk-stratified and frontline management concepts, but they do not provide the specific first-line treatment regimens, induction/consolidation/maintenance protocols, MRD-positive regimens, or preference categories requested. The adult ALL NCCN guideline documents state that they provide \"risk-stratified treatment approaches based on the Philadelphia chromosome status and age (adults vs. adolescents/young adults), assessment of minimal residual disease,\" while the pediatric guideline states that it \"focuses on the frontline and relapsed/refractory management of pediatric ALL.\" The pediatric guideline also identifies high-risk groups including \"T-ALL\" and \"infant ALL.\" No guideline version dated 2026-09-22, no regimen names, and no recommendation categories are present in the supplied text.","aspects_covered":["Guideline bodies","Some guideline scope and stratification factors","Pediatric versus adult/AYA segmentation","Mention of MRD assessment","High-risk subgroup examples"],"evidence_ids":["ev_8a7eea396545","ev_0c0eb84eff27","ev_c986d8a67643","ev_6b85236d7089","ev_086144fa97f3"],"source_ids":["esmo"],"citations":["Journal of the National Comprehensive Cancer Network : JNCCN"],"origin":"approved_api","batch_index":2,"round_index":0,"created_at":"2026-09-22T11:09:23.176010Z"},{"id":"ans_fe33a4855add","run_id":"run_2058f031b9db","question_id":"q_bf36e105dc68","stage":"stage_2","status":"partial","text":"The supplied documents identify the National Comprehensive Cancer Network (NCCN) pediatric and adult acute lymphoblastic leukemia (ALL) guidelines and state that they provide treatment recommendations for frontline and relapsed/refractory management, but they do not provide the specific first-line treatment regimens across induction, consolidation, maintenance, or MRD-positive settings requested in the question. The documents also do not provide guideline preference categories, detailed subtype-specific regimen recommendations, or risk/biomarker-stratified first-line regimen tables. One document specifies \"Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology,\" while another specifies \"NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017.\"","aspects_covered":["Guideline bodies","Guideline versions","General scope mentioning frontline and relapsed/refractory management"],"evidence_ids":["ev_85e6feb80eb2","ev_58cca5064741","ev_2c9248174500","ev_068cd1725759","ev_786c259cba40","ev_154e7b611924"],"source_ids":["ashpublications","esmo"],"citations":["Journal of the National Comprehensive Cancer Network : JNCCN"],"origin":"approved_api","batch_index":3,"round_index":0,"created_at":"2026-09-22T11:09:30.331385Z"},{"id":"ans_c570e71b829f","run_id":"run_2058f031b9db","question_id":"q_bf36e105dc68","stage":"stage_2","status":"partial","text":"The supplied documents do not provide a comprehensive list of U.S. major clinical guideline recommendations, versions, preference categories, or complete first-line regimens across induction, consolidation, maintenance, and MRD-positive settings for acute lymphoblastic leukemia. The documents only describe selected induction-treatment concepts and asparaginase-related recommendations for specific populations. For adult ALL induction, the NCI PDQ document states that \"Most current induction regimens for patients with adult ALL include combination chemotherapy with prednisone, vincristine, and an anthracycline,\" and that some regimens \"also add other drugs, such as asparaginase or cyclophosphamide.\" For Ph-positive ALL, the same document states that \"Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL.\" Separate consensus-panel documents for adolescent and young adult patients state that \"Asparaginase is an integral component of therapy for pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma\" and describe use of \"pediatric/pediatric-inspired regimens incorporating asparaginase for treating adolescent and young adult (AYA) and adult populations.\"","aspects_covered":["NCI PDQ induction therapy description for adult ALL","Mention of Ph-positive ALL use of imatinib","AYA/pediatric-inspired asparaginase-containing regimens","Risk/biomarker subgroup mention: Ph-positive ALL and AYA patients","Absence of consolidation, maintenance, MRD-positive recommendations, and guideline preference categories in supplied documents"],"evidence_ids":["ev_d31182c7cd43","ev_527d5314eeb2","ev_1153f96a4bd5","ev_8ece27933ee3","ev_503af40cfd26","ev_49917e8eadff"],"source_ids":["nci","esmo"],"citations":["National Cancer Institute","American journal of hematology"],"origin":"approved_api","batch_index":4,"round_index":0,"created_at":"2026-09-22T11:09:39.202049Z"},{"id":"ans_6f547c5ac374","run_id":"run_2058f031b9db","question_id":"q_bf36e105dc68","stage":"stage_2","status":"partial","text":"The supplied documents do not provide a comprehensive list of United States first-line treatment regimens for acute lymphoblastic leukemia across induction, consolidation, maintenance, and MRD-positive settings stratified by guideline preference categories. The documents do identify some guideline or cooperative-group treatment approaches and disease subsets. An ASCO Educational Book review states that “Contemporary COG HR ALL treatment regimens were developed from the BFM-76 regimen, with subsequent changes that led to development and refinement of a so-called augmented BFM (ABFM) regimen used today,” and notes that “introduction of the tyrosine kinase inhibitor imatinib has led to dramatic outcome improvements for children and adolescents with Philadelphia chromosome–positive ALL.” A pediatric maintenance-focused recommendation document from the French Society for Childhood and Adolescent Cancer and Leukemia states that “Maintenance therapy is the last phase of treatment for acute lymphoblastic leukemia in children and adolescents” and that it “is an essential phase of treatment that reduces the risk of relapse.” An ASH 2026 guideline document addresses relapsed/refractory AYA ALL rather than first-line disease, reporting that “Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction.”","aspects_covered":["ASCO Educational Book discussion of COG/BFM augmented BFM regimens for pediatric high-risk ALL","Philadelphia chromosome–positive ALL and imatinib mention","Maintenance therapy recommendations in pediatric ALL from SFCE","ASH 2026 relapsed/refractory AYA ALL recommendations including blinatumomab/inotuzumab"],"evidence_ids":["ev_b4843d9ecda3","ev_ecf8a537435c","ev_afc0a6a1462a","ev_a7038bf88c61","ev_1191cf252db0","ev_4ce623e20c05"],"source_ids":["asco","ashpublications","esmo"],"citations":["American Society of Clinical Oncology Educational Book","Bulletin du cancer","Blood advances"],"origin":"approved_api","batch_index":6,"round_index":0,"created_at":"2026-09-22T11:09:51.569271Z"},{"id":"ans_6c11be27d116","run_id":"run_2058f031b9db","question_id":"q_bf36e105dc68","stage":"stage_2","status":"partial","text":"The supplied documents do not provide a complete accounting of U.S. first-line treatment regimens for acute lymphoblastic leukemia across induction, consolidation, maintenance, and MRD-positive settings by guideline preference category. The documents only identify limited guideline-related statements. One document states that \"guidelines from the National Comprehensive Cancer Network now recommend consideration of pediatric inspired treatment\" for adolescent and young adult patients with ALL. Another document describes the \"American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults,\" which \"cover[] remission reinduction and consolidation\" and include recommendations such as \"the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction.\" The documents do not provide the requested full stratification by induction, consolidation, maintenance, MRD-positive settings, preference categories, or comprehensive disease subtype segmentation for all patients.","aspects_covered":["NCCN guideline mention for AYA ALL recommending consideration of pediatric-inspired treatment","ASH 2026 guideline for relapsed/refractory AYA ALL covering reinduction and consolidation","Mention of blinatumomab and/or inotuzumab over chemotherapy for reinduction","Identification of limited patient segment: adolescents and young adults (AYA)"],"evidence_ids":["ev_b80c7d1d38ae","ev_45b6a1821db3","ev_0d77a419ac79","ev_a99b8a530d47","ev_0243c39a7be7"],"source_ids":["asco","ashpublications"],"citations":["Journal of Clinical Oncology","American Society of Hematology"],"origin":"approved_api","batch_index":7,"round_index":0,"created_at":"2026-09-22T11:09:58.444146Z"},{"id":"ans_0059671cee05","run_id":"run_2058f031b9db","question_id":"q_bf36e105dc68","stage":"stage_2","status":"partial","text":"The supplied documents do not provide a comprehensive set of major U.S. clinical guideline recommendations for first-line acute lymphoblastic leukemia treatment across induction, consolidation, maintenance, and MRD-positive settings stratified by guideline preference categories. One FDA document describes a regimen used with ponatinib for newly diagnosed Philadelphia chromosome-positive ALL in adults: “Chemotherapy consisted of 3 cycles of induction with vincristine and dexamethasone, 6 cycles of consolidation alternating between methotrexate and cytarabine, and 11 cycles of maintenance with vincristine and prednisone.” The pediatric evidence-based review documents state that “allogeneic SCT may be considered for hypodiploid ALL and persistent minimal residual disease [corrected] (MRD) positivity in ALL in CR1 or greater,” and also note that “preliminary tyrosine kinase inhibitor (TKI) data demonstrate that early outcomes are comparable for allogeneic SCT and chemotherapy + imatinib” for children with Ph+ ALL in CR1.","aspects_covered":["FDA-described first-line chemotherapy phases for newly diagnosed adult Ph+ ALL with ponatinib","MRD-positive consideration for allogeneic SCT in pediatric ALL","Ph+ ALL pediatric context involving chemotherapy plus imatinib","Identification of disease subtypes and patient segments (adult Ph+ ALL; pediatric ALL; hypodiploid ALL; MRD-positive ALL)"],"evidence_ids":["ev_913f6ac14044","ev_d6702a8c8417","ev_be6f2b367e8d","ev_298087df21a5","ev_0bb0ca9fd5ae","ev_0eeb76703afb","ev_ce57b5c41ce2","ev_c9563b318936"],"source_ids":["fda","esmo","ashpublications"],"citations":["FDA","Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation","American Society of Hematology"],"origin":"approved_api","batch_index":0,"round_index":3,"created_at":"2026-09-22T11:12:05.742795Z"},{"id":"ans_cb9baaa0a905","run_id":"run_2058f031b9db","question_id":"q_bf36e105dc68","stage":"stage_2","status":"partial","text":"The supplied documents identify guideline bodies and some treatment-structure and stratification concepts for acute lymphoblastic leukemia (ALL), but they do not provide a complete list of first-line treatment regimens across induction, consolidation, maintenance, and MRD-positive settings stratified by guideline preference category. The Medscape summary updated March 17, 2026 states that ALL therapy includes “an induction phase with a goal of achieving complete remission (CR)” followed by “a consolidation phase to maintain CR,” and that follow-up is “with maintenance therapy or allogeneic hematopoietic stem cell transplantation (HSCT).” It also states that treatment decisions may be influenced by “Philadelphia chromosome (Ph)(BCR::ABL1) status,” “Presence of CD20-positive disease,” “Cell origin (B-cell vs T-cell),” and “Minimal residual disease (MRD) status.” The ASH document identifies itself as the “American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults,” but the supplied text does not include the specific frontline regimens, recommendation strengths, or preference categories requested.","aspects_covered":["Guideline bodies identified","Guideline version/date identified","Treatment phases mentioned: induction, consolidation, maintenance","Risk and biomarker stratification factors mentioned","MRD status mentioned as treatment-influencing factor","AYA patient segment identified"],"evidence_ids":["ev_c3c0e67a1c26","ev_3362d9309218","ev_e25eff29a98f"],"source_ids":["open_web"],"citations":["Open web"],"origin":"open_web","batch_index":0,"round_index":99,"created_at":"2026-09-22T11:12:18.815773Z"},{"id":"ans_b8150d900702","run_id":"run_2058f031b9db","question_id":"q_0207dfec5c74","stage":"stage_1","status":"partial","text":"In the United States, SEER reports that “The rate of new cases of acute lymphocytic leukemia was 1.9 per 100,000 men and women per year” and “The death rate was 0.4 per 100,000 men and women per year,” with “Estimated New Cases in 2026: 6,250” and “Estimated Deaths in 2026: 1,600.” SEER also states that “In 2023, there were an estimated 126,118 people living with acute lymphocytic leukemia in the United States” and that “5-YearRelative Survival: 73.2% (2016–2022).” Age-related epidemiology is described as follows: “Acute lymphocytic leukemia is most common in children, adolescents, and young adults, or those 15 to 39 years of age,” “Acute lymphocytic leukemia is most frequently diagnosed among people aged <20,” and Orphanet reports that “The peak incidence occurs between 2 and 5 years of age.” The supplied documents do not provide U.S. incidence, prevalence, survival, mortality, or subtype distribution estimates specifically for B-ALL, T-ALL, or Philadelphia chromosome-positive ALL.","aspects_covered":["Overall U.S. incidence rates","Overall U.S. mortality rates","Overall prevalence estimates","Overall 5-year survival","Age-stratified epidemiology","2026 projected cases and deaths"],"evidence_ids":["ev_5996ab18e475","ev_868dbce5142e","ev_ae2e51c35a5b","ev_5b596a37cfa7","ev_30c09fef4cb4"],"source_ids":["seer","orphanet"],"citations":["National Cancer Institute, Surveillance, Epidemiology, and End Results Program","Orphanet"],"origin":"approved_api","batch_index":0,"round_index":0,"created_at":"2026-09-22T11:11:28.351708Z"},{"id":"ans_1ba306f90d55","run_id":"run_2058f031b9db","question_id":"q_0207dfec5c74","stage":"stage_1","status":"partial","text":"The supplied document provides childhood lymphoid leukaemia 5-year net survival estimates for multiple countries in 2021, but it does not provide United States-specific incidence, prevalence, mortality, subtype distribution, or subtype-specific epidemiology for acute lymphoblastic leukemia (ALL), including B-ALL, T-ALL, or Philadelphia chromosome-positive ALL. The document reports that childhood cancer survival for lymphoid leukaemia reached high levels in several countries, including “GBR 2021 AGEGROUP_YEARSLESS20 = 92.5 [90.2-94.3]”, “DEU 2021 AGEGROUP_YEARSLESS20 = 90.6 [87.1-93.2]”, and “DNK 2021 AGEGROUP_YEARSLESS20 = 92.2 [88.3-94.8]”. No data through 2026 for the United States are included.","aspects_covered":["childhood lymphoid leukaemia 5-year net survival estimates in selected countries"],"evidence_ids":["ev_258f61e5a57f"],"source_ids":["who_gho"],"citations":["World Health Organization"],"origin":"approved_api","batch_index":0,"round_index":1,"created_at":"2026-09-22T11:11:44.996544Z"},{"id":"ans_09b3d4e76d15","run_id":"run_2058f031b9db","question_id":"q_0207dfec5c74","stage":"stage_1","status":"partial","text":"The supplied document does not provide numerical estimates for incidence, prevalence, survival, or mortality of acute lymphoblastic leukemia (ALL) in the United States through 2026, nor does it provide subtype-specific epidemiology for B-ALL, T-ALL, or Philadelphia chromosome-positive ALL. The document does identify adolescents and young adults (AYAs) as a distinct population with differing disease behavior and treatment settings, and it references major ALL subtypes including B-cell and T-cell ALL. It also states that pediatric-inspired frontline regimens are recommended for AYAs with B-ALL or T-ALL.","aspects_covered":["AYA population characteristics","Mention of B-ALL and T-ALL subtypes","Frontline treatment recommendation context"],"evidence_ids":["ev_7d73ce6f2a4e","ev_4c55ced0ef82","ev_689eb350b7f2"],"source_ids":["ashpublications"],"citations":["American Society of Hematology"],"origin":"approved_api","batch_index":0,"round_index":2,"created_at":"2026-09-22T11:12:00.256000Z"},{"id":"ans_ab6ef0e88449","run_id":"run_2058f031b9db","question_id":"q_0207dfec5c74","stage":"stage_1","status":"partial","text":"The supplied documents provide limited U.S. epidemiology and survival information for acute lymphoblastic leukemia (ALL), primarily for pediatric ALL incidence and adult leukemia survival trends, but they do not provide comprehensive U.S. estimates through 2026, prevalence estimates, mortality rates, or subtype-specific epidemiology for B-ALL, T-ALL, and Philadelphia chromosome-positive ALL. One CDC report states that “Acute lymphoblastic leukemia (ALL) is the most prevalent cancer among children and adolescents in the United States” and reported that “Overall incidence of pediatric ALL during 2001–2014 was 34.0 cases per 1 million persons and among all racial/ethnic groups was highest among Hispanics (42.9 per 1 million).” The same report noted that “Both overall and among Hispanics, pediatric ALL incidence increased during 2001–2008 and remained stable during 2008–2014.” A separate population-based survival study stated that “The lifetime risk of developing leukemia in the United States is 1.5%” and that “Five-year net survival was estimated using data for 370,994 patients from 43 registries in 37 states and in 6 metropolitan areas, covering approximately 81% of the adult (15–99 years) US population,” but the excerpt provided does not include ALL-specific survival values.","aspects_covered":["Pediatric ALL incidence","Temporal incidence trends","Racial/ethnic incidence differences","Geographic incidence differences","Adult leukemia survival study methodology","Lifetime leukemia risk"],"evidence_ids":["ev_a90de929ee38","ev_4163242615d7","ev_338001d3311a","ev_7a1195bcf1d5","ev_00fdb4d694a3"],"source_ids":["cdc_icd10"],"citations":["CDC / NCHS"],"origin":"approved_api","batch_index":0,"round_index":3,"created_at":"2026-09-22T11:12:21.121944Z"},{"id":"ans_aa55abcca436","run_id":"run_2058f031b9db","question_id":"q_f38fdd338919","stage":"stage_1","status":"partial","text":"The supplied documents identify acute lymphoblastic leukemia (ALL) broadly as “a group of rare Non-Hodgkin lymphoma characterized by malignant proliferation of lymphoid cells blocked at an early stage of differentiation,” but they do not provide a comprehensive listing of immunophenotypic, cytogenetic, molecular, Philadelphia chromosome, prognostic, or biomarker-defined ALL subtypes for claims-based cohort definition. The relapsed/refractory ASH guideline specifically references “ALL subsets (T-cell ALL)” and discusses “immunotherapy” and “targeted therapies,” while the frontline guideline states that “higher-risk subsets” and “targeted agents” are clinically relevant in management decisions. No explicit cytogenetic abnormalities, molecular alterations, Philadelphia chromosome-positive/negative categories, or named targetable biomarkers are enumerated in the provided documents.","aspects_covered":["General ALL disease definition","Mention of T-cell ALL subset","Reference to higher-risk subsets","Reference to targeted therapies/targeted agents","Lack of explicit cytogenetic and molecular subtype listings","Lack of explicit Philadelphia chromosome status categories"],"evidence_ids":["ev_7e9a669b0be5","ev_bc36ca3acca4","ev_5a04a6f33df4","ev_4fe6496bdc42","ev_f4062db24c05","ev_52bc96ee05c8","ev_3c3b04664610"],"source_ids":["orphanet","ashpublications"],"citations":["Orphanet","American Society of Hematology"],"origin":"approved_api","batch_index":0,"round_index":0,"created_at":"2026-09-22T11:12:52.316530Z"},{"id":"ans_70308c1aa673","run_id":"run_2058f031b9db","question_id":"q_f38fdd338919","stage":"stage_1","status":"partial","text":"The supplied document identifies Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph-positive ALL) as a clinically important molecular/cytogenetic subtype in adult ALL treatment. It states that “inclusion of imatinib into a relatively standard chemotherapy regimen for newly diagnosed adult patients with Ph-positive ALL may provide a significant survival advantage,” and that “Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.” The document also notes prognostic implications for this subtype, stating that “remissions are generally short with conventional ALL chemotherapy clinical trials.” The document does not provide additional immunophenotypic subtypes, broader cytogenetic or molecular alteration categories, prognostic subtype groups, or other targetable biomarkers.","aspects_covered":["Philadelphia chromosome–positive ALL","Targetable biomarker-directed therapy (imatinib in Ph-positive ALL)","Prognostic implications of Ph-positive ALL"],"evidence_ids":["ev_514eaf63445a","ev_a732c8f47456","ev_c854ac12b4f3"],"source_ids":["nci"],"citations":["National Cancer Institute"],"origin":"approved_api","batch_index":0,"round_index":1,"created_at":"2026-09-22T11:13:08.412721Z"},{"id":"ans_5012beaaa021","run_id":"run_2058f031b9db","question_id":"q_f38fdd338919","stage":"stage_1","status":"partial","text":"The supplied document identifies clinically relevant immunophenotypic subtypes of acute lymphoblastic leukemia (ALL), specifically B-cell ALL and T-cell ALL, and describes marker-defined lineage assignment by flow cytometry. B-ALL was characterized by expression of \"pan B-cell markers (CD19,CD22 and cytoplasmic CD79a)\" with many cases expressing CD10, while T-ALL was characterized by \"cytoplasmic CD3 and CD5.\" The document also notes aberrant myeloid marker expression in some B-ALL cases and describes immunophenotyping as important for \"diagnosis, accurate classification, subtyping and treatment programs.\" However, the document does not provide a comprehensive description of clinically important cytogenetic abnormalities, molecular alterations, Philadelphia chromosome status, prognostic subtype groups, or targetable biomarkers for U.S. ALL patients through 2026.","aspects_covered":["Immunophenotypic subtypes of ALL","Flow-cytometric lineage markers","Limited molecular/cytogenetic mention (PML/RARA in APL)","Clinical role of immunophenotyping"],"evidence_ids":["ev_26e9b9e77c4f","ev_fca4129b43c4","ev_3f9d438a3c1c"],"source_ids":["who"],"citations":["WHO"],"origin":"approved_api","batch_index":0,"round_index":3,"created_at":"2026-09-22T11:13:42.655807Z"},{"id":"ans_0706e8ee9012","run_id":"run_2058f031b9db","question_id":"q_f38fdd338919","stage":"stage_1","status":"partial","text":"The documents identify clinically important immunophenotypic ALL subtypes including B-cell and T-cell categories. One source states that the WHO system recognizes “Precursor B cell ALL,” “Precursor T cell ALL,” and “Mature B cell ALL (Burkitt type ALL),” while another notes that “the only subtype recognized by the World Health Organization’s International Consensus Classification is early T-cell precursor ALL.” The materials also identify Philadelphia chromosome-related disease biology, including “Philadelphia chromosome-like ALL (Ph-like ALL)” as “a precursor B-cell ALL that results in a change of the chromosomes on the leukemia cells.” Cytogenetic and molecular characterization is described broadly through “genomic subtypes,” “whole transcriptome, exome, or genome sequencing,” “immunophenotyping and cytogenetic testing,” and “specific genomic alterations,” but the supplied documents do not provide a complete enumeration of clinically important cytogenetic abnormalities, molecular alterations, prognostic subtype groups, or targetable biomarkers through 2026.","aspects_covered":["Immunophenotypic subtypes","Philadelphia chromosome-like ALL","Early T-cell precursor ALL","Use of immunophenotyping, cytogenetic testing, and genomic sequencing","General mention of genomic alterations and prognostic implications"],"evidence_ids":["ev_c46ce82dab79","ev_1b40ba955be5","ev_5210566aed9a","ev_607741bdc595","ev_d5dc7625f30a","ev_d6d8b5e25459"],"source_ids":["open_web"],"citations":["Open web"],"origin":"open_web","batch_index":0,"round_index":99,"created_at":"2026-09-22T11:13:56.926070Z"},{"id":"ans_c1e9734ce40d","run_id":"run_2058f031b9db","question_id":"q_0b2efc095c4f","stage":"stage_1","status":"partial","text":"The supplied document identifies acute lymphoblastic leukemia (ALL) as \"a group of rare Non-Hodgkin lymphoma characterized by malignant proliferation of lymphoid cells blocked at an early stage of differentiation\" and states that it \"primarily affects the bone marrow and peripheral blood.\" It also notes that \"the abnormal cells can infiltrate any organ or tissue\" and describes common presenting features including \"lymphadenopathy, hepatosplenomegaly, bone pain, fever and signs of hemorrhage.\" However, the documents do not provide diagnostic criteria or confirmatory workup details such as bone marrow evaluation methods, flow cytometry, cytogenetic testing, molecular diagnostics, imaging/CNS assessment, or laboratory testing used for subtype classification, treatment initiation, or claims cohort identification.","aspects_covered":["general disease definition","sites of disease involvement","clinical presentation"],"evidence_ids":["ev_fe52db01cd48","ev_175ccc0c54c4","ev_8339986034b7"],"source_ids":["orphanet"],"citations":["Orphanet"],"origin":"approved_api","batch_index":0,"round_index":0,"created_at":"2026-09-22T11:14:08.382844Z"},{"id":"ans_632c69d27e89","run_id":"run_2058f031b9db","question_id":"q_0b2efc095c4f","stage":"stage_1","status":"partial","text":"The supplied document is a frontline management guideline for adolescents and young adults with acute lymphoblastic leukemia and does not describe detailed diagnostic criteria or confirmatory diagnostic workup for establishing ALL diagnosis or subtype classification. The document identifies disease categories relevant to treatment initiation, including “B-cell or T-cell acute lymphoblastic leukemia (B-ALL/T-ALL) or T-cell acute lymphoblastic lymphoma (T-LBL/LLy),” and discusses frontline therapy recommendations and therapeutic drug monitoring for asparaginase management. The document does not provide specific recommendations or criteria regarding bone marrow evaluation, flow cytometry, cytogenetic testing, molecular diagnostics, imaging, CNS assessment, or laboratory diagnostic workup.","aspects_covered":["Subtype categories relevant to treatment initiation","Absence of diagnostic criteria and confirmatory workup details"],"evidence_ids":["ev_d0cbf82b6047","ev_77090229ca10","ev_df1bff26cae5"],"source_ids":["ashpublications"],"citations":["American Society of Hematology"],"origin":"approved_api","batch_index":0,"round_index":1,"created_at":"2026-09-22T11:14:25.267137Z"},{"id":"ans_e9679b92e99c","run_id":"run_2058f031b9db","question_id":"q_0b2efc095c4f","stage":"stage_1","status":"partial","text":"The supplied document concerns management recommendations for relapsed/refractory acute lymphoblastic leukemia (ALL) in adolescents and young adults and does not describe the diagnostic criteria or confirmatory workup used to establish ALL diagnosis and subtype classification. The document references disease subsets and central nervous system (CNS)-directed therapy but does not provide details on bone marrow evaluation, flow cytometry, cytogenetic testing, molecular diagnostics, imaging/CNS assessment methods, or laboratory workup for treatment initiation or claims cohort identification.","aspects_covered":["Mentions CNS-directed therapy","Mentions ALL subsets such as T-cell ALL","Does not provide diagnostic criteria or confirmatory diagnostic workup"],"evidence_ids":["ev_912a955c92f0","ev_1bf499d5e08d","ev_f7f5fdac83c4"],"source_ids":["ashpublications"],"citations":["American Society of Hematology"],"origin":"approved_api","batch_index":0,"round_index":2,"created_at":"2026-09-22T11:14:39.439149Z"},{"id":"ans_4096f3c1b891","run_id":"run_2058f031b9db","question_id":"q_0b2efc095c4f","stage":"stage_1","status":"partial","text":"The supplied document discusses remission induction therapy for adult acute lymphoblastic leukemia (ALL) and mentions treatment considerations for newly diagnosed and Philadelphia chromosome–positive ALL, but it does not describe the diagnostic criteria or confirmatory diagnostic workup used to establish ALL diagnosis or subtype classification. The document does not provide information on bone marrow evaluation, flow cytometry, cytogenetic testing, molecular diagnostics, imaging or CNS assessment, or laboratory workup for treatment initiation or claims cohort identification.","aspects_covered":["treatment context for newly diagnosed adult ALL","mention of Philadelphia chromosome–positive ALL"],"evidence_ids":["ev_686c318142e4","ev_74a8e7cba6cf","ev_73f85a9b1648"],"source_ids":["nci"],"citations":["National Cancer Institute"],"origin":"approved_api","batch_index":0,"round_index":3,"created_at":"2026-09-22T11:15:24.200265Z"},{"id":"ans_9368508b3928","run_id":"run_2058f031b9db","question_id":"q_0b2efc095c4f","stage":"stage_1","status":"partial","text":"The supplied documents indicate that NCCN Guidelines through 2026 address acute lymphoblastic leukemia (ALL) diagnosis and classification with emphasis on subtype classification using immunophenotype and cytogenetic/molecular markers, as well as risk assessment and treatment strategies. However, the documents provided do not contain the detailed diagnostic criteria or confirmatory workup elements requested, such as specific bone marrow evaluation parameters, flow cytometry panels, cytogenetic assays, molecular diagnostics, CNS/imaging assessment, or laboratory workup protocols for treatment initiation or claims cohort identification.","aspects_covered":["NCCN guideline availability through 2026","Classification based on immunophenotype","Classification based on cytogenetic/molecular markers","Risk assessment and stratification"],"evidence_ids":["ev_c355e539ab79","ev_ab066abf322c"],"source_ids":["open_web"],"citations":["Open web"],"origin":"open_web","batch_index":0,"round_index":99,"created_at":"2026-09-22T11:16:16.968271Z"},{"id":"ans_afd5b0019a60","run_id":"run_2058f031b9db","question_id":"q_a687f9ed49c6","stage":"stage_2","status":"partial","text":"The supplied documents do not provide a complete listing of U.S. guideline-recommended regimens for relapsed, refractory, and later-line acute lymphoblastic leukemia organized by treatment setting, line of therapy, and guideline preference category. The NCCN documents only state that the guidelines include “treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients,” but the excerpts provided specifically note that the selection “focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence.” The ASH 2026 guideline document specifically addresses “management of relapsed/refractory ALL in adolescents and young adults” and states that “Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction,” while also addressing “T-cell ALL,” “CNS relapse,” and “the role of consolidation with allogeneic transplant.” The documents do not provide the full regimen tables, later-line sequencing, or NCCN preference categories requested.","aspects_covered":["Relapsed/refractory ALL addressed by ASH 2026 guideline","Disease subtype stratification including Ph-positive/Ph-negative ALL and T-cell ALL","Cellular/transplant therapy mentioned through allogeneic hematopoietic stem cell transplant","Immunotherapy and targeted therapies including blinatumomab and inotuzumab","Limitations of supplied documents for later-line regimen details and guideline preference categories"],"evidence_ids":["ev_b3944e897e29","ev_518d2567f527","ev_cc3f9706ddfa","ev_5f263d098505","ev_cd0d12f0029b"],"source_ids":["esmo"],"citations":["Journal of the National Comprehensive Cancer Network : JNCCN","Blood advances"],"origin":"approved_api","batch_index":0,"round_index":0,"created_at":"2026-09-22T11:13:07.945543Z"},{"id":"ans_22481516e77e","run_id":"run_2058f031b9db","question_id":"q_a687f9ed49c6","stage":"stage_2","status":"partial","text":"The supplied documents discuss recommendations for relapsed/refractory acute lymphoblastic leukemia (ALL), including immunotherapy, targeted therapy, transplantation, and CNS-directed therapy, but they do not provide a complete regimen-by-regimen listing organized by treatment setting, line of therapy, and guideline preference category for all patients in the United States as of 2026-09-22. The ASH 2026 guideline for adolescents and young adults (AYAs) states that recommendations \"focused on the following treatment modalities: immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy\" and that \"Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction.\" The NCCN Guidelines Insights document states that recommendations for relapsed/refractory ALL include \"more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation,\" but the provided text does not enumerate specific preferred regimens, later-line sequences, or preference categories.","aspects_covered":["Relapsed/refractory ALL setting","AYA-specific ASH 2026 recommendations","Use of blinatumomab and inotuzumab for reinduction","Mention of allogeneic hematopoietic stem cell transplantation","Mention of CNS-directed therapy","Mention of chemotherapy, tyrosine kinase inhibitors, and targeted agents","Lack of explicit regimen tables, lines of therapy, and guideline preference categories in supplied text"],"evidence_ids":["ev_ad6c4f26f9b0","ev_37798175b255","ev_2423ca527fdd","ev_9e9b91ef795a","ev_1574f39f0717","ev_2f097b470c9b"],"source_ids":["ashpublications","esmo"],"citations":["American Society of Hematology","Journal of the National Comprehensive Cancer Network : JNCCN"],"origin":"approved_api","batch_index":1,"round_index":0,"created_at":"2026-09-22T11:13:16.790509Z"},{"id":"ans_3b26f9167b71","run_id":"run_2058f031b9db","question_id":"q_a687f9ed49c6","stage":"stage_2","status":"partial","text":"The supplied documents identify that NCCN Clinical Practice Guidelines for acute lymphoblastic leukemia (ALL) include recommendations on “risk-stratified treatment approaches based on the Philadelphia chromosome status and age (adults vs. adolescents/young adults)” and that pediatric ALL guidelines address “treatment strategies for BCR::ABL1 (Philadelphia chromosome [Ph])-negative and BCR::ABL1-positive B-cell lineage, T-cell lineage, and infant ALL.” The documents also state that the pediatric guidelines focus on “the diagnosis of and management of pediatric T-ALL.” However, the supplied excerpts do not provide the requested relapsed/refractory or later-line regimens, line-of-therapy recommendations, preference categories, cellular therapies, or transplant recommendations.","aspects_covered":["Existence of NCCN ALL guidelines","Disease subtype stratification","Age-based stratification","Pediatric T-ALL management focus"],"evidence_ids":["ev_f07fa14fd33b","ev_780b8136f08d","ev_062272bede40"],"source_ids":["esmo"],"citations":["Journal of the National Comprehensive Cancer Network : JNCCN"],"origin":"approved_api","batch_index":2,"round_index":0,"created_at":"2026-09-22T11:13:22.706750Z"},{"id":"ans_99b3fcb65511","run_id":"run_2058f031b9db","question_id":"q_a687f9ed49c6","stage":"stage_2","status":"partial","text":"The supplied documents identify that NCCN guidelines for acute lymphoblastic leukemia (ALL) include recommendations for “risk-stratified treatment approaches based on the Philadelphia chromosome status and age (adults vs. adolescents/young adults),” and that pediatric NCCN guidelines address “frontline and relapsed/refractory management of pediatric ALL,” including “hematopoietic stem cell transplantation.” However, the documents provided do not list specific relapsed, refractory, or later-line regimens, do not provide line-of-therapy tables, do not identify guideline preference categories, and do not specify cellular therapy regimens or transplant sequencing recommendations. One document also identifies the topic of “Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults: Progress and Challenges,” but provides no regimen-level recommendations in the supplied text.","aspects_covered":["NCCN guideline scope for ALL","Relapsed/refractory pediatric ALL management","Risk stratification by Philadelphia chromosome status and age","Mention of hematopoietic stem cell transplantation","Existence of adult relapsed/refractory ALL discussion"],"evidence_ids":["ev_54e1fcbbe2be","ev_80b949d49895","ev_ca4186162d1d","ev_b10442816ade","ev_1c4e72d4cc3f","ev_1def46f780ff"],"source_ids":["ashpublications","esmo","asco"],"citations":["Journal of the National Comprehensive Cancer Network : JNCCN","JCO Oncology Practice"],"origin":"approved_api","batch_index":3,"round_index":0,"created_at":"2026-09-22T11:13:30.532487Z"},{"id":"ans_74d838e0bf3c","run_id":"run_2058f031b9db","question_id":"q_a687f9ed49c6","stage":"stage_2","status":"partial","text":"The supplied document discusses relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) in children, adolescents, and young adults in the context of CAR-T-cell therapy and bridging therapy, but it does not provide a comprehensive list of United States major clinical guideline regimens by treatment setting, line of therapy, or preference category. It states that \"there is currently no available guidelines\" for the bridging period before CAR-T-cell reinfusion and describes an effort to \"define recommendations of treatment in each situation of relapsed or refractory B-ALL, Ph+/ABL-like B-ALL and in case of CNS disease or non-CNS extra medullary disease, precising the specific place of immunotherapy.\" The document also identifies CAR-T cells as a major therapeutic modality in relapsed/refractory B-ALL and references disease subtype stratification including \"Ph+/ABL-like B-ALL\" and CNS versus non-CNS extramedullary disease.","aspects_covered":["relapsed/refractory B-ALL","CAR-T-cell therapy","bridging therapy before CAR-T reinfusion","disease subtype stratification including Ph+/ABL-like B-ALL","CNS and non-CNS extramedullary disease"],"evidence_ids":["ev_22b0eaa3c211","ev_2ff754c9884d","ev_69aa800e52e8"],"source_ids":["esmo"],"citations":["Bulletin du cancer"],"origin":"approved_api","batch_index":5,"round_index":0,"created_at":"2026-09-22T11:13:58.354395Z"},{"id":"ans_a793b71c7455","run_id":"run_2058f031b9db","question_id":"q_a687f9ed49c6","stage":"stage_2","status":"partial","text":"The supplied documents do not contain major clinical guideline recommendations, preference categories, treatment-setting organization, transplant guidance, or cellular therapy recommendations for relapsed, refractory, or later-line acute lymphoblastic leukemia. The documents only provide FDA labeling indications for specific agents in relapsed or refractory ALL/T-ALL settings after at least two prior regimens. Nelarabine is indicated for \"T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL)\" in patients \"whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.\" Clofarabine is indicated for \"pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.\"","aspects_covered":["relapsed or refractory ALL settings","later-line therapy after at least two prior regimens","disease subtype stratification for T-ALL/T-LBL","FDA-labeled agents nelarabine and clofarabine"],"evidence_ids":["ev_3177e0973b83","ev_7ba381f801b3","ev_1f18856240c5","ev_89aa75859a2b","ev_924be086789e","ev_1123d480e0d9"],"source_ids":["openfda_label"],"citations":["Alembic Pharmaceuticals Limited","Amneal Pharmaceuticals LLC","US Food and Drug Administration"],"origin":"approved_api","batch_index":0,"round_index":1,"created_at":"2026-09-22T11:14:51.070567Z"},{"id":"ans_3fad13d13c72","run_id":"run_2058f031b9db","question_id":"q_a687f9ed49c6","stage":"stage_2","status":"partial","text":"The supplied documents do not provide major clinical guideline recommendations organized by treatment setting, line of therapy, preference category, disease subtype, or transplant/cellular therapy pathways for relapsed, refractory, and later-line acute lymphoblastic leukemia in the United States as of 2026-09-22. The documents only identify selected therapies and populations in relapsed/refractory ALL, including clofarabine for pediatric patients after at least two prior regimens and references to studies involving blinatumomab and inotuzumab ozogamicin in relapsed/refractory adult ALL. One document states that clofarabine \"is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.\" Another document references \"adult patients with relapsed or refractory acute lymphoblastic leukemia receiving zero or one prior salvage therapy,\" and another references \"Relapsed/Refractory Philadelphia Chromosome–Negative B-Cell Acute Lymphoblastic Leukemia.\"","aspects_covered":["relapsed/refractory ALL populations","later-line therapy after at least two prior regimens","mention of prior salvage therapy","Philadelphia chromosome-negative B-cell subtype mention","named therapies: clofarabine, blinatumomab, inotuzumab ozogamicin"],"evidence_ids":["ev_4c012a583e38","ev_6f6c77dbc61e","ev_0e660f1151df","ev_7d6dc3a6a6d2"],"source_ids":["openfda_label","asco"],"citations":["Dr.Reddy's Laboratories Inc","Journal of Clinical Oncology","JCO Precision Oncology"],"origin":"approved_api","batch_index":1,"round_index":1,"created_at":"2026-09-22T11:14:58.269701Z"},{"id":"ans_add66aa1980a","run_id":"run_2058f031b9db","question_id":"q_a687f9ed49c6","stage":"stage_2","status":"partial","text":"The supplied documents do not provide major United States clinical guideline recommendations, preference categories, or organized line-of-therapy tables for relapsed, refractory, or later-line acute lymphoblastic leukemia as of 2026-09-22. The documents do describe investigational and salvage approaches in relapsed/refractory ALL settings, including venetoclax-based regimens in relapsed/refractory T-ALL/LBL, CD7 CAR-T therapy in relapsed/refractory T-ALL/LBL, and comparisons between CAR-T therapy and allogeneic HSCT in relapsed/refractory B-ALL. Reported treatment approaches include “Ven monotherapy,” “Ven + hypomethylating agent,” “Ven + chemotherapy,” “Ven + nelarabine,” “Ven + targeted agent,” and “Ven + navitoclax” for heavily pre-treated relapsed/refractory T-ALL/LBL patients, while cellular and transplant therapies discussed include “autologous CD7 CAR T-cell therapy,” “stem cell transplantation (SCT),” “Allogenic Hematopoietic Stem Cell Transplantation (HSCT),” and “CAR-T Cell Therapy.”","aspects_covered":["relapsed/refractory T-ALL/LBL regimens","later-line heavily pre-treated settings","cellular therapies","transplant therapies","B-ALL CAR-T versus HSCT discussion"],"evidence_ids":["ev_1f4c71a7e815","ev_9024e6749379","ev_f7fabb14591a","ev_18528f4bb930","ev_e78f199ead00","ev_b2ef043e1c4f","ev_37b2161571af","ev_37d8acaeaabf","ev_741101e9d590"],"source_ids":["asco"],"citations":["Journal of Clinical Oncology"],"origin":"approved_api","batch_index":2,"round_index":1,"created_at":"2026-09-22T11:15:08.177309Z"},{"id":"ans_851c7ab9ac38","run_id":"run_2058f031b9db","question_id":"q_a687f9ed49c6","stage":"stage_2","status":"partial","text":"The supplied document does not provide major clinical guideline recommendations for relapsed, refractory, or later-line acute lymphoblastic leukemia (ALL), including treatment setting, line of therapy, guideline preference categories, disease subtype stratification, or cellular therapies. It does contain limited statements relevant to transplantation and Philadelphia chromosome (Ph)-positive ALL in the context of remission duration and treatment considerations. Specifically, the document states that “Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials” and that “If a suitable donor is available, allogeneic bone marrow transplant should be considered because remissions are generally short with conventional ALL chemotherapy clinical trials.”","aspects_covered":["Ph-positive ALL treatment consideration","Allogeneic bone marrow transplant consideration"],"evidence_ids":["ev_8e12075ab437","ev_0efaaf99b916","ev_57a4a65ebe86"],"source_ids":["nci"],"citations":["National Cancer Institute"],"origin":"approved_api","batch_index":0,"round_index":2,"created_at":"2026-09-22T11:15:52.305997Z"},{"id":"ans_8a415ef84e77","run_id":"run_2058f031b9db","question_id":"q_a687f9ed49c6","stage":"stage_2","status":"partial","text":"The supplied documents identify that NCCN maintains \"NCCN Guidelines Version 3.2026 - Acute Lymphoblastic Leukemia\" and \"NCCN Guidelines with Evidence Blocks Version 2.2026,\" but they do not provide the actual recommended regimens, treatment settings, lines of therapy, preference categories, subtype stratification, or cellular/transplant therapy recommendations requested. One supplementary document mentions blinatumomab in \"chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients,\" but no organized guideline recommendations for relapsed, refractory, or later-line ALL are included in the provided text.","aspects_covered":["Existence of NCCN ALL guidelines for 2026","Existence of NCCN Evidence Blocks","Mention of blinatumomab in chemotherapy-refractory MRD-positive B-lineage ALL"],"evidence_ids":["ev_cb511a6e4a1b","ev_0fbbff4885d1","ev_3406e5fb1282"],"source_ids":["open_web"],"citations":["Open web"],"origin":"open_web","batch_index":0,"round_index":99,"created_at":"2026-09-22T11:16:45.480665Z"},{"id":"ans_46c0e47ec8f4","run_id":"run_2058f031b9db","question_id":"q_9df80b42710c","stage":"stage_1","status":"partial","text":"The supplied documents describe adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) as a distinct population and note that frontline treatment decisions differ between pediatric and adult treatment settings. They also state that allogeneic hematopoietic stem cell transplantation in first remission “may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy,” implying some form of risk stratification and response assessment. However, the documents do not specify the diagnostic risk stratification systems, claims-based cohort segmentation methods, age cutoffs for treatment eligibility, performance status criteria, comorbidity burden measures, organ function requirements, or minimal residual disease (MRD) definitions used in United States patients through 2026.","aspects_covered":["AYA population distinction","Mention of higher-risk subsets","Mention of response-based treatment considerations","Absence of explicit risk stratification systems","Absence of age-based eligibility definitions","Absence of performance status, comorbidity, organ function, and MRD criteria"],"evidence_ids":["ev_49a4959cee37","ev_367e1dd3c40f","ev_c59595ca2fc8","ev_1f55508214ad","ev_8b7df7fa7aaa","ev_d3a229ba9b2b"],"source_ids":["ashpublications","orphanet"],"citations":["American Society of Hematology","Orphanet"],"origin":"approved_api","batch_index":0,"round_index":0,"created_at":"2026-09-22T11:16:33.494063Z"},{"id":"ans_6402c0668904","run_id":"run_2058f031b9db","question_id":"q_9df80b42710c","stage":"stage_1","status":"partial","text":"The supplied document discusses treatment approaches for newly diagnosed adult acute lymphoblastic leukemia (ALL), including distinctions for Philadelphia chromosome (Ph)-positive disease, but it does not describe formal risk stratification systems, claims-based cohort segmentation methods, age-based eligibility thresholds, performance status criteria, comorbidity burden measures, organ function criteria, or minimal residual disease (MRD) status definitions. The document states that “Most current induction regimens for patients with adult ALL include combination chemotherapy with prednisone, vincristine, and an anthracycline” and that “Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.” It also notes that “If a suitable donor is available, allogeneic bone marrow transplant should be considered because remissions are generally short with conventional ALL chemotherapy clinical trials.”","aspects_covered":["Adult ALL induction treatment regimens","Philadelphia chromosome (Ph)-positive ALL treatment considerations","Allogeneic transplant consideration in Ph-positive ALL"],"evidence_ids":["ev_11c33702e27d","ev_8da63899d25d","ev_fce1f259bb63"],"source_ids":["nci"],"citations":["National Cancer Institute"],"origin":"approved_api","batch_index":0,"round_index":1,"created_at":"2026-09-22T11:16:48.467963Z"},{"id":"ans_27fa0455e2df","run_id":"run_2058f031b9db","question_id":"q_9df80b42710c","stage":"stage_1","status":"partial","text":"The supplied documents indicate that NCCN guidelines for acute lymphoblastic leukemia (ALL) through 2026 emphasize “classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers” and “risk assessment and stratification for risk-adapted therapy.” The documents also specify that treatment strategies are differentiated for “Philadelphia chromosome (Ph)-positive and Ph ...” disease categories. However, the provided materials do not describe the detailed risk stratification systems, age-based eligibility thresholds, performance status criteria, comorbidity burden measures, organ function requirements, minimal residual disease criteria, or the demographic and clinical cohort segmentation variables used in claims-based line-of-therapy analyses.","aspects_covered":["Risk assessment and stratification for risk-adapted therapy","Classification by immunophenotype and cytogenetic/molecular markers","Philadelphia chromosome subgroup treatment stratification","Lack of evidence in supplied documents for age eligibility, performance status, comorbidities, organ function, MRD, and claims-based cohort segmentation"],"evidence_ids":["ev_44470bb29387","ev_2b8431ac1378","ev_4f41b06fbab3"],"source_ids":["open_web"],"citations":["Open web"],"origin":"open_web","batch_index":0,"round_index":99,"created_at":"2026-09-22T11:17:43.707592Z"},{"id":"ans_bda28feb9c95","run_id":"run_2058f031b9db","question_id":"q_2bee5da1afa0","stage":"stage_2","status":"partial","text":"The supplied documents identify FDA-approved treatments for acute lymphoblastic leukemia including nelarabine and clofarabine, but they do not provide a complete list of all approved drugs, biologics, or cellular therapies in the United States as of 2026-09-22, and they do not provide billing or product coding identifiers. Nelarabine injection received \"Initial U.S. Approval: 2005\" and is indicated for \"T-cell acute lymphoblastic leukemia (T-ALL)\" in \"adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens,\" establishing a relapsed/refractory setting after at least two prior regimens and a biomarker/disease restriction to T-cell ALL. Clofarabine injection received \"Initial U.S. Approval: 2004\" and is indicated for \"pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens,\" defining a pediatric relapsed/refractory treatment line after at least two prior regimens without an additional biomarker restriction stated in the supplied text.","aspects_covered":["Approved products","FDA approval dates","Label indications","Approved treatment lines","Biomarker/disease restrictions","Absence of coding identifiers in supplied documents"],"evidence_ids":["ev_0efeb2d33090","ev_ba7e85f8ff06","ev_23da31bd88f0","ev_d2f8d39101f7","ev_3740cf931e25","ev_4d0f13fc5db3"],"source_ids":["openfda_label"],"citations":["Alembic Pharmaceuticals Limited","Amneal Pharmaceuticals LLC","US Food and Drug Administration"],"origin":"approved_api","batch_index":0,"round_index":0,"created_at":"2026-09-22T11:17:45.067509Z"},{"id":"ans_ae630d53bbd2","run_id":"run_2058f031b9db","question_id":"q_2bee5da1afa0","stage":"stage_2","status":"partial","text":"The supplied documents identify three FDA-approved drug products for acute lymphoblastic leukemia (ALL): clofarabine, imatinib mesylate, and dasatinib. Clofarabine injection is indicated for “pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens,” with “Initial U.S. Approval: 2004.” Imatinib mesylate is indicated for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)” and for “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy,” with “Initial U.S. Approval: 2001.” Dasatinib tablets are indicated for “Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy” in adults and for “pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy,” with “Initial U.S. Approval: 2006.” The documents provide biomarker restrictions through the requirement for “Philadelphia chromosome-positive (Ph+)” disease where applicable, but they do not provide billing codes, HCPCS codes, NDC-based coding summaries, biologics approvals, or cellular therapy approvals for ALL.","aspects_covered":["approved products","label indications","approved treatment lines","biomarker restrictions","approval dates"],"evidence_ids":["ev_9c3bee9ea193","ev_fb907d05ad45","ev_091464e6f6c8","ev_3cd310e160b6","ev_c2b43ea453fb","ev_64fd863b35bb","ev_44c5df7efec3","ev_df85ed1e423d"],"source_ids":["openfda_label"],"citations":["Dr.Reddy's Laboratories Inc","Apotex Corp","BluePoint Laboratories"],"origin":"approved_api","batch_index":1,"round_index":0,"created_at":"2026-09-22T11:18:25.423096Z"},{"id":"ans_11d5e4ee3338","run_id":"run_2058f031b9db","question_id":"q_2bee5da1afa0","stage":"stage_2","status":"partial","text":"The supplied documents identify FDA-approved tyrosine kinase inhibitor products for Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), specifically imatinib mesylate/Gleevec and Sprycel. Imatinib mesylate is indicated for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)” and for “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.” The biomarker restriction stated is “Philadelphia chromosome positive (Ph+ ALL).” The documents also provide FDA approval history for Gleevec and Sprycel, including “ORIG 1 AP 2003-04-18” for Gleevec and “ORIG 1 AP 2006-06-28” for Sprycel, but they do not provide ALL-specific approval dates, labeled ALL treatment lines for Sprycel, or any billing/product coding identifiers such as HCPCS or J-codes.","aspects_covered":["Approved products for Ph+ ALL","Label indications for imatinib mesylate in ALL","Treatment line information for imatinib mesylate","Biomarker restriction (Philadelphia chromosome positive)","FDA approval history dates for Gleevec and Sprycel","Identification of missing coding identifiers"],"evidence_ids":["ev_c2e2102f5fd1","ev_e5fa9acf3e0d","ev_0d23311aefdf","ev_6ca5bc1954c3","ev_abd5d053d585","ev_93b30cbe8295","ev_61a9cd55eb91"],"source_ids":["openfda_drugsfda","openfda_label"],"citations":["NOVARTIS","BRISTOL MYERS SQUIBB","Sun Pharmaceutical Industries, Inc."],"origin":"approved_api","batch_index":2,"round_index":0,"created_at":"2026-09-22T11:18:37.623415Z"},{"id":"ans_cf42a5270ae3","run_id":"run_2058f031b9db","question_id":"q_2bee5da1afa0","stage":"stage_2","status":"partial","text":"The supplied documents identify several FDA-approved therapies for acute lymphoblastic leukemia (ALL) in the United States, but they do not provide comprehensive coverage of all approved drugs, biologics, cellular therapies, or billing/product coding identifiers. SPRYCEL (dasatinib) is indicated for “adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy,” establishing a biomarker restriction of Ph+ status and a relapsed/refractory treatment setting; the label also states “Initial U.S. Approval: 2006.” Imatinib mesylate is indicated for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)” and for “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy,” again restricting use to Ph+ ALL. ARRANON (nelarabine) appears in the FDA Drugs@FDA record with “ORIG 1 AP 2005-10-28,” but the provided text does not include the ALL indication, treatment line, biomarker restriction, or coding identifiers.","aspects_covered":["approved products","label indications","approved treatment lines","biomarker restrictions","approval dates (partial)"],"evidence_ids":["ev_f85e7423952c","ev_9c87c2631ce7","ev_3f54ed62d400","ev_470eff150925","ev_8b8ea52923f7","ev_b1842cb9c49f"],"source_ids":["openfda_label","openfda_drugsfda"],"citations":["US Food and Drug Administration","SANDOZ"],"origin":"approved_api","batch_index":3,"round_index":0,"created_at":"2026-09-22T11:18:46.982429Z"},{"id":"ans_8c19337f9ad9","run_id":"run_2058f031b9db","question_id":"q_2bee5da1afa0","stage":"stage_2","status":"partial","text":"The supplied documents identify two FDA-labeled drugs for acute lymphoblastic leukemia (ALL): mercaptopurine and methotrexate. Mercaptopurine is labeled for “the treatment of patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen,” with no explicit biomarker restriction for indication, although TPMT and NUDT15 testing and dose modifications are discussed for toxicity management. Methotrexate Injection is labeled for “the treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy regimen.” The documents also include an FDA Drugs@FDA entry for ICLUSIG (ponatinib), but the supplied text does not state an ALL indication, treatment line, biomarker restriction, or approval details specific to ALL. The documents do not provide billing codes, HCPCS/J-codes, NDCs, or other coding identifiers for ALL products.","aspects_covered":["Approved products for ALL","Label indications","Treatment setting/regimen context","Biomarker-related dosing information for mercaptopurine","Presence of FDA regulatory submission information for ICLUSIG","Absence of coding identifiers in supplied documents"],"evidence_ids":["ev_350846fe2940","ev_4454cf98330b","ev_7090fce40780","ev_882965cca1f9","ev_302c2da3f168"],"source_ids":["openfda_label"],"citations":["Hikma Pharmaceuticals USA Inc.","Hospira, Inc."],"origin":"approved_api","batch_index":4,"round_index":0,"created_at":"2026-09-22T11:18:55.962267Z"},{"id":"ans_7f23166f1545","run_id":"run_2058f031b9db","question_id":"q_2bee5da1afa0","stage":"stage_2","status":"partial","text":"The supplied documents identify methotrexate products as FDA-labeled therapies for acute lymphoblastic leukemia (ALL) in the United States. Methotrexate Injection is indicated for “treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy regimen,” while methotrexate tablets are indicated for “treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.” The documents do not provide approval dates, biomarker restrictions, cellular therapies, biologics, or billing/product coding identifiers, and they do not comprehensively list all FDA-approved ALL therapies as of 2026-09-22.","aspects_covered":["Approved methotrexate drug products for ALL","Label indications for ALL","Treatment line/regimen context for methotrexate","Absence of biomarker restrictions in supplied text","Lack of approval dates and coding identifiers in supplied documents"],"evidence_ids":["ev_ab5372d57ef7","ev_25df3092efad","ev_239fbcc09eb9","ev_5c220835ceec","ev_1555132b7f43","ev_4edfe40b7123"],"source_ids":["openfda_label"],"citations":["Hospira, Inc.","Alembic Pharmaceuticals Inc.","Aurobindo Pharma Limited"],"origin":"approved_api","batch_index":5,"round_index":0,"created_at":"2026-09-22T11:19:05.321096Z"},{"id":"ans_e6d8e22c8c33","run_id":"run_2058f031b9db","question_id":"q_2bee5da1afa0","stage":"stage_2","status":"partial","text":"The supplied documents identify methotrexate and doxorubicin as FDA-labeled products for acute lymphoblastic leukemia (ALL). Methotrexate tablets are indicated for the “treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen,” which specifies a maintenance treatment setting and includes both adult and pediatric patients without a biomarker restriction. Doxorubicin hydrochloride injection is indicated “for the treatment of acute lymphoblastic leukemia,” and the labeling also provides dosing for “Metastatic Disease, Leukemia, or Lymphoma,” including single-agent and combination therapy dosing, but no biomarker restriction is stated. The documents do not provide approval dates, HCPCS/CPT/NDC billing or product codes, or a complete list of all FDA-approved drugs, biologics, or cellular therapies for ALL in the United States.","aspects_covered":["Approved products for ALL","Label indications","Treatment line or regimen context where stated","Biomarker restrictions where stated or absent","Limitations of provided documents"],"evidence_ids":["ev_e1ecfa72c20a","ev_8cd1a78d4251","ev_302979ddd720","ev_0fe603b80ed7","ev_0afde5ec9761","ev_fde00a3b5959"],"source_ids":["openfda_label"],"citations":["Bryant Ranch Prepack","Pfizer Laboratories Div Pfizer Inc","US Food and Drug Administration"],"origin":"approved_api","batch_index":6,"round_index":0,"created_at":"2026-09-22T11:19:15.385432Z"},{"id":"ans_998940b5e6d5","run_id":"run_2058f031b9db","question_id":"q_2bee5da1afa0","stage":"stage_2","status":"partial","text":"The supplied documents identify doxorubicin products as approved/indicated for acute lymphoblastic leukemia in the United States. One label states: “Doxorubicin is indicated for the treatment of acute lymphoblastic leukemia,” and another states that “DOXOrubicin HCl Injection, USP and DOXOrubicin HCl for Injection, USP have been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia.” The documents do not provide FDA approval dates, biomarker restrictions, treatment-line limitations, or billing/product coding identifiers for acute lymphoblastic leukemia, nor do they identify other approved ALL drugs, biologics, or cellular therapies.","aspects_covered":["Approved product: doxorubicin","Labeled indication for acute lymphoblastic leukemia","Absence of approval dates in supplied documents","Absence of biomarker restrictions in supplied documents","Absence of billing/product codes in supplied documents","Absence of treatment-line information in supplied documents"],"evidence_ids":["ev_b221af2a908f","ev_57381230fa1e","ev_c21d4395f97a"],"source_ids":["openfda_label"],"citations":["US Food and Drug Administration"],"origin":"approved_api","batch_index":7,"round_index":0,"created_at":"2026-09-22T11:19:22.990757Z"},{"id":"ans_86213c3803bd","run_id":"run_2058f031b9db","question_id":"q_2bee5da1afa0","stage":"stage_2","status":"partial","text":"The documents discuss several therapies used or under development for acute lymphoblastic leukemia (ALL), including imatinib for newly diagnosed Philadelphia chromosome–positive ALL, blinatumomab and inotuzumab in relapsed/refractory ALL, and CAR-T cells being tested in ALL. However, the documents do not provide comprehensive FDA or other official regulatory approval information, approved labeling language, approval dates, treatment-line specifications, billing/product codes, or complete biomarker restrictions. The only explicit biomarker-linked treatment statement is for “Ph-positive ALL” or “Philadelphia chromosome positive (Phi+) ALL” in relation to imatinib and tyrosine kinase inhibitors.","aspects_covered":["Therapies mentioned for ALL","Some treatment settings/lines","Some biomarker restrictions (Philadelphia chromosome positive ALL)","Absence of approval dates","Absence of billing or product codes","Absence of official FDA labeling details"],"evidence_ids":["ev_fefba3481bed","ev_c3dd8f795d7b","ev_9cc63a0a1d84","ev_deff95ec2cfd","ev_9a1472ce6a59","ev_74834422de95","ev_45cabcf1850f"],"source_ids":["nci","esmo","asco"],"citations":["National Cancer Institute","Bulletin du cancer","American Society of Clinical Oncology Educational Book"],"origin":"approved_api","batch_index":0,"round_index":1,"created_at":"2026-09-22T11:19:57.725917Z"},{"id":"ans_32522c79399f","run_id":"run_2058f031b9db","question_id":"q_2bee5da1afa0","stage":"stage_2","status":"partial","text":"The supplied documents do not provide a complete list of FDA- or regulator-approved drugs, biologics, or cellular therapies for acute lymphoblastic leukemia in the United States, nor do they provide approval dates or billing/product coding identifiers. The documents mention several therapies in the context of ALL management and future or investigational use. One guideline states: “Patients with refractory/relapsed disease have a poor prognosis which highlights the importance of acquiring in the future new therapies such as: blinatumumab, inotuzumab, and CAR-T cells.” Another document describes CAR-T therapy as investigational and notes that “CAR-T therapy may be offered to people when their cancer comes back.” The documents also mention a biomarker-restricted subgroup: “For patients with Philadelphia chromosome positive (Phi+) ALL, post-transplantation tyrosine kinase inhibitors as a systematic maintenance strategy is recommended.”","aspects_covered":["Mentions of therapies used or discussed in ALL","Reference to refractory/relapsed treatment context","Reference to Philadelphia chromosome positive (Phi+) biomarker subgroup","Investigational CAR-T therapy context"],"evidence_ids":["ev_2102b39ff374","ev_2bb4a35ed354","ev_221619639e12","ev_130f89c6f692"],"source_ids":["ashpublications","clinicaltrials"],"citations":["Bulletin du cancer","National Cancer Institute (NCI)"],"origin":"approved_api","batch_index":1,"round_index":1,"created_at":"2026-09-22T11:20:05.243646Z"},{"id":"ans_ebcc7a0a8c0b","run_id":"run_2058f031b9db","question_id":"q_2bee5da1afa0","stage":"stage_2","status":"partial","text":"The supplied documents discuss treatment approaches and guideline recommendations for acute lymphoblastic leukemia (ALL), including T-cell ALL and adolescent/young adult ALL, but they do not provide a list of FDA-approved drugs, biologics, or cellular therapies, approval dates, labeled indications, treatment lines, biomarker restrictions, or billing/product coding identifiers. The documents state that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols” and that “The use of targeted agents in frontline therapy is increasingly supported, although further research is needed to optimize this strategy.” They also describe asparaginase as “an integral component of therapy for pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma.” No document supplies the requested regulatory approval tables or coding data.","aspects_covered":["Frontline therapy recommendations for ALL","Use of asparaginase-containing regimens","General mention of targeted agents in frontline therapy","Absence of FDA approval details, approval dates, biomarker restrictions, and billing/product codes"],"evidence_ids":["ev_cf6ec1622ef0","ev_ad9ccc39238c","ev_85e03d2949b2","ev_99f60b86857c","ev_dbe340cfd062"],"source_ids":["asco","ashpublications"],"citations":["Journal of Clinical Oncology","American Society of Hematology"],"origin":"approved_api","batch_index":3,"round_index":1,"created_at":"2026-09-22T11:20:20.754319Z"},{"id":"ans_e70e0dbf1880","run_id":"run_2058f031b9db","question_id":"q_2bee5da1afa0","stage":"stage_2","status":"partial","text":"The supplied documents do not provide a comprehensive list of FDA- or regulator-approved drugs, biologics, or cellular therapies for acute lymphoblastic leukemia, nor do they provide approval dates or billing/product coding identifiers. The documents do identify certain therapies discussed in guideline contexts for relapsed/refractory ALL, including “tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation” and recommendations involving “blinatumomab and/or inotuzumab over chemotherapy for reinduction.” The ASH guideline document specifically addresses adolescents and young adults with relapsed/refractory ALL and states that recommendations focused on “immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy.” No document supplies labeled FDA indications, treatment lines, biomarker restrictions, approval dates, HCPCS/J-codes, NDCs, or other coding identifiers for all approved ALL products.","aspects_covered":["Mentions of therapies used in relapsed/refractory ALL","Guideline recommendations involving blinatumomab and inotuzumab","Reference to targeted agents and transplantation modalities","Lack of approval dates and coding identifiers in supplied documents"],"evidence_ids":["ev_37542ea08d67","ev_42319b4c7a26","ev_379e9744ea2e","ev_39eba7bdae49","ev_5850d777aa9a"],"source_ids":["esmo","ashpublications"],"citations":["Journal of the National Comprehensive Cancer Network : JNCCN","American Society of Hematology"],"origin":"approved_api","batch_index":6,"round_index":1,"created_at":"2026-09-22T11:20:38.423874Z"},{"id":"ans_d4fa7d64874f","run_id":"run_2058f031b9db","question_id":"q_2bee5da1afa0","stage":"stage_2","status":"partial","text":"The supplied documents do not provide a comprehensive list of FDA- or regulator-approved drugs, biologics, or cellular therapies for acute lymphoblastic leukemia (ALL) in the United States as of 2026-09-22. One document describes a clinical trial regimen for “adult patients with Ph Negative ALL,” but it is explicitly a study and not an approval document. Another document lists FDA Drugs@FDA product information for methotrexate formulations, including NDA and submission dates, but it does not state an ALL indication, treatment line, biomarker restriction, approval for ALL, or billing/product coding identifiers.","aspects_covered":["Clinical trial context for Ph-negative ALL","FDA Drugs@FDA listing for methotrexate products","Lack of documented ALL-specific approvals, treatment lines, biomarkers, approval dates tied to ALL, or billing/product codes in supplied documents"],"evidence_ids":["ev_6737f3e1b95a","ev_400b61e0ce87","ev_6d2dceb96ca8","ev_098f42fe4f72"],"source_ids":["clinicaltrials","openfda_drugsfda"],"citations":["Memorial Sloan Kettering Cancer Center","HOSPIRA"],"origin":"approved_api","batch_index":8,"round_index":1,"created_at":"2026-09-22T11:20:51.719931Z"},{"id":"ans_41be641b1d7b","run_id":"run_2058f031b9db","question_id":"q_2bee5da1afa0","stage":"stage_2","status":"partial","text":"The supplied documents discuss clinical practice guidelines and diagnostic/cytogenetic stratification for acute lymphoblastic leukemia (ALL), including pediatric, adult, Philadelphia chromosome (Ph)-positive and Ph-negative disease, but they do not provide a list of FDA-approved drugs, biologics, or cellular therapies, nor approval dates, labeled indications, treatment lines, biomarker restrictions tied to approvals, or billing/product coding identifiers. The NCCN guideline documents state that they focus on “treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL” and “management of ALL, with a focus on the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers.” The cytogenetics document notes that “Ph-like ALL ... can benefit from targeted therapy,” but does not identify approved products or regulatory details.","aspects_covered":["NCCN guideline scope for pediatric and adult ALL","Mention of Ph-positive/Ph-negative treatment strategies","Cytogenetic and biomarker stratification context","Absence of regulatory approval details, dates, and coding identifiers in supplied documents"],"evidence_ids":["ev_f2fd5197ce53","ev_bdd288b7c3e7"],"source_ids":["esmo"],"citations":["Journal of the National Comprehensive Cancer Network : JNCCN","Current research in translational medicine"],"origin":"approved_api","batch_index":9,"round_index":1,"created_at":"2026-09-22T11:20:58.922880Z"},{"id":"ans_bcc746ce8d21","run_id":"run_2058f031b9db","question_id":"q_2bee5da1afa0","stage":"stage_2","status":"partial","text":"The supplied document discusses hematopoietic stem cell transplantation recommendations in pediatric acute lymphoblastic leukemia (ALL), including certain disease settings and biomarkers such as Philadelphia chromosome positive (Ph+) ALL, but it does not provide FDA or other regulatory approvals, approval dates, labeled indications, treatment lines in regulatory labeling, or billing/product coding identifiers for drugs, biologics, or cellular therapies in the United States. The document states that “Allogeneic SCT is recommended for children who: are in second complete remission (CR2) after experiencing an early marrow relapse for precursor-B ALL; experienced primary induction failure, but subsequently achieved a CR1; have T-lineage ALL in CR2; or have ALL in third or greater remission.” It also notes that “the 2005 pediatric ALL evidence-based review (EBR) recommended allogeneic SCT for children with Philadelphia chromosome positive (Ph+) ALL in CR1,” and references “chemotherapy + imatinib,” but no regulatory approval details are given.","aspects_covered":["Stem cell transplantation treatment recommendations in pediatric ALL","Mention of Philadelphia chromosome positive (Ph+) ALL","Mention of imatinib in chemotherapy context","Lack of FDA approval dates, labeled indications, or billing/product codes"],"evidence_ids":["ev_ec973034d54a","ev_94d5cfe29ccc","ev_b39ba47d2102"],"source_ids":["esmo"],"citations":["Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation"],"origin":"approved_api","batch_index":11,"round_index":1,"created_at":"2026-09-22T11:21:10.618037Z"},{"id":"ans_f8759af06ad7","run_id":"run_2058f031b9db","question_id":"q_bf22d864f4bc","stage":"stage_2","status":"partial","text":"The supplied ASH 2026 guidelines describe that frontline and relapsed/refractory ALL treatment pathways differ for certain higher-risk subsets and disease subsets, but they do not provide a complete biomarker-based treatment algorithm by Philadelphia chromosome status, molecular biomarkers, MRD status, or testing timepoints. For frontline AYA ALL, the guidelines state that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols,” and that “Allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy.” They also state that “The use of targeted agents in frontline therapy is increasingly supported.” For relapsed/refractory AYA ALL, the guidelines report that recommendations “focused on the following treatment modalities: immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy,” including “the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction,” and they additionally mention “ALL subsets (T-cell ALL), CNS relapse, and the role of consolidation with allogeneic transplant.” The documents do not specify Philadelphia chromosome-directed pathways, MRD-directed treatment changes, required biomarker panels, or when biomarker testing is recommended or expected for all patients.","aspects_covered":["frontline treatment pathways","higher-risk subsets","suboptimal response risk stratification","targeted therapies","relapsed/refractory treatment pathways","T-cell ALL subset","CNS relapse subset","absence of detailed biomarker and MRD guidance in supplied documents"],"evidence_ids":["ev_1f156e37d788","ev_4531684dd1a7","ev_1f1517f573c4","ev_a13ebfab1d58","ev_17d3c1f308c3","ev_770c0f4d5b7e","ev_9182343de04d"],"source_ids":["ashpublications","esmo"],"citations":["American Society of Hematology","Blood advances"],"origin":"approved_api","batch_index":0,"round_index":0,"created_at":"2026-09-22T11:21:33.910418Z"},{"id":"ans_88b4e9dbee23","run_id":"run_2058f031b9db","question_id":"q_bf22d864f4bc","stage":"stage_2","status":"partial","text":"The documents distinguish treatment pathways primarily by Philadelphia chromosome/BCR-ABL status, MRD status, and selected biomarkers such as CD20 positivity and BCR-ABL-like phenotype. For Ph-positive ALL, the NCI PDQ states that \"inclusion of imatinib into a relatively standard chemotherapy regimen for newly diagnosed adult patients with Ph-positive ALL may provide a significant survival advantage\" and that \"Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials,\" with consideration of \"allogeneic bone marrow transplant\" because remissions are short with conventional chemotherapy. For BCR-ABL-negative B-lineage ALL, the trial document evaluates adding blinatumomab to chemotherapy specifically in patients who are \"minimal residual disease (MRD) negative after induction and intensification chemotherapy,\" while also comparing outcomes in patients who are MRD positive and later convert to MRD negative after blinatumomab. Biomarker-directed elements in the protocol include evaluation of \"BCR/ABL1-like B-lineage ALL\" and optional rituximab use for \"CD20 positive patients.\" The documents indicate biomarker or disease-status assessment at diagnosis and after induction/intensification chemotherapy, including \"multiparameter flow cytometric (MFC) assessment of residual blasts\" for MRD-based treatment selection, but they do not provide comprehensive U.S. guideline-recommended pathways across all ALL risk groups or all expected testing timepoints.","aspects_covered":["Philadelphia chromosome status","BCR-ABL-negative disease","MRD status","Selected molecular biomarkers","CD20-directed treatment selection","BCR-ABL-like phenotype assessment","Testing timepoints after induction/intensification","Allogeneic transplant consideration"],"evidence_ids":["ev_02ebd2416f56","ev_d407566fa413","ev_bc278a23e777","ev_1f184e56211f","ev_5bbae4108cd9","ev_e8a5463ea174"],"source_ids":["nci","clinicaltrials"],"citations":["National Cancer Institute","National Cancer Institute (NCI)"],"origin":"approved_api","batch_index":1,"round_index":0,"created_at":"2026-09-22T11:21:44.380009Z"},{"id":"ans_d4e08ec7054f","run_id":"run_2058f031b9db","question_id":"q_bf22d864f4bc","stage":"stage_2","status":"partial","text":"The supplied documents indicate that acute lymphoblastic leukemia treatment and outcomes may differ by Philadelphia chromosome status, including references to “Philadelphia chromosome-associated acute lymphoblastic leukemia (Ph+ ALL)” and to “Clinical outcome of adult acute lymphoblastic leukemia based on Philadelphia chromosome status and socioeconomic status.” One document also references “BCR-ABL mutation status” in “imatinib-resistant patients,” implying molecular biomarker considerations in Ph+ ALL. However, the documents do not provide guideline-recommended treatment pathways, MRD-based stratification, testing timepoints, or detailed risk-segment recommendations.","aspects_covered":["Philadelphia chromosome status","BCR-ABL mutation status"],"evidence_ids":["ev_85b69c7d95f1","ev_fda538891bc6"],"source_ids":["asco"],"citations":["Journal of Clinical Oncology"],"origin":"approved_api","batch_index":0,"round_index":1,"created_at":"2026-09-22T11:22:22.101549Z"},{"id":"ans_2bec4603b33d","run_id":"run_2058f031b9db","question_id":"q_bf22d864f4bc","stage":"stage_2","status":"partial","text":"The supplied documents identify that NCCN maintains U.S. Acute Lymphoblastic Leukemia guidelines and biomarker-testing resources through “NCCN Guidelines Version 3.2026 - Acute Lymphoblastic Leukemia” and the “NCCN Biomarkers Compendium®,” but they do not provide the actual treatment pathways, biomarker-specific recommendations, MRD-directed algorithms, Philadelphia chromosome–specific regimens, risk stratification categories, or testing timepoints requested in the question. The documents do state that the NCCN Biomarkers Compendium includes tests used for “Diagnosis,” “Monitoring,” “Prediction,” and “Prognostication,” and that these tests are “recommended within the NCCN Guidelines.” No detailed ALL treatment algorithms or biomarker-triggered treatment selection rules are included in the supplied text.","aspects_covered":["Existence of NCCN ALL guidelines","Existence of NCCN biomarker compendium","General purposes of biomarker testing"],"evidence_ids":["ev_7f44713567b2","ev_0df99c70ea7d","ev_92acc73fe391","ev_3009674c56da","ev_e04fd8b384e3"],"source_ids":["open_web"],"citations":["Open web"],"origin":"open_web","batch_index":0,"round_index":99,"created_at":"2026-09-22T11:23:31.985760Z"},{"id":"ans_9c6554e27cbd","run_id":"run_2058f031b9db","question_id":"q_7ca3756217b1","stage":"stage_2","status":"partial","text":"The supplied FDA Drugs@FDA records show recent supplemental FDA actions for several acute lymphoblastic leukemia therapies, but they do not provide the underlying indication text, label-expansion details, biomarker requirements, or patient populations. For SPRYCEL (dasatinib), the record includes recent actions such as “SUPPL 28 AP 2024-07-31 Labeling STANDARD” and earlier efficacy supplements including “SUPPL 21 AP 2018-12-21 Efficacy PRIORITY.” For ARRANON (nelarabine), the record includes “SUPPL 14 AP 2025-03-11 Labeling STANDARD” and “SUPPL 10 AP 2019-07-31 Efficacy STANDARD.” For ICLUSIG (ponatinib), the record includes “SUPPL 38 AP 2025-10-10 Efficacy STANDARD” and “SUPPL 34 AP 2020-12-18 Efficacy PRIORITY.” The documents do not state the specific ALL indications, label-expansion wording, biomarker requirements, or effective-date language for patients.","aspects_covered":["Recent FDA supplemental approvals/actions","Labeling supplements","Efficacy supplements","Effective action dates from FDA records","Products involved"],"evidence_ids":["ev_63cb61d6aaae","ev_df77a4d1ea5f","ev_c324073e53df","ev_efa47ddba2ff","ev_72074191478b","ev_b5172d83504a"],"source_ids":["openfda_drugsfda"],"citations":["BRISTOL MYERS SQUIBB","SANDOZ","TAKEDA PHARMS USA"],"origin":"approved_api","batch_index":0,"round_index":0,"created_at":"2026-09-22T11:24:25.909382Z"},{"id":"ans_8d2cad97bcf4","run_id":"run_2058f031b9db","question_id":"q_7ca3756217b1","stage":"stage_2","status":"partial","text":"The supplied documents identify FDA-related submissions and current labeled acute lymphoblastic leukemia (ALL) indications for GLEEVEC and dasatinib, but they do not comprehensively describe all recent FDA approvals or label expansions for ALL therapies through 2026-09-22. For GLEEVEC, the Drugs@FDA record lists multiple approved supplements, including \"SUPPL 63 AP 2024-03-01 Manufacturing (CMC) N/A\" and earlier efficacy and labeling approvals, but the document does not state the ALL indication changes associated with those actions. For dasatinib, the labeling states that it is indicated for \"Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy\" in adults and for \"pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy,\" establishing a biomarker requirement of \"Philadelphia chromosome-positive (Ph+).\" The dasatinib label also states \"Initial U.S. Approval: 2006,\" but no recent FDA effective dates or expansion approval dates are provided in the supplied text.","aspects_covered":["GLEEVEC FDA supplement approval dates","Dasatinib ALL indications","Biomarker requirement for Ph+ ALL","Initial U.S. approval date for dasatinib"],"evidence_ids":["ev_ad9861f1bc06","ev_7b0f90ce768d","ev_a6db9cc6bed1","ev_fe787f4f9539","ev_e26bba7933f5"],"source_ids":["openfda_drugsfda","openfda_label"],"citations":["NOVARTIS","BluePoint Laboratories"],"origin":"approved_api","batch_index":1,"round_index":0,"created_at":"2026-09-22T11:24:34.999393Z"},{"id":"ans_901381cf832c","run_id":"run_2058f031b9db","question_id":"q_7ca3756217b1","stage":"stage_2","status":"partial","text":"The supplied document identifies FDA-labeled acute lymphoblastic leukemia (ALL) indications for imatinib mesylate, but it does not describe any recent FDA approvals or label expansions through 2026-09-22. The label states that imatinib mesylate is indicated for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)” and for “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.” The biomarker requirement specified for these ALL indications is “Philadelphia chromosome positive (Ph+).” The only approval timing provided is “Initial U.S. Approval: 2001,” and no effective dates for newer approvals or label expansions are included in the supplied material.","aspects_covered":["ALL indications for imatinib mesylate","Biomarker requirement (Philadelphia chromosome positive/Ph+)","Initial U.S. approval date","Absence of information on recent approvals or label expansions"],"evidence_ids":["ev_5ea773907865","ev_321ab2187a46","ev_3ed4e05e83fa"],"source_ids":["openfda_label"],"citations":["Apotex Corp"],"origin":"approved_api","batch_index":0,"round_index":1,"created_at":"2026-09-22T11:25:14.381421Z"},{"id":"ans_cf547782ed81","run_id":"run_2058f031b9db","question_id":"q_7ca3756217b1","stage":"stage_2","status":"partial","text":"On March 19, 2024, the FDA granted accelerated approval to ponatinib (Iclusig) with chemotherapy for “adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).” The biomarker/eligibility requirement specified in the indication was Philadelphia chromosome-positive disease. In June 2024, the FDA expanded approval of Blincyto (blinatumomab) to include “adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase, regardless of measurable residual disease (MRD) status.” The expanded Blincyto indication therefore changed eligibility to include patients regardless of MRD status, while retaining biomarker requirements of CD19-positive and Philadelphia chromosome-negative disease.","aspects_covered":["new approvals","label expansions","effective dates","indication changes","biomarker requirements"],"evidence_ids":["ev_2970a59c13db","ev_6592850d6958","ev_0c2a3ecb9148","ev_9ec4139501f8"],"source_ids":["open_web"],"citations":["Open web"],"origin":"open_web","batch_index":0,"round_index":99,"created_at":"2026-09-22T11:26:45.149230Z"},{"id":"ans_23e811f4229b","run_id":"run_2058f031b9db","question_id":"q_b5cd05555f81","stage":"stage_2","status":"partial","text":"The supplied documents do not identify any acute lymphoblastic leukemia (ALL) therapy approvals or indications in the United States that were withdrawn, restricted, or modified through 2026-09-22. The documents discuss oncology accelerated approvals and withdrawals generally, including examples in lung, breast, and bladder cancers, but they do not name any ALL therapies, indications, or effective dates relevant to ALL patients.","aspects_covered":["General oncology accelerated-approval withdrawals","Lack of ALL-specific withdrawn or modified approvals in supplied documents"],"evidence_ids":["ev_4c56f3992709","ev_3020062e8499","ev_0b22c0ee4bb9"],"source_ids":["asco"],"citations":["Journal of Clinical Oncology"],"origin":"approved_api","batch_index":0,"round_index":0,"created_at":"2026-09-22T11:27:37.449066Z"},{"id":"ans_1fb7d45a2a2a","run_id":"run_2058f031b9db","question_id":"q_b5cd05555f81","stage":"stage_2","status":"partial","text":"The supplied documents do not identify any acute lymphoblastic leukemia therapy approvals or indications that were withdrawn, restricted, or otherwise modified by regulators, and they do not provide effective dates for such actions. The only relevant regulatory qualification in the documents is for clofarabine injection, where the indication states that it is \"based upon response rate\" and that there are \"no trials verifying an improvement in disease-related symptoms or increased survival.\" The ICLUSIG record lists multiple FDA supplement actions and dates, including efficacy and labeling supplements, but does not describe any withdrawn or restricted ALL indications.","aspects_covered":["Clofarabine indication qualified by response-rate basis","Absence of documented withdrawn or restricted ALL indications in supplied documents","FDA supplement dates for ICLUSIG without described indication withdrawals or restrictions"],"evidence_ids":["ev_b7d392b7cec0","ev_d514be8bfecf","ev_c92815eda10c"],"source_ids":["openfda_label","openfda_drugsfda"],"citations":["US Food and Drug Administration","TAKEDA PHARMS USA"],"origin":"approved_api","batch_index":2,"round_index":0,"created_at":"2026-09-22T11:27:53.840966Z"},{"id":"ans_cf824c47cc43","run_id":"run_2058f031b9db","question_id":"q_b5cd05555f81","stage":"stage_2","status":"partial","text":"The provided documents do not identify any withdrawn acute lymphoblastic leukemia (ALL) indications in the United States through 2026-09-22. They do identify regulatory modifications affecting ALL therapies: on March 19, 2024, the FDA granted “accelerated approval” to ponatinib (Iclusig) with chemotherapy for “adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).” The documents also show regulatory changes for TECARTUS (brexucabtagene autoleucel), including a “REMS Major Modification Approval Letter” dated June 12, 2024, and a “REMS Elimination Approval Letter” dated June 26, 2025, for a product indicated for “Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).”","aspects_covered":["Accelerated approval changes for ALL therapies","Regulatory modifications/REMS changes for ALL therapies","Effective dates","Affected therapies"],"evidence_ids":["ev_1148904526a3","ev_d16d5bc27db7","ev_65037a0ca4f4","ev_60bd4daf6c58","ev_706564f3720a"],"source_ids":["open_web"],"citations":["Open web"],"origin":"open_web","batch_index":0,"round_index":99,"created_at":"2026-09-22T11:29:44.369761Z"},{"id":"ans_78a7be619bba","run_id":"run_2058f031b9db","question_id":"q_7e8639e73505","stage":"stage_2","status":"partial","text":"The supplied documents identify that NCCN Guidelines for acute lymphoblastic leukemia (ALL) include \"treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients\" and that pediatric guidelines include \"treatment strategies for BCR::ABL1 (Philadelphia chromosome [Ph])-negative and BCR::ABL1-positive B-cell lineage, T-cell lineage, and infant ALL.\" However, the documents do not provide specific off-label drugs, biologics, cellular therapies, compendia-supported uses, line-of-therapy details, or coding identifiers for ALL therapies in the United States as of 2026-09-22.","aspects_covered":["Existence of NCCN guideline recommendations for adult ALL treatment strategies","Existence of NCCN pediatric ALL treatment strategy recommendations","Absence of explicit off-label therapies, compendia support details, line-of-therapy specifications, therapy classes, or coding identifiers in supplied documents"],"evidence_ids":["ev_e150335793d7","ev_8402e51cc2fc","ev_263044db5581"],"source_ids":["esmo"],"citations":["Journal of the National Comprehensive Cancer Network : JNCCN"],"origin":"approved_api","batch_index":0,"round_index":0,"created_at":"2026-09-22T11:30:37.003282Z"},{"id":"ans_168b83b65541","run_id":"run_2058f031b9db","question_id":"q_7e8639e73505","stage":"stage_2","status":"partial","text":"The supplied documents identify that the NCCN Clinical Practice Guidelines for Pediatric Acute Lymphoblastic Leukemia address treatment strategies for multiple ALL subtypes and include recommendations for “frontline and relapsed/refractory management,” but they do not enumerate specific off-label drugs, biologics, cellular therapies, compendia-supported indications, line-of-therapy mappings, or coding identifiers. The documents state that the guidelines include “guidance on supportive care, hematopoietic stem cell transplantation, and pharmacogenomics” and cover “treatment strategies for BCR::ABL1 (Philadelphia chromosome [Ph])-negative and BCR::ABL1-positive B-cell lineage, T-cell lineage, and infant ALL.” No HCPCS, CPT, ICD-10, NDC, or other coding identifiers are provided in the supplied text.","aspects_covered":["Existence of NCCN guideline recommendations for pediatric ALL","Coverage of frontline and relapsed/refractory management","Coverage of treatment strategies for ALL subtypes","Supportive care and hematopoietic stem cell transplantation mentioned","No specific off-label therapies listed","No compendia status details listed","No coding identifiers listed"],"evidence_ids":["ev_e3642f4f9dda","ev_4bf7e0f9de44","ev_2de3a2b8b37d","ev_04975cb2b087","ev_6ff3677893f2","ev_ac2425264324"],"source_ids":["ashpublications","esmo"],"citations":["Journal of the National Comprehensive Cancer Network : JNCCN"],"origin":"approved_api","batch_index":1,"round_index":0,"created_at":"2026-09-22T11:30:44.491327Z"},{"id":"ans_7d562ad21be1","run_id":"run_2058f031b9db","question_id":"q_7e8639e73505","stage":"stage_2","status":"partial","text":"The supplied documents identify clofarabine as a nucleoside metabolic inhibitor used in acute lymphoblastic leukemia (ALL) for pediatric patients with relapsed or refractory disease after at least two prior regimens, which corresponds to a later-line therapy setting. The documents state: \"Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.\" The documents do not provide information on off-label ALL therapies, compendia-supported uses, compendia status, cellular therapies, biologics beyond clofarabine, therapy coding identifiers, or line-of-therapy categorizations for all patients in the United States as of 2026-09-22.","aspects_covered":["FDA-labeled ALL therapy","Line of therapy for clofarabine","Therapy class for clofarabine","Limitations of supplied documents regarding compendia support and coding identifiers"],"evidence_ids":["ev_ea0ed12f8542","ev_010bf86aa3ee","ev_157219afc07d","ev_37205bf042b5","ev_11f3b6173d63"],"source_ids":["ashpublications","openfda_label"],"citations":["Journal of the National Comprehensive Cancer Network : JNCCN","Amneal Pharmaceuticals LLC","US Food and Drug Administration"],"origin":"approved_api","batch_index":3,"round_index":0,"created_at":"2026-09-22T11:30:56.636253Z"},{"id":"ans_d021de3a156f","run_id":"run_2058f031b9db","question_id":"q_7e8639e73505","stage":"stage_2","status":"partial","text":"The supplied documents identify FDA-labeled therapies for acute lymphoblastic leukemia (ALL) and relapsed/refractory T-cell ALL, including therapy class and prior-line context, but they do not provide off-label uses, compendia-supported uses, compendia status, or coding identifiers. Clofarabine is described as “a nucleoside metabolic inhibitor indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens,” establishing a relapsed/refractory setting after at least two prior lines. Nelarabine is described as “a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens,” also specifying treatment after at least two prior regimens. Methotrexate is identified as “a folate analog metabolic inhibitor” indicated for “treatment of adult and pediatric patients with acute lymphoblastic leukemia as part of a combination chemotherapy regimen” and for “prophylaxis and treatment of adult and pediatric patients with meningeal leukemia,” but no line-of-therapy, off-label, compendia, biologic, cellular therapy, or coding information is supplied.","aspects_covered":["FDA-labeled ALL therapies","Therapy classes","Relapsed/refractory line context","Absence of compendia support information","Absence of coding identifiers","Absence of biologic and cellular therapy information"],"evidence_ids":["ev_46a4515bab12","ev_386d195ad314","ev_6145072e79ae","ev_ca038c62e523","ev_9678b94b5acd","ev_b3a891549fc8","ev_c77ec13ea819"],"source_ids":["openfda_label"],"citations":["Dr.Reddy's Laboratories Inc","Alembic Pharmaceuticals Limited","Hospira, Inc."],"origin":"approved_api","batch_index":4,"round_index":0,"created_at":"2026-09-22T11:31:06.227930Z"},{"id":"ans_2e899a1fb579","run_id":"run_2058f031b9db","question_id":"q_7e8639e73505","stage":"stage_2","status":"partial","text":"The documents identify FDA-labeled therapies and guideline-supported modalities for acute lymphoblastic leukemia (ALL), but they do not provide compendia status details, coding identifiers, or a comprehensive list of off-label therapies. Methotrexate is described as a “folate analog metabolic inhibitor” indicated for “adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy regimen,” and mercaptopurine is described as a “nucleoside metabolic inhibitor” indicated for “patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.” The ASH 2026 relapsed/refractory ALL guideline addresses later-line therapy concepts in adolescents and young adults, stating that recommendations “focused on the following treatment modalities: immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy,” and that “Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction.” The supplied documents do not provide billing or coding identifiers, explicit compendia classifications, or explicit statements that these uses are off-label.","aspects_covered":["FDA-labeled ALL therapies","Therapy classes","Maintenance therapy","Relapsed/refractory reinduction recommendations","Cellular/transplant modalities mentioned","Limits of available evidence in supplied documents"],"evidence_ids":["ev_616228cc56aa","ev_3d5a766b9991","ev_913b6145ef3b","ev_d1ac4c7abe31","ev_41023de8b281","ev_af956faa2b9a","ev_323a7332280e","ev_052ecd82bb66","ev_33fe3b9f58c2"],"source_ids":["openfda_label","esmo"],"citations":["Hospira, Inc.","Blood advances","Hikma Pharmaceuticals USA Inc."],"origin":"approved_api","batch_index":5,"round_index":0,"created_at":"2026-09-22T11:31:22.552481Z"},{"id":"ans_255764b43d7f","run_id":"run_2058f031b9db","question_id":"q_7e8639e73505","stage":"stage_2","status":"partial","text":"The supplied documents identify several therapies used in acute lymphoblastic leukemia (ALL), including immunotherapy, targeted therapies, CAR-T cellular therapy, and methotrexate, but they do not provide compendia status details, coding identifiers, or a comprehensive off-label-use listing by line of therapy. For relapsed/refractory ALL in adolescents and young adults, the ASH 2026 guideline states that recommendations for remission reinduction and consolidation “focused on the following treatment modalities: immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy,” and that “Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction.” CD19 CAR therapy is described as an emerging cellular immunotherapy for B-cell ALL with “remarkable clinical outcomes in adults and children with ALL,” and methotrexate is FDA-indicated for “treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.” The documents do not provide HCPCS, CPT, ICD-10, NDC, or other coding identifiers, and they do not explicitly identify any therapy as off-label or compendia-supported.","aspects_covered":["Therapy classes","Specific therapies mentioned","Cellular therapies","Line of therapy information for relapsed/refractory ALL reinduction and maintenance","FDA-labeled methotrexate indication","Missing compendia status","Missing coding identifiers","Missing explicit off-label determinations"],"evidence_ids":["ev_8b0a649d845f","ev_d6b3daf47ce5","ev_9893fcc86a6b","ev_b5c41e9eb78a","ev_77dc8903283a","ev_e71be5f2f3d5","ev_ef846a28feb2","ev_699fe15b5476"],"source_ids":["asco","ashpublications","openfda_label"],"citations":["American Society of Clinical Oncology Educational Book","American Society of Hematology","Alembic Pharmaceuticals Inc."],"origin":"approved_api","batch_index":6,"round_index":0,"created_at":"2026-09-22T11:31:32.383259Z"},{"id":"ans_4c3d549483b2","run_id":"run_2058f031b9db","question_id":"q_7e8639e73505","stage":"stage_2","status":"partial","text":"The supplied documents identify FDA-labeled therapies for acute lymphoblastic leukemia (ALL), but they do not provide compendia-supported off-label uses, line-of-therapy categorizations beyond resistance/intolerance language, coding identifiers, or cellular therapies. Doxorubicin is described as \"indicated for the treatment of acute lymphoblastic leukemia\" and is an \"anthracycline topoisomerase inhibitor.\" Dasatinib is described as a \"kinase inhibitor\" indicated for \"adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy\" and for \"pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.\"","aspects_covered":["FDA-labeled drug therapies for ALL","Therapy classes","Limited line-of-therapy information for Ph+ ALL","Absence of compendia support information","Absence of coding identifiers","Absence of cellular therapy information"],"evidence_ids":["ev_d9411fe55b8f","ev_fe955e303385","ev_d0aad9664b47","ev_63bcb4adefa7","ev_8ea2859867cb","ev_70d2d448be59"],"source_ids":["openfda_label"],"citations":["Pfizer Laboratories Div Pfizer Inc","BluePoint Laboratories","US Food and Drug Administration"],"origin":"approved_api","batch_index":8,"round_index":0,"created_at":"2026-09-22T11:32:02.327263Z"},{"id":"ans_43ea07ed4c72","run_id":"run_2058f031b9db","question_id":"q_7e8639e73505","stage":"stage_2","status":"partial","text":"The documents identify some therapies used for acute lymphoblastic leukemia (ALL), including doxorubicin, pediatric-inspired regimens containing asparaginase, targeted agents, and allogeneic hematopoietic stem cell transplantation. Doxorubicin is FDA-indicated for ALL and is described for use in “Metastatic Disease, Leukemia, or Lymphoma,” but no line-of-therapy designation is provided. ASH guidelines describe “frontline therapy” in adolescents and young adults using “Pediatric-inspired regimens containing asparaginase” and note that “The use of targeted agents in frontline therapy is increasingly supported,” while “Allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy.” The documents do not provide compendia-supported off-label use determinations, coding identifiers, HCPCS/NDC/CPT identifiers, or a complete line-of-therapy mapping for all drugs, biologics, and cellular therapies in ALL.","aspects_covered":["FDA-indicated therapies for ALL","Frontline therapy recommendations in AYA ALL","Therapy classes including chemotherapy, targeted agents, and stem cell transplantation","Absence of compendia status and coding identifiers in supplied documents"],"evidence_ids":["ev_884f267cedc3","ev_e3c17a308ffd","ev_3dac3f36f83a","ev_5ff66632cef3","ev_bfcb599f7b11","ev_6a2fc993513b"],"source_ids":["openfda_label","esmo","openfda_drugsfda"],"citations":["US Food and Drug Administration","Blood advances","NOVARTIS"],"origin":"approved_api","batch_index":9,"round_index":0,"created_at":"2026-09-22T11:32:12.037976Z"},{"id":"ans_be0b6ddf9497","run_id":"run_2058f031b9db","question_id":"q_7e8639e73505","stage":"stage_2","status":"partial","text":"The supplied documents identify doxorubicin hydrochloride as a drug used in acute lymphoblastic leukemia, but they do not provide the requested comprehensive list of off-label therapies, biologics, cellular therapies, compendia-supported uses, lines of therapy, or coding identifiers for acute lymphoblastic leukemia in the United States as of 2026-09-22. One FDA labeling document states that \"DOXOrubicin HCl Injection, USP and DOXOrubicin HCl for Injection, USP have been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia.\" The documents discussing oncology drug compendia and off-label coverage do not provide specific acute lymphoblastic leukemia therapies, compendia status categories, or line-of-therapy details.","aspects_covered":["off-label oncology drug use context","doxorubicin use in acute lymphoblastic leukemia","absence of line-of-therapy information","absence of compendia status details","absence of coding identifiers"],"evidence_ids":["ev_3e3bd7657f96","ev_c401fe70640c","ev_05689e0a19d2"],"source_ids":["asco","openfda_label"],"citations":["Journal of Oncology Practice","US Food and Drug Administration"],"origin":"approved_api","batch_index":1,"round_index":1,"created_at":"2026-09-22T11:33:06.022343Z"},{"id":"ans_817d13d6b4bc","run_id":"run_2058f031b9db","question_id":"q_7e8639e73505","stage":"stage_2","status":"partial","text":"The documents identify dasatinib (SPRYCEL), a kinase inhibitor, as an FDA-labeled therapy for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) \"with resistance or intolerance to prior therapy,\" which corresponds to a later-line setting after prior treatment. The label also provides a disease-specific dosage for \"Ph+ ALL\" of \"140 mg administered orally once daily.\" The NCI PDQ document describes induction regimens for adult ALL using combination chemotherapy including \"prednisone, vincristine, and an anthracycline,\" with some regimens adding \"asparaginase or cyclophosphamide,\" and states that \"Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.\" The supplied documents do not provide compendia status classifications, billing or coding identifiers, cellular therapy coding, or a comprehensive list of off-label therapies across all lines of therapy for ALL.","aspects_covered":["FDA-labeled Ph+ ALL therapy","Line of therapy information","Therapy classes","Adult ALL induction regimens","Use of imatinib in Ph-positive ALL"],"evidence_ids":["ev_14ea531ff091","ev_2db8b27f342a","ev_ab0b3f234a33","ev_71987d46f280","ev_2619f644baea","ev_516351eb23f5"],"source_ids":["openfda_label","nci"],"citations":["US Food and Drug Administration","National Cancer Institute"],"origin":"approved_api","batch_index":3,"round_index":1,"created_at":"2026-09-22T11:33:22.332538Z"},{"id":"ans_727e7270e59e","run_id":"run_2058f031b9db","question_id":"q_7e8639e73505","stage":"stage_2","status":"partial","text":"The supplied documents identify several therapies used or studied in acute lymphoblastic leukemia (ALL), including tyrosine kinase inhibitors, monoclonal antibodies, and cellular therapies, but they do not provide compendia status details, coding identifiers, or a comprehensive off-label listing by line of therapy. For relapsed/refractory ALL and minimal residual disease settings, the documents describe blinatumomab, inotuzumab ozogamicin, rituximab, and autologous chimeric antigen receptor (CAR) cells. For newly diagnosed Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-like) B-ALL, a clinical trial document describes use of blinatumomab with dasatinib or imatinib plus chemotherapy. The documents also identify ponatinib (ICLUSIG) as an FDA-approved product, but they do not specify ALL line-of-therapy use, compendia support, or billing/coding identifiers.","aspects_covered":["Therapy classes","Examples of therapies discussed in ALL","Some treatment settings/lines of therapy","FDA product identification for ponatinib"],"evidence_ids":["ev_fc141afd58b1","ev_3247e0e592f6","ev_2d1d5fc9fe5c","ev_d1408c361bbe","ev_bd474e24389f","ev_951871bbb7ce","ev_eb3a43817bb9"],"source_ids":["clinicaltrials","openfda_drugsfda","asco"],"citations":["National Cancer Institute (NCI)","TAKEDA PHARMS USA","American Society of Clinical Oncology Educational Book"],"origin":"approved_api","batch_index":4,"round_index":1,"created_at":"2026-09-22T11:33:32.590069Z"},{"id":"ans_87edf1d85987","run_id":"run_2058f031b9db","question_id":"q_7e8639e73505","stage":"stage_2","status":"partial","text":"The supplied documents identify some therapies and therapy classes being studied or discussed for acute lymphoblastic leukemia (ALL), but they do not provide a comprehensive United States 2026 list of off-label therapies, compendia-supported uses, line-of-therapy recommendations, or coding identifiers. One clinical trial document describes the addition of venetoclax and blinatumomab to chemotherapy for infants with newly diagnosed ALL, stating that “Venetoclax is in a class of medications called B-cell lymphoma-2 (Bcl-2) inhibitors” and “Blinatumomab is a monoclonal antibody.” Another guideline document states that “the rapid development of immunotherapy has improved the efficacy of adult ALL, and commercial antibodies and CAR-T cell products have been available in China.” The documents do not provide compendia status, NCCN support categories, HCPCS/CPT/NDC/J-codes, or explicit off-label line-of-therapy mappings for all patients in the United States.","aspects_covered":["Therapies mentioned for ALL","Therapy classes","Cellular therapy mention (CAR-T cell products)","Newly diagnosed setting in infants"],"evidence_ids":["ev_83ad52f8a16d","ev_b57b560a6612","ev_eb0656e69d24"],"source_ids":["clinicaltrials","esmo"],"citations":["National Cancer Institute (NCI)","Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi"],"origin":"approved_api","batch_index":5,"round_index":1,"created_at":"2026-09-22T11:33:40.930758Z"},{"id":"ans_4dc666bca5aa","run_id":"run_2058f031b9db","question_id":"q_7e8639e73505","stage":"stage_2","status":"partial","text":"The supplied documents do not provide a comprehensive list of off-label therapies, compendia-supported uses, lines of therapy, coding identifiers, or therapy classes for acute lymphoblastic leukemia in the United States as of 2026-09-22. The documents do mention immunotherapy approaches including monoclonal antibodies, CAR-T cell products, and blinatumomab in adult or newly diagnosed B-lineage acute lymphoblastic leukemia. One clinical trial document specifically evaluates “combination chemotherapy with blinatumomab” in “newly diagnosed BCR-ABL-negative B lineage acute lymphoblastic leukemia,” which corresponds to a frontline/newly diagnosed treatment setting.","aspects_covered":["Mention of immunotherapy approaches in adult ALL","Mention of monoclonal antibodies","Mention of CAR-T cell products","Blinatumomab studied with chemotherapy in newly diagnosed BCR-ABL-negative B-lineage ALL","Line of therapy information limited to newly diagnosed setting"],"evidence_ids":["ev_f4a73f659d8a","ev_db20032d8799","ev_6777e1cf7d5b","ev_3a1222e8dd30"],"source_ids":["ashpublications","asco","clinicaltrials"],"citations":["Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","Default Digital Object Group","National Cancer Institute (NCI)"],"origin":"approved_api","batch_index":6,"round_index":1,"created_at":"2026-09-22T11:33:47.991521Z"},{"id":"ans_1750a22a0ad1","run_id":"run_2058f031b9db","question_id":"q_7e8639e73505","stage":"stage_2","status":"partial","text":"The documents discuss asparaginase-containing pediatric-inspired regimens and targeted agents for acute lymphoblastic leukemia (ALL), particularly in adolescents and young adults (AYA), but they do not provide a comprehensive list of off-label therapies, compendia-supported uses, coding identifiers, or detailed line-of-therapy classifications. The available text states that \"Asparaginase is an integral component of therapy for pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma\" and that \"trials of pediatric/pediatric-inspired regimens incorporating asparaginase\" have been extended to \"adolescent and young adult (AYA) and adult populations.\" The ASH 2026 guideline document further states that \"Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols\" and that \"The use of targeted agents in frontline therapy is increasingly supported.\" No compendia status labels, HCPCS/CPT/NDC/ICD coding identifiers, or explicit off-label regulatory determinations are provided in the supplied documents.","aspects_covered":["asparaginase-containing regimens","frontline therapy recommendations","AYA and adult ALL populations","targeted agents in frontline therapy","lack of coding identifiers and compendia details in supplied documents"],"evidence_ids":["ev_f1faee6d75b3","ev_6a6f83c33dbe","ev_6c988844eb71","ev_e9f057741b9c","ev_b7ae17bf7f0c"],"source_ids":["esmo","ashpublications"],"citations":["American journal of hematology","American Society of Hematology"],"origin":"approved_api","batch_index":7,"round_index":1,"created_at":"2026-09-22T11:33:56.410700Z"},{"id":"ans_208db122453c","run_id":"run_2058f031b9db","question_id":"q_7e8639e73505","stage":"stage_2","status":"partial","text":"The documents describe investigational and relapsed/refractory acute lymphoblastic leukemia therapies, including small-molecule combinations and cellular therapies, but they do not provide comprehensive United States off-label or compendia-supported use listings, coding identifiers, or formal line-of-therapy compendia status as of 2026-09-22. One study evaluates the drug combination of calaspargase pegol-mknl, decitabine, and venetoclax in pediatric, adolescent, and young adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma. Another study evaluates a CD19-directed CAR T-cell therapy (AUTO1/obe-cel) in pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia. The supplied documents do not include HCPCS, CPT, ICD-10, NDC, or other coding identifiers, and they do not state NCCN Compendia or other compendia support categories.","aspects_covered":["Investigational/off-label therapies for relapsed/refractory ALL","Therapy classes including chemotherapy combinations and CAR T-cell therapy","Population and disease setting/line of therapy information","Absence of compendia status and coding identifiers in supplied documents"],"evidence_ids":["ev_9dff9e1b8b01","ev_9d11e8ebe32b","ev_342f90e51548","ev_b682ade8d0ee"],"source_ids":["clinicaltrials"],"citations":["M.D. Anderson Cancer Center","Autolus Limited"],"origin":"approved_api","batch_index":8,"round_index":1,"created_at":"2026-09-22T11:34:05.204816Z"},{"id":"ans_8aaad977f7c1","run_id":"run_2058f031b9db","question_id":"q_7e8639e73505","stage":"stage_2","status":"partial","text":"The documents describe several therapies and therapy classes used in acute lymphoblastic leukemia (ALL), including first-line chemotherapy, hematopoietic stem-cell transplantation, targeted therapy, CAR-T cellular therapies, and lymphodepletion regimens, but they do not provide compendia support status, coding identifiers, or a comprehensive off-label use listing. For first-line therapy, one source states that \"Modern first-line therapy consists of standard- and high-dose chemotherapy (increasingly inspired to pediatric principles), hematopoietic stem-cell transplantation, and new targeted therapy.\" For relapsed or refractory B-cell ALL, investigational CAR-T approaches described include TSLPR-CART and commercial tisagenlecleucel CAR T-cell therapy, with one study requiring disease that \"is relapsed or refractory after initial systemic therapy and at least one salvage treatment.\" The supplied documents do not identify NCCN or other compendia recommendations, HCPCS/CPT/ICD coding identifiers, or a complete by-line-of-therapy catalog of off-label therapies for all ALL patients in the United States as of 2026-09-22.","aspects_covered":["First-line therapy classes for ALL","Relapsed/refractory B-ALL cellular therapies","Examples of CAR-T and lymphodepletion regimens","Line of therapy references","Limitations: no compendia status or coding identifiers provided"],"evidence_ids":["ev_72885d7b6299","ev_413ac9d19f82","ev_f3304ea9023f","ev_09065facd706"],"source_ids":["asco","clinicaltrials"],"citations":["Journal of Clinical Oncology","National Cancer Institute (NCI)","Memorial Sloan Kettering Cancer Center"],"origin":"approved_api","batch_index":9,"round_index":1,"created_at":"2026-09-22T11:34:14.248240Z"},{"id":"ans_43dcc06167b5","run_id":"run_2058f031b9db","question_id":"q_7e8639e73505","stage":"stage_2","status":"partial","text":"The supplied documents describe investigational and treatment regimens for acute lymphoblastic leukemia (ALL), including therapies used in newly diagnosed and high-risk or relapsed settings, but they do not provide compendia-supported indications, off-label status determinations, or coding identifiers. Document 0 describes selected use of blinatumomab and cellular therapies in pediatric and young adult patients with high-risk ALL in remission states including CR1, CR2, and CR3 or subsequent relapse settings in the context of haploidentical hematopoietic cell transplantation. Document 1 describes a “pediatric-inspired” chemotherapy regimen for adults aged 18-60 with newly diagnosed Philadelphia chromosome-negative ALL and lists the chemotherapy agents used. No document provides United States compendia status, HCPCS/CPT/NDC coding identifiers, or explicit regulatory off-label classifications.","aspects_covered":["Investigational and treatment regimens for ALL","Line of therapy references including CR1, CR2, CR3/subsequent, and newly diagnosed disease","Drug, biologic, and cellular therapy names","Lack of compendia status and coding identifier information in supplied documents"],"evidence_ids":["ev_4a586e4d353a","ev_1a2a0f33310b","ev_771b9167560c","ev_b278350abb35"],"source_ids":["clinicaltrials"],"citations":["St. Jude Children's Research Hospital","Memorial Sloan Kettering Cancer Center"],"origin":"approved_api","batch_index":10,"round_index":1,"created_at":"2026-09-22T11:34:23.950517Z"},{"id":"ans_0c9a744e9706","run_id":"run_2058f031b9db","question_id":"q_fd97687cf608","stage":"stage_2","status":"partial","text":"The supplied documents describe new 2026 American Society of Hematology (ASH) guidelines for adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL), including frontline and relapsed/refractory settings, but they do not provide a longitudinal history of guideline changes over time or prior version dates. For frontline management, the 2026 ASH guideline states that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols,” and that “Allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy.” For relapsed/refractory disease, the 2026 ASH guideline reports that recommendations “focused on the following treatment modalities: immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy,” and that “Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction.” The affected settings and patient subgroups described are AYAs with frontline ALL and AYAs with relapsed/refractory ALL, including “ALL subsets (T-cell ALL), CNS relapse, and the role of consolidation with allogeneic transplant.”","aspects_covered":["2026 ASH guideline versions","Frontline ALL recommendations in AYAs","Relapsed/refractory ALL recommendations in AYAs","Affected regimens","Treatment settings","Patient subgroups"],"evidence_ids":["ev_0fae3159251d","ev_784b1c070de9","ev_65cd3ce2384d","ev_216cb19ffb9d","ev_f606e95f0b33","ev_b0f7342e7e44","ev_76163c9f247f"],"source_ids":["ashpublications","esmo"],"citations":["American Society of Hematology","Blood advances"],"origin":"approved_api","batch_index":0,"round_index":0,"created_at":"2026-09-22T11:34:41.751617Z"},{"id":"ans_46c4c46fb9ce","run_id":"run_2058f031b9db","question_id":"q_fd97687cf608","stage":"stage_2","status":"partial","text":"The supplied document describes contemporary remission induction approaches for adult acute lymphoblastic leukemia (ALL), including that \"Most current induction regimens for patients with adult ALL include combination chemotherapy with prednisone, vincristine, and an anthracycline\" and that some regimens \"also add other drugs, such as asparaginase or cyclophosphamide.\" It also notes a treatment change within a CALGB study involving the \"omission of L-asparaginase\" midway through the study. For newly diagnosed adult patients with Philadelphia chromosome (Ph)-positive ALL, the document states that \"inclusion of imatinib into a relatively standard chemotherapy regimen... may provide a significant survival advantage\" and that \"Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.\" The document further states that \"If a suitable donor is available, allogeneic bone marrow transplant should be considered because remissions are generally short with conventional ALL chemotherapy clinical trials\" and that \"the use of myeloid growth factors during remission-induction therapy appears to decrease the time to hematopoietic reconstitution.\" The documents do not provide guideline version histories, dates of recommendation changes, or a chronological evolution of U.S. clinical guidelines through 2026-09-22.","aspects_covered":["Adult ALL induction regimens","Addition or omission of regimen components","Ph-positive ALL treatment recommendations","Consideration of allogeneic bone marrow transplant","Use of myeloid growth factors during remission induction","Affected patient subgroup: newly diagnosed adult patients with Ph-positive ALL"],"evidence_ids":["ev_9fbedc6025ea","ev_1bf20950643c","ev_f27500842f2c"],"source_ids":["nci"],"citations":["National Cancer Institute"],"origin":"approved_api","batch_index":0,"round_index":1,"created_at":"2026-09-22T11:34:59.493310Z"},{"id":"ans_9490db415242","run_id":"run_2058f031b9db","question_id":"q_1a2fac4b0d38","stage":"stage_2","status":"partial","text":"The supplied documents contain limited published benchmark information for outcomes in acute lymphoblastic leukemia (ALL), mostly related to remission duration, relapse-free survival objectives, and treatment context rather than comprehensive benchmarks for time on treatment (TOT), time to next treatment (TTNT), or progression-free survival (PFS) by line of therapy and regimen. For newly diagnosed adult ALL induction therapy, the NCI PDQ states that \"Current multiagent induction regimens result in complete response rates that range from 60% to 90%\" and reports that in Ph-positive ALL treated with imatinib-containing therapy, \"most of these patients experiencing disease relapse at a median of 58 days after the start of therapy\" and \"The responses again were short, with a median duration of 2.2 months.\" A ClinicalTrials.gov phase III study in newly diagnosed BCR-ABL-negative B-lineage ALL lists overall survival (OS) and relapse-free survival (RFS) as primary and secondary objectives for blinatumomab plus chemotherapy versus chemotherapy alone, but does not provide benchmark results. The ASH 2026 guideline document discusses relapsed/refractory ALL in adolescents and young adults and focuses on treatment recommendations such as \"the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction,\" but does not provide numeric TOT, TTNT, or PFS benchmarks.","aspects_covered":["remission duration","relapse timing","relapse-free survival objectives","overall survival objectives","newly diagnosed ALL induction regimens","relapsed/refractory ALL recommendations","key regimens including chemotherapy, imatinib, and blinatumomab","data sources"],"evidence_ids":["ev_71c9ad8ae308","ev_99f68b1f1fcc","ev_a52e9eb48e4e","ev_1703fdf5e463","ev_a2bd9afb5a1b","ev_0e9f346a433d","ev_8f9e286213b4","ev_891d264c0c5b","ev_f5559e5a7017"],"source_ids":["nci","clinicaltrials","ashpublications"],"citations":["National Cancer Institute","National Cancer Institute (NCI)","American Society of Hematology"],"origin":"approved_api","batch_index":0,"round_index":0,"created_at":"2026-09-22T11:37:42.056256Z"},{"id":"ans_0f2da134f2fb","run_id":"run_2058f031b9db","question_id":"q_1a2fac4b0d38","stage":"stage_2","status":"partial","text":"The supplied document is an ASH guideline for relapsed/refractory acute lymphoblastic leukemia (ALL) in adolescents and young adults and discusses treatment recommendations by regimen and disease setting, but it does not provide published benchmarks for time on treatment, time to next treatment, progression-free survival, or related outcomes by line of therapy. The document identifies treatment modalities and regimens including “blinatumomab,” “inotuzumab,” “CAR T-cell therapy,” and “chemotherapy” in relapsed/refractory B-ALL and references remission status such as “second (or greater) remission (CR2).” The document is a guideline evidence review source rather than an outcomes benchmark dataset.","aspects_covered":["line of therapy","key regimens","data source"],"evidence_ids":["ev_a692331b8f0c","ev_180c5c21ede1","ev_83fb787fde0e"],"source_ids":["esmo"],"citations":["Blood advances"],"origin":"approved_api","batch_index":1,"round_index":0,"created_at":"2026-09-22T11:37:49.386632Z"},{"id":"ans_02b1e2cc9bb2","run_id":"run_2058f031b9db","question_id":"q_1a2fac4b0d38","stage":"stage_2","status":"partial","text":"The provided document discusses frontline management recommendations for acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs), including regimen selection and supportive care considerations, but it does not provide published benchmarks for time on treatment, time to next treatment, progression-free survival, or related outcomes by line of therapy and regimen. The document does identify frontline therapy approaches and key regimens, particularly pediatric-inspired asparaginase-containing regimens versus adult-inspired protocols. No quantitative benchmark data sources for treatment duration or survival endpoints are reported in the supplied material.","aspects_covered":["frontline therapy","key regimens","absence of time on treatment benchmarks","absence of time to next treatment benchmarks","absence of progression-free survival benchmarks","data source identified as ASH guideline"],"evidence_ids":["ev_66e4f3d80648","ev_0536c7d5f381","ev_c94a42709031"],"source_ids":["ashpublications"],"citations":["American Society of Hematology"],"origin":"approved_api","batch_index":0,"round_index":2,"created_at":"2026-09-22T11:38:23.750806Z"},{"id":"ans_460c46a9c735","run_id":"run_2058f031b9db","question_id":"q_1a2fac4b0d38","stage":"stage_2","status":"partial","text":"The supplied documents do not provide published benchmarks for “time on treatment,” “time to next treatment,” or “progression-free survival” in acute lymphoblastic leukemia stratified by line of therapy and key regimen. The documents instead discuss overall treatment duration and frontline regimen recommendations. One review states that “Contemporary ALL therapy usually consists of cycles of multiagent chemotherapy administered over 2 to 3 years” and that “ALL therapy typically begins with 5 to 9 months of more-intensive chemotherapy followed by a prolonged low-intensity maintenance phase.” The ASH 2026 guideline document provides frontline treatment recommendations for adolescents and young adults, including that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols,” but it does not report benchmark outcomes such as progression-free survival, time on treatment, or time to next treatment by line of therapy.","aspects_covered":["overall treatment duration in ALL","maintenance therapy duration","frontline therapy recommendations in AYA ALL","absence of published benchmarks for TOT, TTNT, and PFS in supplied documents"],"evidence_ids":["ev_e68c3a57a70a","ev_391bd052fba3","ev_bce7a247cd9d","ev_8af0d24d05d7"],"source_ids":["open_web"],"citations":["Open web"],"origin":"open_web","batch_index":0,"round_index":99,"created_at":"2026-09-22T11:39:18.042975Z"}],"insights":[{"id":"ins_5dcf4aa6d9df","run_id":"run_2058f031b9db","stage":"stage_1","bucket":"A","category":"Clinical","title":"Epidemiology","summary":"Acute lymphocytic leukemia in the United States has SEER estimates of 6,250 new cases and 1,600 deaths in 2026, with 5-year relative survival of 73.2% for 2016–2022. The disease is most frequently diagnosed among people aged less than 20 years, with peak incidence between 2 and 5 years of age.","detail":"","number":1,"card_key":"epidemiology","evidence_type":"metrics","evidence":[{"label":"New US cases per year","value":"6,250"},{"label":"Deaths per year","value":"1,600"},{"label":"Incidence rate","value":"1.9 per 100,000"},{"label":"Mortality rate","value":"0.4 per 100,000"},{"label":"US prevalence","value":"126,118"},{"label":"5-year survival","value":"73.2%"}],"interpretation":"Claims-based ALL cohorts in the United States should expect concentration in pediatric, adolescent, and young adult populations. Survival and prevalence figures indicate a substantial population living with treated disease and potential longitudinal therapy exposure.","review_note":"Verify that all epidemiology metrics consistently refer to acute lymphocytic/leukoblastic leukemia overall rather than pediatric-only subsets.","covered":true,"confidence":"ready","input_reason":"","tag":"INFERENCE","evidence_ids":["ev_4163242615d7","ev_c9706e9f4f7c","ev_5996ab18e475","ev_868dbce5142e","ev_ae2e51c35a5b","ev_ca4a962dac12","ev_338001d3311a","ev_f7fb02fda72b","ev_4ad9686adf8f","ev_66731dfaf256","ev_f627156d82c2","ev_258f61e5a57f","ev_30c09fef4cb4","ev_018c0d99b1c3","ev_dfedeb04e1d0","ev_a90de929ee38","ev_5b596a37cfa7","ev_d657beab5bba","ev_9e42f72ef49a","ev_2e69084f0f32","ev_7d73ce6f2a4e","ev_689eb350b7f2","ev_4c55ced0ef82","ev_939986aec67f","ev_a08dd3413d0e","ev_546f67a67fc0"],"source_ids":["cdc_icd10","orphanet","seer","nci","who_gho","pubmed","ashpublications","open_web"],"question_ids":["q_6f442701d567","q_0207dfec5c74"],"used_web_fallback":true,"review_action":"approved","user_input":"","revision_note":"","reviewer_input":"","reviewer_files":[],"reviewed_at":"2026-09-30T16:08:55.021438Z","impacted_insight_ids":[],"table_titles":["Epidemiology snapshot table"],"created_at":"2026-09-22T11:18:56.740441Z"},{"id":"ins_5e3a07930de0","run_id":"run_2058f031b9db","stage":"stage_1","bucket":"A","category":"Clinical","title":"Patient Population & Segmentation","summary":"The supplied materials support segmentation of ALL cohorts by age group, lineage subtype, Philadelphia chromosome status, relapse/remission state, and response/risk category. B-cell ALL and T-cell ALL are explicitly identified immunophenotypic subtypes, and Philadelphia chromosome-positive ALL is treated as a distinct therapeutic subgroup.","detail":"","number":2,"card_key":"population_segmentation","evidence_type":"table","evidence":{"columns":["Segment","Approximate share","Defining feature"],"rows":[["Children, adolescents, and young adults","Not quantified","Most frequently diagnosed among people aged <20"],["B-cell acute lymphoblastic leukemia (B-ALL)","79.3%","CD19, CD22, cytoplasmic CD79a markers"],["T-cell acute lymphoblastic leukemia (T-ALL)","20.7%","Cytoplasmic CD3 and CD5 markers"],["Philadelphia chromosome-positive ALL","Not provided","Imatinib incorporated into therapy"],["Philadelphia chromosome-like ALL","Not provided","Precursor B-cell ALL chromosomal alteration subtype"],["Relapsed/refractory ALL","Not provided","Greater treatment resistance and higher risk"],["CR2 and greater remission states","Not provided","Second or greater remission referenced"]]},"interpretation":"Lineage subtype, Philadelphia chromosome status, age group, and relapse/remission status are directly relevant cohort-defining forks for claims analyses. The supplied evidence does not provide operational MRD or performance-status segmentation criteria.","review_note":"Check whether the cited B-ALL and T-ALL percentage shares are representative beyond the referenced study population.","covered":true,"confidence":"ready","input_reason":"","tag":"INFERENCE","evidence_ids":["ev_514eaf63445a","ev_fca4129b43c4","ev_26e9b9e77c4f","ev_a732c8f47456","ev_3f9d438a3c1c","ev_8da63899d25d","ev_11c33702e27d","ev_fce1f259bb63","ev_7e9a669b0be5","ev_c854ac12b4f3","ev_d3a229ba9b2b","ev_c59595ca2fc8","ev_3c3b04664610","ev_49a4959cee37","ev_4fe6496bdc42","ev_f4062db24c05","ev_367e1dd3c40f","ev_2a6244027a00","ev_65d7b862056c","ev_1dd338e2d267","ev_93081b84add9","ev_c46ce82dab79","ev_1b40ba955be5","ev_44470bb29387","ev_2b8431ac1378","ev_4f41b06fbab3"],"source_ids":["nci","who","orphanet","ashpublications","pubmed","open_web"],"question_ids":["q_f38fdd338919","q_9df80b42710c"],"used_web_fallback":true,"review_action":"pending","user_input":"","revision_note":"","reviewer_input":"","reviewer_files":[],"reviewed_at":null,"impacted_insight_ids":[],"table_titles":["Subtype / biology breakdown table","Key clinical variables and cohort-defining forks"],"created_at":"2026-09-22T11:18:56.741066Z"},{"id":"ins_86272ce81740","run_id":"run_2058f031b9db","stage":"stage_1","bucket":"A","category":"Clinical","title":"Disease Definition & Taxonomy","summary":"ALL is defined as a group of rare Non-Hodgkin lymphoma characterized by malignant proliferation of lymphoid cells blocked at an early stage of differentiation. The disease primarily affects bone marrow and peripheral blood but can infiltrate any organ or tissue.","detail":"","number":3,"card_key":"disease_definition","evidence_type":"table","evidence":{"columns":["Classification","Category","Note"],"rows":[["Acute lymphoblastic leukemia","Rare Non-Hodgkin lymphoma","Malignant proliferation of lymphoid cells"],["Disease involvement","Bone marrow and peripheral blood","Can infiltrate any organ or tissue"],["B-cell ALL","Immunophenotypic lineage subtype","CD19, CD22, cytoplasmic CD79a markers"],["T-cell ALL","Immunophenotypic lineage subtype","Cytoplasmic CD3 and CD5 markers"],["Philadelphia chromosome-positive ALL","Molecular/cytogenetic subtype","Imatinib incorporated into treatment"],["Philadelphia chromosome-like ALL","Precursor B-cell ALL subtype","Chromosomal alteration subtype"],["Early T-cell precursor ALL","Recognized subtype","Referenced in supplied summary text"]]},"interpretation":"Disease taxonomy for claims-based analyses should preserve lineage subtype and Philadelphia chromosome status because these influence treatment selection. The supplied materials do not provide formal WHO/ICC diagnostic thresholds or comprehensive molecular classification schemas.","review_note":"Confirm whether early T-cell precursor ALL wording reflects a direct source quotation or summary-level characterization.","covered":true,"confidence":"ready","input_reason":"","tag":"INFERENCE","evidence_ids":["ev_c9706e9f4f7c","ev_514eaf63445a","ev_fca4129b43c4","ev_26e9b9e77c4f","ev_a732c8f47456","ev_3f9d438a3c1c","ev_ca4a962dac12","ev_f7fb02fda72b","ev_4ad9686adf8f","ev_66731dfaf256","ev_f627156d82c2","ev_018c0d99b1c3","ev_dfedeb04e1d0","ev_7e9a669b0be5","ev_c854ac12b4f3","ev_d657beab5bba","ev_3c3b04664610","ev_9e42f72ef49a","ev_2e69084f0f32","ev_4fe6496bdc42","ev_f4062db24c05","ev_939986aec67f","ev_2a6244027a00","ev_1dd338e2d267","ev_c46ce82dab79","ev_1b40ba955be5","ev_a08dd3413d0e","ev_546f67a67fc0"],"source_ids":["orphanet","nci","who","seer","pubmed","ashpublications","open_web"],"question_ids":["q_6f442701d567","q_f38fdd338919"],"used_web_fallback":true,"review_action":"pending","user_input":"","revision_note":"","reviewer_input":"","reviewer_files":[],"reviewed_at":null,"impacted_insight_ids":[],"table_titles":["Subtype / biology breakdown table"],"created_at":"2026-09-22T11:18:56.741905Z"},{"id":"ins_16059806cedd","run_id":"run_2058f031b9db","stage":"stage_1","bucket":"A","category":"Clinical","title":"Diagnostic Foundation","summary":"The supplied materials describe diagnosis around clinical presentation, marrow and blood involvement, immunophenotypic lineage assignment, and cytogenetic or molecular subtype evaluation including Philadelphia chromosome status.","detail":"","number":4,"card_key":"diagnostic_foundation","evidence_type":"steps","evidence":["Assess presenting symptoms","Evaluate marrow and blood involvement","Assess extranodal tissue infiltration","Perform immunophenotyping","Identify B-cell lineage markers","Identify T-cell lineage markers","Evaluate cytogenetic or molecular subtype","Determine Philadelphia chromosome status"],"interpretation":"Claims-based diagnostic identification can leverage lineage markers, disease site involvement, and Philadelphia chromosome-associated treatment patterns. The supplied evidence does not define formal blast thresholds, CNS workup standards, or MRD criteria.","review_note":"Specific diagnostic assay methods and thresholds were not supplied and may require expert supplementation.","covered":true,"confidence":"ready","input_reason":"","tag":"INFERENCE","evidence_ids":["ev_fe52db01cd48","ev_8339986034b7","ev_175ccc0c54c4","ev_74a8e7cba6cf","ev_686c318142e4","ev_73f85a9b1648","ev_d0cbf82b6047","ev_77090229ca10","ev_912a955c92f0","ev_ab066abf322c","ev_c355e539ab79"],"source_ids":["orphanet","nci","ashpublications","open_web"],"question_ids":["q_0b2efc095c4f"],"used_web_fallback":true,"review_action":"pending","user_input":"","revision_note":"","reviewer_input":"","reviewer_files":[],"reviewed_at":null,"impacted_insight_ids":[],"table_titles":["Diagnostic workup table"],"created_at":"2026-09-22T11:18:56.742096Z"},{"id":"ins_9d1489b30c05","run_id":"run_2058f031b9db","stage":"stage_1","bucket":"A","category":"Clinical","title":"Natural History & Disease Journey","summary":"The supplied materials describe ALL progression from presentation and diagnosis through subtype classification, treatment stratification, remission states, and relapsed or refractory disease.","detail":"","number":5,"card_key":"disease_journey","evidence_type":"steps","evidence":["Present with systemic symptoms","Diagnose marrow or blood disease","Classify lineage subtype","Assess Philadelphia chromosome status","Select risk-adapted therapy","Achieve remission state","Monitor for relapse","Treat relapsed or refractory disease"],"interpretation":"Disease course and line-of-therapy analyses should account for remission transitions and relapsed or refractory states, especially across lineage and Philadelphia chromosome-defined subgroups. Age setting differences between pediatric and adult care may also affect treatment sequencing.","review_note":"The supplied materials reference CR2 and greater remission states without operational timing definitions.","covered":true,"confidence":"ready","input_reason":"","tag":"INFERENCE","evidence_ids":["ev_c9706e9f4f7c","ev_ca4a962dac12","ev_8da63899d25d","ev_f7fb02fda72b","ev_4ad9686adf8f","ev_66731dfaf256","ev_f627156d82c2","ev_11c33702e27d","ev_018c0d99b1c3","ev_dfedeb04e1d0","ev_fce1f259bb63","ev_d3a229ba9b2b","ev_d657beab5bba","ev_c59595ca2fc8","ev_9e42f72ef49a","ev_2e69084f0f32","ev_49a4959cee37","ev_367e1dd3c40f","ev_939986aec67f","ev_65d7b862056c","ev_93081b84add9","ev_a08dd3413d0e","ev_546f67a67fc0","ev_44470bb29387","ev_2b8431ac1378","ev_4f41b06fbab3"],"source_ids":["orphanet","nci","seer","pubmed","ashpublications","open_web"],"question_ids":["q_6f442701d567","q_9df80b42710c"],"used_web_fallback":true,"review_action":"pending","user_input":"","revision_note":"","reviewer_input":"","reviewer_files":[],"reviewed_at":null,"impacted_insight_ids":[],"table_titles":["Key clinical variables and cohort-defining forks"],"created_at":"2026-09-22T11:18:56.744757Z"},{"id":"ins_95e56c028b14","run_id":"run_2058f031b9db","stage":"stage_2","bucket":"C","category":"Treatment","title":"Treatment Landscape","summary":"The supplied documents do not provide a comprehensive list of United States first-line treatment regimens for acute lymphoblastic leukemia across induction, consolidation, maintenance, and MRD-positive settings stratified by guideline preference categories. The documents do identify some guideline or cooperative-group treatment approaches and disease subsets. An ASCO Educational Book review states that “Contemporary COG HR ALL treatment regimens were developed from the BFM-76 regimen, with subse","detail":"","number":6,"card_key":"treatment_landscape","evidence_type":"table","evidence":{"columns":["Agent","Class or MOA","Status: approved / compendia-supported / off-label","Approved line","Biomarker restriction","Approval date","Primary code"],"rows":[["FDA grants accelerated approval to ponatinib with chemotherapy for ...","[VERIFIED] Chemotherapy consisted of 3 cycles of induction with vincristine and dexamethasone, 6 cycles of consolidation alternating between methotrexate and cytarabine, and 11 cycles of maintenance with vincristine and prednisone.","[VERIFIED] Chemotherapy consisted of 3 cycles of induction with vincristine and dexamethasone, 6 cycles of consolidation alternating between methotrexate and cytarabine, and 11 cycles of maintenance with vincristine and prednisone.","[VERIFIED] Chemotherapy consisted of 3 cycles of induction with vincristine and dexamethasone, 6 cycles of consolidation alternating between methotrexate and cytarabine, and 11 cycles of maintenance with vincristine and prednisone.","[VERIFIED] Chemotherapy consisted of 3 cycles of induction with vincristine and dexamethasone, 6 cycles of consolidation alternating between methotrexate and cytarabine, and 11 cycles of maintenance with vincristine and prednisone.","[VERIFIED] Chemotherapy consisted of 3 cycles of induction with vincristine and dexamethasone, 6 cycles of consolidation alternating between methotrexate and cytarabine, and 11 cycles of maintenance with vincristine and prednisone.","[Source: FDA]"],["Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice…","[VERIFIED] This selection from the NCCN Guidelines for ALL focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence.","[VERIFIED] This selection from the NCCN Guidelines for ALL focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence.","[VERIFIED] This selection from the NCCN Guidelines for ALL focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence.","[VERIFIED] This selection from the NCCN Guidelines for ALL focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence.","[VERIFIED] This selection from the NCCN Guidelines for ALL focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence.","[Source: Journal of the National Comprehensive Cancer Network : JNCCN]"],["NELARABINE (NELARABINE)","[VERIFIED] Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following…","[VERIFIED] Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following…","[VERIFIED] Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following…","[VERIFIED] Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following…","[VERIFIED] Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following…","[Source: Alembic Pharmaceuticals Limited]"],["[Choice of bridging therapy prior to reinjection of autologous CAR-T…","[VERIFIED] Consequently, there is currently no available guidelines.","[VERIFIED] Consequently, there is currently no available guidelines.","[VERIFIED] Consequently, there is currently no available guidelines.","[VERIFIED] Consequently, there is currently no available guidelines.","[VERIFIED] Consequently, there is currently no available guidelines.","[Source: Bulletin du cancer]"],["Clofarabine (CLOFARABINE)","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[Source: Amneal Pharmaceuticals LLC]"]]},"interpretation":"","review_note":"","covered":true,"confidence":"ready","input_reason":"No source returned usable evidence. Add what you know, or tell Celestra where to look.","tag":"INFERENCE","evidence_ids":["ev_d6702a8c8417","ev_518d2567f527","ev_3177e0973b83","ev_2ff754c9884d","ev_1f18856240c5","ev_0efeb2d33090","ev_23da31bd88f0","ev_02ebd2416f56","ev_d407566fa413","ev_a6db9cc6bed1","ev_5ea773907865","ev_ea0ed12f8542","ev_6145072e79ae","ev_9fbedc6025ea","ev_49c6e81c290d","ev_d31182c7cd43","ev_913f6ac14044","ev_2ef71da17f30","ev_cd0d12f0029b","ev_fe787f4f9539","ev_2de3a2b8b37d","ev_f1faee6d75b3","ev_1153f96a4bd5","ev_fefba3481bed","ev_a52e9eb48e4e","ev_0efaaf99b916","ev_deff95ec2cfd","ev_ec973034d54a","ev_76163c9f247f","ev_c3dd8f795d7b","ev_b7d392b7cec0","ev_1bf20950643c","ev_8e12075ab437","ev_b5172d83504a","ev_516351eb23f5","ev_63cb61d6aaae","ev_9182343de04d","ev_c324073e53df","ev_83fb787fde0e","ev_d514be8bfecf","ev_71c9ad8ae308","ev_bc278a23e777","ev_71987d46f280","ev_a692331b8f0c","ev_f27500842f2c","ev_6ca5bc1954c3","ev_99f68b1f1fcc","ev_93b30cbe8295","ev_180c5c21ede1","ev_c92815eda10c","ev_1846adef13fd","ev_d1408c361bbe","ev_df7e8b4455c2","ev_6a2fc993513b","ev_8ed3c32d2fb3","ev_556436b02457","ev_c5bca0d585a6","ev_c620fdd21783","ev_7787a43e64f8","ev_5bbae4108cd9","ev_f7fabb14591a","ev_6c988844eb71","ev_9dff9e1b8b01","ev_0fae3159251d","ev_b0f7342e7e44","ev_6737f3e1b95a","ev_342f90e51548","ev_784b1c070de9","ev_fbe4c741d329","ev_4531684dd1a7","ev_85b69c7d95f1","ev_2c9248174500","ev_1f4c71a7e815","ev_1f184e56211f","ev_951871bbb7ce","ev_f9db53789436","ev_b80c7d1d38ae","ev_0243c39a7be7","ev_54e1fcbbe2be","ev_9a1472ce6a59","ev_1f156e37d788","ev_72885d7b6299","ev_d6b3daf47ce5","ev_cf6ec1622ef0","ev_400b61e0ce87","ev_66e4f3d80648","ev_5850d777aa9a","ev_ad6c4f26f9b0","ev_0536c7d5f381","ev_74834422de95","ev_a2bd9afb5a1b","ev_b4843d9ecda3","ev_3020062e8499","ev_fda538891bc6","ev_1703fdf5e463","ev_4c56f3992709","ev_1e61c95d0f76","ev_04afdf650765","ev_0b22c0ee4bb9","ev_9252fe2e2a48","ev_29faee036ecb","ev_2af9506a4cbf","ev_6bc1dcf4a899","ev_c3c0e67a1c26","ev_3362d9309218","ev_6592850d6958","ev_2970a59c13db","ev_1148904526a3","ev_cb511a6e4a1b","ev_e68c3a57a70a","ev_391bd052fba3","ev_92acc73fe391","ev_65037a0ca4f4","ev_7f44713567b2","ev_0c2a3ecb9148","ev_706564f3720a","ev_0fbbff4885d1"],"source_ids":["fda","esmo","openfda_label","nci","openfda_drugsfda","clinicaltrials","asco","ashpublications","open_web"],"question_ids":["q_bf36e105dc68","q_a687f9ed49c6","q_2bee5da1afa0","q_bf22d864f4bc","q_7ca3756217b1","q_b5cd05555f81","q_7e8639e73505","q_fd97687cf608","q_1a2fac4b0d38","q_e71eae3bd237"],"used_web_fallback":true,"review_action":"approved","user_input":"","revision_note":"","reviewer_input":"","reviewer_files":[],"reviewed_at":"2026-09-30T10:42:41.364424Z","impacted_insight_ids":[],"table_titles":["Drug and biologic inventory"],"created_at":"2026-09-22T11:59:47.123415Z"},{"id":"ins_2ab61d2ff343","run_id":"run_2058f031b9db","stage":"stage_2","bucket":"C","category":"Treatment","title":"Guideline / Standard of Care","summary":"The supplied documents discuss recommendations for relapsed/refractory acute lymphoblastic leukemia (ALL), including immunotherapy, targeted therapy, transplantation, and CNS-directed therapy, but they do not provide a complete regimen-by-regimen listing organized by treatment setting, line of therapy, and guideline preference category for all patients in the United States as of 2026-09-22. The ASH 2026 guideline for adolescents and young adults (AYAs) states that recommendations \"focused on the","detail":"","number":7,"card_key":"standard_of_care","evidence_type":"table","evidence":{"columns":["Body","Guideline","Current version"],"rows":[["FDA grants accelerated approval to ponatinib with chemotherapy for ...","[VERIFIED] Chemotherapy consisted of 3 cycles of induction with vincristine and dexamethasone, 6 cycles of consolidation alternating between methotrexate and cytarabine, and 11 cycles of maintenance with vincristine and prednisone.","[Source: FDA]"],["Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice…","[VERIFIED] This selection from the NCCN Guidelines for ALL focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence.","[Source: Journal of the National Comprehensive Cancer Network : JNCCN]"],["NELARABINE (NELARABINE)","[VERIFIED] Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following…","[Source: Alembic Pharmaceuticals Limited]"],["[Choice of bridging therapy prior to reinjection of autologous CAR-T…","[VERIFIED] Consequently, there is currently no available guidelines.","[Source: Bulletin du cancer]"],["Clofarabine (CLOFARABINE)","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[Source: Amneal Pharmaceuticals LLC]"]]},"interpretation":"","review_note":"","covered":true,"confidence":"ready","input_reason":"","tag":"INFERENCE","evidence_ids":["ev_d6702a8c8417","ev_518d2567f527","ev_3177e0973b83","ev_2ff754c9884d","ev_1f18856240c5","ev_02ebd2416f56","ev_d407566fa413","ev_9fbedc6025ea","ev_49c6e81c290d","ev_d31182c7cd43","ev_913f6ac14044","ev_2ef71da17f30","ev_cd0d12f0029b","ev_1153f96a4bd5","ev_0efaaf99b916","ev_76163c9f247f","ev_1bf20950643c","ev_8e12075ab437","ev_9182343de04d","ev_bc278a23e777","ev_f27500842f2c","ev_c5bca0d585a6","ev_7787a43e64f8","ev_5bbae4108cd9","ev_f7fabb14591a","ev_0fae3159251d","ev_b0f7342e7e44","ev_784b1c070de9","ev_4531684dd1a7","ev_85b69c7d95f1","ev_2c9248174500","ev_1f4c71a7e815","ev_1f184e56211f","ev_b80c7d1d38ae","ev_0243c39a7be7","ev_54e1fcbbe2be","ev_1f156e37d788","ev_ad6c4f26f9b0","ev_b4843d9ecda3","ev_fda538891bc6","ev_1e61c95d0f76","ev_04afdf650765","ev_9252fe2e2a48","ev_29faee036ecb","ev_2af9506a4cbf","ev_6bc1dcf4a899","ev_c3c0e67a1c26","ev_3362d9309218","ev_cb511a6e4a1b","ev_92acc73fe391","ev_7f44713567b2","ev_0fbbff4885d1"],"source_ids":["fda","esmo","openfda_label","nci","clinicaltrials","asco","ashpublications","open_web"],"question_ids":["q_bf36e105dc68","q_a687f9ed49c6","q_bf22d864f4bc","q_fd97687cf608"],"used_web_fallback":true,"review_action":"pending","user_input":"","revision_note":"","reviewer_input":"","reviewer_files":[],"reviewed_at":null,"impacted_insight_ids":[],"table_titles":["Guideline bodies and current versions table","Guideline change log"],"created_at":"2026-09-22T11:59:47.140677Z"},{"id":"ins_b27725e4628d","run_id":"run_2058f031b9db","stage":"stage_2","bucket":"C","category":"Treatment","title":"Approved Therapy & Label Intelligence","summary":"The supplied documents identify three FDA-approved drug products for acute lymphoblastic leukemia (ALL): clofarabine, imatinib mesylate, and dasatinib. Clofarabine injection is indicated for “pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens,” with “Initial U.S. Approval: 2004.” Imatinib mesylate is indicated for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (","detail":"","number":8,"card_key":"approved_therapy","evidence_type":"table","evidence":{"columns":["Setting","Intent","Guideline-preferred regimens"],"rows":[["FDA grants accelerated approval to ponatinib with chemotherapy for ...","[VERIFIED] Chemotherapy consisted of 3 cycles of induction with vincristine and dexamethasone, 6 cycles of consolidation alternating between methotrexate and cytarabine, and 11 cycles of maintenance with vincristine and prednisone.","[Source: FDA]"],["Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice…","[VERIFIED] This selection from the NCCN Guidelines for ALL focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence.","[Source: Journal of the National Comprehensive Cancer Network : JNCCN]"],["NELARABINE (NELARABINE)","[VERIFIED] Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following…","[Source: Alembic Pharmaceuticals Limited]"],["[Choice of bridging therapy prior to reinjection of autologous CAR-T…","[VERIFIED] Consequently, there is currently no available guidelines.","[Source: Bulletin du cancer]"],["Clofarabine (CLOFARABINE)","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[Source: Amneal Pharmaceuticals LLC]"]]},"interpretation":"","review_note":"","covered":true,"confidence":"ready","input_reason":"","tag":"INFERENCE","evidence_ids":["ev_0efeb2d33090","ev_23da31bd88f0","ev_a6db9cc6bed1","ev_5ea773907865","ev_ea0ed12f8542","ev_6145072e79ae","ev_fe787f4f9539","ev_2de3a2b8b37d","ev_f1faee6d75b3","ev_fefba3481bed","ev_deff95ec2cfd","ev_ec973034d54a","ev_c3dd8f795d7b","ev_b7d392b7cec0","ev_b5172d83504a","ev_516351eb23f5","ev_63cb61d6aaae","ev_c324073e53df","ev_d514be8bfecf","ev_71987d46f280","ev_6ca5bc1954c3","ev_93b30cbe8295","ev_c92815eda10c","ev_1846adef13fd","ev_d1408c361bbe","ev_df7e8b4455c2","ev_6a2fc993513b","ev_8ed3c32d2fb3","ev_556436b02457","ev_c620fdd21783","ev_6c988844eb71","ev_9dff9e1b8b01","ev_6737f3e1b95a","ev_342f90e51548","ev_951871bbb7ce","ev_9a1472ce6a59","ev_72885d7b6299","ev_d6b3daf47ce5","ev_cf6ec1622ef0","ev_400b61e0ce87","ev_5850d777aa9a","ev_74834422de95","ev_3020062e8499","ev_4c56f3992709","ev_0b22c0ee4bb9","ev_6592850d6958","ev_2970a59c13db","ev_1148904526a3","ev_65037a0ca4f4","ev_0c2a3ecb9148","ev_706564f3720a"],"source_ids":["openfda_label","esmo","nci","openfda_drugsfda","ashpublications","clinicaltrials","asco","open_web"],"question_ids":["q_2bee5da1afa0","q_7ca3756217b1","q_b5cd05555f81","q_7e8639e73505"],"used_web_fallback":true,"review_action":"pending","user_input":"","revision_note":"","reviewer_input":"","reviewer_files":[],"reviewed_at":null,"impacted_insight_ids":[],"table_titles":["Drug and biologic inventory"],"created_at":"2026-09-22T11:59:47.156204Z"},{"id":"ins_43b8afcc6e36","run_id":"run_2058f031b9db","stage":"stage_2","bucket":"C","category":"Synthesis","title":"Key Clinical & Treatment Insights","summary":"The discovery phase established 8 findings across 2 stage report(s); the points below should inform downstream modelling.","detail":"","number":9,"card_key":"key_clinical_treatment_insights","evidence_type":"list","evidence":["[VERIFIED] ALL is described as a rare lymphoid malignancy affecting marrow and blood with potential infiltration into any organ or tissue. [Source: Orphanet]","[VERIFIED] The disease burden is concentrated in children, adolescents, and young adults, with diagnoses most frequent in patients younger than 20 years. [Source: National Cancer Institute, Surveillan","[VERIFIED] U.S. SEER estimates include 6,250 projected new cases and 1,600 projected deaths in 2026. [Source: National Cancer Institute, Surveillance, Epidemiology, and End Results Program]","The supplied documents do not provide a comprehensive list of United States first-line treatment regimens for acute lymphoblastic leukemia across induction, consolidation, maintenance, and MRD-positiv","The supplied documents discuss recommendations for relapsed/refractory acute lymphoblastic leukemia (ALL), including immunotherapy, targeted therapy, transplantation, and CNS-directed therapy, but the","The supplied documents identify three FDA-approved drug products for acute lymphoblastic leukemia (ALL): clofarabine, imatinib mesylate, and dasatinib. Clofarabine injection is indicated for “pediatri"],"interpretation":"","review_note":"","covered":true,"confidence":"ready","input_reason":"","tag":"INFERENCE","evidence_ids":["ev_4163242615d7","ev_c9706e9f4f7c","ev_5996ab18e475","ev_868dbce5142e","ev_ae2e51c35a5b","ev_ca4a962dac12","ev_338001d3311a","ev_f7fb02fda72b","ev_4ad9686adf8f","ev_66731dfaf256","ev_f627156d82c2","ev_258f61e5a57f","ev_30c09fef4cb4","ev_018c0d99b1c3","ev_dfedeb04e1d0","ev_a90de929ee38","ev_5b596a37cfa7","ev_d657beab5bba","ev_9e42f72ef49a","ev_2e69084f0f32","ev_7d73ce6f2a4e","ev_689eb350b7f2","ev_4c55ced0ef82","ev_939986aec67f","ev_a08dd3413d0e","ev_546f67a67fc0","ev_514eaf63445a","ev_fca4129b43c4","ev_26e9b9e77c4f","ev_a732c8f47456","ev_3f9d438a3c1c","ev_8da63899d25d","ev_11c33702e27d","ev_fce1f259bb63","ev_7e9a669b0be5","ev_c854ac12b4f3","ev_d3a229ba9b2b","ev_c59595ca2fc8","ev_3c3b04664610","ev_49a4959cee37","ev_4fe6496bdc42","ev_f4062db24c05","ev_367e1dd3c40f","ev_2a6244027a00","ev_65d7b862056c","ev_1dd338e2d267","ev_93081b84add9","ev_c46ce82dab79","ev_1b40ba955be5","ev_44470bb29387","ev_2b8431ac1378","ev_4f41b06fbab3","ev_c9706e9f4f7c","ev_514eaf63445a","ev_fca4129b43c4","ev_26e9b9e77c4f","ev_a732c8f47456","ev_3f9d438a3c1c","ev_ca4a962dac12","ev_f7fb02fda72b","ev_4ad9686adf8f","ev_66731dfaf256","ev_f627156d82c2","ev_018c0d99b1c3","ev_dfedeb04e1d0","ev_7e9a669b0be5","ev_c854ac12b4f3","ev_d657beab5bba","ev_3c3b04664610","ev_9e42f72ef49a","ev_2e69084f0f32","ev_4fe6496bdc42","ev_f4062db24c05","ev_939986aec67f","ev_2a6244027a00","ev_1dd338e2d267","ev_c46ce82dab79","ev_1b40ba955be5","ev_a08dd3413d0e","ev_546f67a67fc0","ev_fe52db01cd48","ev_8339986034b7","ev_175ccc0c54c4","ev_74a8e7cba6cf","ev_686c318142e4","ev_73f85a9b1648","ev_d0cbf82b6047","ev_77090229ca10","ev_912a955c92f0","ev_ab066abf322c","ev_c355e539ab79","ev_c9706e9f4f7c","ev_ca4a962dac12","ev_8da63899d25d","ev_f7fb02fda72b","ev_4ad9686adf8f","ev_66731dfaf256","ev_f627156d82c2","ev_11c33702e27d","ev_018c0d99b1c3","ev_dfedeb04e1d0","ev_fce1f259bb63","ev_d3a229ba9b2b","ev_d657beab5bba","ev_c59595ca2fc8","ev_9e42f72ef49a","ev_2e69084f0f32","ev_49a4959cee37","ev_367e1dd3c40f","ev_939986aec67f","ev_65d7b862056c","ev_93081b84add9","ev_a08dd3413d0e","ev_546f67a67fc0","ev_44470bb29387","ev_2b8431ac1378","ev_4f41b06fbab3","ev_d6702a8c8417","ev_518d2567f527","ev_3177e0973b83","ev_2ff754c9884d","ev_1f18856240c5","ev_0efeb2d33090","ev_23da31bd88f0","ev_02ebd2416f56","ev_d407566fa413","ev_a6db9cc6bed1","ev_5ea773907865","ev_ea0ed12f8542","ev_6145072e79ae","ev_9fbedc6025ea","ev_49c6e81c290d","ev_d31182c7cd43","ev_913f6ac14044","ev_2ef71da17f30","ev_cd0d12f0029b","ev_fe787f4f9539","ev_2de3a2b8b37d","ev_f1faee6d75b3","ev_1153f96a4bd5","ev_fefba3481bed","ev_a52e9eb48e4e","ev_0efaaf99b916","ev_deff95ec2cfd","ev_ec973034d54a","ev_76163c9f247f","ev_c3dd8f795d7b","ev_b7d392b7cec0","ev_1bf20950643c","ev_8e12075ab437","ev_b5172d83504a","ev_516351eb23f5","ev_63cb61d6aaae","ev_9182343de04d","ev_c324073e53df","ev_83fb787fde0e","ev_d514be8bfecf","ev_71c9ad8ae308","ev_bc278a23e777","ev_71987d46f280","ev_a692331b8f0c","ev_f27500842f2c","ev_6ca5bc1954c3","ev_99f68b1f1fcc","ev_93b30cbe8295","ev_180c5c21ede1","ev_c92815eda10c","ev_1846adef13fd","ev_d1408c361bbe","ev_df7e8b4455c2","ev_6a2fc993513b","ev_8ed3c32d2fb3","ev_556436b02457","ev_c5bca0d585a6","ev_c620fdd21783","ev_7787a43e64f8","ev_5bbae4108cd9","ev_f7fabb14591a","ev_6c988844eb71","ev_9dff9e1b8b01","ev_0fae3159251d","ev_b0f7342e7e44","ev_6737f3e1b95a","ev_342f90e51548","ev_784b1c070de9","ev_fbe4c741d329","ev_4531684dd1a7","ev_85b69c7d95f1","ev_2c9248174500","ev_1f4c71a7e815","ev_1f184e56211f","ev_951871bbb7ce","ev_f9db53789436","ev_b80c7d1d38ae","ev_0243c39a7be7","ev_54e1fcbbe2be","ev_9a1472ce6a59","ev_1f156e37d788","ev_72885d7b6299","ev_d6b3daf47ce5"],"source_ids":["cdc_icd10","orphanet","seer","nci","who_gho","pubmed","ashpublications","open_web","who","fda","esmo","openfda_label","openfda_drugsfda","clinicaltrials","asco"],"question_ids":["q_6f442701d567","q_0207dfec5c74","q_f38fdd338919","q_9df80b42710c","q_6f442701d567","q_f38fdd338919","q_0b2efc095c4f","q_6f442701d567","q_9df80b42710c","q_bf36e105dc68","q_a687f9ed49c6","q_2bee5da1afa0","q_bf22d864f4bc","q_7ca3756217b1","q_b5cd05555f81","q_7e8639e73505","q_fd97687cf608","q_1a2fac4b0d38","q_e71eae3bd237","q_bf36e105dc68","q_a687f9ed49c6","q_bf22d864f4bc","q_fd97687cf608","q_2bee5da1afa0","q_7ca3756217b1","q_b5cd05555f81","q_7e8639e73505"],"used_web_fallback":false,"review_action":"pending","user_input":"","revision_note":"","reviewer_input":"","reviewer_files":[],"reviewed_at":null,"impacted_insight_ids":[],"table_titles":[],"created_at":"2026-09-22T11:59:47.829821Z"}],"contradictions":[],"stage_reports":[{"id":"stg_7311699caffe","run_id":"run_2058f031b9db","stage":"stage_1","bucket":"A","name":"Disease & Diagnostic Foundation","core_question":"Who gets the disease and how is it diagnosed?","agent_name":"Clinical Landscape Agent","framework_steps":["Disease definition and natural history","Epidemiology, incidence, prevalence, mortality","Subtype and molecular/cytogenetic classification","Diagnostic criteria and confirmatory workup","Risk stratification and the patient characteristics that drive cohort segmentation and treatment eligibility (age, comorbidity, performance status, organ function)"],"step_numbers":[1,2],"substeps":{"2A":"Diagnostic criteria and confirmatory-workup research","2B":"Align diagnostic criteria with disease taxonomy, subtypes, stages and population"},"gate":"Reconciliation gate — diagnostic definitions aligned with disease taxonomy and population","output_name":"DiseaseDiagnosisProfile","what_happens":"This stage establishes the foundational disease definition, epidemiology, subtype framework, diagnostic context, and cohort-segmenting clinical variables for acute lymphoblastic leukemia (ALL) in the United States through 2026. The supplied evidence supports characterization of ALL as a rare lymphoid malignancy affecting marrow, blood, and potentially extranodal tissues, with important distinctions by age group, lineage subtype, and Philadelphia chromosome status. The stage also identifies which diagnostic and biologic elements are directly evidenced versus incompletely described in the supplied materials for claims-based cohort construction.","expected_output":["Epidemiology snapshot table (Metric | Value | Stage or subtype | Source)","Subtype / biology breakdown table (Subtype | Approximate share | Notes)","Diagnostic criteria summary (classification, immunophenotype, cytogenetics, molecular, staging)","Diagnostic workup table","Key clinical variables and cohort-defining forks (age, comorbidity, performance status, organ function)","Key takeaways"],"synthesis":"[VERIFIED] Acute lymphoblastic leukemia (ALL) is defined as \"a group of rare Non-Hodgkin lymphoma characterized by malignant proliferation of lymphoid cells blocked at an early stage of differentiation,\" and the disease \"primarily affects the bone marrow and peripheral blood\" although \"the abnormal cells can infiltrate any organ or tissue.\" [VERIFIED] Patients may present with \"lymphadenopathy, hepatosplenomegaly, bone pain, fever and signs of hemorrhage\" or may remain asymptomatic. [VERIFIED] U.S. epidemiology sources state that acute lymphocytic leukemia is \"most common in children, adolescents, and young adults\" and \"most frequently diagnosed among people aged <20,\" with peak incidence reported between 2 and 5 years of age. [VERIFIED] SEER estimates for the United States include \"Estimated New Cases in 2026: 6,250,\" \"Estimated Deaths in 2026: 1,600,\" a \"5-Year Relative Survival: 73.2% (2016–2022),\" and \"an estimated 126,118 people living with acute lymphocytic leukemia in the United States\" in 2023. [VERIFIED] Immunophenotypic lineage categories identified in the supplied documents include B-cell ALL and T-cell ALL, with B-ALL associated with \"pan B-cell markers (CD19,CD22 and cytoplasmic CD79a)\" and T-ALL associated with \"cytoplasmic CD3 and CD5.\" [VERIFIED] Philadelphia chromosome–positive ALL is specifically identified as a clinically important subtype because \"Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL.\" [VERIFIED] Adolescents and young adults are described as \"a unique population\" in whom \"Treatment regimens can vary significantly depending on whether they receive care in a pediatric or in an adult setting.\" [INFERENCE] The supplied evidence supports age group, lineage subtype, relapse status, and Philadelphia chromosome status as clinically relevant cohort-defining forks for claims-based analyses, but detailed formal diagnostic criteria, MRD definitions, and comprehensive cytogenetic classification schemas were not provided in the supplied materials.","narratives":[{"heading":"Diagnostic criteria summary","body":"[VERIFIED] The supplied materials define ALL as \"a group of rare Non-Hodgkin lymphoma characterized by malignant proliferation of lymphoid cells blocked at an early stage of differentiation.\" [VERIFIED] Disease involvement primarily includes bone marrow and peripheral blood, although leukemic cells \"can infiltrate any organ or tissue.\" [VERIFIED] Immunophenotypic lineage assignment is described through B-cell and T-cell categories, with B-ALL characterized by markers including CD19, CD22, and cytoplasmic CD79a, while T-ALL is associated with cytoplasmic CD3 and CD5. [VERIFIED] The supplied materials identify Philadelphia chromosome-positive ALL as a clinically important molecular/cytogenetic subtype because imatinib is incorporated into treatment for this subgroup. [VERIFIED] NCCN guidance referenced in the supplied evidence notes classification using immunophenotype and cytogenetic/molecular markers together with risk assessment and stratification for therapy selection. [NOT VERIFIED] Specific WHO/ICC blast thresholds, bone marrow diagnostic criteria, molecular assay standards, CNS staging methods, and formal staging systems were not provided in the supplied materials."},{"heading":"Key takeaways","body":"1. [VERIFIED] ALL is primarily a pediatric and young adult malignancy, with disease most frequently diagnosed among people aged less than 20 years and peak incidence between ages 2 and 5. [Source: National Cancer Institute, Surveillance, Epidemiology, and End Results Program; Orphanet]\n2. [VERIFIED] U.S. SEER estimates project 6,250 new cases and 1,600 deaths from acute lymphocytic leukemia in 2026, with 5-year relative survival reported at 73.2% for 2016–2022. [Source: National Cancer Institute, Surveillance, Epidemiology, and End Results Program]\n3. [VERIFIED] B-cell and T-cell ALL are clinically relevant immunophenotypic categories supported by lineage marker data from flow cytometry-related evidence. [Source: WHO]\n4. [VERIFIED] Philadelphia chromosome-positive ALL is an explicitly distinct treatment subgroup because imatinib is incorporated into therapy for this population. [Source: National Cancer Institute]\n5. [INFERENCE] Claims-based cohort construction can directly leverage age group, lineage subtype, Philadelphia chromosome status, and relapse/remission state where observable coding or treatment signals exist, but the supplied evidence does not provide validated MRD, performance status, or organ function definitions. [Source: Derived from supplied evidence]"}],"tables":[{"title":"Epidemiology snapshot table","columns":["Metric","Value","Stage or subtype","Source"],"rows":[["[VERIFIED] Estimated new cases in 2026","[VERIFIED] 6,250","[VERIFIED] Acute lymphocytic leukemia overall","[VERIFIED] National Cancer Institute, Surveillance, Epidemiology, and End Results Program [Source: National Cancer Institute, Surveillance, Epidemiology, and End Results Program]"],["[VERIFIED] Estimated deaths in 2026","[VERIFIED] 1,600","[VERIFIED] Acute lymphocytic leukemia overall","[VERIFIED] National Cancer Institute, Surveillance, Epidemiology, and End Results Program [Source: National Cancer Institute, Surveillance, Epidemiology, and End Results Program]"],["[VERIFIED] Rate of new cases","[VERIFIED] 1.9 per 100,000 men and women per year","[VERIFIED] Acute lymphocytic leukemia overall","[VERIFIED] National Cancer Institute, Surveillance, Epidemiology, and End Results Program [Source: National Cancer Institute, Surveillance, Epidemiology, and End Results Program]"],["[VERIFIED] Death rate","[VERIFIED] 0.4 per 100,000 men and women per year","[VERIFIED] Acute lymphocytic leukemia overall","[VERIFIED] National Cancer Institute, Surveillance, Epidemiology, and End Results Program [Source: National Cancer Institute, Surveillance, Epidemiology, and End Results Program]"],["[VERIFIED] Estimated prevalence in 2023","[VERIFIED] 126,118 people living with acute lymphocytic leukemia in the United States","[VERIFIED] Acute lymphocytic leukemia overall","[VERIFIED] National Cancer Institute, Surveillance, Epidemiology, and End Results Program [Source: National Cancer Institute, Surveillance, Epidemiology, and End Results Program]"],["[VERIFIED] 5-year relative survival","[VERIFIED] 73.2% (2016–2022)","[VERIFIED] Acute lymphocytic leukemia overall","[VERIFIED] National Cancer Institute, Surveillance, Epidemiology, and End Results Program [Source: National Cancer Institute, Surveillance, Epidemiology, and End Results Program]"],["[VERIFIED] Pediatric ALL incidence during 2001–2014","[VERIFIED] 34.0 cases per 1 million persons","[VERIFIED] Pediatric ALL","[VERIFIED] CDC / NCHS [Source: CDC / NCHS]"],["[VERIFIED] Highest pediatric incidence racial/ethnic group","[VERIFIED] Hispanics: 42.9 per 1 million","[VERIFIED] Pediatric ALL","[VERIFIED] CDC / NCHS [Source: CDC / NCHS]"],["[VERIFIED] Peak incidence age","[VERIFIED] Between 2 and 5 years of age","[VERIFIED] ALL overall","[VERIFIED] Orphanet [Source: Orphanet]"]],"footnote":"[VERIFIED] The supplied materials do not provide U.S. subtype-specific incidence, prevalence, survival, or mortality estimates for B-ALL, T-ALL, or Philadelphia chromosome-positive ALL.","question_ids":["q_0207dfec5c74"]},{"title":"Subtype / biology breakdown table","columns":["Subtype","Approximate share","Notes"],"rows":[["[VERIFIED] B-cell acute lymphoblastic leukemia (B-ALL)","[VERIFIED] 79.3% of acute lymphoblastic leukemia cases in cited study","[VERIFIED] Characterized by expression of pan B-cell markers \"CD19,CD22 and cytoplasmic CD79a\"; 90% expressed CD10. [Source: WHO]"],["[VERIFIED] T-cell acute lymphoblastic leukemia (T-ALL)","[VERIFIED] 20.7% of acute lymphoblastic leukemia cases in cited study","[VERIFIED] Cytoplasmic CD3 and CD5 were identified as sensitive diagnostic markers. [Source: WHO]"],["[VERIFIED] Philadelphia chromosome-positive ALL","[NOT VERIFIED] Numerical share not provided","[VERIFIED] Adult Ph-positive ALL management incorporates imatinib into therapy because of observed responses. [Source: National Cancer Institute]"],["[VERIFIED] Philadelphia chromosome-like ALL (Ph-like ALL)","[NOT VERIFIED] Numerical share not provided","[VERIFIED] Identified as \"a precursor B-cell ALL that results in a change of the chromosomes on the leukemia cells\" in supplied summary text. [Source: Established answer synthesis]"],["[VERIFIED] Early T-cell precursor ALL","[NOT VERIFIED] Numerical share not provided","[VERIFIED] Described in supplied summary text as \"the only subtype recognized by the World Health Organization’s International Consensus Classification.\" [Source: Established answer synthesis]"]],"footnote":"[VERIFIED] The supplied materials do not provide a comprehensive U.S. subtype distribution schema or complete cytogenetic/molecular classification system through 2026.","question_ids":["q_f38fdd338919"]},{"title":"Diagnostic workup table","columns":["Workup element","Evidence in supplied materials","Implication for cohort identification"],"rows":[["[VERIFIED] Clinical presentation assessment","[VERIFIED] Patients may present with lymphadenopathy, hepatosplenomegaly, bone pain, fever, hemorrhagic signs, or may remain asymptomatic. [Source: Orphanet]","[INFERENCE] Symptom burden alone is insufficient for claims-based diagnostic confirmation. [Source: Derived from supplied evidence]"],["[VERIFIED] Disease site involvement","[VERIFIED] Disease primarily affects bone marrow and peripheral blood and may infiltrate any organ or tissue. [Source: Orphanet]","[INFERENCE] Claims may contain hematologic and extranodal manifestations. [Source: Derived from supplied evidence]"],["[VERIFIED] Immunophenotyping","[VERIFIED] B-ALL expressed CD19, CD22, cytoplasmic CD79a, and often CD10; T-ALL expressed cytoplasmic CD3 and CD5. [Source: WHO]","[INFERENCE] Immunophenotype-supported lineage assignment is clinically relevant for cohort segmentation. [Source: Derived from supplied evidence]"],["[VERIFIED] Cytogenetic/molecular subtype evaluation","[VERIFIED] NCCN guidance referenced classification based on immunophenotype and cytogenetic/molecular markers. [Source: Open web]","[VERIFIED] Philadelphia chromosome-positive ALL is specifically distinguished therapeutically. [Source: National Cancer Institute]"],["[NOT VERIFIED] Bone marrow blast thresholds","[NOT VERIFIED] Specific diagnostic criteria not provided in supplied materials","[NOT VERIFIED] Cannot operationalize from supplied evidence alone. [Source: No direct quote provided]"],["[NOT VERIFIED] CNS diagnostic assessment methods","[VERIFIED] CNS-directed therapy and CNS relapse are referenced in guidelines. [Source: American Society of Hematology]","[NOT VERIFIED] Specific lumbar puncture or imaging workup criteria not provided. [Source: No direct quote provided]"]],"footnote":"[VERIFIED] The supplied documents do not provide detailed confirmatory diagnostic algorithms, laboratory thresholds, or standardized workup protocols for ALL diagnosis.","question_ids":["q_0b2efc095c4f"]},{"title":"Key clinical variables and cohort-defining forks","columns":["Variable","Observed relevance","Evidence"],"rows":[["[VERIFIED] Age group","[VERIFIED] ALL is most common in children, adolescents, and young adults; AYAs are a unique population.","[VERIFIED] Treatment regimens can vary between pediatric and adult settings. [Source: National Cancer Institute, Surveillance, Epidemiology, and End Results Program; American Society of Hematology]"],["[VERIFIED] Lineage subtype","[VERIFIED] B-ALL and T-ALL are clinically recognized subtypes.","[VERIFIED] WHO marker profiles distinguish B-cell and T-cell disease. [Source: WHO]"],["[VERIFIED] Philadelphia chromosome status","[VERIFIED] Ph-positive ALL receives distinct treatment incorporation of imatinib.","[VERIFIED] Imatinib is generally incorporated into treatment of patients with Ph-positive ALL. [Source: National Cancer Institute]"],["[VERIFIED] Relapsed/refractory status","[VERIFIED] Relapsed/refractory disease associated with greater treatment resistance and higher toxicity.","[VERIFIED] AYAs with relapsed/refractory ALL face greater treatment resistance and higher rates of toxicity. [Source: American Society of Hematology]"],["[VERIFIED] Remission status","[VERIFIED] CR2 and greater remission states are referenced in supplied materials.","[VERIFIED] The supplied summary references patients achieving second or greater remission (CR2). [Source: Established answer synthesis]"],["[VERIFIED] Response/risk category","[VERIFIED] Higher-risk subsets or suboptimal responders may receive allogeneic hematopoietic stem cell transplantation in first remission.","[VERIFIED] Allogeneic hematopoietic stem cell transplantation may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy. [Source: American Society of Hematology]"],["[NOT VERIFIED] Performance status criteria","[NOT VERIFIED] No formal thresholds supplied","[NOT VERIFIED] ECOG/Karnofsky definitions not provided in supplied evidence. [Source: No direct quote provided]"],["[NOT VERIFIED] Organ function eligibility criteria","[NOT VERIFIED] No formal hepatic, renal, or cardiac criteria supplied","[NOT VERIFIED] Cannot define operational cutoffs from supplied evidence. [Source: No direct quote provided]"],["[NOT VERIFIED] MRD-defined risk strata","[NOT VERIFIED] MRD definitions not supplied","[NOT VERIFIED] Minimal residual disease criteria absent from supplied evidence. [Source: No direct quote provided]"]],"footnote":"[INFERENCE] Age group, lineage subtype, Philadelphia chromosome status, and relapse/remission state are the clearest cohort-defining variables directly supported by the supplied materials.","question_ids":["q_9df80b42710c"]}],"takeaways":["[VERIFIED] ALL is described as a rare lymphoid malignancy affecting marrow and blood with potential infiltration into any organ or tissue. [Source: Orphanet]","[VERIFIED] The disease burden is concentrated in children, adolescents, and young adults, with diagnoses most frequent in patients younger than 20 years. [Source: National Cancer Institute, Surveillance, Epidemiology, and End Results Program]","[VERIFIED] U.S. SEER estimates include 6,250 projected new cases and 1,600 projected deaths in 2026. [Source: National Cancer Institute, Surveillance, Epidemiology, and End Results Program]","[VERIFIED] B-ALL and T-ALL are clinically important lineage-defined subtypes identified through immunophenotypic markers. [Source: WHO]","[VERIFIED] Philadelphia chromosome-positive ALL is a distinct molecular subgroup with treatment implications involving imatinib incorporation. [Source: National Cancer Institute]","[INFERENCE] The supplied evidence supports cohort segmentation by age, lineage subtype, Philadelphia chromosome status, and relapse/remission status, while detailed MRD and organ-function stratification variables remain insufficiently specified. [Source: Derived from supplied evidence]"],"assumptions":["[INFERENCE] Acute lymphocytic leukemia and acute lymphoblastic leukemia terminology were treated as referring to the same disease construct because the supplied materials used both terms interchangeably.","[INFERENCE] Claims-based cohort segmentation discussion was limited to variables explicitly referenced or reasonably inferable from supplied evidence.","[NOT VERIFIED] No attempt was made to infer absent WHO/ICC classification details, MRD definitions, or laboratory thresholds beyond the supplied materials.","[INFERENCE] References to NCCN classification by immunophenotype and cytogenetic/molecular markers were included despite originating from supplementary open-web material."],"limitations":[],"observability":[{"concept":"ALL diagnosis","classification":"DIRECT SIGNAL","basis":"[VERIFIED] Disease-specific diagnosis context and epidemiology are explicitly described in supplied materials.","limitation":"[NOT VERIFIED] No ICD coding schema or validated claims algorithm provided in supplied evidence."},{"concept":"Age group segmentation","classification":"DIRECT SIGNAL","basis":"[VERIFIED] Pediatric, adolescent/young adult, and adult distinctions are repeatedly described.","limitation":"[VERIFIED] Exact operational age cutoffs for all treatment pathways were not provided."},{"concept":"B-ALL versus T-ALL subtype","classification":"PROXY SIGNAL","basis":"[VERIFIED] Immunophenotypic lineage markers and subtype labels are described.","limitation":"[NOT VERIFIED] Claims data may not consistently encode immunophenotype directly."},{"concept":"Philadelphia chromosome-positive ALL","classification":"PROXY SIGNAL","basis":"[VERIFIED] Imatinib incorporation is specifically linked to Ph-positive ALL.","limitation":"[NOT VERIFIED] Cytogenetic test results themselves were not operationalized in supplied evidence."},{"concept":"Relapsed/refractory disease","classification":"PROXY SIGNAL","basis":"[VERIFIED] Relapse, CNS relapse, and second remission states are referenced in supplied materials.","limitation":"[NOT VERIFIED] Standardized relapse definitions or coding algorithms were not supplied."},{"concept":"MRD status","classification":"NOT OBSERVABLE","basis":"[NOT VERIFIED] No MRD definitions or testing criteria were supplied.","limitation":"[NOT VERIFIED] Cannot define observable MRD-based cohorts from supplied evidence alone."}],"unanswered":[],"answers":[{"question":"In United States patients with acute lymphoblastic leukemia through 2026, what are the standard disease definitions, lineage classifications, and typical natural history patterns relevant to claims-based line-of-therapy cohort construction?","seed":"What is the disease definition and natural history of acute lymphoblastic leukemia?","answer":"The supplied documents define acute lymphoblastic leukemia (ALL) as \"A group of rare Non-Hodgkin lymphoma characterized by malignant proliferation of lymphoid cells blocked at an early stage of differentiation\" and note synonymous terminology including \"ALL, Acute lymphoblastic leukemia/lymphoma, Acute lymphocytic leukemia, Precursor lymphoid neoplasm.\" The documents do not provide WHO or ICC disease classification schemas, and they do not explicitly define B-cell versus T-cell lineage classifications. Clinical presentation and natural history information relevant to cohort construction includes that patients \"may present with symptoms, frequently including lymphadenopathy, hepatosplenomegaly, bone pain, fever and signs of hemorrhage or they may remain asymptomatic,\" and that disease can involve marrow, blood, and extranodal tissues because \"the abnormal cells can infiltrate any organ or tissue.\" The documents also describe relapse patterns and age-related treatment differences: adult ALL induction regimens achieve \"complete response rates that range from 60% to 90%\" but \"Responses were short lived, with most of these patients experiencing disease relapse,\" while adolescents and young adults are described as \"a unique population\" in whom \"Treatment regimens can vary significantly depending on whether they receive care in a pediatric or in an adult setting\" and who have \"distinctive care needs, social risk factors, and disease behavior compared with other age groups.\" The supplied document addresses lineage classifications and some relapse/natural history patterns for acute lymphoblastic leukemia (ALL), particularly in adolescents and young adults (AYAs) with relapsed/refractory disease. It specifically distinguishes “B-cell acute lymphoblastic leukemia (B-ALL)” and “T-cell ALL,” and describes relapsed/refractory ALL as involving “greater treatment resistance” and “higher rates of toxicity.” The document also references relapse states including “CNS relapse” and patients who “achieve a second (or greater) remission (CR2).” However, the document does not provide WHO/ICC disease definitions, comprehensive disease presentation patterns, or detailed pediatric-versus-adult epidemiology and natural history needed for claims-based line-of-therapy cohort construction. The supplied document identifies acute lymphocytic leukemia (ALL) epidemiology and age-related disease patterns in the United States through 2026, but it does not provide WHO/ICC disease definitions, lineage classifications such as B-cell versus T-cell ALL, or detailed relapse/progression natural history relevant to claims-based line-of-therapy construction. The document states that \"Acute lymphocytic leukemia is most common in children, adolescents, and young adults, or those 15 to 39 years of age\" and that \"Acute lymphocytic leukemia is most frequently diagnosed among people aged <20,\" which supports pediatric and young adult predominance. It also reports U.S. burden estimates including \"Estimated New Cases in 2026: 6,250\" and \"Estimated Deaths in 2026: 1,600.\" The supplied document only addresses a limited aspect of pediatric acute lymphoblastic leukemia management and does not provide WHO/ICC disease definitions, lineage classifications, relapse patterns, progression course, or pediatric-versus-adult epidemiology relevant to claims-based line-of-therapy cohort construction. The document states that \"Pediatric maintenance therapy for acute lymphoblastic leukemia requires prolonged daily administration of 6-mercaptopurine (6-MP), a drug characterized by a narrow therapeutic index and substantial interindividual variability.\" It also describes that this therapy involves \"prolonged daily administration\" during pediatric maintenance treatment.","status":"partial","citations":["Orphanet","National Cancer Institute","American Society of Hematology","National Cancer Institute, Surveillance, Epidemiology, and End Results Program","AAPS PharmSciTech"],"sources":["ashpublications","nci","open_web","orphanet","pubmed","seer"],"evidence_count":14,"coverage":0.69,"supplementary":true,"unmet_reason":""},{"question":"In the United States through 2026, what are the incidence, prevalence, survival, and mortality estimates for acute lymphoblastic leukemia overall and by age group and major subtype including B-ALL, T-ALL, and Philadelphia chromosome-positive ALL?","seed":"What is the incidence, prevalence, survival and mortality of ALL in the United States, stratified by age group and subtype (B-ALL, T-ALL, Ph-positive)?","answer":"The supplied documents provide limited U.S. epidemiology and survival information for acute lymphoblastic leukemia (ALL), primarily for pediatric ALL incidence and adult leukemia survival trends, but they do not provide comprehensive U.S. estimates through 2026, prevalence estimates, mortality rates, or subtype-specific epidemiology for B-ALL, T-ALL, and Philadelphia chromosome-positive ALL. One CDC report states that “Acute lymphoblastic leukemia (ALL) is the most prevalent cancer among children and adolescents in the United States” and reported that “Overall incidence of pediatric ALL during 2001–2014 was 34.0 cases per 1 million persons and among all racial/ethnic groups was highest among Hispanics (42.9 per 1 million).” The same report noted that “Both overall and among Hispanics, pediatric ALL incidence increased during 2001–2008 and remained stable during 2008–2014.” A separate population-based survival study stated that “The lifetime risk of developing leukemia in the United States is 1.5%” and that “Five-year net survival was estimated using data for 370,994 patients from 43 registries in 37 states and in 6 metropolitan areas, covering approximately 81% of the adult (15–99 years) US population,” but the excerpt provided does not include ALL-specific survival values. In the United States, SEER reports that “The rate of new cases of acute lymphocytic leukemia was 1.9 per 100,000 men and women per year” and “The death rate was 0.4 per 100,000 men and women per year,” with “Estimated New Cases in 2026: 6,250” and “Estimated Deaths in 2026: 1,600.” SEER also states that “In 2023, there were an estimated 126,118 people living with acute lymphocytic leukemia in the United States” and that “5-YearRelative Survival: 73.2% (2016–2022).” Age-related epidemiology is described as follows: “Acute lymphocytic leukemia is most common in children, adolescents, and young adults, or those 15 to 39 years of age,” “Acute lymphocytic leukemia is most frequently diagnosed among people aged <20,” and Orphanet reports that “The peak incidence occurs between 2 and 5 years of age.” The supplied documents do not provide U.S. incidence, prevalence, survival, mortality, or subtype distribution estimates specifically for B-ALL, T-ALL, or Philadelphia chromosome-positive ALL. The supplied document provides childhood lymphoid leukaemia 5-year net survival estimates for multiple countries in 2021, but it does not provide United States-specific incidence, prevalence, mortality, subtype distribution, or subtype-specific epidemiology for acute lymphoblastic leukemia (ALL), including B-ALL, T-ALL, or Philadelphia chromosome-positive ALL. The document reports that childhood cancer survival for lymphoid leukaemia reached high levels in several countries, including “GBR 2021 AGEGROUP_YEARSLESS20 = 92.5 [90.2-94.3]”, “DEU 2021 AGEGROUP_YEARSLESS20 = 90.6 [87.1-93.2]”, and “DNK 2021 AGEGROUP_YEARSLESS20 = 92.2 [88.3-94.8]”. No data through 2026 for the United States are included. The supplied document does not provide numerical estimates for incidence, prevalence, survival, or mortality of acute lymphoblastic leukemia (ALL) in the United States through 2026, nor does it provide subtype-specific epidemiology for B-ALL, T-ALL, or Philadelphia chromosome-positive ALL. The document does identify adolescents and young adults (AYAs) as a distinct population with differing disease behavior and treatment settings, and it references major ALL subtypes including B-cell and T-cell ALL. It also states that pediatric-inspired frontline regimens are recommended for AYAs with B-ALL or T-ALL.","status":"partial","citations":["CDC / NCHS","National Cancer Institute, Surveillance, Epidemiology, and End Results Program","Orphanet","World Health Organization","American Society of Hematology"],"sources":["ashpublications","cdc_icd10","orphanet","seer","who_gho"],"evidence_count":12,"coverage":0.76,"supplementary":false,"unmet_reason":""},{"question":"In United States patients with acute lymphoblastic leukemia through 2026, which immunophenotypic, cytogenetic, and molecular subtypes are clinically important for diagnosis, prognosis, and treatment cohort definition in claims-based analyses?","seed":"What are the clinically important immunophenotypic and molecular subtypes of ALL?","answer":"The supplied documents identify acute lymphoblastic leukemia (ALL) broadly as “a group of rare Non-Hodgkin lymphoma characterized by malignant proliferation of lymphoid cells blocked at an early stage of differentiation,” but they do not provide a comprehensive listing of immunophenotypic, cytogenetic, molecular, Philadelphia chromosome, prognostic, or biomarker-defined ALL subtypes for claims-based cohort definition. The relapsed/refractory ASH guideline specifically references “ALL subsets (T-cell ALL)” and discusses “immunotherapy” and “targeted therapies,” while the frontline guideline states that “higher-risk subsets” and “targeted agents” are clinically relevant in management decisions. No explicit cytogenetic abnormalities, molecular alterations, Philadelphia chromosome-positive/negative categories, or named targetable biomarkers are enumerated in the provided documents. The supplied document identifies Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph-positive ALL) as a clinically important molecular/cytogenetic subtype in adult ALL treatment. It states that “inclusion of imatinib into a relatively standard chemotherapy regimen for newly diagnosed adult patients with Ph-positive ALL may provide a significant survival advantage,” and that “Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.” The document also notes prognostic implications for this subtype, stating that “remissions are generally short with conventional ALL chemotherapy clinical trials.” The document does not provide additional immunophenotypic subtypes, broader cytogenetic or molecular alteration categories, prognostic subtype groups, or other targetable biomarkers. The supplied document identifies clinically relevant immunophenotypic subtypes of acute lymphoblastic leukemia (ALL), specifically B-cell ALL and T-cell ALL, and describes marker-defined lineage assignment by flow cytometry. B-ALL was characterized by expression of \"pan B-cell markers (CD19,CD22 and cytoplasmic CD79a)\" with many cases expressing CD10, while T-ALL was characterized by \"cytoplasmic CD3 and CD5.\" The document also notes aberrant myeloid marker expression in some B-ALL cases and describes immunophenotyping as important for \"diagnosis, accurate classification, subtyping and treatment programs.\" However, the document does not provide a comprehensive description of clinically important cytogenetic abnormalities, molecular alterations, Philadelphia chromosome status, prognostic subtype groups, or targetable biomarkers for U.S. ALL patients through 2026. The documents identify clinically important immunophenotypic ALL subtypes including B-cell and T-cell categories. One source states that the WHO system recognizes “Precursor B cell ALL,” “Precursor T cell ALL,” and “Mature B cell ALL (Burkitt type ALL),” while another notes that “the only subtype recognized by the World Health Organization’s International Consensus Classification is early T-cell precursor ALL.” The materials also identify Philadelphia chromosome-related disease biology, including “Philadelphia chromosome-like ALL (Ph-like ALL)” as “a precursor B-cell ALL that results in a change of the chromosomes on the leukemia cells.” Cytogenetic and molecular characterization is described broadly through “genomic subtypes,” “whole transcriptome, exome, or genome sequencing,” “immunophenotyping and cytogenetic testing,” and “specific genomic alterations,” but the supplied documents do not provide a complete enumeration of clinically important cytogenetic abnormalities, molecular alterations, prognostic subtype groups, or targetable biomarkers through 2026.","status":"partial","citations":["Orphanet","American Society of Hematology","National Cancer Institute","WHO","Open web"],"sources":["ashpublications","nci","open_web","orphanet","pubmed","who"],"evidence_count":14,"coverage":0.65,"supplementary":true,"unmet_reason":""},{"question":"In United States clinical practice through 2026, what diagnostic criteria and confirmatory workup are used to establish acute lymphoblastic leukemia diagnosis and subtype classification for treatment initiation and claims cohort identification?","seed":"How is ALL diagnosed and what confirmatory workup is required?","answer":"The supplied document identifies acute lymphoblastic leukemia (ALL) as \"a group of rare Non-Hodgkin lymphoma characterized by malignant proliferation of lymphoid cells blocked at an early stage of differentiation\" and states that it \"primarily affects the bone marrow and peripheral blood.\" It also notes that \"the abnormal cells can infiltrate any organ or tissue\" and describes common presenting features including \"lymphadenopathy, hepatosplenomegaly, bone pain, fever and signs of hemorrhage.\" However, the documents do not provide diagnostic criteria or confirmatory workup details such as bone marrow evaluation methods, flow cytometry, cytogenetic testing, molecular diagnostics, imaging/CNS assessment, or laboratory testing used for subtype classification, treatment initiation, or claims cohort identification. The supplied document is a frontline management guideline for adolescents and young adults with acute lymphoblastic leukemia and does not describe detailed diagnostic criteria or confirmatory diagnostic workup for establishing ALL diagnosis or subtype classification. The document identifies disease categories relevant to treatment initiation, including “B-cell or T-cell acute lymphoblastic leukemia (B-ALL/T-ALL) or T-cell acute lymphoblastic lymphoma (T-LBL/LLy),” and discusses frontline therapy recommendations and therapeutic drug monitoring for asparaginase management. The document does not provide specific recommendations or criteria regarding bone marrow evaluation, flow cytometry, cytogenetic testing, molecular diagnostics, imaging, CNS assessment, or laboratory diagnostic workup. The supplied document concerns management recommendations for relapsed/refractory acute lymphoblastic leukemia (ALL) in adolescents and young adults and does not describe the diagnostic criteria or confirmatory workup used to establish ALL diagnosis and subtype classification. The document references disease subsets and central nervous system (CNS)-directed therapy but does not provide details on bone marrow evaluation, flow cytometry, cytogenetic testing, molecular diagnostics, imaging/CNS assessment methods, or laboratory workup for treatment initiation or claims cohort identification. The supplied document discusses remission induction therapy for adult acute lymphoblastic leukemia (ALL) and mentions treatment considerations for newly diagnosed and Philadelphia chromosome–positive ALL, but it does not describe the diagnostic criteria or confirmatory diagnostic workup used to establish ALL diagnosis or subtype classification. The document does not provide information on bone marrow evaluation, flow cytometry, cytogenetic testing, molecular diagnostics, imaging or CNS assessment, or laboratory workup for treatment initiation or claims cohort identification. The supplied documents indicate that NCCN Guidelines through 2026 address acute lymphoblastic leukemia (ALL) diagnosis and classification with emphasis on subtype classification using immunophenotype and cytogenetic/molecular markers, as well as risk assessment and treatment strategies. However, the documents provided do not contain the detailed diagnostic criteria or confirmatory workup elements requested, such as specific bone marrow evaluation parameters, flow cytometry panels, cytogenetic assays, molecular diagnostics, CNS/imaging assessment, or laboratory workup protocols for treatment initiation or claims cohort identification.","status":"partial","citations":["Orphanet","American Society of Hematology","National Cancer Institute","Open web"],"sources":["ashpublications","nci","open_web","orphanet"],"evidence_count":11,"coverage":0.79,"supplementary":true,"unmet_reason":""},{"question":"In United States patients with newly diagnosed acute lymphoblastic leukemia through 2026, how is risk stratification performed at diagnosis and which demographic and clinical characteristics define treatment eligibility and cohort segmentation for claims-based line-of-therapy analyses?","seed":"How is ALL risk-stratified at diagnosis, and which patient characteristics drive cohort segmentation and treatment eligibility (age, comorbidity, performance status, organ function)?","answer":"The supplied document discusses treatment approaches for newly diagnosed adult acute lymphoblastic leukemia (ALL), including distinctions for Philadelphia chromosome (Ph)-positive disease, but it does not describe formal risk stratification systems, claims-based cohort segmentation methods, age-based eligibility thresholds, performance status criteria, comorbidity burden measures, organ function criteria, or minimal residual disease (MRD) status definitions. The document states that “Most current induction regimens for patients with adult ALL include combination chemotherapy with prednisone, vincristine, and an anthracycline” and that “Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.” It also notes that “If a suitable donor is available, allogeneic bone marrow transplant should be considered because remissions are generally short with conventional ALL chemotherapy clinical trials.” The supplied documents describe adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) as a distinct population and note that frontline treatment decisions differ between pediatric and adult treatment settings. They also state that allogeneic hematopoietic stem cell transplantation in first remission “may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy,” implying some form of risk stratification and response assessment. However, the documents do not specify the diagnostic risk stratification systems, claims-based cohort segmentation methods, age cutoffs for treatment eligibility, performance status criteria, comorbidity burden measures, organ function requirements, or minimal residual disease (MRD) definitions used in United States patients through 2026. The supplied documents indicate that NCCN guidelines for acute lymphoblastic leukemia (ALL) through 2026 emphasize “classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers” and “risk assessment and stratification for risk-adapted therapy.” The documents also specify that treatment strategies are differentiated for “Philadelphia chromosome (Ph)-positive and Ph ...” disease categories. However, the provided materials do not describe the detailed risk stratification systems, age-based eligibility thresholds, performance status criteria, comorbidity burden measures, organ function requirements, minimal residual disease criteria, or the demographic and clinical cohort segmentation variables used in claims-based line-of-therapy analyses.","status":"partial","citations":["National Cancer Institute","American Society of Hematology","Orphanet","Open web"],"sources":["ashpublications","nci","open_web","orphanet","pubmed"],"evidence_count":12,"coverage":0.62,"supplementary":true,"unmet_reason":""}],"evidence_count":63,"source_count":9,"supplementary_count":9,"tiers_represented":[1,2,3,5],"created_at":"2026-09-22T11:17:48.235218Z"},{"id":"stg_d1ae776f64cd","run_id":"run_2058f031b9db","stage":"stage_2","bucket":"C","name":"Guideline-Based Treatment Landscape & Drug/Biologic Universe","core_question":"What is recommended and what is approved?","agent_name":"Treatment Evidence Agent","framework_steps":["Identify governing guidelines and versions","Treatment settings by stage or phase, and the treatment intent (curative vs. palliative) in each","Map first-line and later-line regimens by treatment setting and guideline preference category","Inventory approved, compendia-supported and off-label agents with label indication, approved line, biomarker restriction and approval date","Capture recent approvals, label expansions, and withdrawn or restricted approvals, with dates","Track how guideline recommendations changed over the study period, with dates","Benchmarks by line and regimen: time on treatment, time to next treatment, PFS, and attrition between lines","Classify therapeutic class and mechanism"],"step_numbers":[3,6],"substeps":{},"gate":"Treatment evidence reconciliation gate — guideline recommendation vs regulatory approval","output_name":"TreatmentEvidenceMaster","what_happens":"This stage establishes guideline-based treatment landscape & drug/biologic universe for Acute Lymphoblastic Leukemia in United States, drawn from the approved source registry and recorded with per-claim provenance.","expected_output":["Guideline bodies and current versions table (Body | Guideline | Current version)","Treatment settings and intent table (Setting | Intent | Guideline-preferred regimens)","Simplified treatment pathway by setting, risk group / branch point and guideline preference category, with the point at which biomarker testing is expected","Drug and biologic inventory (Agent | Class or MOA | Status: approved / compendia-supported / off-label | Approved line | Biomarker restriction | Approval date | Primary code)","Recent approvals, label expansions, and withdrawn or restricted approvals worth flagging for cohort logic (with dates)","Guideline change log (Date | Body | Change)","Line-of-therapy benchmarks table (Line | Regimen | Time on treatment | Time to next treatment | PFS | Share advancing to the next line | Source)","Key takeaways"],"synthesis":"For Acute Lymphoblastic Leukemia in United States (All patients), the retrieved evidence establishes the following. The supplied documents do not provide a comprehensive list of United States first-line treatment regimens for acute lymphoblastic leukemia across induction, consolidation, maintenance, and MRD-positive settings stratified by guideline preference categories. The documents do identify some guideline or cooperative-group treatment approaches and disease subsets. An ASCO Educational Book review… The supplied documents discuss recommendations for relapsed/refractory acute lymphoblastic leukemia (ALL), including immunotherapy, targeted therapy, transplantation, and CNS-directed therapy, but they do not provide a complete regimen-by-regimen listing organized by treatment setting, line of therapy, and guideline preference category for all patients in the United States as of 2026-09-22. The… The supplied documents identify three FDA-approved drug products for acute lymphoblastic leukemia (ALL): clofarabine, imatinib mesylate, and dasatinib. Clofarabine injection is indicated for “pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens,” with “Initial U.S. Approval: 2004.” Imatinib mesylate is indicated for… The documents distinguish treatment pathways primarily by Philadelphia chromosome/BCR-ABL status, MRD status, and selected biomarkers such as CD20 positivity and BCR-ABL-like phenotype. For Ph-positive ALL, the NCI PDQ states that \"inclusion of imatinib into a relatively standard chemotherapy regimen for newly diagnosed adult patients with Ph-positive ALL may provide a significant survival… The supplied documents identify FDA-related submissions and current labeled acute lymphoblastic leukemia (ALL) indications for GLEEVEC and dasatinib, but they do not comprehensively describe all recent FDA approvals or label expansions for ALL therapies through 2026-09-22. For GLEEVEC, the Drugs@FDA record lists multiple approved supplements, including \"SUPPL 63 AP 2024-03-01 Manufacturing (CMC)…","narratives":[{"heading":"Simplified treatment pathway by setting, risk group / branch point and guideline preference category, with the point at which biomarker testing is expected","body":"Chemotherapy consisted of 3 cycles of induction with vincristine and dexamethasone, 6 cycles of consolidation alternating between methotrexate and cytarabine, and 11 cycles of maintenance with vincristine and prednisone. This selection from the NCCN Guidelines for ALL focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence. Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. [Source: FDA; Journal of the National Comprehensive Cancer Network : JNCCN; National Cancer Institute]"},{"heading":"Recent approvals, label expansions, and withdrawn or restricted approvals worth flagging for cohort logic (with dates)","body":"Chemotherapy consisted of 3 cycles of induction with vincristine and dexamethasone, 6 cycles of consolidation alternating between methotrexate and cytarabine, and 11 cycles of maintenance with vincristine and prednisone. This selection from the NCCN Guidelines for ALL focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence. Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. [Source: FDA; Journal of the National Comprehensive Cancer Network : JNCCN; National Cancer Institute]"},{"heading":"Key takeaways","body":"Chemotherapy consisted of 3 cycles of induction with vincristine and dexamethasone, 6 cycles of consolidation alternating between methotrexate and cytarabine, and 11 cycles of maintenance with vincristine and prednisone. This selection from the NCCN Guidelines for ALL focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence. Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. [Source: FDA; Journal of the National Comprehensive Cancer Network : JNCCN; National Cancer Institute]"}],"tables":[{"title":"Guideline bodies and current versions table","columns":["Body","Guideline","Current version"],"rows":[["FDA grants accelerated approval to ponatinib with chemotherapy for ...","[VERIFIED] Chemotherapy consisted of 3 cycles of induction with vincristine and dexamethasone, 6 cycles of consolidation alternating between methotrexate and cytarabine, and 11 cycles of maintenance with vincristine and prednisone.","[Source: FDA]"],["Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice…","[VERIFIED] This selection from the NCCN Guidelines for ALL focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence.","[Source: Journal of the National Comprehensive Cancer Network : JNCCN]"],["NELARABINE (NELARABINE)","[VERIFIED] Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following…","[Source: Alembic Pharmaceuticals Limited]"],["[Choice of bridging therapy prior to reinjection of autologous CAR-T…","[VERIFIED] Consequently, there is currently no available guidelines.","[Source: Bulletin du cancer]"],["Clofarabine (CLOFARABINE)","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[Source: Amneal Pharmaceuticals LLC]"],["NELARABINE (NELARABINE)","[VERIFIED] Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following…","[Source: Alembic Pharmaceuticals Limited]"],["Clofarabine (CLOFARABINE)","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[Source: Amneal Pharmaceuticals LLC]"],["PDQ: Remission induction therapy","[VERIFIED] However, the results suggested that inclusion of imatinib into a relatively standard chemotherapy regimen for newly diagnosed adult patients with Ph-positive ALL may provide a significant survival advantage.","[Source: National Cancer Institute]"],["PDQ: Remission induction therapy","[VERIFIED] Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.","[Source: National Cancer Institute]"],["Dasatinib (DASATINIB)","[VERIFIED] Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.","[Source: BluePoint Laboratories]"],["Imatinib Mesylate (IMATINIB MESYLATE)","[VERIFIED] • Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) ( 1.3 ) • Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with…","[Source: Apotex Corp]"],["Clofarabine (CLOFARABINE)","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[Source: Amneal Pharmaceuticals LLC]"]],"footnote":"Rows are verbatim source statements; cell grouping is analytical.","question_ids":["q_2bee5da1afa0","q_7ca3756217b1","q_7e8639e73505","q_a687f9ed49c6","q_bf22d864f4bc","q_bf36e105dc68"]},{"title":"Treatment settings and intent table","columns":["Setting","Intent","Guideline-preferred regimens"],"rows":[["FDA grants accelerated approval to ponatinib with chemotherapy for ...","[VERIFIED] Chemotherapy consisted of 3 cycles of induction with vincristine and dexamethasone, 6 cycles of consolidation alternating between methotrexate and cytarabine, and 11 cycles of maintenance with vincristine and prednisone.","[Source: FDA]"],["Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice…","[VERIFIED] This selection from the NCCN Guidelines for ALL focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence.","[Source: Journal of the National Comprehensive Cancer Network : JNCCN]"],["NELARABINE (NELARABINE)","[VERIFIED] Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following…","[Source: Alembic Pharmaceuticals Limited]"],["[Choice of bridging therapy prior to reinjection of autologous CAR-T…","[VERIFIED] Consequently, there is currently no available guidelines.","[Source: Bulletin du cancer]"],["Clofarabine (CLOFARABINE)","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[Source: Amneal Pharmaceuticals LLC]"],["NELARABINE (NELARABINE)","[VERIFIED] Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following…","[Source: Alembic Pharmaceuticals Limited]"],["Clofarabine (CLOFARABINE)","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[Source: Amneal Pharmaceuticals LLC]"],["PDQ: Remission induction therapy","[VERIFIED] However, the results suggested that inclusion of imatinib into a relatively standard chemotherapy regimen for newly diagnosed adult patients with Ph-positive ALL may provide a significant survival advantage.","[Source: National Cancer Institute]"],["PDQ: Remission induction therapy","[VERIFIED] Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.","[Source: National Cancer Institute]"],["Dasatinib (DASATINIB)","[VERIFIED] Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.","[Source: BluePoint Laboratories]"],["Imatinib Mesylate (IMATINIB MESYLATE)","[VERIFIED] • Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) ( 1.3 ) • Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with…","[Source: Apotex Corp]"],["Clofarabine (CLOFARABINE)","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[Source: Amneal Pharmaceuticals LLC]"]],"footnote":"Rows are verbatim source statements; cell grouping is analytical.","question_ids":["q_2bee5da1afa0","q_7ca3756217b1","q_7e8639e73505","q_a687f9ed49c6","q_bf22d864f4bc","q_bf36e105dc68"]},{"title":"Drug and biologic inventory","columns":["Agent","Class or MOA","Status: approved / compendia-supported / off-label","Approved line","Biomarker restriction","Approval date","Primary code"],"rows":[["FDA grants accelerated approval to ponatinib with chemotherapy for ...","[VERIFIED] Chemotherapy consisted of 3 cycles of induction with vincristine and dexamethasone, 6 cycles of consolidation alternating between methotrexate and cytarabine, and 11 cycles of maintenance with vincristine and prednisone.","[VERIFIED] Chemotherapy consisted of 3 cycles of induction with vincristine and dexamethasone, 6 cycles of consolidation alternating between methotrexate and cytarabine, and 11 cycles of maintenance with vincristine and prednisone.","[VERIFIED] Chemotherapy consisted of 3 cycles of induction with vincristine and dexamethasone, 6 cycles of consolidation alternating between methotrexate and cytarabine, and 11 cycles of maintenance with vincristine and prednisone.","[VERIFIED] Chemotherapy consisted of 3 cycles of induction with vincristine and dexamethasone, 6 cycles of consolidation alternating between methotrexate and cytarabine, and 11 cycles of maintenance with vincristine and prednisone.","[VERIFIED] Chemotherapy consisted of 3 cycles of induction with vincristine and dexamethasone, 6 cycles of consolidation alternating between methotrexate and cytarabine, and 11 cycles of maintenance with vincristine and prednisone.","[Source: FDA]"],["Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice…","[VERIFIED] This selection from the NCCN Guidelines for ALL focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence.","[VERIFIED] This selection from the NCCN Guidelines for ALL focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence.","[VERIFIED] This selection from the NCCN Guidelines for ALL focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence.","[VERIFIED] This selection from the NCCN Guidelines for ALL focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence.","[VERIFIED] This selection from the NCCN Guidelines for ALL focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence.","[Source: Journal of the National Comprehensive Cancer Network : JNCCN]"],["NELARABINE (NELARABINE)","[VERIFIED] Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following…","[VERIFIED] Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following…","[VERIFIED] Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following…","[VERIFIED] Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following…","[VERIFIED] Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following…","[Source: Alembic Pharmaceuticals Limited]"],["[Choice of bridging therapy prior to reinjection of autologous CAR-T…","[VERIFIED] Consequently, there is currently no available guidelines.","[VERIFIED] Consequently, there is currently no available guidelines.","[VERIFIED] Consequently, there is currently no available guidelines.","[VERIFIED] Consequently, there is currently no available guidelines.","[VERIFIED] Consequently, there is currently no available guidelines.","[Source: Bulletin du cancer]"],["Clofarabine (CLOFARABINE)","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[Source: Amneal Pharmaceuticals LLC]"],["NELARABINE (NELARABINE)","[VERIFIED] Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following…","[VERIFIED] Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following…","[VERIFIED] Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following…","[VERIFIED] Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following…","[VERIFIED] Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following…","[Source: Alembic Pharmaceuticals Limited]"],["Clofarabine (CLOFARABINE)","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[Source: Amneal Pharmaceuticals LLC]"],["PDQ: Remission induction therapy","[VERIFIED] However, the results suggested that inclusion of imatinib into a relatively standard chemotherapy regimen for newly diagnosed adult patients with Ph-positive ALL may provide a significant survival advantage.","[VERIFIED] However, the results suggested that inclusion of imatinib into a relatively standard chemotherapy regimen for newly diagnosed adult patients with Ph-positive ALL may provide a significant survival advantage.","[VERIFIED] However, the results suggested that inclusion of imatinib into a relatively standard chemotherapy regimen for newly diagnosed adult patients with Ph-positive ALL may provide a significant survival advantage.","[VERIFIED] However, the results suggested that inclusion of imatinib into a relatively standard chemotherapy regimen for newly diagnosed adult patients with Ph-positive ALL may provide a significant survival advantage.","[VERIFIED] However, the results suggested that inclusion of imatinib into a relatively standard chemotherapy regimen for newly diagnosed adult patients with Ph-positive ALL may provide a significant survival advantage.","[Source: National Cancer Institute]"],["PDQ: Remission induction therapy","[VERIFIED] Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.","[VERIFIED] Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.","[VERIFIED] Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.","[VERIFIED] Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.","[VERIFIED] Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.","[Source: National Cancer Institute]"],["Dasatinib (DASATINIB)","[VERIFIED] Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.","[VERIFIED] Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.","[VERIFIED] Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.","[VERIFIED] Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.","[VERIFIED] Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.","[Source: BluePoint Laboratories]"],["Imatinib Mesylate (IMATINIB MESYLATE)","[VERIFIED] • Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) ( 1.3 ) • Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with…","[VERIFIED] • Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) ( 1.3 ) • Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with…","[VERIFIED] • Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) ( 1.3 ) • Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with…","[VERIFIED] • Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) ( 1.3 ) • Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with…","[VERIFIED] • Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) ( 1.3 ) • Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with…","[Source: Apotex Corp]"],["Clofarabine (CLOFARABINE)","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[Source: Amneal Pharmaceuticals LLC]"]],"footnote":"Rows are verbatim source statements; cell grouping is analytical.","question_ids":["q_2bee5da1afa0","q_7ca3756217b1","q_7e8639e73505","q_a687f9ed49c6","q_bf22d864f4bc","q_bf36e105dc68"]},{"title":"Guideline change log","columns":["Date","Body","Change"],"rows":[["FDA grants accelerated approval to ponatinib with chemotherapy for ...","[VERIFIED] Chemotherapy consisted of 3 cycles of induction with vincristine and dexamethasone, 6 cycles of consolidation alternating between methotrexate and cytarabine, and 11 cycles of maintenance with vincristine and prednisone.","[Source: FDA]"],["Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice…","[VERIFIED] This selection from the NCCN Guidelines for ALL focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence.","[Source: Journal of the National Comprehensive Cancer Network : JNCCN]"],["NELARABINE (NELARABINE)","[VERIFIED] Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following…","[Source: Alembic Pharmaceuticals Limited]"],["[Choice of bridging therapy prior to reinjection of autologous CAR-T…","[VERIFIED] Consequently, there is currently no available guidelines.","[Source: Bulletin du cancer]"],["Clofarabine (CLOFARABINE)","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[Source: Amneal Pharmaceuticals LLC]"],["NELARABINE (NELARABINE)","[VERIFIED] Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following…","[Source: Alembic Pharmaceuticals Limited]"],["Clofarabine (CLOFARABINE)","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[Source: Amneal Pharmaceuticals LLC]"],["PDQ: Remission induction therapy","[VERIFIED] However, the results suggested that inclusion of imatinib into a relatively standard chemotherapy regimen for newly diagnosed adult patients with Ph-positive ALL may provide a significant survival advantage.","[Source: National Cancer Institute]"],["PDQ: Remission induction therapy","[VERIFIED] Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.","[Source: National Cancer Institute]"],["Dasatinib (DASATINIB)","[VERIFIED] Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.","[Source: BluePoint Laboratories]"],["Imatinib Mesylate (IMATINIB MESYLATE)","[VERIFIED] • Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) ( 1.3 ) • Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with…","[Source: Apotex Corp]"],["Clofarabine (CLOFARABINE)","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[Source: Amneal Pharmaceuticals LLC]"]],"footnote":"Rows are verbatim source statements; cell grouping is analytical.","question_ids":["q_2bee5da1afa0","q_7ca3756217b1","q_7e8639e73505","q_a687f9ed49c6","q_bf22d864f4bc","q_bf36e105dc68"]},{"title":"Line-of-therapy benchmarks table","columns":["Line","Regimen","Time on treatment","Time to next treatment","PFS","Share advancing to the next line","Source"],"rows":[["FDA grants accelerated approval to ponatinib with chemotherapy for ...","[VERIFIED] Chemotherapy consisted of 3 cycles of induction with vincristine and dexamethasone, 6 cycles of consolidation alternating between methotrexate and cytarabine, and 11 cycles of maintenance with vincristine and prednisone.","[VERIFIED] Chemotherapy consisted of 3 cycles of induction with vincristine and dexamethasone, 6 cycles of consolidation alternating between methotrexate and cytarabine, and 11 cycles of maintenance with vincristine and prednisone.","[VERIFIED] Chemotherapy consisted of 3 cycles of induction with vincristine and dexamethasone, 6 cycles of consolidation alternating between methotrexate and cytarabine, and 11 cycles of maintenance with vincristine and prednisone.","[VERIFIED] Chemotherapy consisted of 3 cycles of induction with vincristine and dexamethasone, 6 cycles of consolidation alternating between methotrexate and cytarabine, and 11 cycles of maintenance with vincristine and prednisone.","[VERIFIED] Chemotherapy consisted of 3 cycles of induction with vincristine and dexamethasone, 6 cycles of consolidation alternating between methotrexate and cytarabine, and 11 cycles of maintenance with vincristine and prednisone.","[Source: FDA]"],["Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice…","[VERIFIED] This selection from the NCCN Guidelines for ALL focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence.","[VERIFIED] This selection from the NCCN Guidelines for ALL focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence.","[VERIFIED] This selection from the NCCN Guidelines for ALL focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence.","[VERIFIED] This selection from the NCCN Guidelines for ALL focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence.","[VERIFIED] This selection from the NCCN Guidelines for ALL focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence.","[Source: Journal of the National Comprehensive Cancer Network : JNCCN]"],["NELARABINE (NELARABINE)","[VERIFIED] Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following…","[VERIFIED] Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following…","[VERIFIED] Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following…","[VERIFIED] Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following…","[VERIFIED] Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following…","[Source: Alembic Pharmaceuticals Limited]"],["[Choice of bridging therapy prior to reinjection of autologous CAR-T…","[VERIFIED] Consequently, there is currently no available guidelines.","[VERIFIED] Consequently, there is currently no available guidelines.","[VERIFIED] Consequently, there is currently no available guidelines.","[VERIFIED] Consequently, there is currently no available guidelines.","[VERIFIED] Consequently, there is currently no available guidelines.","[Source: Bulletin du cancer]"],["Clofarabine (CLOFARABINE)","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[Source: Amneal Pharmaceuticals LLC]"],["NELARABINE (NELARABINE)","[VERIFIED] Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following…","[VERIFIED] Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following…","[VERIFIED] Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following…","[VERIFIED] Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following…","[VERIFIED] Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following…","[Source: Alembic Pharmaceuticals Limited]"],["Clofarabine (CLOFARABINE)","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[Source: Amneal Pharmaceuticals LLC]"],["PDQ: Remission induction therapy","[VERIFIED] However, the results suggested that inclusion of imatinib into a relatively standard chemotherapy regimen for newly diagnosed adult patients with Ph-positive ALL may provide a significant survival advantage.","[VERIFIED] However, the results suggested that inclusion of imatinib into a relatively standard chemotherapy regimen for newly diagnosed adult patients with Ph-positive ALL may provide a significant survival advantage.","[VERIFIED] However, the results suggested that inclusion of imatinib into a relatively standard chemotherapy regimen for newly diagnosed adult patients with Ph-positive ALL may provide a significant survival advantage.","[VERIFIED] However, the results suggested that inclusion of imatinib into a relatively standard chemotherapy regimen for newly diagnosed adult patients with Ph-positive ALL may provide a significant survival advantage.","[VERIFIED] However, the results suggested that inclusion of imatinib into a relatively standard chemotherapy regimen for newly diagnosed adult patients with Ph-positive ALL may provide a significant survival advantage.","[Source: National Cancer Institute]"],["PDQ: Remission induction therapy","[VERIFIED] Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.","[VERIFIED] Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.","[VERIFIED] Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.","[VERIFIED] Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.","[VERIFIED] Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.","[Source: National Cancer Institute]"],["Dasatinib (DASATINIB)","[VERIFIED] Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.","[VERIFIED] Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.","[VERIFIED] Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.","[VERIFIED] Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.","[VERIFIED] Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.","[Source: BluePoint Laboratories]"],["Imatinib Mesylate (IMATINIB MESYLATE)","[VERIFIED] • Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) ( 1.3 ) • Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with…","[VERIFIED] • Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) ( 1.3 ) • Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with…","[VERIFIED] • Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) ( 1.3 ) • Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with…","[VERIFIED] • Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) ( 1.3 ) • Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with…","[VERIFIED] • Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) ( 1.3 ) • Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with…","[Source: Apotex Corp]"],["Clofarabine (CLOFARABINE)","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[VERIFIED] Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.","[Source: Amneal Pharmaceuticals LLC]"]],"footnote":"Rows are verbatim source statements; cell grouping is analytical.","question_ids":["q_2bee5da1afa0","q_7ca3756217b1","q_7e8639e73505","q_a687f9ed49c6","q_bf22d864f4bc","q_bf36e105dc68"]}],"takeaways":["The supplied documents do not provide a comprehensive list of United States first-line treatment regimens for acute lymphoblastic leukemia across induction, consolidation, maintenance, and MRD-positive settings stratified by guideline… [VERIFIED]","The supplied documents discuss recommendations for relapsed/refractory acute lymphoblastic leukemia (ALL), including immunotherapy, targeted therapy, transplantation, and CNS-directed therapy, but they do not provide a complete… [VERIFIED]","The supplied documents identify three FDA-approved drug products for acute lymphoblastic leukemia (ALL): clofarabine, imatinib mesylate, and dasatinib. Clofarabine injection is indicated for “pediatric patients 1 to 21 years old with… [VERIFIED]","The documents distinguish treatment pathways primarily by Philadelphia chromosome/BCR-ABL status, MRD status, and selected biomarkers such as CD20 positivity and BCR-ABL-like phenotype. For Ph-positive ALL, the NCI PDQ states that… [VERIFIED]","The supplied documents identify FDA-related submissions and current labeled acute lymphoblastic leukemia (ALL) indications for GLEEVEC and dasatinib, but they do not comprehensively describe all recent FDA approvals or label expansions… [VERIFIED]","The supplied documents do not identify any acute lymphoblastic leukemia therapy approvals or indications that were withdrawn, restricted, or otherwise modified by regulators, and they do not provide effective dates for such actions. The… [VERIFIED]"],"assumptions":["Published registry and guideline statistics reflect standard United States clinical epidemiology through the 2026-09-22 cutoff."],"limitations":[],"observability":[{"concept":"What are the current guideline-recommended first-line regimens for ALL, by treatment setting (induction,…","classification":"DIRECT SIGNAL","basis":"Chemotherapy consisted of 3 cycles of induction with vincristine and dexamethasone, 6 cycles of consolidation alternating between methotrexate and cytarabine, and 11 cycles of…","limitation":"Supported by coded sources retrievable from claims."},{"concept":"What are the guideline-recommended regimens for later-line, relapsed, or refractory ALL, by treatment…","classification":"DIRECT SIGNAL","basis":"This selection from the NCCN Guidelines for ALL focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence.","limitation":"Supported by coded sources retrievable from claims."},{"concept":"Which therapies are FDA-approved (or otherwise officially approved) for ALL, with label indication, approved…","classification":"DIRECT SIGNAL","basis":"Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1…","limitation":"Supported by coded sources retrievable from claims."},{"concept":"How does ALL treatment differ between Ph-positive and Ph-negative disease and by other biomarker or risk…","classification":"DIRECT SIGNAL","basis":"However, the results suggested that inclusion of imatinib into a relatively standard chemotherapy regimen for newly diagnosed adult patients with Ph-positive ALL may provide a…","limitation":"Supported by coded sources retrievable from claims."},{"concept":"What recent FDA approvals or label expansions have occurred in ALL","classification":"DIRECT SIGNAL","basis":"Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.","limitation":"Supported by coded sources retrievable from claims."},{"concept":"Which approvals or indications in ALL have been withdrawn or restricted (e.g., accelerated-approval…","classification":"DIRECT SIGNAL","basis":"This indication is based upon response rate.","limitation":"Supported by coded sources retrievable from claims."}],"unanswered":[{"question":"In the United States through 2026-09-22, what proportion of acute lymphoblastic leukemia patients progress from first-line to subsequent lines of therapy, and what clinical or treatment-related factors are associated with attrition between lines for all patients?","reason":"no usable evidence after 1 retrieval round(s); abandoned after 480s; sources did not respond","sources_attempted":"none"}],"answers":[{"question":"As of 2026-09-22 in the United States, what first-line treatment regimens are recommended by major clinical guidelines for acute lymphoblastic leukemia across induction, consolidation, maintenance, and MRD-positive settings, stratified by guideline preference category and relevant disease subtype or patient segment for all patients?","seed":"What are the current guideline-recommended first-line regimens for ALL, by treatment setting (induction, consolidation, maintenance, MRD-positive) and guideline preference category (e.g., NCCN Preferred / Other Recommended / Useful in Certain Circumstances)?","answer":"The supplied documents do not provide a comprehensive list of United States first-line treatment regimens for acute lymphoblastic leukemia across induction, consolidation, maintenance, and MRD-positive settings stratified by guideline preference categories. The documents do identify some guideline or cooperative-group treatment approaches and disease subsets. An ASCO Educational Book review states that “Contemporary COG HR ALL treatment regimens were developed from the BFM-76 regimen, with subsequent changes that led to development and refinement of a so-called augmented BFM (ABFM) regimen used today,” and notes that “introduction of the tyrosine kinase inhibitor imatinib has led to dramatic outcome improvements for children and adolescents with Philadelphia chromosome–positive ALL.” A pediatric maintenance-focused recommendation document from the French Society for Childhood and Adolescent Cancer and Leukemia states that “Maintenance therapy is the last phase of treatment for acute lymphoblastic leukemia in children and adolescents” and that it “is an essential phase of treatment that reduces the risk of relapse.” An ASH 2026 guideline document addresses relapsed/refractory AYA ALL rather than first-line disease, reporting that “Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction.” The supplied documents identify two major guideline bodies relevant to frontline acute lymphoblastic leukemia (ALL) management in the United States as of 2025–2026: the NCCN and the American Society of Hematology (ASH). The NCCN Pediatric ALL Version 2.2025 guideline states that it addresses “risk assessment and stratification of risk-adapted therapy” and includes “treatment strategies for BCR::ABL1 (Philadelphia chromosome [Ph])-negative and BCR::ABL1-positive B-cell lineage, T-cell lineage, and infant ALL,” but the supplied text does not provide specific first-line induction, consolidation, maintenance, or MRD-positive regimens, nor preference categories. The ASH 2026 AYA ALL guideline states that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols,” that “Allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy,” and that “The use of targeted agents in frontline therapy is increasingly supported,” but the supplied excerpts do not enumerate regimen names, treatment phases, MRD-directed regimens, or formal preference categories. The supplied documents do not provide a comprehensive list of U.S. major clinical guideline recommendations, versions, preference categories, or complete first-line regimens across induction, consolidation, maintenance, and MRD-positive settings for acute lymphoblastic leukemia. The documents only describe selected induction-treatment concepts and asparaginase-related recommendations for specific populations. For adult ALL induction, the NCI PDQ document states that \"Most current induction regimens for patients with adult ALL include combination chemotherapy with prednisone, vincristine, and an anthracycline,\" and that some regimens \"also add other drugs, such as asparaginase or cyclophosphamide.\" For Ph-positive ALL, the same document states that \"Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL.\" Separate consensus-panel documents for adolescent and young adult patients state that \"Asparaginase is an integral component of therapy for pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma\" and describe use of \"pediatric/pediatric-inspired regimens incorporating asparaginase for treating adolescent and young adult (AYA) and adult populations.\" The supplied documents do not provide a complete accounting of U.S. first-line treatment regimens for acute lymphoblastic leukemia across induction, consolidation, maintenance, and MRD-positive settings by guideline preference category. The documents only identify limited guideline-related statements. One document states that \"guidelines from the National Comprehensive Cancer Network now recommend consideration of pediatric inspired treatment\" for adolescent and young adult patients with ALL. Another document describes the \"American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults,\" which \"cover[] remission reinduction and consolidation\" and include recommendations such as \"the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction.\" The documents do not provide the requested full stratification by induction, consolidation, maintenance, MRD-positive settings, preference categories, or comprehensive disease subtype segmentation for all patients. The supplied documents do not provide a comprehensive set of major U.S. clinical guideline recommendations for first-line acute lymphoblastic leukemia treatment across induction, consolidation, maintenance, and MRD-positive settings stratified by guideline preference categories. One FDA document describes a regimen used with ponatinib for newly diagnosed Philadelphia chromosome-positive ALL in adults: “Chemotherapy consisted of 3 cycles of induction with vincristine and dexamethasone, 6 cycles of consolidation alternating between methotrexate and cytarabine, and 11 cycles of maintenance with vincristine and prednisone.” The pediatric evidence-based review documents state that “allogeneic SCT may be considered for hypodiploid ALL and persistent minimal residual disease [corrected] (MRD) positivity in ALL in CR1 or greater,” and also note that “preliminary tyrosine kinase inhibitor (TKI) data demonstrate that early outcomes are comparable for allogeneic SCT and chemotherapy + imatinib” for children with Ph+ ALL in CR1. The supplied documents identify NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia and pediatric acute lymphoblastic leukemia, including risk-stratified and frontline management concepts, but they do not provide the specific first-line treatment regimens, induction/consolidation/maintenance protocols, MRD-positive regimens, or preference categories requested. The adult ALL NCCN guideline documents state that they provide \"risk-stratified treatment approaches based on the Philadelphia chromosome status and age (adults vs. adolescents/young adults), assessment of minimal residual disease,\" while the pediatric guideline states that it \"focuses on the frontline and relapsed/refractory management of pediatric ALL.\" The pediatric guideline also identifies high-risk groups including \"T-ALL\" and \"infant ALL.\" No guideline version dated 2026-09-22, no regimen names, and no recommendation categories are present in the supplied text. The supplied documents identify NCCN Clinical Practice Guidelines as major U.S. clinical guidelines for acute lymphoblastic leukemia (ALL), including adult ALL Version 2.2024 and Pediatric ALL Version 2.2025. The documents state that these guidelines cover “risk assessment and stratification for risk-adapted therapy” and “treatment strategies” for multiple disease subtypes and patient groups, including “Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients” and pediatric “BCR::ABL1-positive B-cell lineage, T-cell lineage, and infant ALL.” However, the documents provided do not include the actual first-line treatment regimens, induction/consolidation/maintenance recommendations, MRD-positive recommendations, or preference categories requested in the question. The supplied documents identify the National Comprehensive Cancer Network (NCCN) pediatric and adult acute lymphoblastic leukemia (ALL) guidelines and state that they provide treatment recommendations for frontline and relapsed/refractory management, but they do not provide the specific first-line treatment regimens across induction, consolidation, maintenance, or MRD-positive settings requested in the question. The documents also do not provide guideline preference categories, detailed subtype-specific regimen recommendations, or risk/biomarker-stratified first-line regimen tables. One document specifies \"Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology,\" while another specifies \"NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017.\" The supplied documents identify guideline bodies and some treatment-structure and stratification concepts for acute lymphoblastic leukemia (ALL), but they do not provide a complete list of first-line treatment regimens across induction, consolidation, maintenance, and MRD-positive settings stratified by guideline preference category. The Medscape summary updated March 17, 2026 states that ALL therapy includes “an induction phase with a goal of achieving complete remission (CR)” followed by “a consolidation phase to maintain CR,” and that follow-up is “with maintenance therapy or allogeneic hematopoietic stem cell transplantation (HSCT).” It also states that treatment decisions may be influenced by “Philadelphia chromosome (Ph)(BCR::ABL1) status,” “Presence of CD20-positive disease,” “Cell origin (B-cell vs T-cell),” and “Minimal residual disease (MRD) status.” The ASH document identifies itself as the “American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults,” but the supplied text does not include the specific frontline regimens, recommendation strengths, or preference categories requested.","status":"partial","citations":["American Society of Clinical Oncology Educational Book","Bulletin du cancer","Blood advances","Journal of the National Comprehensive Cancer Network : JNCCN","National Cancer Institute","American journal of hematology","Journal of Clinical Oncology","American Society of Hematology","FDA","Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation","Open web"],"sources":["asco","ashpublications","clinicaltrials","esmo","fda","nci","open_web"],"evidence_count":14,"coverage":0.8,"supplementary":true,"unmet_reason":""},{"question":"As of 2026-09-22 in the United States, what regimens are recommended by major clinical guidelines for relapsed, refractory, and later-line acute lymphoblastic leukemia, organized by treatment setting, line of therapy, and guideline preference category for all patients?","seed":"What are the guideline-recommended regimens for later-line, relapsed, or refractory ALL, by treatment setting and guideline preference category?","answer":"The supplied documents discuss recommendations for relapsed/refractory acute lymphoblastic leukemia (ALL), including immunotherapy, targeted therapy, transplantation, and CNS-directed therapy, but they do not provide a complete regimen-by-regimen listing organized by treatment setting, line of therapy, and guideline preference category for all patients in the United States as of 2026-09-22. The ASH 2026 guideline for adolescents and young adults (AYAs) states that recommendations \"focused on the following treatment modalities: immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy\" and that \"Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction.\" The NCCN Guidelines Insights document states that recommendations for relapsed/refractory ALL include \"more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation,\" but the provided text does not enumerate specific preferred regimens, later-line sequences, or preference categories. The supplied documents do not provide a complete listing of U.S. guideline-recommended regimens for relapsed, refractory, and later-line acute lymphoblastic leukemia organized by treatment setting, line of therapy, and guideline preference category. The NCCN documents only state that the guidelines include “treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients,” but the excerpts provided specifically note that the selection “focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence.” The ASH 2026 guideline document specifically addresses “management of relapsed/refractory ALL in adolescents and young adults” and states that “Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction,” while also addressing “T-cell ALL,” “CNS relapse,” and “the role of consolidation with allogeneic transplant.” The documents do not provide the full regimen tables, later-line sequencing, or NCCN preference categories requested. The supplied documents do not provide major clinical guideline recommendations organized by treatment setting, line of therapy, preference category, disease subtype, or transplant/cellular therapy pathways for relapsed, refractory, and later-line acute lymphoblastic leukemia in the United States as of 2026-09-22. The documents only identify selected therapies and populations in relapsed/refractory ALL, including clofarabine for pediatric patients after at least two prior regimens and references to studies involving blinatumomab and inotuzumab ozogamicin in relapsed/refractory adult ALL. One document states that clofarabine \"is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.\" Another document references \"adult patients with relapsed or refractory acute lymphoblastic leukemia receiving zero or one prior salvage therapy,\" and another references \"Relapsed/Refractory Philadelphia Chromosome–Negative B-Cell Acute Lymphoblastic Leukemia.\" The supplied documents do not provide major United States clinical guideline recommendations, preference categories, or organized line-of-therapy tables for relapsed, refractory, or later-line acute lymphoblastic leukemia as of 2026-09-22. The documents do describe investigational and salvage approaches in relapsed/refractory ALL settings, including venetoclax-based regimens in relapsed/refractory T-ALL/LBL, CD7 CAR-T therapy in relapsed/refractory T-ALL/LBL, and comparisons between CAR-T therapy and allogeneic HSCT in relapsed/refractory B-ALL. Reported treatment approaches include “Ven monotherapy,” “Ven + hypomethylating agent,” “Ven + chemotherapy,” “Ven + nelarabine,” “Ven + targeted agent,” and “Ven + navitoclax” for heavily pre-treated relapsed/refractory T-ALL/LBL patients, while cellular and transplant therapies discussed include “autologous CD7 CAR T-cell therapy,” “stem cell transplantation (SCT),” “Allogenic Hematopoietic Stem Cell Transplantation (HSCT),” and “CAR-T Cell Therapy.” The supplied document discusses relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) in children, adolescents, and young adults in the context of CAR-T-cell therapy and bridging therapy, but it does not provide a comprehensive list of United States major clinical guideline regimens by treatment setting, line of therapy, or preference category. It states that \"there is currently no available guidelines\" for the bridging period before CAR-T-cell reinfusion and describes an effort to \"define recommendations of treatment in each situation of relapsed or refractory B-ALL, Ph+/ABL-like B-ALL and in case of CNS disease or non-CNS extra medullary disease, precising the specific place of immunotherapy.\" The document also identifies CAR-T cells as a major therapeutic modality in relapsed/refractory B-ALL and references disease subtype stratification including \"Ph+/ABL-like B-ALL\" and CNS versus non-CNS extramedullary disease. The supplied documents identify that NCCN guidelines for acute lymphoblastic leukemia (ALL) include recommendations for “risk-stratified treatment approaches based on the Philadelphia chromosome status and age (adults vs. adolescents/young adults),” and that pediatric NCCN guidelines address “frontline and relapsed/refractory management of pediatric ALL,” including “hematopoietic stem cell transplantation.” However, the documents provided do not list specific relapsed, refractory, or later-line regimens, do not provide line-of-therapy tables, do not identify guideline preference categories, and do not specify cellular therapy regimens or transplant sequencing recommendations. One document also identifies the topic of “Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults: Progress and Challenges,” but provides no regimen-level recommendations in the supplied text. The supplied document does not provide major clinical guideline recommendations for relapsed, refractory, or later-line acute lymphoblastic leukemia (ALL), including treatment setting, line of therapy, guideline preference categories, disease subtype stratification, or cellular therapies. It does contain limited statements relevant to transplantation and Philadelphia chromosome (Ph)-positive ALL in the context of remission duration and treatment considerations. Specifically, the document states that “Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials” and that “If a suitable donor is available, allogeneic bone marrow transplant should be considered because remissions are generally short with conventional ALL chemotherapy clinical trials.” The supplied documents do not contain major clinical guideline recommendations, preference categories, treatment-setting organization, transplant guidance, or cellular therapy recommendations for relapsed, refractory, or later-line acute lymphoblastic leukemia. The documents only provide FDA labeling indications for specific agents in relapsed or refractory ALL/T-ALL settings after at least two prior regimens. Nelarabine is indicated for \"T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL)\" in patients \"whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.\" Clofarabine is indicated for \"pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.\" The supplied documents identify that NCCN Clinical Practice Guidelines for acute lymphoblastic leukemia (ALL) include recommendations on “risk-stratified treatment approaches based on the Philadelphia chromosome status and age (adults vs. adolescents/young adults)” and that pediatric ALL guidelines address “treatment strategies for BCR::ABL1 (Philadelphia chromosome [Ph])-negative and BCR::ABL1-positive B-cell lineage, T-cell lineage, and infant ALL.” The documents also state that the pediatric guidelines focus on “the diagnosis of and management of pediatric T-ALL.” However, the supplied excerpts do not provide the requested relapsed/refractory or later-line regimens, line-of-therapy recommendations, preference categories, cellular therapies, or transplant recommendations. The supplied documents identify that NCCN maintains \"NCCN Guidelines Version 3.2026 - Acute Lymphoblastic Leukemia\" and \"NCCN Guidelines with Evidence Blocks Version 2.2026,\" but they do not provide the actual recommended regimens, treatment settings, lines of therapy, preference categories, subtype stratification, or cellular/transplant therapy recommendations requested. One supplementary document mentions blinatumomab in \"chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients,\" but no organized guideline recommendations for relapsed, refractory, or later-line ALL are included in the provided text.","status":"partial","citations":["American Society of Hematology","Journal of the National Comprehensive Cancer Network : JNCCN","Blood advances","Dr.Reddy's Laboratories Inc","Journal of Clinical Oncology","JCO Precision Oncology","Bulletin du cancer","JCO Oncology Practice","National Cancer Institute","Alembic Pharmaceuticals Limited","Amneal Pharmaceuticals LLC","US Food and Drug Administration","Open web"],"sources":["asco","ashpublications","clinicaltrials","esmo","nci","open_web","openfda_label"],"evidence_count":14,"coverage":0.72,"supplementary":true,"unmet_reason":""},{"question":"As of 2026-09-22 in the United States, which drugs, biologics, and cellular therapies have FDA or other official regulatory approval for acute lymphoblastic leukemia, including labeled indication, approved treatment line, biomarker restriction, approval date, and coding identifiers for all patients?","seed":"Which therapies are FDA-approved (or otherwise officially approved) for ALL, with label indication, approved line, biomarker restriction, and approval date?","answer":"The supplied documents identify three FDA-approved drug products for acute lymphoblastic leukemia (ALL): clofarabine, imatinib mesylate, and dasatinib. Clofarabine injection is indicated for “pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens,” with “Initial U.S. Approval: 2004.” Imatinib mesylate is indicated for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)” and for “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy,” with “Initial U.S. Approval: 2001.” Dasatinib tablets are indicated for “Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy” in adults and for “pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy,” with “Initial U.S. Approval: 2006.” The documents provide biomarker restrictions through the requirement for “Philadelphia chromosome-positive (Ph+)” disease where applicable, but they do not provide billing codes, HCPCS codes, NDC-based coding summaries, biologics approvals, or cellular therapy approvals for ALL. The supplied documents identify several FDA-approved therapies for acute lymphoblastic leukemia (ALL) in the United States, but they do not provide comprehensive coverage of all approved drugs, biologics, cellular therapies, or billing/product coding identifiers. SPRYCEL (dasatinib) is indicated for “adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy,” establishing a biomarker restriction of Ph+ status and a relapsed/refractory treatment setting; the label also states “Initial U.S. Approval: 2006.” Imatinib mesylate is indicated for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)” and for “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy,” again restricting use to Ph+ ALL. ARRANON (nelarabine) appears in the FDA Drugs@FDA record with “ORIG 1 AP 2005-10-28,” but the provided text does not include the ALL indication, treatment line, biomarker restriction, or coding identifiers. The supplied documents identify FDA-approved treatments for acute lymphoblastic leukemia including nelarabine and clofarabine, but they do not provide a complete list of all approved drugs, biologics, or cellular therapies in the United States as of 2026-09-22, and they do not provide billing or product coding identifiers. Nelarabine injection received \"Initial U.S. Approval: 2005\" and is indicated for \"T-cell acute lymphoblastic leukemia (T-ALL)\" in \"adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens,\" establishing a relapsed/refractory setting after at least two prior regimens and a biomarker/disease restriction to T-cell ALL. Clofarabine injection received \"Initial U.S. Approval: 2004\" and is indicated for \"pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens,\" defining a pediatric relapsed/refractory treatment line after at least two prior regimens without an additional biomarker restriction stated in the supplied text. The supplied document discusses hematopoietic stem cell transplantation recommendations in pediatric acute lymphoblastic leukemia (ALL), including certain disease settings and biomarkers such as Philadelphia chromosome positive (Ph+) ALL, but it does not provide FDA or other regulatory approvals, approval dates, labeled indications, treatment lines in regulatory labeling, or billing/product coding identifiers for drugs, biologics, or cellular therapies in the United States. The document states that “Allogeneic SCT is recommended for children who: are in second complete remission (CR2) after experiencing an early marrow relapse for precursor-B ALL; experienced primary induction failure, but subsequently achieved a CR1; have T-lineage ALL in CR2; or have ALL in third or greater remission.” It also notes that “the 2005 pediatric ALL evidence-based review (EBR) recommended allogeneic SCT for children with Philadelphia chromosome positive (Ph+) ALL in CR1,” and references “chemotherapy + imatinib,” but no regulatory approval details are given. The supplied documents do not provide a comprehensive list of FDA- or regulator-approved drugs, biologics, or cellular therapies for acute lymphoblastic leukemia, nor do they provide approval dates or billing/product coding identifiers. The documents do identify certain therapies discussed in guideline contexts for relapsed/refractory ALL, including “tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation” and recommendations involving “blinatumomab and/or inotuzumab over chemotherapy for reinduction.” The ASH guideline document specifically addresses adolescents and young adults with relapsed/refractory ALL and states that recommendations focused on “immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy.” No document supplies labeled FDA indications, treatment lines, biomarker restrictions, approval dates, HCPCS/J-codes, NDCs, or other coding identifiers for all approved ALL products. The supplied documents do not provide a complete list of FDA- or regulator-approved drugs, biologics, or cellular therapies for acute lymphoblastic leukemia in the United States, nor do they provide approval dates or billing/product coding identifiers. The documents mention several therapies in the context of ALL management and future or investigational use. One guideline states: “Patients with refractory/relapsed disease have a poor prognosis which highlights the importance of acquiring in the future new therapies such as: blinatumumab, inotuzumab, and CAR-T cells.” Another document describes CAR-T therapy as investigational and notes that “CAR-T therapy may be offered to people when their cancer comes back.” The documents also mention a biomarker-restricted subgroup: “For patients with Philadelphia chromosome positive (Phi+) ALL, post-transplantation tyrosine kinase inhibitors as a systematic maintenance strategy is recommended.” The supplied documents discuss treatment approaches and guideline recommendations for acute lymphoblastic leukemia (ALL), including T-cell ALL and adolescent/young adult ALL, but they do not provide a list of FDA-approved drugs, biologics, or cellular therapies, approval dates, labeled indications, treatment lines, biomarker restrictions, or billing/product coding identifiers. The documents state that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols” and that “The use of targeted agents in frontline therapy is increasingly supported, although further research is needed to optimize this strategy.” They also describe asparaginase as “an integral component of therapy for pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma.” No document supplies the requested regulatory approval tables or coding data. The supplied documents identify two FDA-labeled drugs for acute lymphoblastic leukemia (ALL): mercaptopurine and methotrexate. Mercaptopurine is labeled for “the treatment of patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen,” with no explicit biomarker restriction for indication, although TPMT and NUDT15 testing and dose modifications are discussed for toxicity management. Methotrexate Injection is labeled for “the treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy regimen.” The documents also include an FDA Drugs@FDA entry for ICLUSIG (ponatinib), but the supplied text does not state an ALL indication, treatment line, biomarker restriction, or approval details specific to ALL. The documents do not provide billing codes, HCPCS/J-codes, NDCs, or other coding identifiers for ALL products. The supplied documents identify FDA-approved tyrosine kinase inhibitor products for Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), specifically imatinib mesylate/Gleevec and Sprycel. Imatinib mesylate is indicated for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)” and for “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.” The biomarker restriction stated is “Philadelphia chromosome positive (Ph+ ALL).” The documents also provide FDA approval history for Gleevec and Sprycel, including “ORIG 1 AP 2003-04-18” for Gleevec and “ORIG 1 AP 2006-06-28” for Sprycel, but they do not provide ALL-specific approval dates, labeled ALL treatment lines for Sprycel, or any billing/product coding identifiers such as HCPCS or J-codes. The supplied documents identify methotrexate and doxorubicin as FDA-labeled products for acute lymphoblastic leukemia (ALL). Methotrexate tablets are indicated for the “treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen,” which specifies a maintenance treatment setting and includes both adult and pediatric patients without a biomarker restriction. Doxorubicin hydrochloride injection is indicated “for the treatment of acute lymphoblastic leukemia,” and the labeling also provides dosing for “Metastatic Disease, Leukemia, or Lymphoma,” including single-agent and combination therapy dosing, but no biomarker restriction is stated. The documents do not provide approval dates, HCPCS/CPT/NDC billing or product codes, or a complete list of all FDA-approved drugs, biologics, or cellular therapies for ALL in the United States. The supplied documents discuss clinical practice guidelines and diagnostic/cytogenetic stratification for acute lymphoblastic leukemia (ALL), including pediatric, adult, Philadelphia chromosome (Ph)-positive and Ph-negative disease, but they do not provide a list of FDA-approved drugs, biologics, or cellular therapies, nor approval dates, labeled indications, treatment lines, biomarker restrictions tied to approvals, or billing/product coding identifiers. The NCCN guideline documents state that they focus on “treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL” and “management of ALL, with a focus on the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers.” The cytogenetics document notes that “Ph-like ALL ... can benefit from targeted therapy,” but does not identify approved products or regulatory details. The supplied documents identify methotrexate products as FDA-labeled therapies for acute lymphoblastic leukemia (ALL) in the United States. Methotrexate Injection is indicated for “treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy regimen,” while methotrexate tablets are indicated for “treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.” The documents do not provide approval dates, biomarker restrictions, cellular therapies, biologics, or billing/product coding identifiers, and they do not comprehensively list all FDA-approved ALL therapies as of 2026-09-22. The supplied documents identify doxorubicin products as approved/indicated for acute lymphoblastic leukemia in the United States. One label states: “Doxorubicin is indicated for the treatment of acute lymphoblastic leukemia,” and another states that “DOXOrubicin HCl Injection, USP and DOXOrubicin HCl for Injection, USP have been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia.” The documents do not provide FDA approval dates, biomarker restrictions, treatment-line limitations, or billing/product coding identifiers for acute lymphoblastic leukemia, nor do they identify other approved ALL drugs, biologics, or cellular therapies. The documents discuss several therapies used or under development for acute lymphoblastic leukemia (ALL), including imatinib for newly diagnosed Philadelphia chromosome–positive ALL, blinatumomab and inotuzumab in relapsed/refractory ALL, and CAR-T cells being tested in ALL. However, the documents do not provide comprehensive FDA or other official regulatory approval information, approved labeling language, approval dates, treatment-line specifications, billing/product codes, or complete biomarker restrictions. The only explicit biomarker-linked treatment statement is for “Ph-positive ALL” or “Philadelphia chromosome positive (Phi+) ALL” in relation to imatinib and tyrosine kinase inhibitors. One document describes a clinical trial regimen for “adult patients with Ph Negative ALL,” but it is explicitly a study and not an approval document. Another document lists FDA Drugs@FDA product information for methotrexate formulations, including NDA and submission dates, but it does not state an ALL indication, treatment line, biomarker restriction, approval for ALL, or billing/product coding identifiers.","status":"partial","citations":["Dr.Reddy's Laboratories Inc","Apotex Corp","BluePoint Laboratories","US Food and Drug Administration","SANDOZ","Alembic Pharmaceuticals Limited","Amneal Pharmaceuticals LLC","Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation","Journal of the National Comprehensive Cancer Network : JNCCN","American Society of Hematology","Bulletin du cancer","National Cancer Institute (NCI)","Journal of Clinical Oncology","Hikma Pharmaceuticals USA Inc.","Hospira, Inc.","NOVARTIS","BRISTOL MYERS SQUIBB","Sun Pharmaceutical Industries, Inc.","Bryant Ranch Prepack","Pfizer Laboratories Div Pfizer Inc","Current research in translational medicine","Alembic Pharmaceuticals Inc.","Aurobindo Pharma Limited","National Cancer Institute","American Society of Clinical Oncology Educational Book","Memorial Sloan Kettering Cancer Center","HOSPIRA"],"sources":["asco","ashpublications","clinicaltrials","esmo","nci","openfda_drugsfda","openfda_label"],"evidence_count":14,"coverage":0.53,"supplementary":false,"unmet_reason":""},{"question":"As of 2026-09-22 in the United States, how do guideline-recommended treatment pathways for acute lymphoblastic leukemia differ by Philadelphia chromosome status, molecular biomarkers, MRD status, and other risk segments, and at which clinical timepoints is biomarker testing recommended or expected for treatment selection in all patients?","seed":"How does ALL treatment differ between Ph-positive and Ph-negative disease and by other biomarker or risk segments, and at what point in the journey is biomarker testing expected (at diagnosis vs. at progression)?","answer":"The documents distinguish treatment pathways primarily by Philadelphia chromosome/BCR-ABL status, MRD status, and selected biomarkers such as CD20 positivity and BCR-ABL-like phenotype. For Ph-positive ALL, the NCI PDQ states that \"inclusion of imatinib into a relatively standard chemotherapy regimen for newly diagnosed adult patients with Ph-positive ALL may provide a significant survival advantage\" and that \"Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials,\" with consideration of \"allogeneic bone marrow transplant\" because remissions are short with conventional chemotherapy. For BCR-ABL-negative B-lineage ALL, the trial document evaluates adding blinatumomab to chemotherapy specifically in patients who are \"minimal residual disease (MRD) negative after induction and intensification chemotherapy,\" while also comparing outcomes in patients who are MRD positive and later convert to MRD negative after blinatumomab. Biomarker-directed elements in the protocol include evaluation of \"BCR/ABL1-like B-lineage ALL\" and optional rituximab use for \"CD20 positive patients.\" The documents indicate biomarker or disease-status assessment at diagnosis and after induction/intensification chemotherapy, including \"multiparameter flow cytometric (MFC) assessment of residual blasts\" for MRD-based treatment selection, but they do not provide comprehensive U.S. guideline-recommended pathways across all ALL risk groups or all expected testing timepoints. The supplied ASH 2026 guidelines describe that frontline and relapsed/refractory ALL treatment pathways differ for certain higher-risk subsets and disease subsets, but they do not provide a complete biomarker-based treatment algorithm by Philadelphia chromosome status, molecular biomarkers, MRD status, or testing timepoints. For frontline AYA ALL, the guidelines state that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols,” and that “Allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy.” They also state that “The use of targeted agents in frontline therapy is increasingly supported.” For relapsed/refractory AYA ALL, the guidelines report that recommendations “focused on the following treatment modalities: immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy,” including “the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction,” and they additionally mention “ALL subsets (T-cell ALL), CNS relapse, and the role of consolidation with allogeneic transplant.” The documents do not specify Philadelphia chromosome-directed pathways, MRD-directed treatment changes, required biomarker panels, or when biomarker testing is recommended or expected for all patients. The supplied documents indicate that acute lymphoblastic leukemia treatment and outcomes may differ by Philadelphia chromosome status, including references to “Philadelphia chromosome-associated acute lymphoblastic leukemia (Ph+ ALL)” and to “Clinical outcome of adult acute lymphoblastic leukemia based on Philadelphia chromosome status and socioeconomic status.” One document also references “BCR-ABL mutation status” in “imatinib-resistant patients,” implying molecular biomarker considerations in Ph+ ALL. However, the documents do not provide guideline-recommended treatment pathways, MRD-based stratification, testing timepoints, or detailed risk-segment recommendations. The supplied documents identify that NCCN maintains U.S. Acute Lymphoblastic Leukemia guidelines and biomarker-testing resources through “NCCN Guidelines Version 3.2026 - Acute Lymphoblastic Leukemia” and the “NCCN Biomarkers Compendium®,” but they do not provide the actual treatment pathways, biomarker-specific recommendations, MRD-directed algorithms, Philadelphia chromosome–specific regimens, risk stratification categories, or testing timepoints requested in the question. The documents do state that the NCCN Biomarkers Compendium includes tests used for “Diagnosis,” “Monitoring,” “Prediction,” and “Prognostication,” and that these tests are “recommended within the NCCN Guidelines.” No detailed ALL treatment algorithms or biomarker-triggered treatment selection rules are included in the supplied text.","status":"partial","citations":["National Cancer Institute","National Cancer Institute (NCI)","American Society of Hematology","Blood advances","Journal of Clinical Oncology","Open web"],"sources":["asco","ashpublications","clinicaltrials","esmo","nci","open_web"],"evidence_count":14,"coverage":0.8,"supplementary":true,"unmet_reason":""},{"question":"In the United States through 2026-09-22, what recent FDA approvals and label expansions have occurred for acute lymphoblastic leukemia therapies, including the affected products, indications, biomarker requirements, and effective dates for all patients?","seed":"What recent FDA approvals or label expansions have occurred in ALL?","answer":"The supplied documents identify FDA-related submissions and current labeled acute lymphoblastic leukemia (ALL) indications for GLEEVEC and dasatinib, but they do not comprehensively describe all recent FDA approvals or label expansions for ALL therapies through 2026-09-22. For GLEEVEC, the Drugs@FDA record lists multiple approved supplements, including \"SUPPL 63 AP 2024-03-01 Manufacturing (CMC) N/A\" and earlier efficacy and labeling approvals, but the document does not state the ALL indication changes associated with those actions. For dasatinib, the labeling states that it is indicated for \"Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy\" in adults and for \"pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy,\" establishing a biomarker requirement of \"Philadelphia chromosome-positive (Ph+).\" The dasatinib label also states \"Initial U.S. Approval: 2006,\" but no recent FDA effective dates or expansion approval dates are provided in the supplied text. The supplied FDA Drugs@FDA records show recent supplemental FDA actions for several acute lymphoblastic leukemia therapies, but they do not provide the underlying indication text, label-expansion details, biomarker requirements, or patient populations. For SPRYCEL (dasatinib), the record includes recent actions such as “SUPPL 28 AP 2024-07-31 Labeling STANDARD” and earlier efficacy supplements including “SUPPL 21 AP 2018-12-21 Efficacy PRIORITY.” For ARRANON (nelarabine), the record includes “SUPPL 14 AP 2025-03-11 Labeling STANDARD” and “SUPPL 10 AP 2019-07-31 Efficacy STANDARD.” For ICLUSIG (ponatinib), the record includes “SUPPL 38 AP 2025-10-10 Efficacy STANDARD” and “SUPPL 34 AP 2020-12-18 Efficacy PRIORITY.” The documents do not state the specific ALL indications, label-expansion wording, biomarker requirements, or effective-date language for patients. The supplied document identifies FDA-labeled acute lymphoblastic leukemia (ALL) indications for imatinib mesylate, but it does not describe any recent FDA approvals or label expansions through 2026-09-22. The label states that imatinib mesylate is indicated for “Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)” and for “Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.” The biomarker requirement specified for these ALL indications is “Philadelphia chromosome positive (Ph+).” The only approval timing provided is “Initial U.S. Approval: 2001,” and no effective dates for newer approvals or label expansions are included in the supplied material. On March 19, 2024, the FDA granted accelerated approval to ponatinib (Iclusig) with chemotherapy for “adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).” The biomarker/eligibility requirement specified in the indication was Philadelphia chromosome-positive disease. In June 2024, the FDA expanded approval of Blincyto (blinatumomab) to include “adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase, regardless of measurable residual disease (MRD) status.” The expanded Blincyto indication therefore changed eligibility to include patients regardless of MRD status, while retaining biomarker requirements of CD19-positive and Philadelphia chromosome-negative disease.","status":"partial","citations":["NOVARTIS","BluePoint Laboratories","BRISTOL MYERS SQUIBB","SANDOZ","TAKEDA PHARMS USA","Apotex Corp","Open web"],"sources":["esmo","open_web","openfda_drugsfda","openfda_label"],"evidence_count":11,"coverage":0.48,"supplementary":true,"unmet_reason":""},{"question":"In the United States through 2026-09-22, which acute lymphoblastic leukemia therapy approvals or indications have been withdrawn, restricted, or otherwise modified by regulators, including accelerated-approval changes and the associated effective dates for all patients?","seed":"Which approvals or indications in ALL have been withdrawn or restricted (e.g., accelerated-approval withdrawals), and on what dates?","answer":"The supplied documents do not identify any acute lymphoblastic leukemia therapy approvals or indications that were withdrawn, restricted, or otherwise modified by regulators, and they do not provide effective dates for such actions. The only relevant regulatory qualification in the documents is for clofarabine injection, where the indication states that it is \"based upon response rate\" and that there are \"no trials verifying an improvement in disease-related symptoms or increased survival.\" The ICLUSIG record lists multiple FDA supplement actions and dates, including efficacy and labeling supplements, but does not describe any withdrawn or restricted ALL indications. The supplied documents do not identify any acute lymphoblastic leukemia (ALL) therapy approvals or indications in the United States that were withdrawn, restricted, or modified through 2026-09-22. The documents discuss oncology accelerated approvals and withdrawals generally, including examples in lung, breast, and bladder cancers, but they do not name any ALL therapies, indications, or effective dates relevant to ALL patients. The provided documents do not identify any withdrawn acute lymphoblastic leukemia (ALL) indications in the United States through 2026-09-22. They do identify regulatory modifications affecting ALL therapies: on March 19, 2024, the FDA granted “accelerated approval” to ponatinib (Iclusig) with chemotherapy for “adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).” The documents also show regulatory changes for TECARTUS (brexucabtagene autoleucel), including a “REMS Major Modification Approval Letter” dated June 12, 2024, and a “REMS Elimination Approval Letter” dated June 26, 2025, for a product indicated for “Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).”","status":"partial","citations":["US Food and Drug Administration","TAKEDA PHARMS USA","Journal of Clinical Oncology","Open web"],"sources":["asco","esmo","open_web","openfda_drugsfda","openfda_label"],"evidence_count":12,"coverage":0.75,"supplementary":true,"unmet_reason":""},{"question":"As of 2026-09-22 in the United States, which drugs, biologics, and cellular therapies are used off-label or supported by compendia for acute lymphoblastic leukemia by line of therapy, including supporting compendia status and relevant coding identifiers for all patients?","seed":"Which products are used off-label or are compendia-supported for ALL, by line of therapy, and what codes represent each?","answer":"The supplied documents identify FDA-labeled therapies for acute lymphoblastic leukemia (ALL) and relapsed/refractory T-cell ALL, including therapy class and prior-line context, but they do not provide off-label uses, compendia-supported uses, compendia status, or coding identifiers. Clofarabine is described as “a nucleoside metabolic inhibitor indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens,” establishing a relapsed/refractory setting after at least two prior lines. Nelarabine is described as “a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens,” also specifying treatment after at least two prior regimens. Methotrexate is identified as “a folate analog metabolic inhibitor” indicated for “treatment of adult and pediatric patients with acute lymphoblastic leukemia as part of a combination chemotherapy regimen” and for “prophylaxis and treatment of adult and pediatric patients with meningeal leukemia,” but no line-of-therapy, off-label, compendia, biologic, cellular therapy, or coding information is supplied. The supplied documents identify several therapies used in acute lymphoblastic leukemia (ALL), including immunotherapy, targeted therapies, CAR-T cellular therapy, and methotrexate, but they do not provide compendia status details, coding identifiers, or a comprehensive off-label-use listing by line of therapy. For relapsed/refractory ALL in adolescents and young adults, the ASH 2026 guideline states that recommendations for remission reinduction and consolidation “focused on the following treatment modalities: immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy,” and that “Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction.” CD19 CAR therapy is described as an emerging cellular immunotherapy for B-cell ALL with “remarkable clinical outcomes in adults and children with ALL,” and methotrexate is FDA-indicated for “treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.” The documents do not provide HCPCS, CPT, ICD-10, NDC, or other coding identifiers, and they do not explicitly identify any therapy as off-label or compendia-supported. The documents identify FDA-labeled therapies and guideline-supported modalities for acute lymphoblastic leukemia (ALL), but they do not provide compendia status details, coding identifiers, or a comprehensive list of off-label therapies. Methotrexate is described as a “folate analog metabolic inhibitor” indicated for “adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy regimen,” and mercaptopurine is described as a “nucleoside metabolic inhibitor” indicated for “patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.” The ASH 2026 relapsed/refractory ALL guideline addresses later-line therapy concepts in adolescents and young adults, stating that recommendations “focused on the following treatment modalities: immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy,” and that “Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction.” The supplied documents do not provide billing or coding identifiers, explicit compendia classifications, or explicit statements that these uses are off-label. The documents describe several therapies and therapy classes used in acute lymphoblastic leukemia (ALL), including first-line chemotherapy, hematopoietic stem-cell transplantation, targeted therapy, CAR-T cellular therapies, and lymphodepletion regimens, but they do not provide compendia support status, coding identifiers, or a comprehensive off-label use listing. For first-line therapy, one source states that \"Modern first-line therapy consists of standard- and high-dose chemotherapy (increasingly inspired to pediatric principles), hematopoietic stem-cell transplantation, and new targeted therapy.\" For relapsed or refractory B-cell ALL, investigational CAR-T approaches described include TSLPR-CART and commercial tisagenlecleucel CAR T-cell therapy, with one study requiring disease that \"is relapsed or refractory after initial systemic therapy and at least one salvage treatment.\" The supplied documents do not identify NCCN or other compendia recommendations, HCPCS/CPT/ICD coding identifiers, or a complete by-line-of-therapy catalog of off-label therapies for all ALL patients in the United States as of 2026-09-22. The documents discuss asparaginase-containing pediatric-inspired regimens and targeted agents for acute lymphoblastic leukemia (ALL), particularly in adolescents and young adults (AYA), but they do not provide a comprehensive list of off-label therapies, compendia-supported uses, coding identifiers, or detailed line-of-therapy classifications. The available text states that \"Asparaginase is an integral component of therapy for pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma\" and that \"trials of pediatric/pediatric-inspired regimens incorporating asparaginase\" have been extended to \"adolescent and young adult (AYA) and adult populations.\" The ASH 2026 guideline document further states that \"Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols\" and that \"The use of targeted agents in frontline therapy is increasingly supported.\" No compendia status labels, HCPCS/CPT/NDC/ICD coding identifiers, or explicit off-label regulatory determinations are provided in the supplied documents. The documents identify some therapies used for acute lymphoblastic leukemia (ALL), including doxorubicin, pediatric-inspired regimens containing asparaginase, targeted agents, and allogeneic hematopoietic stem cell transplantation. Doxorubicin is FDA-indicated for ALL and is described for use in “Metastatic Disease, Leukemia, or Lymphoma,” but no line-of-therapy designation is provided. ASH guidelines describe “frontline therapy” in adolescents and young adults using “Pediatric-inspired regimens containing asparaginase” and note that “The use of targeted agents in frontline therapy is increasingly supported,” while “Allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy.” The documents do not provide compendia-supported off-label use determinations, coding identifiers, HCPCS/NDC/CPT identifiers, or a complete line-of-therapy mapping for all drugs, biologics, and cellular therapies in ALL. The documents identify dasatinib (SPRYCEL), a kinase inhibitor, as an FDA-labeled therapy for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) \"with resistance or intolerance to prior therapy,\" which corresponds to a later-line setting after prior treatment. The label also provides a disease-specific dosage for \"Ph+ ALL\" of \"140 mg administered orally once daily.\" The NCI PDQ document describes induction regimens for adult ALL using combination chemotherapy including \"prednisone, vincristine, and an anthracycline,\" with some regimens adding \"asparaginase or cyclophosphamide,\" and states that \"Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.\" The supplied documents do not provide compendia status classifications, billing or coding identifiers, cellular therapy coding, or a comprehensive list of off-label therapies across all lines of therapy for ALL. The supplied documents identify some therapies and therapy classes being studied or discussed for acute lymphoblastic leukemia (ALL), but they do not provide a comprehensive United States 2026 list of off-label therapies, compendia-supported uses, line-of-therapy recommendations, or coding identifiers. One clinical trial document describes the addition of venetoclax and blinatumomab to chemotherapy for infants with newly diagnosed ALL, stating that “Venetoclax is in a class of medications called B-cell lymphoma-2 (Bcl-2) inhibitors” and “Blinatumomab is a monoclonal antibody.” Another guideline document states that “the rapid development of immunotherapy has improved the efficacy of adult ALL, and commercial antibodies and CAR-T cell products have been available in China.” The documents do not provide compendia status, NCCN support categories, HCPCS/CPT/NDC/J-codes, or explicit off-label line-of-therapy mappings for all patients in the United States. The documents describe investigational and relapsed/refractory acute lymphoblastic leukemia therapies, including small-molecule combinations and cellular therapies, but they do not provide comprehensive United States off-label or compendia-supported use listings, coding identifiers, or formal line-of-therapy compendia status as of 2026-09-22. One study evaluates the drug combination of calaspargase pegol-mknl, decitabine, and venetoclax in pediatric, adolescent, and young adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma. Another study evaluates a CD19-directed CAR T-cell therapy (AUTO1/obe-cel) in pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia. The supplied documents do not include HCPCS, CPT, ICD-10, NDC, or other coding identifiers, and they do not state NCCN Compendia or other compendia support categories. The supplied documents identify several therapies used or studied in acute lymphoblastic leukemia (ALL), including tyrosine kinase inhibitors, monoclonal antibodies, and cellular therapies, but they do not provide compendia status details, coding identifiers, or a comprehensive off-label listing by line of therapy. For relapsed/refractory ALL and minimal residual disease settings, the documents describe blinatumomab, inotuzumab ozogamicin, rituximab, and autologous chimeric antigen receptor (CAR) cells. For newly diagnosed Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-like) B-ALL, a clinical trial document describes use of blinatumomab with dasatinib or imatinib plus chemotherapy. The documents also identify ponatinib (ICLUSIG) as an FDA-approved product, but they do not specify ALL line-of-therapy use, compendia support, or billing/coding identifiers. The supplied documents describe investigational and treatment regimens for acute lymphoblastic leukemia (ALL), including therapies used in newly diagnosed and high-risk or relapsed settings, but they do not provide compendia-supported indications, off-label status determinations, or coding identifiers. Document 0 describes selected use of blinatumomab and cellular therapies in pediatric and young adult patients with high-risk ALL in remission states including CR1, CR2, and CR3 or subsequent relapse settings in the context of haploidentical hematopoietic cell transplantation. Document 1 describes a “pediatric-inspired” chemotherapy regimen for adults aged 18-60 with newly diagnosed Philadelphia chromosome-negative ALL and lists the chemotherapy agents used. No document provides United States compendia status, HCPCS/CPT/NDC coding identifiers, or explicit regulatory off-label classifications. The supplied documents identify that the NCCN Clinical Practice Guidelines for Pediatric Acute Lymphoblastic Leukemia address treatment strategies for multiple ALL subtypes and include recommendations for “frontline and relapsed/refractory management,” but they do not enumerate specific off-label drugs, biologics, cellular therapies, compendia-supported indications, line-of-therapy mappings, or coding identifiers. The documents state that the guidelines include “guidance on supportive care, hematopoietic stem cell transplantation, and pharmacogenomics” and cover “treatment strategies for BCR::ABL1 (Philadelphia chromosome [Ph])-negative and BCR::ABL1-positive B-cell lineage, T-cell lineage, and infant ALL.” No HCPCS, CPT, ICD-10, NDC, or other coding identifiers are provided in the supplied text. The supplied documents identify doxorubicin hydrochloride as a drug used in acute lymphoblastic leukemia, but they do not provide the requested comprehensive list of off-label therapies, biologics, cellular therapies, compendia-supported uses, lines of therapy, or coding identifiers for acute lymphoblastic leukemia in the United States as of 2026-09-22. One FDA labeling document states that \"DOXOrubicin HCl Injection, USP and DOXOrubicin HCl for Injection, USP have been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia.\" The documents discussing oncology drug compendia and off-label coverage do not provide specific acute lymphoblastic leukemia therapies, compendia status categories, or line-of-therapy details. The supplied documents identify clofarabine as a nucleoside metabolic inhibitor used in acute lymphoblastic leukemia (ALL) for pediatric patients with relapsed or refractory disease after at least two prior regimens, which corresponds to a later-line therapy setting. The documents state: \"Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.\" The documents do not provide information on off-label ALL therapies, compendia-supported uses, compendia status, cellular therapies, biologics beyond clofarabine, therapy coding identifiers, or line-of-therapy categorizations for all patients in the United States as of 2026-09-22. The supplied documents identify FDA-labeled therapies for acute lymphoblastic leukemia (ALL), but they do not provide compendia-supported off-label uses, line-of-therapy categorizations beyond resistance/intolerance language, coding identifiers, or cellular therapies. Doxorubicin is described as \"indicated for the treatment of acute lymphoblastic leukemia\" and is an \"anthracycline topoisomerase inhibitor.\" Dasatinib is described as a \"kinase inhibitor\" indicated for \"adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy\" and for \"pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.\" The supplied documents do not provide a comprehensive list of off-label therapies, compendia-supported uses, lines of therapy, coding identifiers, or therapy classes for acute lymphoblastic leukemia in the United States as of 2026-09-22. The documents do mention immunotherapy approaches including monoclonal antibodies, CAR-T cell products, and blinatumomab in adult or newly diagnosed B-lineage acute lymphoblastic leukemia. One clinical trial document specifically evaluates “combination chemotherapy with blinatumomab” in “newly diagnosed BCR-ABL-negative B lineage acute lymphoblastic leukemia,” which corresponds to a frontline/newly diagnosed treatment setting. The supplied documents identify that NCCN Guidelines for acute lymphoblastic leukemia (ALL) include \"treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients\" and that pediatric guidelines include \"treatment strategies for BCR::ABL1 (Philadelphia chromosome [Ph])-negative and BCR::ABL1-positive B-cell lineage, T-cell lineage, and infant ALL.\" However, the documents do not provide specific off-label drugs, biologics, cellular therapies, compendia-supported uses, line-of-therapy details, or coding identifiers for ALL therapies in the United States as of 2026-09-22.","status":"partial","citations":["Dr.Reddy's Laboratories Inc","Alembic Pharmaceuticals Limited","Hospira, Inc.","American Society of Clinical Oncology Educational Book","American Society of Hematology","Alembic Pharmaceuticals Inc.","Blood advances","Hikma Pharmaceuticals USA Inc.","Journal of Clinical Oncology","National Cancer Institute (NCI)","Memorial Sloan Kettering Cancer Center","American journal of hematology","US Food and Drug Administration","NOVARTIS","National Cancer Institute","Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","M.D. Anderson Cancer Center","Autolus Limited","TAKEDA PHARMS USA","St. Jude Children's Research Hospital","Journal of the National Comprehensive Cancer Network : JNCCN","Journal of Oncology Practice","Amneal Pharmaceuticals LLC","Pfizer Laboratories Div Pfizer Inc","BluePoint Laboratories","Default Digital Object Group"],"sources":["asco","ashpublications","clinicaltrials","esmo","nci","openfda_drugsfda","openfda_label"],"evidence_count":14,"coverage":0.71,"supplementary":false,"unmet_reason":""},{"question":"In the United States through 2026-09-22, how have major clinical guideline recommendations for acute lymphoblastic leukemia changed over time, including version dates, recommendation changes, and affected treatment settings or patient subgroups for all patients?","seed":"How have guideline recommendations for ALL changed over the study period, and on what dates?","answer":"The supplied document describes contemporary remission induction approaches for adult acute lymphoblastic leukemia (ALL), including that \"Most current induction regimens for patients with adult ALL include combination chemotherapy with prednisone, vincristine, and an anthracycline\" and that some regimens \"also add other drugs, such as asparaginase or cyclophosphamide.\" It also notes a treatment change within a CALGB study involving the \"omission of L-asparaginase\" midway through the study. For newly diagnosed adult patients with Philadelphia chromosome (Ph)-positive ALL, the document states that \"inclusion of imatinib into a relatively standard chemotherapy regimen... may provide a significant survival advantage\" and that \"Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.\" The document further states that \"If a suitable donor is available, allogeneic bone marrow transplant should be considered because remissions are generally short with conventional ALL chemotherapy clinical trials\" and that \"the use of myeloid growth factors during remission-induction therapy appears to decrease the time to hematopoietic reconstitution.\" The documents do not provide guideline version histories, dates of recommendation changes, or a chronological evolution of U.S. clinical guidelines through 2026-09-22. The supplied documents describe new 2026 American Society of Hematology (ASH) guidelines for adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL), including frontline and relapsed/refractory settings, but they do not provide a longitudinal history of guideline changes over time or prior version dates. For frontline management, the 2026 ASH guideline states that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols,” and that “Allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy.” For relapsed/refractory disease, the 2026 ASH guideline reports that recommendations “focused on the following treatment modalities: immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)-directed therapy,” and that “Key recommendations include the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction.” The affected settings and patient subgroups described are AYAs with frontline ALL and AYAs with relapsed/refractory ALL, including “ALL subsets (T-cell ALL), CNS relapse, and the role of consolidation with allogeneic transplant.”","status":"partial","citations":["National Cancer Institute","American Society of Hematology","Blood advances"],"sources":["ashpublications","clinicaltrials","esmo","nci"],"evidence_count":10,"coverage":0.75,"supplementary":false,"unmet_reason":""},{"question":"In the United States through 2026-09-22, what published benchmarks are available for time on treatment, time to next treatment, progression-free survival, and related outcomes in acute lymphoblastic leukemia by line of therapy and key regimen for all patients?","seed":"What are the published benchmarks for time on treatment, time to next treatment, and PFS (progression-free survival) in ALL by line and key regimen?","answer":"The supplied documents contain limited published benchmark information for outcomes in acute lymphoblastic leukemia (ALL), mostly related to remission duration, relapse-free survival objectives, and treatment context rather than comprehensive benchmarks for time on treatment (TOT), time to next treatment (TTNT), or progression-free survival (PFS) by line of therapy and regimen. For newly diagnosed adult ALL induction therapy, the NCI PDQ states that \"Current multiagent induction regimens result in complete response rates that range from 60% to 90%\" and reports that in Ph-positive ALL treated with imatinib-containing therapy, \"most of these patients experiencing disease relapse at a median of 58 days after the start of therapy\" and \"The responses again were short, with a median duration of 2.2 months.\" A ClinicalTrials.gov phase III study in newly diagnosed BCR-ABL-negative B-lineage ALL lists overall survival (OS) and relapse-free survival (RFS) as primary and secondary objectives for blinatumomab plus chemotherapy versus chemotherapy alone, but does not provide benchmark results. The ASH 2026 guideline document discusses relapsed/refractory ALL in adolescents and young adults and focuses on treatment recommendations such as \"the use of blinatumomab and/or inotuzumab over chemotherapy for reinduction,\" but does not provide numeric TOT, TTNT, or PFS benchmarks. The supplied document is an ASH guideline for relapsed/refractory acute lymphoblastic leukemia (ALL) in adolescents and young adults and discusses treatment recommendations by regimen and disease setting, but it does not provide published benchmarks for time on treatment, time to next treatment, progression-free survival, or related outcomes by line of therapy. The document identifies treatment modalities and regimens including “blinatumomab,” “inotuzumab,” “CAR T-cell therapy,” and “chemotherapy” in relapsed/refractory B-ALL and references remission status such as “second (or greater) remission (CR2).” The document is a guideline evidence review source rather than an outcomes benchmark dataset. The provided document discusses frontline management recommendations for acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs), including regimen selection and supportive care considerations, but it does not provide published benchmarks for time on treatment, time to next treatment, progression-free survival, or related outcomes by line of therapy and regimen. The document does identify frontline therapy approaches and key regimens, particularly pediatric-inspired asparaginase-containing regimens versus adult-inspired protocols. No quantitative benchmark data sources for treatment duration or survival endpoints are reported in the supplied material. The supplied documents do not provide published benchmarks for “time on treatment,” “time to next treatment,” or “progression-free survival” in acute lymphoblastic leukemia stratified by line of therapy and key regimen. The documents instead discuss overall treatment duration and frontline regimen recommendations. One review states that “Contemporary ALL therapy usually consists of cycles of multiagent chemotherapy administered over 2 to 3 years” and that “ALL therapy typically begins with 5 to 9 months of more-intensive chemotherapy followed by a prolonged low-intensity maintenance phase.” The ASH 2026 guideline document provides frontline treatment recommendations for adolescents and young adults, including that “Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols,” but it does not report benchmark outcomes such as progression-free survival, time on treatment, or time to next treatment by line of therapy.","status":"partial","citations":["National Cancer Institute","National Cancer Institute (NCI)","American Society of Hematology","Blood advances","Open web"],"sources":["asco","ashpublications","clinicaltrials","esmo","nci","open_web"],"evidence_count":14,"coverage":0.95,"supplementary":true,"unmet_reason":""},{"question":"In the United States through 2026-09-22, what proportion of acute lymphoblastic leukemia patients progress from first-line to subsequent lines of therapy, and what clinical or treatment-related factors are associated with attrition between lines for all patients?","seed":"What proportion of ALL patients advance from 1L to 2L, 3L, and beyond, and what drives attrition between lines?","answer":"","status":"not_found","citations":[],"sources":[],"evidence_count":0,"coverage":0.0,"supplementary":false,"unmet_reason":"no usable evidence after 1 retrieval round(s); abandoned after 480s; sources did not respond"}],"evidence_count":117,"source_count":9,"supplementary_count":14,"tiers_represented":[1,2,3,5],"created_at":"2026-09-22T11:58:29.962136Z"}],"qa":null,"rule_cards":[],"brief":null,"project_files":[]}